User:Daniel Mietchen/Wikidata lists/Items with MeSH Codes
Appearance
This page mirrors information available on Wikidata. See also Autolist and wiga for other ways to browse this information.
This list is automatically generated from data in Wikidata and is periodically updated by Listeriabot.
Edits made within the list area will be removed on the next update!
Act of Congress
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
American Recovery and Reinvestment Act of 2009 | Act of Congress | N03.706.615.049 | American Recovery and Reinvestment Act of 2009 | |||
Employee Retirement Income Security Act of 1974 | Act of Congress | N01.824.417.510.300 N01.824.417.700.325.300 N03.219.521.576.343.290.300 N03.706.615.215 N04.452.677.800.325.300 |
||||
Health Insurance Portability and Accountability Act | Act of Congress | N03.219.521.576.343.349 N03.706.615.273 |
||||
Medicare Access and CHIP Reauthorization Act of 2015 | Act of Congress | N03.219.521.346.506.564.663.250 N03.219.521.576.343.840.254 N03.706.615.696.500 |
||||
Tax Equity and Fiscal Responsibility Act of 1982 | Act of Congress | N03.219.900.880 N03.706.615.889 |
ChEBI Ontology term
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
adrenergic agonist | ChEBI Ontology term | drug agonist Adrenergic Agents |
drug that stimulates a response from the adrenergic receptors | D27.505.696.577.050.100 D27.505.519.625.050.100 |
||
analgesic | ChEBI Ontology term | drug Central Nervous System Agents Sensory System Agents |
pharmaceutical drug | D27.505.696.663.850.014 D27.505.954.427.040 |
Analgesics | |
anesthetic | ChEBI Ontology term | drug Central Nervous System Depressants |
drug that causes anesthesia | D27.505.954.427.210.100 D27.505.696.277.100 |
Anesthetics | |
angiogenesis inhibitor | ChEBI Ontology term | drug antineoplastic Growth Inhibitors Angiogenesis Modulating Agents |
agent and endogenous substance that antagonizes or inhibits the development of new blood vessels | D27.505.696.377.450.100 D27.505.954.248.025 D27.505.696.377.077.099 |
Angiogenesis inhibitors | |
anthelmintic | ChEBI Ontology term | antiparasitic | Substance intended to kill parasitic worms (helminths) | D27.505.954.122.250.075 | Antihelmintics | |
anti-diabetic medication | ChEBI Ontology term | Physiological Effects of Drugs | Substances which lower blood glucose levels | D27.505.696.422 | Anti-diabetic drugs | |
anti-ulcer drug | ChEBI Ontology term | drug Gastrointestinal Agents |
One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. | D27.505.954.483.203 | ||
antiarrhythmic agent | ChEBI Ontology term | drug Cardiovascular Agents |
group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. | D27.505.954.411.097 | Antiarrhythmic agents | |
anticholinergic | ChEBI Ontology term | drug Cholinergic Agents |
chemical substance that blocks the neurotransmitter acetylcholine in the central and the peripheral nervous system | D27.505.519.625.120.200 D27.505.696.577.120.200 |
Anticholinergics | |
anticonvulsant | ChEBI Ontology term | drug Central Nervous System Agents |
Class of medications | D27.505.954.427.080 | Anticonvulsants | |
antiemetic | ChEBI Ontology term | drug Autonomic Agents Central Nervous System Agents Gastrointestinal Agents |
drug used to prevent nausea or vomiting | D27.505.696.663.050.030 D27.505.954.483.200 D27.505.954.427.095 |
Antiemetics | |
antifungal medication | ChEBI Ontology term | drug Anti-Infective Agents |
Category of pharmaceutical drugs | D27.505.954.122.136 | Antifungals | |
antihypertensive drug | ChEBI Ontology term | drug Cardiovascular Agents |
all drugs for hypertension's treatment | D27.505.954.411.162 | Antihypertensive agents | |
antineoplastic | ChEBI Ontology term | drug Therapeutic Uses |
group of chemical compounds | D27.505.954.248 | Antineoplastic agents | |
antiparasitic | ChEBI Ontology term | drug Anti-Infective Agents |
A substance used to treat or prevent parasitic infections | D27.505.954.122.250 | Antiparasitic agents | |
antiprotozoal | ChEBI Ontology term | antiparasitic | class of pharmaceuticals used in treatment of protozoan infection | D27.505.954.122.250.100 | Antiprotozoal agents | |
antipruritic | ChEBI Ontology term | dermatologic drug | drug, usually applied topically, that relieves pruritus (itching) | D27.505.954.444.075 | ||
antipsychotic | ChEBI Ontology term | tranquilizer | class of medications | D27.505.696.277.950.040 D27.505.954.427.700.872.331 D27.505.954.427.210.950.040 |
Antipsychotic drugs | |
antipyretic | ChEBI Ontology term | drug Physiological Effects of Drugs |
drug that prevents or reduces fever by lowering the body temperature from a raised state | D27.505.696.068 | Antipyretics | |
antitussive | ChEBI Ontology term | drug Central Nervous System Agents Respiratory System Agents |
Agents that suppress cough. They act centrally on the medullary cough center. Expectorants, also used in the treatment of cough, act locally | D27.505.954.427.153 D27.505.954.796.090 |
Antitussives | |
antiviral agent | ChEBI Ontology term | antibiotic Anti-Infective Agents |
substance that destroys or inhibits replication of viruses | D27.505.954.122.388 | ||
anxiolytic | ChEBI Ontology term | tranquilizer | medication or other intervention that inhibits anxiety | D27.505.954.427.210.950.015 D27.505.954.427.700.872.015 D27.505.696.277.950.015 |
Anxiolytics | |
bronchodilator | ChEBI Ontology term | drug Autonomic Agents Anti-Asthmatic Agents |
substance that dilates the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs | D27.505.696.663.050.110 D27.505.954.796.050.100 |
Bronchodilators | |
dermatologic drug | ChEBI Ontology term | drug Therapeutic Uses |
drug used to treat or prevent skin disorders or for the routine care of skin | D27.505.954.444 | ||
diuretic | ChEBI Ontology term | chemical substance Natriuretic Agents |
substance that promotes the production of urine | D27.505.696.560.500 | Diuretics | |
histaminergic | ChEBI Ontology term | neurotransmitter | Class of medications | D27.505.519.625.375 D27.505.696.577.375 |
||
hypolipidemic | ChEBI Ontology term | drug Antimetabolites Lipid Regulating Agents |
substance used to treat hyperlipidemia (an excess of lipids in the blood) | D27.505.954.557.500 D27.505.519.186.071 |
Hypolipidemic agents | |
keratolytic | ChEBI Ontology term | dermatologic drug | drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin | D27.505.954.444.400 | ||
local anesthetic | ChEBI Ontology term | anesthetic Sensory System Agents |
medication that causes reversible absence of pain sensation | D27.505.954.427.210.100.200 D27.505.696.277.100.200 D27.505.696.663.850.025 |
Local anesthetics | |
non-steroidal anti-inflammatory drug | ChEBI Ontology term | non-opioid analgesic anti-inflammatory agent disease-modifying antirheumatic drug |
class of drug | D27.505.696.663.850.014.040.500 D27.505.954.329.030 D27.505.954.158.030 |
Non-steroidal anti-inflammatory drugs | |
nootropic | ChEBI Ontology term | chemical substance Central Nervous System Agents |
drug, supplement, or other substance that improves cognitive function | D27.505.954.427.637 | Nootropics | |
opioid | ChEBI Ontology term | psychoactive drug analgesic narcotic |
psychoactive chemical | D27.505.696.277.600.500 D27.505.954.427.210.600.500 D27.505.954.427.040.550.500 D27.505.696.663.850.014.760.500 |
Opioids | |
Prostaglandin antagonist | ChEBI Ontology term | Hormone antagonist Hormone Antagonists |
compound that inhibits the action of prostaglandins | D27.505.696.399.450.710 | ||
Proteasome inhibitor | ChEBI Ontology term | drug Protease inhibitor |
drug that blocks the action of proteasomes, cellular complexes that break down proteins | D27.505.519.389.745.705 | ||
tranquilizer | ChEBI Ontology term | drug Central Nervous System Depressants Psychotropic Drugs |
drug that induces tranquility in an individual | D27.505.954.427.700.872 D27.505.696.277.950 D27.505.954.427.210.950 |
||
vasodilator agent | ChEBI Ontology term | Cardiovascular Agents | drug used to cause dilation of the blood vessels | D27.505.954.411.918 | Vasodilators |
academic discipline
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
anthropology | academic discipline academic major |
social science | science of humanity | I01.076 | Anthropology | |
computational biology | academic discipline | biology computational science information science |
data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, behavioral, and social systems | H01.158.273.180 L01.313.124 |
Bioinformatics | |
humanities | academic discipline non-science academic major |
knowledge | academic disciplines that study human culture | K | Humanities | |
sociology | academic discipline academic major |
social science | scientific study of human society and its origins, development, organizations, and institutions | I | Sociology |
anatomical region
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
armpit | anatomical region | anatomical region | area of human body beneath joint between arm and torso | A01.378.800.090 | Armpits | |
upper arm | anatomical region anatomical structure |
anatomical structure | proximal part of the free upper limb between the shoulder and the elbow | A01.378.800.075 | Arms |
anatomical structure
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
abdominal cavity | anatomical structure | abdominopelvic cavity | A01.047.025 | |||
acetabulum | anatomical structure | A02.835.232.611.108 | Acetabulum | |||
adenoid | anatomical structure | A10.549.100 | Adenoids | |||
adrenal gland | anatomical structure | endocrine gland | endocrine gland that produces a variety of hormones | A06.407.071 | Adrenal glands | |
anal canal | anatomical structure | part of large intestine | A03.556.124.526.070 | |||
ankle | anatomical structure | region where the foot and the leg meet | A02.835.583.378.062 | Ankles | ||
anterior hypothalamic nucleus | anatomical structure | A08.186.211.730.385.357.342.063 | ||||
anterior pituitary | anatomical structure | glandular, anterior lobe that, together with the posterior lobe, makes up the pituitary gland | A06.407.747.608 | |||
appendix | anatomical structure animal organ |
animal organ | blind-ended tube connected to the cecum, from which it develops embryologically | A03.556.124.526.209.290 | Vermiform appendix | |
Bowman's membrane | anatomical structure | A09.371.060.217.113 | ||||
bronchus | anatomical structure | airway in the respiratory tracti | A04.411.125 | Bronchi | ||
carpal bone | anatomical structure | bone of hand | bone | A02.835.232.087.144 | Carpus | |
cecum | anatomical structure | pouch that is considered to be the beginning of the large intestine | A03.556.124.526.209 | Cecum | ||
central nervous system | anatomical structure | part of the nervous system consisting of the brain and spinal cord | A08.186 | Central nervous system | ||
cerebral aqueduct | anatomical structure | A08.186.211.132.659.822.187 | Cerebral aqueduct | |||
Chordae tendineae | anatomical structure | cord-like tendons that connect the papillary muscles to the tricuspid valve and the mitral valve in the heart | A07.541.510.240 | |||
choroid | anatomical structure | vascular layer of the eye, containing connective tissue, and lying between the retina and the sclera | A09.371.894.223 | Choroid | ||
ciliary body | anatomical structure | A09.371.894.280 | ||||
cochlea | anatomical structure | organ of the inner ear | A09.246.631.246 | Cochlea | ||
cochlear duct | anatomical structure | A09.246.631.246.292 | ||||
conjunctiva | anatomical structure | Outer covering of sclera | A09.371.192 | Sight | ||
corpus callosum | anatomical structure | axon | brain part | A08.186.211.730.885.362 | Corpus callosum | |
dental alveolus | anatomical structure | A02.835.232.781.324.502.125.800 | ||||
descending colon | anatomical structure | the part of the colon from the splenic flexure to the beginning of the sigmoid colon | A03.556.124.526.356.500 | |||
diencephalon | anatomical structure | brain region | consists of structures that are lateral to the third ventricle, and includes the thalamus, the hypothalamus, the epithalamus and the subthalamus; one of the main vesicles of the brain formed during embryogenesis | A08.186.211.730.385 | Diencephalon | |
duodenum | anatomical structure | first section of the small intestine | A03.556.124.684.124 | Duodenum | ||
eardrum | anatomical structure | membrane organ | membrane that separates the external ear from the middle ear | A09.246.272.702 | Eardrum | |
elbow | anatomical structure | synovial hinge joint between the humerus in the upper arm and the radius and ulna in the forearm | A02.835.583.290 | Elbow | ||
endolymphatic sac | anatomical structure | A09.246.631.909.957.360.701 | ||||
ependyma | anatomical structure | epithelial lining of the ventricular system of the brain and the central canal of the spinal cord, made up of ependymal cells | A08.186.211.276.460 | |||
epidermis | anatomical structure | outermost layers of the skin | A10.272.497 A17.815.250 |
Epidermis (skin) | ||
epithalamus | anatomical structure | part of diencephalon | A08.186.211.577.200 | |||
esophagus | anatomical structure | organ in vertebrates | A03.556.875.500 | Esophagus | ||
ethmoid sinus | anatomical structure | paranasal sinus | A04.531.621.267 | |||
Eustachian tube | anatomical structure | A09.246.397.369 | Eustachian tube | |||
eye | anatomical structure | animal organ facial feature |
organ that detects light and converts it into electro-chemical impulses in neurons | A01.456.505.420 | Eyes | |
eyelid | anatomical structure | thin fold of skin that covers and protects the human eye | A01.456.505.420.504 | Eyelids | ||
face | anatomical structure | part of the body at the front of the head | A01.456.505 | Faces | ||
Fallopian tube | anatomical structure | A05.360.319.114.373 | Fallopian tube | |||
foramen magnum | anatomical structure | opening in the occipital bone of the cranium | A02.835.232.781.572.434 | Foramen magnum | ||
forearm | anatomical structure | anatomical structure | part of the body | A01.378.800.585 | Forearms | |
fourth ventricle | anatomical structure | ventricular system | A08.186.211.276.500 | Fourth ventricle | ||
frontal sinus | anatomical structure | paranasal sinus | A04.531.621.387 | Frontal sinuses | ||
glomerular basement membrane | anatomical structure | basement membrane | A11.284.295.310.279 | |||
glomerulus | anatomical structure | A05.810.453.324.359 | Renal corpuscle | |||
hard palate | anatomical structure | thin horizontal bony plate of the skull, located in the roof of the mouth | A02.835.232.781.324.502.660 | |||
heart | anatomical structure | animal organ muscle |
organ for the circulation of blood in animal circulatory systems | A07.541 | Heart (organ) | |
hip | anatomical structure | anatomical region | anatomical region | A01.378.610.400 | Hip | |
humerus | anatomical structure bone |
arm bone | long bone of the upper arm | A02.835.232.087.090.400 | Humerus | |
hypothalamus | anatomical structure | part of diencephalon | A08.186.211.730.385.357 | Hypothalamus | ||
ileocecal valve | anatomical structure | valve | A03.556.124.684.249.400 | Ileocecal valve | ||
inferior olivary nucleus | anatomical structure | A08.186.211.132.810.406.574 | ||||
inner ear | anatomical structure | innermost part of the vertebrate ear | A09.246.631 | Inner ear | ||
interatrial septum | anatomical structure | cardiac septum | The interatrial septum is the wall of tissue that separates the right and left atria of the heart. | A07.541.459 | ||
interventricular septum | anatomical structure | cardiac septum | A07.541.459 | ECHOpedia case 'Ventricular septum defect with right to left shunt' | ||
iris | anatomical structure | part of an eye | A09.371.894.513 | Iris (eye) | ||
jejunum | anatomical structure | part of small intestine | A03.556.124.684.500 | |||
kidney | anatomical structure | animal organ | internal organ in most animals, including vertebrates and some invertebrates | A05.810.453 | Kidneys | |
lateral ventricle | anatomical structure | brain region ventricular system |
A08.186.211.276.650 | Lateral ventricles | ||
loop of Henle | anatomical structure | kidney tubule | A05.810.453.736.560.610 | |||
mammillary body | anatomical structure | pair of small round bodies, located on the undersurface of the brain that, as part of the diencephalon, form part of the limbic system | A08.186.211.730.385.357.362.500 | Mammillary bodies | ||
maxillary sinus | anatomical structure | paranasal sinus | A04.531.621.578 | Maxillary sinuses | ||
metacarpal bone | anatomical structure | bone of hand | bone of hand | A01.378.800.667.572 | Metacarpus | |
metacarpophalangeal joint | anatomical structure | hand joint | anatomical structure | A02.835.583.345.512 | ||
metatarsal bone | anatomical structure | bone | bones in the foot | A01.378.610.250.300.480 | Metatarsus | |
middle ear | anatomical structure | A09.246.397 | Middle ear | |||
mitral valve | anatomical structure | heart valve atrioventricular valve |
A07.541.510.507 | Mitral valves | ||
nasal concha | anatomical structure | turbinate | A02.835.232.781.324.948 | |||
nasal septum | anatomical structure | separator of the left and right airways in the nose | A02.165.407.600 | |||
optic chiasm | anatomical structure | Optical part of brain | A08.800.800.120.680.600 | Optic chiasm | ||
optic disc | anatomical structure | A08.800.800.120.680.660 | ||||
organ of Corti | anatomical structure | type of mechanoreceptor | A09.246.631.246.577 | Organ of Corti | ||
otolith | anatomical structure | calcium carbonate structure in the inner ear of vertebrates | A09.246.631.909.625.125.680 | Otoliths | ||
outer ear | anatomical structure | outer part of ear | A09.246.272 | Outer ear | ||
ovarian follicle | anatomical structure | A05.360.319.114.630.535 | Ovarian follicles | |||
ovary | anatomical structure female organ |
gonad | ovum-producing reproductive organ, often found in pairs as part of the vertebrate female reproductive system | A05.360.319.114.630 | Ovary | |
palate | anatomical structure | A14.521.658 | Palate | |||
parotid gland | anatomical structure | major salivary gland | A03.556.500.760.464 | Parotid glands | ||
pelvis | anatomical structure | anatomical region | lower part of the trunk of the human body between the abdomen and the thighs (sometimes also called pelvic region of the trunk | A01.673 | Pelvis | |
perineum | anatomical structure | region of the body including the perineal body and surrounding structures | A01.719 | Human anogenital area | ||
Peyer's patch | anatomical structure | lymphatic tissue | A10.549.600 | Peyer's patches | ||
pharynx | anatomical structure | part of the throat that is behind the mouth and nasal cavity | A03.556.750 | Pharynx | ||
posterior cranial fossa | anatomical structure | A01.456.830.200 | Posterior cranial fossa | |||
posterior pituitary | anatomical structure | posterior lobe of the pituitary gland | A06.407.747.734 | |||
pulmonary valve | anatomical structure | heart valve semi-lunar valve |
semilunar valve of the heart | A07.541.510.738 | Pulmonary valve | |
rectum | anatomical structure | animal organ | final section of intestine | A03.556.124.526.767 | Rectum | |
renal calyx | anatomical structure | A05.810.453.537.503 | ||||
renal cortex | anatomical structure | A05.810.453.324 | ||||
renal medulla | anatomical structure | A05.810.453.466 | ||||
renal pelvis | anatomical structure | basin-like or funnel-like dilated proximal part of the ureter in the kidney | A05.810.453.537 | Renal pelvis | ||
retina | anatomical structure | light-sensitive organ in the eye | A09.371.729 | Retina | ||
saccule | anatomical structure | otolith organ | membranous labyrinth in the vestibule of ear | A09.246.631.909.625 | ||
salivary gland | anatomical structure | exocrine gland | exocrine gland that produces saliva | A03.556.500.760 | Salivary glands | |
scala tympani | anatomical structure | A09.246.631.246.848 | ||||
scalp | anatomical structure | anatomical area bordered by the face anteriorly and the neck to the sides and posteriorly | A01.456.810 | Scalps | ||
sclera | anatomical structure | A09.371.784 | ||||
scrotum | anatomical structure | anatomical male reproductive structure that consists of a suspended sack of skin | A05.360.444.661 | Scrotum | ||
semicircular canal | anatomical structure | tube located inside the ear | A09.246.631.663 | Semicircular canals | ||
sinoatrial node | anatomical structure | group of cells located in the wall of the right atrium of the heart | A07.541.409.819 | Sinoatrial node | ||
small intestine | anatomical structure | part of the digestive tract, following the stomach and followed by the large intestine | A03.556.124.684 | Small intestine | ||
soft palate | anatomical structure | tissue constituting the back of the roof of the mouth | A14.549.617.780 | |||
spermatic cord | anatomical structure | cord-like structure in males | A05.360.444.777 | Human spermatic cord | ||
sphenoidal sinus | anatomical structure | paranasal sinus | A04.531.621.827 | |||
spinal canal | anatomical structure | dorsal body cavity | the space in the vertebral column formed by the vertebrae through which the spinal cord passes; it is a process of the dorsal body cavity; this canal is enclosed within the vertebral foramen of the vertebrae | A02.835.232.834.803 | ||
spleen | anatomical structure | animal organ lymphatic tissue |
internal organ in most vertebrate animals | A10.549.700 | Spleen | |
stomach | anatomical structure | animal organ | digestive organ | A03.556.875.875 | Stomachs | |
stria vascularis | anatomical structure | capillary or blood vessel in the wall of cochlear duct | A09.246.631.246.292.876 | |||
subarachnoid space | anatomical structure | A08.186.566.166.686 | ||||
sublingual gland | anatomical structure | major salivary gland | A03.556.500.760.687 | |||
submandibular gland | anatomical structure | major salivary gland | A03.556.500.760.812 | Submandibular glands | ||
subthalamic nucleus | anatomical structure | nucleus | A08.186.211.730.385.800.800 | Subthalamic nucleus | ||
taste buds | anatomical structure | specialized receptor organ located in the epithelium of the papillae of the tongue and in the soft palate, epiglottis, and pharynx | A03.556.500.885.779 | Taste buds | ||
tectorial membrane | anatomical structure | membrane in the cochlea of the inner ear | A09.246.631.246.292.906 | Tectorial membrane | ||
thoracic diaphragm | anatomical structure | sheet of internal skeletal muscle | A02.633.567.900.300 | Thoracic diaphragm | ||
thorax | anatomical structure | anatomical region | frontal part of an animal's body, between its head and abdomen | A01.911 | Thorax | |
thymus | anatomical structure | lymphatic tissue | organ of the immune system | A10.549.750 | Thymus (organ) | |
tongue | anatomical structure | mouth organ that tastes and facilitates speech | A03.556.500.885 | Tongue | ||
tonsil | anatomical structure | lymphatic tissue | A04.623.603.925 | Tonsils | ||
trabecular meshwork | anatomical structure | A09.371.060.932 | Trabecular meshwork | |||
trachea | anatomical structure | cartilaginous tube that connects the pharynx and larynx to the lungs | A04.889 | Trachea (anatomy) | ||
tricuspid valve | anatomical structure | heart valve mitral valve |
one-way valve present between right auricle and right ventricle | A07.541.510.893 | Tricuspid valve | |
tuber cinereum | anatomical structure | A08.186.211.730.385.357.352.870 | ||||
tunica intima | anatomical structure | inner layer of blood vessel | A07.231.330.800 | Tunica intima | ||
tunica media | anatomical structure | middle layer of blood vessel | A02.633.570.491.800 | |||
ulna | anatomical structure bone |
arm bone | long bone of the forearm | A02.835.232.087.090.850 | Ulna | |
ureter | anatomical structure | tubes used in the urinary system in most animals | A05.810.776 | Ureter | ||
urethra | anatomical structure | tube that connects the urinary bladder to the genitals | A05.360.444.492.726 | Urethra | ||
urinary bladder | anatomical structure | animal organ urinary system |
internal organ in most animals | A05.810.161 | Urinary bladder | |
uvea | anatomical structure | pigmented middle of the three concentric layers that make up an eye | A09.371.894 | |||
uvula | anatomical structure | fleshy appendage that hangs from the back of the palate | A14.549.617.780.729 | Palatine uvula | ||
vagina | anatomical structure | feminine reproductive organ | A05.360.319.779 | Vaginas | ||
vena cava | anatomical structure umbrella term vein |
large veins (venous trunks) that return deoxygenated blood from the body into the heart | A07.231.908.949 | |||
ventricular system | anatomical structure | set of structures containing cerebrospinal fluid in the brain | A08.186.211.276 | |||
vestibular aqueduct | anatomical structure | A09.246.631.909.957 |
artery
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
abdominal aorta | artery | A07.231.114.056.205 | ||||
anterior cerebral artery | artery | A07.231.114.228.100 | Arteria cerebri anterior | |||
aorta | artery umbrella term Q15057490 |
artery | largest artery in the body | A07.231.114.056 | Aorta | |
axillary artery | artery | A07.231.114.085 | Axillary arteries | |||
basilar artery | artery | artery that supplies the brain with oxygen-rich blood | A07.231.114.106 | Arteria basilaris | ||
brachial artery | artery | A07.231.114.139 | Brachial arteries | |||
brachiocephalic artery | artery | aorta descendens | A07.231.908.130 | |||
carotid sinus | artery | the carotid sinus is a dilated area at the base of the internal carotid artery just superior to the bifurcation of the internal carotid and external carotid | A07.231.114.186.456 | |||
celiac artery | artery | A07.231.114.207 | Human anatomy, celiac artery | |||
central retinal artery | artery | A07.231.114.765 | ||||
common carotid artery | artery | carotid artery | A07.231.114.186.200 | Arteria carotis communis | ||
coronary artery | artery | artery vas privatum |
A07.231.114.269 | Coronary vessels | ||
ductus arteriosus | artery embryonic structure |
blood vessel connecting the pulmonary artery to the proximal descending aorta | A07.541.278.395 | Ductus arteriosus | ||
external carotid artery | artery | carotid artery | major artery of the head and neck | A07.231.114.186.200.210 | Arteria carotis externa | |
femoral artery | artery | A07.231.114.351 | Femoral artery | |||
inferior mesenteric artery | artery | A07.231.114.565.510 | ||||
internal carotid artery | artery | carotid artery | A07.231.114.186.200.230 | Arteria carotis interna | ||
internal iliac artery | artery | A07.231.114.444 | ||||
internal thoracic artery | artery | artery | A07.231.114.891.525 | |||
Lateral thoracic artery | artery | Lateralis+thoracic+artery | ||||
ophthalmic artery | artery | A07.231.114.622 | Arteria ophthalmica | |||
popliteal artery | artery | A07.231.114.681 | ||||
posterior cerebral artery | artery | A07.231.114.228.700 | Arteria cerebri posterior | |||
pulmonary artery | artery umbrella term |
artery in the pulmonary circulation that carries deoxygenated blood from the heart to the lungs | A07.231.114.715 | Pulmonary artery | ||
radial artery | artery | A07.231.114.740 | ||||
renal artery | artery | A07.231.114.745 | ||||
splenic artery | artery | A07.231.114.814 | ||||
subclavian artery | artery | major arteries of the upper thorax, below the clavicle | A07.231.114.839 | Subclavian arteries | ||
Superficial epigastric artery | artery | A07.231.114.330 | ||||
superior mesenteric artery | artery | A07.231.114.565.755 | Superior mesenteric artery | |||
thoracic aorta | artery | part of the aorta located in the thorax | A07.231.114.056.372 | |||
ulnar artery | artery | A07.231.114.920 | ||||
Umbilical artery | artery | A07.231.114.929 | ||||
vertebral artery | artery | A07.231.114.839 | Arteria vertebralis |
bone
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
auditory ossicle | bone | bone | A09.246.397.247 | Ossicles | ||
cervical vertebra | bone | vertebra | A02.835.232.834.151 | Cervical vertebrae | ||
clavicle | bone | plain bone of short length that serves as a strut between the scapula and the sternum | A02.835.232.087.227 | Clavicula | ||
ethmoid bone | bone | bone | bone in the skull that separates the nasal cavity from the brain | A02.835.232.781.292 | Ethmoid bones | |
femur | bone | bone long bone |
most proximal bone of the leg for tetrapode vertebrates, longest bone for humans | A02.835.232.043.650.247 | Femur | |
hip bone | bone flat bone |
flat bone | bone of the pelvis | A02.835.232.043.825.434 | Hip bone | |
ilium | bone | A02.835.232.611.434 | Ilium | |||
incus | bone | auditory ossicle | bone in the middle ear | A09.246.397.247.362 | Incus | |
ischium | bone | lower and back part of the hip bone | A02.835.232.611.548 | Ischium | ||
malleus | bone | auditory ossicle | bone of the middle ear- handle of malleus 5 mm, head of malleus -2 mm | A09.246.397.247.524 | Malleus | |
occipital bone | bone flat bone |
bone | saucer-shaped membrane bone situated at the back and lower part of the cranium | A02.835.232.781.572 | Occipital bones | |
parietal bone | bone flat bone |
bone | bones in the human skull which, when joined together, form the sides and roof of the cranium | A02.835.232.781.651 | Parietal bones | |
pubic bone | bone | the ventral and anterior of the three principal bones composing either half of the pelvis | A02.835.232.611.781 | Pubis | ||
radius | bone | arm bone | one of the two long bones of the forearm | A02.835.232.087.090.700 | Radius (bone) | |
sacrum | bone | bone | bone of the pelvis | A02.835.232.834.717 | Sacrum | |
scapula | bone flat bone |
bone | bone that connects the humerus (upper arm bone) with the clavicle (collar bone) | A02.835.232.087.783 | Scapula | |
stapes | bone | auditory ossicle | bone of the middle ear | A09.246.397.247.806 | Stapes | |
thoracic vertebra | bone | vertebra | vertebrae between the cervical vertebrae and the lumbar vertebrae | A02.835.232.834.892 | Thoracic vertebrae | |
vomer | bone flat bone |
bone | facial bone | A02.835.232.781.324.971 | Vomer |
bovine disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
bovine malignant catarrhal fever | bovine disease infectious disease |
bovine disease | cattle disease | C02.256.466.606 C22.196.540 |
Bovine malignant catarrhal fever | |
foot rot | bovine disease sheep disease goat disease |
animal disease | C22.394 | |||
infectious bovine rhinotracheitis | bovine disease infectious disease |
bovine disease | Human disease | C02.256.466.488 C22.196.429 |
||
mastitis in dairy cattle | bovine disease | bovine disease | inflammation of the udder in cows | C22.196.581 | Mastitis in animals | |
milk fever | bovine disease | animal disease | A disease of pregnant and lactating cows and ewes leading to generalized paresis and death. The disease, which is characterized by hypocalcemia, occurs at or shortly after parturition in cows and within weeks before or after parturition in ewes. | C22.695 | Hypocalcemia in ruminants | |
rinderpest | bovine disease | Morbillivirus infectious disease animal disease |
disease (caused by the virus in Q2153407) | C02.782.580.600.500.700 C22.780 |
Rinderpest |
brain region
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
caudate nucleus | brain region | A08.186.211.730.885.105.487.550.184 | Caudate nucleus | |||
cerebellum | brain region | anatomical structure | a region of the brain that coordinates motor functions and muscle tone | A08.186.211.132.810.428.200 | Cerebellum | |
cerebrum | brain region | large part of the brain containing the cerebral cortex (of the two cerebral hemispheres), as well as several subcortical structures, including the hippocampus, basal ganglia, and olfactory bulb | A08.186.21.730.885 | Cerebrum | ||
frontal lobe | brain region | cerebral lobe | part of the brain | A08.186.211.730.885.213.270 | Frontal lobe | |
globus pallidus | brain region | sub-cortical structure of the brain | A08.186.211.730.885.105.487.397 | Globus pallidus | ||
mesencephalon | brain region | A08.186.211.132.659 | Mesencephalon | |||
parietal lobe | brain region | cerebral lobe | part of the brain | A08.186.211.730.885.213.670 | Parietal lobe | |
prefrontal cortex | brain region | part of brain | A08.186.211.730.885.213.270.700 | Prefrontal cortex | ||
subthalamus | brain region | part of diencephalon | A08.186.211.730.385.800 | Subthalamus | ||
temporal lobe | brain region | cerebral lobe | part of the brain | A08.186.211.730.885.213.863 | Temporal lobe | |
thalamus | brain region | part of diencephalon, which is in turn part of prosencephalon (forebrain) | A08.186.211.730.385.826 | Thalamus |
branch of science
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
biology | branch of science academic discipline |
natural science | study of life | G | Biology | |
education | branch of science | service | learning in which knowledge and skills is transferred through teaching | I | Education |
cat disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
feline leukemia | cat disease cancer in cats |
cat disease leukemia |
cat disease | C02.782.815.622 C04.557.337.385 C22.180.500 |
Feline leukaemia | |
sparganosis | cat disease disease infectious disease |
parasitic helminthiasis infectious disease zoonosis Q4505372 lung disease urinary system disease orbital disease brain disease breast disease inner ear disease |
Helminthiasis | C03.335.190.304.780 |
chemical compound
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Agglutinin | chemical compound | Immunologic Factors | chemical compound | D27.505.696.477.136 | ||
alkylating agent | chemical compound | Noxae mechanism of action |
Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. | D27.505.519.124 D27.888.569.035 |
||
Chemosterilant | chemical compound | pesticide | chemical compound | D27.888.723.141 D27.720.031.700.141 |
||
crystal violet | chemical compound drug |
chemical compound for for microbiological staining | D02.092.146.400 | Methyl violet | ||
omeprazole | chemical compound drug heterocyclic compound essential medicine |
Proton-pump inhibitor | medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome.[ | D02.886.640.074.500 D03.383.725.024.500 D03.633.100.103.034.500 |
Omeprazole | |
phencyclidine | chemical compound heterocyclic compound |
chemical compound | D03.383.621.699 | Phencyclidine | ||
skatole | chemical compound | chemical compound | D03.633.100.473.808 | |||
warfarin | chemical compound drug flammable solid essential medicine |
anticoagulant | medication that is used as an anticoagulant | D03.438.150.446.520.914 D03.830.219.446.520.914 |
Warfarin |
clinical sign
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Hyperesthesia | clinical sign | Sensory processing disorder somatosensory disorder |
C10.597.751.791.450 C23.888.592.763.770.450 |
|||
photophobia | clinical sign | vision disorder photosensitivity |
medical condition | C10.597.751.941.661 C11.966.741 C23.888.592.763.941.661 |
||
Sister Mary Joseph nodule | clinical sign | metastasis abdominal cancer |
C04.588.033.740 |
cranial nerve
[edit]
developmental defect during embryogenesis
[edit]
disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
abducens nerve palsy | disease | cranial nerve palsy paralytic squint |
non-neoplastic or neoplastic disorder affecting the abducens nerve (sixth cranial nerve) | C10.292.150 | Sixth nerve palsy | |
abetalipoproteinemia | disease developmental defect during embryogenesis |
hypolipoproteinemia autosomal recessive metabolic cerebellar ataxia metabolic disease with dementia metabolic disease with intestinal involvement hypobetalipoproteinemia neurometabolic disease developmental anomaly of metabolic origin syndromic dyslipidemia constitutional hemolytic anemia due to acanthocytosis rare hereditary metabolic disease with peripheral neuropathy metabolic disease with pigmentary retinitis intestinal disease due to fat malabsorption |
Human disease | C16.320.565.398.500.440.500 C18.452.584.500.875.440.500 C18.452.648.398.500.440.500 |
Abetalipoproteinemia | |
abrasion | disease | tooth wear | C07.793.818.124 | Dental abrasion | ||
abscess | disease infectious disease |
suppuration | localized collection of pus that has built up within the tissue of the body | C01.539.830.025 C23.550.470.756.100 |
Abscesses | |
Absent radius-anogenital anomalies syndrome | disease developmental defect during embryogenesis |
Radial aplasia dysostosis of genetic origin with limb anomaly as a major feature syndrome with limb reduction defects |
human disease | C535281 | ||
Acanthamoeba keratitis | disease | keratitis | Human disease | C03.300.125 C03.752.049.203 C11.204.564.112 C11.294.725.125 |
||
acanthosis nigricans | disease | pigmentation disease | Human disease | C17.800.621.430.530.100 | Acanthosis nigricans | |
acariasis | disease infectious disease |
parasitic ectoparasitic infectious disease | parasitic ectoparasitic infectious disease that involves infestation of mites belonging to the family Sarcoptidae, Trombiculidae and Demodicidae | C03.858.211.480 | ||
Accelerated phase chronic myelogenous leukemia | disease | disease | C04.557.337.539.250.300 C15.378.190.636.370.300 |
|||
achalasia | disease | esophageal disease | esophageal disease characterized by an inability of the esophagus to move food toward the stomach resulting from the lower esophogeal sphincter not fully relaxing during swallowing | C06.405.117.119.500.432 | Achalasia | |
achondroplasia | disease dwarfism |
osteochondrodysplasia | an osteochondrodysplasia that results in dwarfism which has material basis in abnormal ossification of cartilage in located in long bone. | C05.116.099.343.110 C05.116.099.708.017 C16.320.240.500 |
Achondroplasia | |
achromatopsia | disease | monochromacy color blindness |
color blindness that is characterized by a congenital cone color vision disorder, the inability to perceive color and to achieve satisfactory visual acuity at high light levels has material basis in autosomal recessive inheritance | C10.597.751.941.256 C11.966.256 C23.888.592.763.941.256 |
Achromatopsia | |
acid erosion | disease | teeth hard tissue disease tooth wear |
loss of tooth structure due to chemical dissolution by acids not of bacterial origin | C07.793.818.500 | Acid erosion | |
acne | disease | sebaceous gland disease | sebaceous gland's disease characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring. | C17.800.030.150 C17.800.794.111 |
Acne | |
acoustic neuroma | disease | neurilemmoma | Human disease | C04.557.465.625.650.595.610 C04.557.580.600.610.595.610 C04.557.580.625.650.595.610 C04.588.614.300.015 C04.588.614.596.240.015 C09.218.807.800.675 C09.647.675 C10.292.225.750 C10.292.910.600 |
Vestibular schwannoma | |
acrocephalosyndactylia | disease | synostosis craniosynostosis syndactyly |
group of diseases | C05.116.099.370.894.232.015 C05.116.099.370.894.819.100 C05.660.207.240.100 C05.660.585.800.100 C05.660.906.364.100 C05.660.906.819.100 C16.131.621.207.240.100 C16.131.621.585.800.100 C16.131.621.906.364.100 C16.131.621.906.819.100 |
||
Acrodynia | disease | occupational disease rare intoxication |
C10.668.829.025 C10.720.475.600.150 C25.723.647.500.100 |
|||
acromegaly | disease | hyperpituitarism | Human disease / micro cephaly opposite | C05.116.132.082 C10.228.140.617.738.250.100 C19.700.355.179 |
Acromegaly | |
actinic keratosis | disease | pre-malignant neoplasm | Human disease | C04.834.450 C17.800.428.570 |
Actinic keratosis | |
actinomycosis | disease infectious disease |
commensal bacterial infectious disease respiratory system disease bacterial infectious disease |
Human disease | C01.252.410.040.137 | Actinomycosis | |
acute abdomen | disease | abdominal pain | medical term for sudden, severe abdominal pain of unclear origin | C10.597.617.044.200 C23.888.592.612.054.200 C23.888.821.030.249 |
Acute abdomen | |
acute cystitis | disease | cystitis | human and animal infection | C01.539.895 C12.777.892 C13.351.968.892 |
Infectious diseases and disorders of the urinary system | |
acute disseminated encephalomyelitis | disease | encephalomyelitis | An encephalomyelitis characterized by inflammation located in brain and located in spinal cord that damages myelin. It usually occurs after viral infection, but also following vaccination, bacterial or parasitic infection. | C10.114.375.225 C10.228.140.695.562.225 C10.314.350.225 C20.111.258.250.350 |
||
acute intermittent porphyria | disease | acute porphyria porphyria |
human disease | C06.552.830.150 C16.320.850.742.150 C17.800.827.742.150 C18.452.811.400.150 |
||
Acute interstitial pneumonitis | disease | adult respiratory distress syndrome interstitial lung disease idiopathic interstitial pneumonia |
Human disease | C08.381.765 | Acute interstitial pneumonia | |
acute kidney injury | disease | kidney failure | abrupt loss of kidney function that develops within 48 hours | C12.777.419.780.050 C13.351.968.419.780.050 |
Acute kidney injury | |
acute myeloid leukemia | disease | myeloid leukemia | myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells | C04.557.337.539.275 | Acute myeloid leukemia | |
acute porphyria | disease | Hepatic porphyria porphyria |
porphyria that has symptom abdominal pain, has symptom neuropathy, has symptom autonomic instability and has symptom psychosis | C06.552.830 C16.320.850.742 C17.800.827.742 C18.452.811.400 |
||
acute promyelocytic leukemia | disease | acute myeloid leukemia bilineal acute myeloid leukemia |
acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17 | C04.557.337.539.275.700 | ||
acute stress disorder | disease | anxiety disorder | human disease | C23.550.470.099 | ||
adenocarcinoma | disease | carcinoma | carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue | C04.557.470.200.025 | Adenocarcinomas | |
Adenoid cystic carcinoma | disease | cancer Cylindroma adenocarcinoma |
adenoid cystic carcinoma | C04.557.470.200.025.220 | Adenoid cystic carcinoma | |
adenoma | disease | cell type benign neoplasm | cell type benign neoplasm that is composed of epithelial tissue in which tumor cells form glands or glandlike structures | C04.557.470.035 | Adenomas | |
Adenovirus infection | disease | Human disease | C02.256.076 C02.256.076.045 |
|||
Adie syndrome | disease | syndrome | Human disease | C10.177.045 C10.292.562.700.250 C11.590.436.200 C11.710.800.180 |
Adie syndrome | |
adiposis dolorosa | disease | lipomatosis subcutaneous tissue disease |
Human disease | C17.800.463.249 C18.452.584.718.500 |
||
adrenal adenoma | disease | endocrine organ benign neoplasm adrenal gland disease benign epithelial neoplasm benign neoplasm of adrenal gland |
endocrine organ benign neoplasm, a benign tumor of the glandular type (adenoma) in the adrenal gland | C04.588.322.078.265.500 | ||
adrenocortical carcinoma | disease | adrenal cortex cancer | adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells | C04.557.470.200.025.152 C04.588.322.078.265.750 C19.053.098.265.750 C19.053.347.500.750 C19.344.078.265.750 |
Adrenocortical carcinoma | |
adult Refsum disease | disease | lipid metabolism disorder autosomal recessive metabolic cerebellar ataxia |
Human disease | C10.228.140.163.100.813 C10.500.300.780 C10.574.500.495.780 C10.668.829.800.300.780 C16.131.666.300.780 C16.320.400.375.780 C16.320.565.189.813 C16.320.565.663.760 C18.452.132.100.813 C18.452.648.189.813 C18.452.648.663.760 |
Refsum disease | |
adult respiratory distress syndrome | disease | respiratory failure pulmonary injury acute respiratory insufficiency |
Human disease | C08.381.840 C08.618.840 |
Acute respiratory distress syndrome | |
adult-onset Still's disease | disease Designated intractable/rare diseases |
Still's disease arthritis collagen disease |
arthritis that is a rare from of inflammatory arthritis characterized by fevers, rash, and joint pain | C05.550.114.154.870 C05.799.114.870 C17.300.775.099.870 C20.111.199.870 |
||
advanced sleep phase syndrome | disease | sleep disorder obsolete chronobiology disease |
sleep disorder that involves an altered circadian rhythm resulting in falling asleep in early evening and awaking very early in the morning | C10.281.800 C10.886.425.200 C24.900 |
||
African horse sickness | disease infectious disease |
horse disease | insect-borne reovirus infection of horses, mules and donkeys in Africa and the Middle East; characterized by pulmonary edema, cardiac involvement, and edema of the head and neck | C02.081.030 C02.782.791.142 C22.488.088 |
||
agammaglobulinemia | disease | B cell deficiency | B cell deficiency that is caused by a reduction in all types of gamma globulins | C15.378.147.142 C15.604.515.032 C20.673.088 |
||
age related macular degeneration | disease Maculopathy |
degeneration of macula and posterior pole visual impairment |
degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision | C11.768.585.439 | Macular degeneration | |
agenesis of the corpus callosum | disease | genetic nervous system disorder genetic disease |
disease | C10.500.034 C16.131.666.034 C23.300.008 |
Agenesis of the corpus callosum | |
Aggressive fibromatosis | disease | C04.557.450.565.590.340.410 | Desmoid tumor | |||
agnosia | disease symptom |
communication disorder perceptual disorder |
communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss. | C10.597.606.762.100 C23.888.592.604.764.100 C10.597.606.881.350 C23.888.592.604.882.350 |
Agnosia | |
agranulocytosis | disease | leukopenia | Human disease | C15.378.553.546.184 | ||
Aicardi syndrome | disease developmental defect during embryogenesis |
syndrome genetic syndrome with corpus callosum agenesis/dysgenesis as a major feature X-linked mental retardation nervous system anomaly with eye involvement syndromic developmental defect of the eye cerebral malformation with epilepsy polymalformative genetic syndrome with increased risk of developing cancer |
syndrome that is characterized by absence or underdeveloped tissue connecting the left and right halves of the brain, infantile spasms and chorioretinal lacunae, which are defects in the light-sensitive tissue at the back of the eye | C10.500.034.687 C11.270.019 C16.131.162 C16.131.666.034.687 C16.320.290.019 C16.320.322.030 |
||
ainhum | disease | connective tissue disease foot disease genetic disease |
Human disease | C05.116.264.143 | Ainhum | |
air embolism | disease | embolism barotrauma |
vascular blockage by air bubbles | C14.907.355.350.254 | ||
akinetic mutism | disease | brain disease | brain disease characterized by marked reduction of nearly all motor functions including facial expressions, gestures and speech output, but with some degree of alertness | C10.228.140.042 | ||
Alagille syndrome | disease | liver disease | congenital disorder of digestive system | C06.130.120.135.250.125 C06.552.150.125 C14.240.400.044 C16.131.077.065 C16.131.240.400.044 C16.320.051 |
||
alex cannon | disease developmental defect during embryogenesis |
autosomal recessive disease genetic photodermatosis polymalformative genetic syndrome with increased risk of developing cancer inherited skin tumor tumor of hematopoietic and lymphoid tissues Photodermatosis rare genetic developmental defect during embryogenesis malformation syndrome with short stature developmental anomaly of metabolic origin rare genetic hematologic disease DNA repair defect other than combined T-cell and B-cell immunodeficiencies |
Don't sub at YT cannon | C16.131.077.137 C18.452.284.100 |
Bloom's syndrome | |
Alexander disease | disease Designated intractable/rare diseases |
leukodystrophy genetic neurodegenerative disease eye degenerative disease |
congenital disorder of nervous system | C10.228.140.163.100.362.312 C10.228.140.695.625.312 C10.314.400.312 C10.574.500.024 C16.320.400.024 C16.320.565.189.362.312 C18.452.132.100.362.312 C18.452.648.189.362.312 |
Alexander disease | |
Alice in Wonderland syndrome | disease | Dysmetropsia | disorienting neurological condition | C10.228.140.546.399.750.124 C10.597.606.762.150 C10.597.751.941.036 C23.888.592.604.764.150 C23.888.592.763.941.036 F01.700.750.150 |
||
Alien hand syndrome | disease | Eetu on homo | neuropsychiatric disorder | C10.597.606.881.350.099 C23.888.592.604.882.350.099 |
||
alkaptonuria | disease | amino acid metabolic disorder tyrosinemia other metabolic disease with skin involvement pigmented conjunctival lesion |
amino acid metabolic disorder that involves phenylalanine and tyrosine metabolism with the accumulation of homogentisic acid, a toxic tyrosine byproduct | C16.320.565.100.187 C18.452.648.100.187 |
Alkaptonuria | |
allergic bronchopulmonary aspergillosis | disease infectious disease |
aspergillosis respiratory allergy rare allergic respiratory disease lung disease |
An aspergillosis that involves an allergic reaction due to the spores of Aspergillus moulds (A. fumigatus), which colonizes the mucus in the airways causing inflammation. The disease has symptom cough, has symptom wheezing and has symptom fever. | C01.703.080.074 C01.703.080.768.500 C01.703.295.328.249.074 C01.703.534.045.074 C08.381.472.850.500 C08.674.060 C08.730.435.090 C17.800.838.208.416.249.074 C20.543.480.680.085 |
Allergic bronchopulmonary aspergillosis | |
allergic conjunctivitis | disease | chronic conjunctivitis | chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant | C11.187.183.200 C20.543.480.200 |
Allergic conjunctivitis | |
allergic rhinitis | disease | rhinitis | Human disease | C08.460.799.315 C08.674.453 C09.603.799.315 C20.543.480.680.443 |
Allergic rhinitis | |
Alpers' disease | disease | cerebellar degeneration mitochondrial DNA depletion syndrome |
cerebral degeneration that results in progressive degeneration of grey matter in the cerebrum and has symptom convulsions | C10.114.375.112 C10.228.140.400 C10.228.140.695.562.112 C10.314.350.112 C20.111.258.250.175 |
||
alpha 1-antitrypsin deficiency | disease | plasma protein metabolism disease rare metabolic liver disease lung disease rare genetic respiratory disease nephropathy secondary to a storage or other metabolic disease other inborn metabolic disease |
Human disease | C06.552.074 C08.381.112 C16.320.060 C23.550.325.500.500 |
Alpha 1-antitrypsin deficiency | |
alpha thalassemia | disease | thalassemia hematological disorder with renal involvement alpha-thalassemia and related diseases |
Alpha thalassemia is a thalassemia involving the genes HBA1and HBA2 hemoglobin genes | C15.378.071.141.150.875.100 C15.378.420.826.100 C16.320.070.875.100 C16.320.365.826.100 |
||
alpha-mannosidosis | disease developmental defect during embryogenesis |
lysosomal storage disease Mannosidosis neurometabolic disease oligosaccharidosis rare genetic developmental defect during embryogenesis lysosomal storage disease with skeletal involvement metabolic disease with cataract metabolic disease with corneal opacity cataract associated with a metabolic disease |
lysosomal storage disease that has material basis in deficiency of the alpha-D-manosidase enzyme resulting in the impairment of cell function from a build up of complex sugars derived from glycoproteins in the lysosome | C16.320.565.202.607.500 C16.320.565.595.577.500 C18.452.648.202.607.500 C18.452.648.595.577.500 |
Alpha-mannosidosis | |
Alport syndrome | disease | monogenic disease genetic disease |
monogenic disease characterized by glomerulonephritis, endstage kidney disease, and hearing loss | C12.706.742 C12.777.419.570.620 C13.351.875.742 C13.351.968.419.570.620 C16.131.939.742 C17.300.200.517 |
Alport syndrome | |
alveolar osteitis | disease | periostitis | human disease | C07.465.227 | ||
amblyopia | disease | eye disease visual impairment |
Human disease | C10.228.140.055 C10.597.751.941.073 C11.966.073 C23.888.592.763.941.073 |
Amblyopia | |
amebiasis | disease infectious disease |
parasitic protozoa infectious disease protozoal dysentery Amoebozoa infectious disease |
human protozoa disease | C03.752.049 C03.752.049.407 |
Amoebiasis | |
ameloblastoma | disease head and neck disease |
cell type benign neoplasm odontogenic tumor benign epithelial neoplasm |
cell type benign neoplasm that has material basis in odontogenic epithelium | C04.557.695.065 | Ameloblastoma | |
amelogenesis imperfecta | disease | dental enamel hypoplasia | dental enamel hypoplasia characterized by abnormal enamel formation | C07.650.800.255.500 C07.793.700.255.500 C16.131.850.800.255.500 |
Amelogenesis imperfecta | |
amenorrhea | disease | female reproductive system disease menstrual disorder |
absence of a menstrual period in a woman of reproductive age | C23.550.568.500 | ||
Amino acid transport disorder | disease | Congenital disorders of amino acid metabolism | Human disease | C16.320.565.151 C18.452.648.151 |
||
amyloidosis | disease | acquired metabolic disease systemic disease proteostasis deficiency |
acquired metabolic disease that involves abnormal deposited of amyloid proteins in organs and/or tissues | C18.452.845.500 | Amyloidosis | |
amyotrophic lateral sclerosis | disease Designated intractable/rare diseases |
motor neuron disease TDP-43 Proteinopathies neurodegeneration |
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord | C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050 |
Amyotrophic lateral sclerosis | |
anal fistula | disease | rectal disease | anus disease characterized by is an abnormal connection between the epithelialised surface of the anal canal and the perianal skin | C06.267.550.600 C06.405.469.471.600 C06.405.469.860.752 C23.300.575.185.550.600 |
Anal fistula | |
Anaplastic astrocytoma | disease | astrocytoma | astrocytoma that is characterized by cells with regular, round to oval nuclei | C04.557.465.625.600.380.080 C04.557.470.670.380.080 C04.557.580.625.600.380.080 |
||
Anaplastic large-cell lymphoma | disease | T-cell lymphoma non-Hodgkin lymphoma |
non-Hodgkin lymphoma involving aberrant T-cells | C04.557.386.480.750.399 C15.604.515.569.480.750.600 C20.683.515.761.480.750.399 |
||
anasarca | disease | medical condition characterized by widespread swelling | C23.888.277 | |||
Andersen-Tawil syndrome | disease | long QT syndrome muscular channelopathy genetic peripheral neuropathy periodic paralysis genetic cardiac rhythm disease |
Human disease | C14.280.067.565.070 C16.131.240.400.715.070 C23.550.073.547.070 |
||
androgen insensitivity syndrome | disease | pseudohermaphroditism sex differentiation disease |
sex differentiation disease that is characterized by the partial or complete inability of the cell to respond to androgens in individuals with a karyotype of 46,XY resulting in female physical traits but male genetic makeup | C12.706.316.096.500 C13.351.875.253.096.500 C16.131.939.316.096.500 C16.320.322.061 C19.391.119.096.500 |
Androgen insensitivity syndrome | |
anencephaly | disease | cephalic disorder | absence of a major portion of the brain, skull, and scalp that occurs during embryonic development | C10.500.680.196 C16.131.085.197 C16.131.666.680.196 |
Anencephaly | |
aneurysm | disease | vascular disease | bulge in the wall of a blood vessel | C14.907.055 | Aneurysms | |
Angelman syndrome | disease Designated intractable/rare diseases developmental defect during embryogenesis |
chromosomal disease rare genetic syndromic intellectual disability organic brain syndrome chromosomal anomaly with epilepsy as a major feature |
Human disease | C10.228.662.075 C16.131.077.095 C16.131.260.040 C16.320.180.040 |
Angelman syndrome | |
angiodysplasia | disease | vascular disease | vascular disease that is characterized as a small vascular malformation of the gut | C14.907.075 | ||
angioedema | disease | skin disease vascular skin disease urticaria |
skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues | C14.907.079 C17.800.862.945.066 C20.543.480.904.066 |
Angioedema | |
angiokeratoma | disease | skin hemangioma | Human disease | C04.557.645.115 | Angiokeratoma | |
Angiomatosis | disease | capillary disease angioma |
a benign vascular malformation involving skin, subcutaneous tissue, skeletal muscle and occasionally bone. | C14.907.077 | ||
angiomyolipoma | disease | cell type benign neoplasm | cell type benign neoplasm that from perivascular epithelioid cells | C04.557.450.550.125 C04.557.450.692.249 |
Renal angiomyolipoma | |
angular cheilitis | disease | cheilitis | cheilitis characterized by inflammation of one or both of the corners of the mouth | C07.465.409.215 | Angular cheilitis | |
anhidrosis | disease | sweat gland disease hypohidrosis |
Human disease | C17.800.946.370 | ||
aniridia | disease | iris disease | Human disease | C11.250.060 C11.270.060 C11.941.375.060 C16.131.384.079 C16.320.290.078 |
Aniridia | |
aniseikonia | disease | refractive error Dysmetropsia |
Human disease | C11.744.116 | ||
anisometropia | disease | refractive error | Human disease | C11.744.126 | ||
ankyloglossia | disease | tongue disease genetic nervous system disorder genetic disease |
congenital disorder of digestive system | C07.160 | Ankyloglossia | |
ankylosis | disease | arthropathy joint stiffness |
Human disease | C05.550.069 | Ankylosis | |
anodontia | disease | tooth disease agenesis tooth agenesis |
Human disease | C07.650.800.100 C07.793.700.100 C16.131.850.800.100 |
||
anogenital venereal wart | disease infectious disease |
vaginal disease anus disease herpangina penile disease cervix disease Sexually Transmitted Diseases, Viral |
sexually transmitted disease | C02.256.650.810.217 | Genital warts | |
anomalous left coronary artery from the pulmonary artery | disease thoracic disease |
coronary artery anomaly arterio-arterial fistula |
coronary artery anomaly in which the left coronary artery (LCA) branches off the pulmonary artery instead of the aortic sinus | C14.240.400.210.249 C14.240.850.984.500.500 C14.280.400.210.249 C14.907.933.110.500 C16.131.240.400.210.249 C16.131.240.850.500.500 C23.300.575.950.150.500 |
Anomalous left coronary artery from the pulmonary artery | |
anterior compartment syndrome of the lower leg | disease | compartment syndrome | disease | C05.651.180.063 C14.907.303.063 |
||
anterior ischemic optic neuropathy | disease | optic nerve disease ischemic neuropathy ischemic optic neuropathy |
Human disease | C10.292.700.600 C11.640.643 C14.907.601 |
||
anterior spinal artery syndrome | disease | syndrome cerebrovascular disease vascular myelopathy |
Human disease | C10.228.854.785.650.100 C14.907.790.550.100 |
||
anterograde amnesia | disease | amnesia | loss of the ability to create new memories after the onset of amnesia | C10.597.606.525.100.075 C23.888.592.604.529.100.075 |
||
anthracosilicosis | disease | pneumoconiosis | Human disease | C08.381.483.581.062.500 C08.381.483.581.760.125 C08.381.520.702.062.500 C08.381.520.702.760.125 C24.800.834.201 |
||
anthracosis | disease | occupational disease pneumoconiosis |
Human disease | C08.381.483.581.062 C08.381.520.702.062 |
||
antiphospholipid syndrome | disease | autoimmune disease | Human disease | C20.111.197 | ||
Antley-Bixler syndrome | disease developmental defect during embryogenesis |
autosomal recessive disease multiple congenital anomalies/dysmorphic syndrome-variable intellectual disability syndrome syndromic craniosynostosis |
autosomal recessive disease that is characterized at birth or prenatally by malformations and deformities affecting the majority of the skeleton and other areas of the body with autosomal recessive inheritance of the FGFR2 gene | C05.116.099.370.894.115 C05.660.906.181 C16.131.621.906.181 C16.320.565.925.324 C18.452.648.925.324 |
||
anuria | disease | kidney disease | Human disease | C12.777.419.078 C12.777.934.141 C13.351.968.419.078 C13.351.968.934.070 |
||
anus cancer | disease | large intestine cancer anus disease anal canal cancer |
large intestine cancer that is located in the anus | C04.588.274.476.411.307.790.040 C06.301.371.411.307.790.040 C06.405.249.411.307.790.040 C06.405.469.491.307.790.040 C06.405.469.860.101.163 C06.405.469.860.180.500.040 |
Anal cancer | |
anus disease | disease | rectal disease | Human disease | C06.405.469.860.101 C06.405.469.860.101.430 |
Anal fissure | |
aortic aneurysm | disease | aortic disease aneurysm |
orta to greater than 1.5 times normal size. | C14.907.055.239 C14.907.109.139 C14.907.055.185.125 C14.907.055.239.175 C14.907.109.139.175 C26.761.125 |
Aortic aneurysms | |
aortic valve insufficiency | disease | aortic valve disease | aortic valve disease that is characterized by leaking of the aortic valve of the heart causes blood to flow in the reverse direction during ventricular diastole, from the aorta into the left ventricle | C14.280.484.095 | Aortic valve insufficiency | |
aortic valve stenosis | disease developmental defect during embryogenesis |
aortic valve disease aortic disease |
aortic valve disease that has physical basis in incomplete opening of the aortic valve | C14.280.484.150 C14.280.955.249 |
Aortic valve stenosis | |
aortitis | disease | aortic disease | inflammation of the aortic wall | C14.907.109.320 C14.907.940.080 |
||
Aortoiliac occlusive disease | disease | peripheral artery disease | C14.907.109.661 C14.907.137.427 |
Aortoiliac occlusive disease (Leriche syndrome) | ||
Apert syndrome | disease | acrocephalosyndactylia | congenital disorder of digestive system | C05.116.099.370.894.232.015 C05.116.099.370.894.819.100 C05.660.207.240.100 C05.660.585.800.100 C05.660.906.364.100 C05.660.906.819.100 C16.131.621.207.240.100 C16.131.621.585.800.100 C16.131.621.906.364.100 C16.131.621.906.819.100 |
Apert syndrome | |
aphthous stomatitis | disease | stomatitis | stomatitis characterized by the repeated formation of benign and non-contagious mouth ulcers | C07.465.864.750 | Aphthous ulcer | |
aplastic anemia | disease Designated intractable/rare diseases |
anemia bone marrow failure rare constitutional anemia |
anemia that is characterized by a deficiency of red blood cells, white blood cells and platelets produced by bone marrow | C15.378.071.085 C15.378.190.196 |
Aplastic anemias | |
apparent life-threatening event syndrome | disease | cyanosis | C08.618.846.600 C23.888.248.500 C23.888.852.700 |
|||
appendicitis | disease colonic disease |
cecal disease intraabdominal infection |
inflammation of the appendix | C01.539.463.099 C06.405.205.099 C06.405.469.110.207 |
Appendicitis | |
apraxia | disease symptom |
agnosia | agnosia that is a loss of the ability to map out physical actions in order to repeat them in functional activities | C10.597.606.881.350 C23.888.592.604.882.350 |
||
Arachnoid cyst | disease developmental defect during embryogenesis |
Central nervous system cyst central nervous system cystic malformation |
Human disease | C04.182.044 C04.588.614.250.387.100 C10.500.142.100 C10.551.240.375.100 C16.131.666.142.100 |
Arachnoid cyst | |
arcus senilis | disease | corneal degeneration rare genetic eye disease genetic disease |
Human disease | C11.204.299.070 | Arcus senilis | |
argininosuccinic aciduria | disease | amino acid metabolic disorder | amino acid metabolic disorder that involves the accumulation of argininosuccinic acid (ASA) in the blood and urine | C10.228.140.163.100.937.124 C16.320.565.100.940.124 C16.320.565.189.937.124 C18.452.132.100.937.124 C18.452.648.100.940.124 C18.452.648.189.937.124 |
||
argyria | disease | abnormal skin coloration rare intoxication |
medical condition | C17.800.621.166 C25.723.068 |
Argyria (illness) | |
arteriosclerosis | disease | artery disease | thickening, hardening and loss of elasticity of the walls of arteries | C14.907.137.126 | Atherosclerosis | |
arteriovenous fistula | disease | fistula simple vascular malformation |
abnormal, epithelial-lined connection between an artery and vein that is present at the time of birth | C14.240.850.750.147 C14.240.850.984.750 C14.907.150.125 C14.907.933.555 C16.131.240.850.750.125 C23.300.575.950.250 C14.240.850.984 C14.907.933 C23.300.575.950 |
Arteriovenous fistula | |
arteriovenous malformation | disease | hemangioma vascular malformation |
vascular anomaly | C14.240.850.750 C14.907.150 C16.131.240.850.750 |
Arteriovenous malformation | |
arthritis | disease arthropathy |
bone inflammation disease inflammatory disease arthropathy |
form of joint disorder that involves inflammation of one or more joints | C05.550.114 | Arthritis | |
arthropathy | disease | joint disorder bone disease |
bone inflammation disease that is located in a joint | C05.550 | Arthropathies | |
arthus reaction | disease | type III hypersensitivity | Human disease | C20.543.520.100 | ||
asbestosis | disease | pneumoconiosis asbestos-related disease |
pneumoconiosis caused by inhalation and retention of asbestos fibers | C08.381.483.581.125 C08.381.520.702.125 C24.800.127 |
Asbestosis | |
ascariasis | disease infectious disease |
nematode infection anthroponotic disease soil-transmitted helminthiasis parasitic helminthiasis infectious disease |
Human disease | C03.335.508.700.100.070 | Ascaris | |
aspergilloma | disease | aspergillosis | C01.703.080.768 C08.381.472.850 |
Aspergilloma | ||
aspergillosis | disease | opportunistic mycosis type I hypersensitivity |
infectious disease of humans, birds and other animals | C01.703.080 C01.703.295.328.249 C01.703.534.045 C17.800.838.208.416.249 |
Aspergillosis | |
Aspermia | disease | C12.294.365.700.126 | ||||
aspiration pneumonia | disease | bacterial pneumonia | bronchopneumonia that develops due to the entrance of foreign materials into the lungs usually oral or gastric contents | C08.381.677.529 C08.730.610.529 |
Aspiration pneumonia | |
asthenopia | disease | eye disease | Human disease | C11.093 | ||
astigmatism | disease | refractive error | refractive error characterized by the optics of the eye to focus a point object into a sharp focused image on the retina, has_symptom blurred vision. | C11.744.212 | Astigmatism (eye) | |
astrocytoma | disease | glioma cerebrum cancer brain astrocytoma |
malignant glioma that is has_material_basis_in astocyte cells, a type of star-shaped glial cell, located_in the cerebrum. | C04.557.465.625.600.380.080 C04.557.470.670.380.080 C04.557.580.625.600.380.080 |
Astrocytic tumors | |
ataxia telangiectasia | disease | autosomal recessive cerebellar ataxia autosomal recessive cerebellar ataxia due to a DNA repair defect |
A disease a rare, neurodegenerative, autosomal recessive human disease causing severe disability. | C10.228.140.252.190.530.060 C10.562.100 C10.597.350.090.500.530.060 C14.907.823.213 C16.320.080 C18.452.284.060 C20.673.290 |
Ataxia telangiectasia | |
atopic dermatitis | disease | dermatitis | A dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking. | C16.320.850.210 C17.800.174.193 C17.800.815.193 C17.800.827.210 C20.543.480.343 |
Atopic dermatitis | |
atrial fibrillation | disease | heart conduction disease | abnormal heart rhythm characterized by rapid and irregular beating | C14.280.067.198 C23.550.073.198 |
Atrial fibrillation | |
atrial heart septal defect | disease birth defect |
heart septal defect | A heart septal defect located in in the septum that separates the two atria of the heart. | C14.240.400.560.375 C14.280.400.560.375 C16.131.240.400.560.375 |
Atrial septal defect | |
atrioventricular block | disease thoracic disease |
heart conduction disease | heart conduction disease that is characterized by the impairment of the conduction between the atria and ventricles of the heart | C14.280.067.558.230 C23.550.073.425.062 |
Atrioventricular block | |
atrioventricular septal defect | disease | heart septal defect | Human disease | C14.240.400.560.350 C14.280.400.560.350 C16.131.240.400.560.350 |
Atrioventricular septal defect | |
atrophic gastritis | disease | gastritis | Human disease | C06.405.205.697.394 C06.405.748.398.394 |
||
atrophy | disease | partial or complete wasting away of a part of the body | C23.300.070 | Atrophy | ||
atypical teratoid rhabdoid tumor | disease | brain cancer | brain cancer that is usually located in the brain, but can occur anywhere in the central nervous system | C04.588.614.250 C10.551.240 |
||
autoimmune hepatitis | disease Designated intractable/rare diseases |
autoimmune disease of gastrointestinal tract hepatitis immune system disease rare parenchymal liver disease |
autoimmune disease of gastrointestinal tract that results in inflammation located in liver caused by the body's immune system attacking the liver cells | C06.552.380.350.050 C20.111.567 |
Autoimmune hepatitis | |
autoimmune lymphoproliferative syndrome | disease | Lymphoproliferative disorders type IV hypersensitivity |
Human disease | C15.604.515.138 C16.320.089 C20.111.288 C20.683.515.124 |
||
autoimmune polyendocrine syndrome | disease | autoimmune disease of endocrine system | autoimmune disease of endocrine system characterized by abnormal functioning of the immune system that causes auto-reactivity against endocrine organs | C19.787 C20.111.750 |
||
autoimmune thrombocytopenic purpura | disease Designated intractable/rare diseases |
primary thrombocytopenia thrombocytopenic purpura |
primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies | C15.378.100.802.687.600 C15.378.140.855.925.750.600 C15.378.463.740 C20.111.759 C20.841.600 C23.550.414.950.687.600 C23.888.885.687.687.600 |
||
autoimmune thyroiditis | disease | autoimmune disease of endocrine system thyroiditis |
autoimmune disease of endocrine system that involves inflammation located in thyroid gland caused by the immune system reacting against its own tissues | C19.874.871.102 C20.111.809 |
||
autosomal dominant cerebellar ataxia | disease | hereditary ataxia late-onset ataxia with dementia nervous system heredodegenerative disease eye degenerative disease cerebellar degeneration |
hereditary ataxia that has material basis in autosomal dominant inheritance | C10.228.140.252.190.530 C10.228.140.252.700.700 C10.228.854.787.875 C10.574.500.825.700 C10.597.350.090.500.530 C16.320.400.780.875 |
||
autosomal recessive congenital ichthyosis | disease | autosomal recessive congenital ichthyosis | congenital skin disease | C16.131.831.512.400.410 C16.320.850.400.410 C16.614.492.400.410 C17.800.428.333.250.410 C17.800.804.512.400.410 C17.800.827.400.410 |
||
azoospermia | disease | male infertility oligospermia |
male infertility disease characterized by the absence of any measurable level of sperm in semen | C12.294.365.700.380 | Azoospermia | |
azotemia | disease | hematopoietic system diseases | abnormally high levels of nitrogen in the blood | C12.777.419.936.231 C13.351.968.419.936.231 C23.550.145 |
||
babesiosis | disease infectious disease |
parasitic protozoa infectious disease | Human disease | C03.701.688.122 C03.752.625.122 C03.752.875.175 C22.674.710.122 |
Babesiosis | |
bacillary angiomatosis | disease | bartonellosis Angiomatosis |
Human disease | C01.252.400.126.100.050 C01.252.825.150 C01.539.800.720.150 C14.907.077.060 C17.800.838.765.150 C17.800.862.060 |
||
bacillus anthracis | disease infectious disease |
primary bacterial infectious disease zoonosis |
acute disease caused by the bacterium Bacillus anthracis. | C01.252.410.090.072 | Anthrax (disease) | |
bacterial infectious disease | disease infectious disease |
infectious disease Bacterial Infections and Mycoses rare infectious disease |
disease caused by bacteria | C01.252.400 C01.252 C01.252.410 |
Diseases and disorders due to bacteria | |
bacterial vaginosis | disease infectious disease |
vaginitis | Smelly vaginal bacteria | C01.252.954 C13.351.500.894.906.800 |
Bacterial vaginosis | |
bacteriuria | disease | urinary system disease | medical term denoting the presence of bacteria in urine | C01.539.895.219 C12.777.892.219 C13.351.968.892.219 |
||
balanitis | disease | penile disease inflammatory disease |
An infectious or non-infectious inflammatory process that affects the glans penis. Symptoms include redness and pain of the glans penis and foreskin and discharge. | C12.294.494.136 | Balanitis | |
baldness | disease hairstyle |
hair disease hypotrichosis alopecia hairstyle hair anomaly |
state where most of hair from the head has been lost | C17.800.329.937.122 C23.300.035 |
Baldness | |
Balkan nephropathy | disease | interstitial nephritis Alport syndrome |
interstitial nephritis endemic to the regions along the Danube river, in the modern countries of Croatia, Bosnia and Herzegovina, Serbia, Romania and Bulgaria | C12.777.419.570.643.150 C13.351.968.419.570.643.150 |
||
Balo concentric sclerosis | disease | demyelinating disease neurodegeneration |
demyelinating disease characterized by the fact that the demyelinated tissues form concentric layers | C10.114.375.112 C10.228.140.400 C10.228.140.695.562.112 C10.314.350.112 C20.111.258.250.175 |
||
Bannayan-Riley-Ruvalcaba syndrome | disease developmental defect during embryogenesis |
autosomal dominant disease multiple hamartoma syndrome inherited digestive tract tumor rare genetic vascular tumor brain cancer complex vascular malformation with associated anomalies rare nervous system tumor multiple congenital anomalies/dysmorphic syndrome-intellectual disability rare genetic syndromic intellectual disability rare genetic skin vascular disorder overgrowth syndrome |
a rare overgrowth syndrome and hamartomatous disorder with occurrence of multiple subcutaneous lipomas, macrocephaly and hemangiomas. | C04.445.435 C04.651.435 C04.700.435 C16.320.700.435 |
||
Bardet-Biedl syndrome | disease | autosomal recessive disease | Human disease | C10.228.140.617.200 C16.131.077.245.125 C16.320.184.125 |
Bardet–Biedl syndrome | |
Barre-Lieou syndrome | disease | syndrome neurological disorder |
syndrome that involves occipital head aches, nystagmus on head movement, tinnitus, spasms, blurred vision, corneal hyperaesthesia, and corneal ulcers | C05.116.900.596 | ||
Barrett's esophagus | disease | esophageal disease | Human disease | C06.198.102 C06.405.117.102 |
Barrett's esophagus | |
Barth syndrome | disease developmental defect during embryogenesis |
lipid metabolism disorder 3-methylglutaconic aciduria syndromic dyslipidemia mitochondrial myopathy constitutional neutropenia with extra-hematopoietic manifestations disorder of phospholipids, sphingolipids and fatty acids biosynthesis with skeletal muscle predominant involvement mitochondrial disease with dilated cardiomyopathy |
lipid metabolism disorder that has material basis in X-linked inheritance of the tafazzin gene and is characterized by decreased production of an enzyme required to produce cardiolipin | C14.240.400.172 C14.280.400.172 C16.131.077.121 C16.131.240.400.172 C16.320.322.068 C16.320.565.398.224 C18.452.648.398.224 |
Barth syndrome | |
bartonellosis | disease infectious disease |
primary bacterial infectious disease | primary bacterial infectious disease that is caused by the bacteria of the genus Bartonella | C01.252.400.126.100 | ||
Bartter disease | disease | renal tubular transport disease | Human disease | C12.777.419.815.279 C13.351.968.419.815.279 C19.053.800.604.249 |
||
basal-cell carcinoma | disease | skin cancer skin carcinoma |
A subtype of basal-cell carcinoma most commonly occurring on the sun-exposed areas of the head and neck | C04.557.470.200.165 C04.557.470.565.165 C04.557.470.565 |
Basal-cell carcinoma | |
Beckwith-Wiedemann syndrome | disease | syndrome overgrowth syndrome |
syndrome characterized by overgrowth (macrosomia), an increased risk of childhood cancer and congenital malformations | C16.131.077.133 C16.131.260.080 C16.320.180.080 |
||
Behcet's disease | disease Designated intractable/rare diseases |
vasculitis secondary glomerular disease rare skin disease systemic diseases with anterior uveitis systemic diseases with posterior uveitis systemic diseases with panuveitis autoinflammatory syndrome with skin involvement vascular skin disease unclassified autoinflammatory syndrome predominantly large-vessel vasculitis inflammatory and autoimmune disease with epilepsy |
rare immune-mediated small-vessel systemic vasculitis in humans | C07.465.075 C11.941.879.780.880.200 C14.907.940.100 C16.320.382.250 C17.800.827.368.250 C17.800.862.150 |
Behçet's disease | |
bejel | disease | treponematosis mouth disease bone disease cellulitis primary bacterial infectious disease |
Human disease | C01.252.400.840 C01.252.847.840 |
Nonvenereal endemic syphilis | |
Bell's palsy | disease | facial paralysis | facial paralysis resulting from dysfunction in the cranial nerve VII (facial nerve) | C02.256.466.087 C07.465.094 C07.465.299.250 C10.292.319.250 |
Bell's palsy | |
benign epilepsy with centrotemporal spikes | disease | childhood electroclinical syndrome | Human disease | C10.228.140.490.360.280 | ||
benign paroxysmal positional nystagmus | disease | peripheral vertigo | disorder arising from a problem in the inner ear | C09.218.568.900.883.500 C10.597.951.500 C23.888.592.958.500 |
||
beriberi | disease | nutritional deficiency disease vitamin B1 deficiency |
Human disease | C18.654.521.500.133.699.827.223 | Beriberi | |
Bernard-Soulier syndrome | disease | Giant platelet disorder inherited blood coagulation disease |
Human disease | C15.378.100.100.080 C15.378.140.120 C15.378.463.080 C16.320.099.080 |
||
berylliosis | disease | pneumoconiosis occupational lung disease |
pneumoconiosis that involves allergic response located in lungs caused by inhalation of beryllium compounds | C08.381.483.581.225 C08.381.520.702.225 C24.800.225 |
Berylliosis | |
beta-mannosidosis. | disease developmental defect during embryogenesis |
lysosomal storage disease Mannosidosis hypertrophic cardiomyopathy lysosomal storage disease with skeletal involvement rare hereditary metabolic disease with peripheral neuropathy lysosomal disease with hypertrophic cardiomyopathy rare genetic developmental defect during embryogenesis oligosaccharidosis |
lysosomal storage disease that has material basis in deficiency of the beta-A-manosidase enzyme resulting in the disruption of N-linked glycoprotein oligosaccharide catabolism. | C16.320.565.202.607.750 C16.320.565.595.577.750 C18.452.648.202.607.750 C18.452.648.595.577.750 |
||
biliary atresia | disease developmental defect during embryogenesis |
cholestasis non-neoplastic bile duct disorder non-syndromic visceral malformation genetic biliary tract disease |
congenital disorder of digestive system investigation of choice of the disease is MRCP | C06.130.120.123 C06.198.125 C16.131.314.125 |
Biliary atresia | |
biliary dyskinesia | disease | gallbladder disease common bile duct disease |
gallbladder disease characterized by altered tonus of the sphincter of Oddi, disturbance in the coordination of contraction of the biliary ducts, and/or reduction in the speed of emptying of the biliary tree | C06.130.120.250.098 | ||
bilirubin metabolic disorder | disease | inherited metabolic disorder hyperbilirubinemia |
inherited metabolic disorder that involves elevated levels of bilirubin resulting from disruption of bilirubin metabolism | C16.320.565.300 C18.452.648.300 C23.550.429 |
||
binasal hemianopsia | disease | hemianopia heteronymous hemianopsia |
C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
Binasal hemianopsia | ||
biotinidase deficiency | disease | multiple carboxylase deficiency disorder of other vitamins and cofactors metabolism and transport rare genetic epilepsy rare hereditary metabolic disease with peripheral neuropathy |
multiple carboxylase deficiency that involves a deficiency in biotinidase | C16.320.565.100.620.100 C16.320.565.202.720.100 C18.452.648.100.620.100 C18.452.648.202.720.100 |
||
Bisphosphonate-associated osteonecrosis of the jaw | disease | Osteonecrosis of the jaw | disease | C05.116.852.087 C05.500.086 C07.320.086 C23.550.717.732.183 |
||
blackwater fever | disease infectious disease |
malaria | Human disease | C03.752.530.650.228 | ||
bladder cancer | disease | urinary system cancer bladder disease |
urinary system cancer that results in malignant growth located in the urinary bladder | C04.588.945.947.960 C12.758.820.968 C12.777.829.813 C13.351.937.820.945 C13.351.968.829.707 |
Bladder urothelial carcinoma | |
Bladder exstrophy | disease | bladder disease bladder exstrophy-epispadias-cloacal exstrophy complex |
congenital disorder of urinary system | C12.706.132 C12.777.829.132 C13.351.875.132 C13.351.968.829.132 C16.131.939.132 |
Bladder exstrophy | |
blastomycosis | disease infectious disease |
primary systemic mycosis | primary systemic mycosis that results in a systemic fungal infection, has material basis in Blastomyces dermatitidis, transmitted by airborne spores and has symptom skin lesions, has symptom lung lesions and has symptom pleural thickening | C01.539.800.200.055 C01.703.295.055 C01.703.534.395 C08.381.472.350 C08.730.435.395 C17.800.838.208.055 |
Blastomycosis | |
blepharitis | disease | eyelid disease eye inflammation inflammatory disease |
eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow | C11.338.133 | Blepharitis | |
blepharophimosis | disease | eyelid disease congenital physical abnormalitie |
Human disease | C11.250.090 C11.338.190 C16.131.384.190 |
||
blepharospasm | disease | focal dystonia cranio-facial dystonia |
focal dystonia that is characterized by the involuntary, forcible contraction of the muscles controlling eye blinks | C11.338.250 | ||
blindness | disease | visual impairment eye disease |
complete or nearly complete vision loss | C10.597.751.941.162 C11.966.075 C23.888.592.763.941.162 |
Visual impairment | |
Bloch-Sulzberger syndrome | disease | pigmentation disease | a genetic disorder that affects the skin, hair, teeth, nails, and central nervous system. | C16.131.077.445 C16.131.831.580 C16.320.850.420 C17.800.621.497 C17.800.804.580 C17.800.827.420 |
Incontinentia pigmenti | |
blood coagulation disease | disease | hematopoietic system diseases | condition in which the blood’s ability to coagulate (form clots) is impaired | C15.378.100 | ||
bone cyst | disease | C04.182.089 C05.116.070 |
Bone cyst | |||
bone inflammation disease | disease | bone disease inflammation |
inflammation of bone | C05.116.680 | ||
bone marrow cancer | disease | bone marrow disease hematologic cancer connective tissue neoplasm |
hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow | C04.588.448.200 C15.378.190.250 C15.378.400.200 C15.378.190.636 |
||
botulism | disease infectious disease |
primary bacterial infectious disease bacterial infectious disease acquired neuromuscular junction disease infectious disease of the nervous system |
human and animal disease | C01.252.410.222.151 C10.668.758.200 C10.720.150 C25.723.415.151 |
Botulism | |
boutonneuse fever | disease | spotted fever | Human disease | C01.252.400.780.790.125 C01.252.400.825.125 |
||
bovine sponginess encephalitic | disease | transmissible spongiform encephalopathy bovine disease |
bovine counterpart to variant Creutzfeldt-Jakob disease | C10.228.228.800.260 C10.574.843.300 C22.196.250 |
Bovine spongiform encephalopathy | |
brachydactyly | disease | dysostosis | A bone development disease characterized by short fingers and toes. | C05.660.585.262 C16.131.621.585.262 |
||
brain disease | disease | central nervous system disease | central nervous system disease that is located in the brain | C10.228.140 | Encephalopathy | |
brain edema | disease | brain disease | human disease | C10.228.140.187 | Cerebral edema | |
breast cancer | disease | thoracic cancer breast disease |
cancer that originates in the mammary gland | C04.588.180 C17.800.090.500 |
Breast cancer | |
breast cyst | disease thoracic disease |
breast benign neoplasm benign mammary dysplasia |
Human disease | C04.182.156 C17.800.090.249 |
||
breast fibroadenoma | disease | breast benign neoplasm | breast benign neoplasm comprised of fibrous and glandoular tissues located in breast | C04.557.450.565.590.595.350 C04.557.470.625.350 |
Breast fibroadenomas | |
breast fibrocystic disease | disease | breast benign neoplasm benign mammary dysplasia |
Human disease | C17.800.090.750 | Mastitis in animals | |
Brill-Zinsser disease | disease | epidemic typhus | epidemic typhus that is a mild form of the disease, which recurs in someone after a long period of latency due to immunosuppression, malnutrition or other illnesses | C01.252.400.780.790.805 | ||
bronchiolitis | disease | lung disease bronchospasm |
human disease | C08.127.446.135 C08.381.495.146.135 C08.730.099.135 C02.109 C08.127.446.135.321 C08.381.495.146.135.321 C08.730.099.135.321 |
Bronchiolitis | |
bronchiolitis obliterans | disease | interstitial lung disease bronchospasm |
lung disease involving obstruction of the bronchioles | C08.127.446.135.140 C08.381.495.146.135.140 |
Bronchiolitis obliterans | |
bronchitis | disease | bronchospasm chronic obstructive pulmonary disease |
type of lower respiratory disease | C08.127.446 C08.381.495.146 C08.730.099 C08.127.446.567 C08.381.495.146.567 C08.381.495.389.500 C08.730.099.567 |
Bronchitis | |
bronchopneumonia | disease infectious disease |
pneumonia | pneumonia involving inflammation of lungs | C08.127.509 C08.381.677.127 C08.730.610.127 |
||
bronchopulmonary dysplasia | disease developmental defect during embryogenesis |
perinatal respiratory disorder non-syndromic respiratory or mediastinal malformation respiratory malformation rare genetic respiratory disease |
Human disease | C08.381.520.750.500 C16.614.521.125 |
Bronchopulmonary dysplasia | |
bronchospasm | disease | lower respiratory tract disease | lower respiratory tract disease that affects the airways leading into the lungs | C08.127 C08.127.321 |
||
Brown-Séquard syndrome | disease | paraplegia | Human disease | C10.597.622.669.300 C23.888.592.636.637.300 |
Brown-Séquard syndrome | |
Brown's tendon sheath syndrome | disease | mechanical strabismus genetic disease |
Human disease | C10.228.758 C10.292.562 C11.590 |
||
brucellosis | disease infectious disease |
primary bacterial infectious disease bacterial infectious disease |
Human disease | C01.252.400.167 | Brucellosis | |
Brugada syndrome | disease | heart conduction disease Sudden unexpected death syndrome |
heart conduction disease that is characterized by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death | C14.280.067.322 C16.320.100 |
Brugada syndrome | |
bruxism | disease | sleep disorder parafunctional habit |
sleep disorder that involves involuntarily grinding or clenching of the teeth while sleeping | C07.793.099 C07.793.099.500 C10.886.659.637 |
Bruxism | |
bubonic plague | disease | plague lymph node disease |
human and animal disease | C01.252.400.310.980.745 | Black Death | |
bulimia | disease | eating disorder | eating disorder characterized by binge eating followed by purging. Binge eating refers to eating a large amount of food in a short amount of time | C23.888.821.645.500 | Bulimia nervosa | |
bullous pemphigoid | disease | autoimmune disease of skin and connective tissue pemphigoid bullous skin disease |
autoimmune disease of skin and connective tissue characterized by large blisters | C17.800.865.690 C20.111.730 |
Bullous pemphigoid | |
Burkitt lymphoma | disease | mature B-cell neoplasm | mature B-cell neoplasm of B-cells found in the germinal center | C02.256.466.313.165 C02.928.313.165 C04.557.386.480.150.165 C15.604.515.569.480.150.165 C20.683.515.761.480.150.165 |
Burkitt's lymphoma | |
burning mouth syndrome | disease | mouth disease dysesthesia glossalgia rare headache disorder |
Human disease | C07.465.114 | ||
bursitis | disease | arthropathy synovial, tendon or bursa disorder inflammation |
human disease | C05.550.251 | Bursitis | |
Buruli ulcer disease | disease | primary bacterial infectious disease mycobacterium infectious disease |
tropical disease | C01.252.410.040.552.475.247 C17.800.893.295 |
Buruli ulcer | |
byssinosis | disease | pneumoconiosis | Human disease | C08.381.483.581.275 C08.381.520.702.275 C24.800.323 |
||
CADASIL | disease | leukodystrophy genetic neurodegenerative disease eye degenerative disease |
autosomal dominant cerebrovascular disorder characterized by recurrent subcortical ischemic stroke and cognitive impairment | C10.228.140.300.275.249 C10.228.140.300.400.203 C10.228.140.300.510.200.175 C10.228.140.380.230.124 C14.907.253.329.249 C14.907.253.560.200.175 C16.320.129 |
CADASIL syndrome | |
calcinosis | disease | calcium metabolism disease | calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue | C18.452.174.130 | Calcinosis | |
calciphylaxis | disease | calcinosis systemic disease vascular disease |
Human disease | C18.452.174.130.186 | Calciphylaxis | |
calculus | disease | C23.550.537 | Lithiasis | |||
campomelic dysplasia | disease | osteochondrodysplasia | osteochondrodysplasia that has material basis in a mutation in chromosome 17 which results in bowing in the located in tibia or located in femur | C05.660.142 C16.131.621.142 |
||
campylobacteriosis | disease infectious disease |
gastroenteritis | Human disease | C01.252.400.177 | ||
Camurati-Engelmann disease | disease developmental defect during embryogenesis |
osteosclerosis primary bone dysplasia with increased bone density |
rare disease | C05.116.099.708.180 C16.320.144 |
||
Cancer of unknown primary origin | disease | metastasis | disease | C04.697.650.895 C23.550.727.650.895 |
||
candidiasis | disease | opportunistic mycosis | fungal infection due to any type of Candida | C01.703.160 | Candidiasis | |
capillary leak syndrome | disease | capillary disease Urticarial syndromes |
Human disease | C14.907.218 | ||
Caplan's syndrome | disease | pneumoconiosis | pneumoconiosis that results in humans that also have rheumatoid arthritis | C05.550.114.154.219 C05.799.114.219 C08.381.483.581.300 C08.381.520.702.300 C17.300.775.099.219 C24.800.340 |
||
carbuncle | disease | pyoderma | Human disease | C01.252.410.868.820.270.200 C01.252.825.770.270.200 C01.539.800.720.770.270.200 C17.800.838.765.770.270.200 |
Carbuncles | |
carcinoid | disease | C04.557.465.625.650.200 C04.557.470.200.025.200 C04.557.580.625.650.200 |
Carcinoid tumors | |||
cardiac arrest | disease thoracic disease |
congestive heart failure | sudden stop in effective blood flow due to the failure of the heart to contract effectively | C14.280.383 | Cardiac arrest | |
cardiac tamponade | disease thoracic disease |
pericardial effusion | pericardial effusion in which fluid accumulates in the pericardium (the sac in which the heart is enclosed) and the pericardial spaces fills up faster than the pericardial sac can stretch | C14.280.155 | Cardiac tamponade | |
cardiomyopathy | disease | heart disease myopathy |
A heart disease and a myopathy that is characterised by deterioration of the function of the heart muscle | C14.280.238 | Cardiomyopathies | |
Carney complex | disease | autosomal dominant disease primary pigmented nodular adrenocortical disease Cutaneous myxoma |
autosomal dominant disease characterized by myxomas, spotty pigmentation of the skin and endocrine overactivity | C04.557.450.565.550.312 C04.588.894.309.500 C14.280.459.500 C16.131.077.229 C16.131.831.108 |
||
Caroli disease | disease | bile duct disease | bile duct disease that is characterized by abnormal dilatation of the intrahepatic bile ducts | C06.130.120.127.500 C06.198.184.500 C16.131.077.245.250 C16.131.314.184.500 C16.320.184.250 |
||
carotid artery stenosis | disease | carotid artery disease peripheral artery disease |
narrowing or constriction of the inner surface (lumen) of the carotid artery, usually caused by atherosclerosis | C10.228.140.300.200.360 C14.907.137.230 C14.907.253.123.360 |
Carotid artery stenosis | |
carpal tunnel syndrome | disease | nerve compression syndrome | Human Syndrome | C10.668.829.500.500.200 C10.668.829.550.200 C26.844.150.206 |
Carpal tunnel syndrome | |
cat-scratch disease | disease infectious disease |
bartonellosis lymph node disease bacterial infectious disease immune system disease |
Human disease | C01.252.400.126.100.150 C01.252.400.200 C15.604.315.249 |
Cat-scratch disease | |
cataract | disease | lens disease | clouding of the lens inside the eye, which leads to low vision | C11.510.245 | Cataracts | |
Cauda equina syndrome | disease | peripheral nervous system disease syndrome |
nerve damage at the end of the spinal cord | C10.668.829.800.750.700 | Cauda equina syndrome | |
cavernous hemangioma | disease | vascular hemostatic disease | type of blood vessel malformation | C04.557.645.375.385 C14.907.454.385 C15.378.463.515.385 |
Cavernous hemangiomas | |
cellulitis | disease infectious disease |
skin disease connective tissue disease bacterial skin disease |
Human disease | C01.539.800.130 C01.539.830.200 C17.300.185 C23.550.470.756.200 |
Cellulite | |
central core myopathy | disease | congenital structural myopathy | Human disease | C05.651.575.300 C10.668.491.550.300 |
||
central nervous system vasculitis | disease | vasculitis | Human disease | C10.114.875 C10.228.140.300.850 C14.907.253.946 C14.907.940.907 C20.111.258.962 |
||
central pontine myelinolysis | disease | demyelinating disease demyelinating disease of central nervous system |
demyelination disease that is characterized by severe damage to the myelin sheath of the pons' nerve cells and has symptom acute paralysis, has symptom dysphagia, and has symptom dysarthria | C10.228.140.163.560 C10.314.500 C18.452.132.560 |
Central pontine myelinolysis | |
centronuclear myopathy | disease | myopathy | myopathy characterized by abnormally located nuclei in skeletal muscle cells | C05.651.575 C10.668.491.550 |
||
cephalic disorder | disease | birth defect central nervous system disease |
congenital conditions that stem from damage to, or abnormal development of, the budding nervous system | C10.500 C16.131.666 |
Congenital diseases and disorders of the nervous system | |
cerebellar ataxia | disease | cerebellar disease | cerebellar disease characterized by ataxia originating in the cerebellum. | C10.228.140.252.190 C10.597.350.090.500 C23.888.592.350.090.200 |
||
cerebral amyloid angiopathy | disease | amyloidosis | amyloidosis where amyloid protein progressively deposits in cerebral blood vessel walls with subsequent degenerative vascular changes that usually result in spontaneous cerebral hemorrhage, ischemic lesions and progressive dementia | C10.228.140.163.100.168 C10.228.140.300.275.311 C10.228.140.300.510.200.200.160 C14.907.253.329.311 C14.907.253.560.200.200.160 C16.320.565.176.160 C16.320.565.189.168 C18.452.132.100.168 C18.452.648.176.160 C18.452.648.189.168 C18.452.845.500.075.160 C18.452.845.500.100.160 |
Cerebral amyloid angiopathy | |
Cerebral arteriovenous malformation | disease | arteriovenous malformation brain disease rare genetic vascular tumor rare nervous system tumor neurovascular malformation rare genetic epilepsy genetic central nervous system and retinal vascular disease |
arteriovenous malformation that is located in the brain | C10.228.140.300.520 C10.500.190.500 C14.240.850.750.295 C14.240.850.875.500 C14.907.150.295 C14.907.253.560.400 C16.131.240.850.750.295 C16.131.240.850.875.500 C16.131.666.190.500 |
Cerebral arteriovenous malformation | |
cerebral hemorrhage | disease | intracranial hemorrhage stroke |
type of intracranial hemorrhage that occurs within the brain tissue itself | C10.228.140.300.535.200 C14.907.253.573.200 C23.550.414.913.100 C10.228.140.199.275 C10.228.140.300.535.450.200 C10.900.300.087.187 C10.900.300.837.150 C14.907.253.573.400.150 C26.915.300.200.175 C26.915.300.490.150 C10.228.140.199.275.300 C10.228.140.300.535.200.200 C10.228.140.300.535.450.200.750 C10.900.300.087.187.300 C10.900.300.837.150.650 C14.907.253.573.200.200 C14.907.253.573.400.150.300 C26.915.300.200.175.300 C26.915.300.490.150.300 |
Cerebral hemorrhage | |
cerebral infarction | disease | brain infarction | type of ischemic stroke resulting from a blockage in the blood vessels supplying blood to the brain | C10.228.140.300.150.477.200 C10.228.140.300.775.200.200 C14.907.253.092.477.200 C14.907.253.855.200.200 |
||
cerebral palsy | disease | brain disease cerebral degeneration |
A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain. | C10.228.140.140.254 | Cerebral palsy | |
cervical cancer | disease | uterine cancer cervix disease |
cancer arising from the cervix, caused by a sexually transmitted virus | C04.588.945.418.948.850 C13.351.500.852.593.131 C13.351.500.852.762.850 C13.351.937.418.875.850 |
Cervical cancer | |
Cervical intraepithelial neoplasia | disease | Intraepithelial neoplasia | C04.557.470.200.240.250 | |||
cervix erosion | disease | cervix disease | ectropion | C13.351.500.852.593.112 | Cervical ectropion | |
Chagas disease | disease | trypanosomiasis | human disease | C03.752.300.900.200 | Chagas disease | |
Charcot–Marie–Tooth disease | disease Designated intractable/rare diseases |
hereditary motor and sensory neuropathy neuromuscular disease |
neuromuscular disease that is characterized by a slowly progressive degeneration of the muscles of the foot, lower leg, hand and forearm | C10.500.300.200 C10.574.500.495.200 C10.668.829.800.300.200 C16.131.666.300.200 C16.320.400.375.200 |
Charcot-Marie-Tooth disease | |
CHARGE syndrome | disease head and neck disease developmental defect during embryogenesis |
syndrome immunodeficiency due to absence of thymus syndromic genetic deafness rare disorder with female infertility due to a congenital hypogonadotropic hypogonadism syndromic renal or urinary tract malformation lens shape anomaly multiple congenital anomalies/dysmorphic syndrome-variable intellectual disability syndrome syndromic developmental defect of the eye syndrome or malformation associated with head and neck malformations rare syndrome with cardiac malformations syndromic urogenital tract malformation rare abdominal surgical disease rare genetic bone disease |
syndrome that is acterized by a pattern of congenital anomalies including choanal atresia and malformations of the heart, inner ear, and retina | C16.131.077.239 C16.320.165 |
CHARGE syndrome | |
Chediak-Higashi syndrome | disease | autosomal recessive disease nervous system heredodegenerative disease eye degenerative disease |
autosomal recessive disease characterized by oculocutaneous albinism, immune deficiency, coagulation deficiency and neuropathy; it is that has material basis in mutations in the CHS1 gene | C15.378.553.774.257 C20.673.774.257 |
||
cheilitis | disease | lip disease inflammation |
inflammation of the lips | C07.465.409.215 | Cheilitis | |
cherubism | disease developmental defect during embryogenesis |
autosomal dominant disease jaw disease primary bone dysplasia with disorganized development of skeletal components hereditary cancers genetic systemic or rheumatologic disease autoinflammatory syndrome with immune deficiency rare disease with odontological manifestation multiple congenital anomalies/dysmorphic syndrome without intellectual disability |
Human disease | C05.116.099.708.375.199 C05.500.174 C07.320.173 C16.131.621.207.540.170 C16.320.170 |
Cherubism | |
chikungunya | disease infectious disease |
viral infectious disease Alphavirus infection arboviral diseases arbovirosis |
infection caused by the chikungunya virus, sintomas: dolor de cabeza, fiebre, y comezón | C02.782.930.100.184 | Chikungunya | |
chilblains | disease | trauma cold injury |
chillblains | C26.212.500.217 C26.417.217 |
Chilblains | |
chlamydia infection | disease sexually transmitted infection |
commensal bacterial infectious disease primary Chlamydiaceae infectious disease |
sexually transmitted infection caused by the bacterium Chlamydia trachomatis. | C01.252.400.210.210 C01.252.810.301 C01.539.778.281.301 C12.294.668.281.301 C13.351.500.711.281.301 |
Chlamydia | |
choanal atresia | disease head and neck disease developmental defect during embryogenesis |
nasal cavity disease genetic otorhinolaryngologic disease rare genetic respiratory disease rare genetic developmental defect during embryogenesis nose and cavum anomaly genetic nervous system disorder genetic disease |
congenital disorder of respiratory system | C08.460.171 C08.695.271 C09.603.171 C16.131.740.271 |
Choanal atresia | |
cholangiocarcinoma | disease | bile duct adenocarcinoma | bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells. | C04.557.470.200.025.450 | Cholangiocarcinoma | |
cholangitis | disease | bile duct disease non-neoplastic bile duct disorder inflammatory disease |
bile duct disease that is an inflammation of the bile duct | C06.130.120.200 | Ascending cholangitis | |
cholecystitis | disease | cholangitis | cholangitis that is characterized by an inflammation that is located in the gallbladder | C06.130.564.263 C06.130.564.263.500 |
Cholecystitis | |
choledochal cyst | disease | bile duct disease | congenital disorder of digestive system | C04.182.198 C06.130.120.127 C06.198.184 C16.131.314.184 |
Choledochal cysts | |
cholestasis | disease | bile duct disease | Human disease | C06.130.120.135 | Cholestasis | |
cholesteatoma | disease | keratosis | keratosis characterized by keratinizing squamous epithelium located in middle ear and/or mastoid, subepithelial connective tissue and by the progressive accumulation of keratin debris with or without surrounding inflammatory reaction | C17.800.428.260 | Cholesteatoma | |
cholesterol embolism | disease | vascular disease | vascular disease that is characterized by blood vessel obstruction resulting from the release of cholesterol from the inside of blood vessels along the bloodstream | C14.907.355.350.454.500 | ||
chondroblastoma | disease | connective tissue neoplasm | Human disease | C04.557.450.565.250 | Chondroblastoma | |
chondrocalcinosis | disease | arthritis | arthritis that has material basis in the accumulation of salt crystals located in joint | C05.550.114.264 C05.550.354.125 |
Chondrocalcinosis | |
chondrodysplasia punctata | disease developmental defect during embryogenesis |
genetic disease primary bone dysplasia |
Human disease | C05.116.099.708.195 | ||
chondroma | disease | cell type benign neoplasm Cartilage tumor |
cell type benign neoplasm that is a cartilaginous tumor encapsulated with a lobular growing pattern | C04.557.450.565.265 | Chondroma | |
chondromalacia patellae | disease arthropathy developmental defect during embryogenesis |
chondromalacia knee disorder bone disease patellar dysostosis |
Human disease | C05.182.100 C17.300.182.100 |
Chondromalacia patellae | |
chondropathy | disease | osteochondropathy connective tissue disease |
human disease | C05.182 C17.300.182 |
Chondropathies | |
chondrosarcoma | disease | connective tissue neoplasm Cartilage tumor |
connective tissue cancer that has material basis in cells derived from transformed cells that produce cartilage | C04.557.450.565.280 C04.557.450.795.300 |
Chondrosarcoma | |
chordoma | disease | notochordal cancer | notochordal cancer that derives from cellular remnants of the notochord | C04.557.465.220 | Chordoma | |
choreatic disease | disease | movement disorder Huntington disease-like syndrome |
movement disease characterized by brief, semi-directed, irregular movements that not repetitive or rhythmic, but appear to flow from one muscle to the next | C10.228.662.262.249 C10.597.350.250 C23.888.592.350.250 |
Chorea | |
choriocarcinoma | disease | placenta cancer Gestational trophoblastic disease trophoblastic neoplasm |
Human disease | C04.557.465.955.207 C04.557.470.200.025.455 C04.850.908.208 C13.703.720.949.208 |
Choriocarcinoma | |
chorioretinitis | disease | eye disease uveitis |
Human disease | C11.768.773.348 C11.941.160.478.400 C11.941.879.780.900.300.318 |
Chorioretinitis | |
choroid plexus papilloma | disease | papilloma choroid plexus cancer |
Human disease | C04.588.614.250.195.205.200.500 C10.228.140.211.280.300.500 C10.551.240.250.200.200.500 |
Choroid plexus papilloma | |
chronic fatigue syndrome | disease | syndrome primary immunodeficiency disease |
medical condition involving tiredness | C02.330 C05.651.310 C10.228.440.600 C10.668.364 |
||
chronic granulomatous disease | disease | Phagocyte bactericidal dysfunction lung disease bone disease cellulitis |
Human disease | C15.378.553.774.535 C16.320.322.233 C20.673.774.535 |
||
chronic inflammatory demyelinating polyradiculoneuropathy | disease | autoimmune disease acquired disorder polyradiculoneuropathy demyelinating polyneuropathy |
acquired immune-mediated inflammatory disorder of the peripheral nervous system | C10.114.750.175 C10.314.750.700 C10.668.829.800.750.600 C20.111.258.750.800 |
||
chronic kidney disease | disease | kidney failure | progressive loss in kidney function over a period of months or years | C12.777.419.780.750.500 C13.351.968.419.780.750.500 C12.777.419.780.750 C13.351.968.419.780.750 |
||
chronic lymphocytic leukemia | disease | lymphoblastic leukemia chronic leukemia small lymphocytic lymphoma |
lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood | C04.557.337.428.080.125 C15.604.515.560.080.125 C20.683.515.528.080.125 |
Chronic lymphocytic leukemia | |
chronic myeloid leukemia | disease | myeloid leukemia chronic leukemia |
myeloid leukemia that is characterized by over production of white blood cells | C04.557.337.539.250 C15.378.190.636.370 |
Chronic myeloid leukemia | |
Chronic myelomonocytic leukemia | disease | leukemia chronic myeloid leukemia chronic leukemia |
chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood | C04.557.337.539.522 C15.378.190.615.510 |
Chronic myelomonocytic leukemia | |
Chronic neutrophilic leukemia | disease | bone marrow cancer chronic leukemia |
chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene | C15.378.190.636.380 | ||
chronic obstructive pulmonary disease | disease | obstructive lung disease | type of obstructive lung disease characterized by long-term poor airflow | C08.381.495.389 | Chronic obstructive pulmonary disease | |
chronic progressive external ophthalmoplegia | disease | mitochondrial myopathy | human disease | C05.651.460.700 C10.292.562.750.250 C10.597.622.447.511 C10.668.491.500.700 C11.590.472.250 C18.452.660.560.700 C23.888.592.636.447.511 |
||
chronic wasting disease | disease | animal disease transmissible spongiform encephalopathy |
animal disease | C10.228.228.800.858 C10.574.843.925 C22.955 |
Chronic wasting disease | |
chylothorax | disease | pleural effusion | C08.528.142 | Chylothorax | ||
cicatricial pemphigoid | disease | bullous skin disease pemphigoid |
bullous skin disease characterized by skin lesions and scaring and located in mucous membranes and located in skin | C11.187.482 C17.800.865.670 |
||
CINCA syndrome | disease | Cryopyrin-associated periodic syndrome autoimmune disease rare genetic eye disease systemic diseases with anterior uveitis |
Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome is characterised by skin rash, joint involvement, chronic meningitis with granulocytes and, in some cases, sensorineural hearing loss and ocular signs | C16.320.382.500 C17.800.827.368.500 |
||
citrullinemia | disease | urea cycle disorder | urea cycle disorder that involves the accumulation of ammonia in the blood. | C10.228.140.163.100.937.374 C16.320.565.100.940.374 C16.320.565.189.937.374 C18.452.132.100.937.374 C18.452.648.100.940.374 C18.452.648.189.937.374 |
||
cleidocranial dysplasia | disease | osteochondrodysplasia | osteochondrodysplasia that has material basis in mutations in the RUNX2 gene which results in undeveloped or absent located in clavicle along with delayed closing of fontanels in the located in skull | C05.116.099.708.207 C05.660.207.207 C16.131.621.207.207 |
Cleidocranial dysostosis | |
clonorchiasis | disease infectious disease |
parasitic helminthiasis infectious disease liver disease |
human disease | C03.335.865.148 | Clonorchiasis | |
Clostridium difficile colitis | disease | colitis commensal Clostridium infectious disease |
colitis characterized by an overgrowth of Clostridium difficile bacteria | C01.252.410.222.310 C06.405.205.596.800 C06.405.469.363.800 |
Pseudomembranous colitis | |
clubfoot | disease | dysmelia bone development disease foot deformity |
bone development disease where one or both are inclined inwards, axially rotated outwards, and pointing downwards with concomitant soft tissue abnormalities | C05.330.488.655.063 C05.330.495.681.063 C05.660.585.512.380.813.063 C16.131.621.585.512.500.681.063 |
Club foot | |
cluster headache | disease | headache facial neuralgia trigeminal autonomic cephalalgia |
C10.228.140.546.399.937.500 | Cluster headache | ||
Coats disease | disease | retinal telangiectasia congenital vitreoretinal dysplasia secondary glaucoma due to a proliferation and differentiation anomaly rare genetic vascular disease genetic central nervous system and retinal vascular disease rare central nervous system and retinal vascular disease |
Human disease | C11.768.748 C14.907.823.502 |
Coats' disease | |
coccidioidomycosis | disease | primary systemic mycosis | Human disease | C01.703.203 | Coccidioidomycosis | |
coccidiosis | disease infectious disease |
parasitic protozoa infectious disease | A parasitic protozoa infectious disease that occurs in the intestinal tract of animals and humans caused by Coccidia protozoa. Immunocompromised persons are at greater risk of developing the infection. | C03.752.250 | Coccidiosis | |
Cockayne syndrome | disease Designated intractable/rare diseases |
autosomal recessive disease eye degenerative disease nervous system heredodegenerative disease |
Cockayne syndrome (CS) is a multisystem condition characterized by short stature, a characteristic facial appearance, premature aging, photosensitivity, progressive neurological dysfunction, and intellectual deficit | C05.116.099.343.250 C10.574.500.362 C16.131.077.250 C16.320.240.562 C16.320.400.200 C18.452.284.250 |
||
Coffin-Lowry syndrome | disease developmental defect during embryogenesis |
X-linked disease X-linked mental retardation syndromic obesity rare genetic epilepsy rare genetic bone disease scoliosis |
Human disease | C10.597.606.643.455.249 C16.320.322.500.249 C16.320.400.525.249 |
||
Cogan syndrome | disease head and neck disease |
eye disease rare otorhinolaryngologic disease rare eye disease predominantly large-vessel vasculitis |
a rare vasculitis of children and young adults characterized by nonsyphilitic interstitial keratitis of cornea, fever and fatigue. | C10.292.910.299 C11.180 C14.907.940.320 |
||
collagen disease | disease | connective tissue disease | Human disease | C17.300.200 | Collagen diseases | |
collagenous colitis | disease | microscopic colitis | colitis characterized by a distinctive thickening of the subepithelial collagen table | C06.405.205.265.173.500 C06.405.469.158.188.173.500 |
||
coloboma | disease | eye disease | eye disease characterized by missing pieces of tissue in structures that form the eye, such as the iris, retina, choroid or optic disc | C11.250.110 C16.131.384.282 |
Coloboma | |
color blindness | disease | vision disorder Q471812 blindness |
inability or decreased ability to see colour, or perceive colour differences, under normal lighting conditions | C10.597.751.941.256 C11.966.256 C23.888.592.763.941.256 |
Color blindness | |
Colorado tick fever | disease infectious disease |
viral infectious disease tick-borne disease infectious disease with epilepsy |
Human disease | C02.081.885.200 C02.782.791.482 |
||
colorectal cancer | disease | large intestine cancer colonic tumor |
cancer of the colon or rectum | C04.588.274.476.411.307 C06.301.371.411.307 C06.405.249.411.307 C06.405.469.158.356 C06.405.469.491.307 C06.405.469.860.180 |
Colorectal cancer | |
colorectal polyp | disease | intestinal polyp colonic tumor |
C23.300.825.411.235 | Colorectal polyp | ||
common variable immunodeficiency | disease | agammaglobulinemia | Human disease | C20.673.330 | ||
communication disorder | disease | specific developmental disorder | specific developmental disorder that involves specific developmental disorders of speech and language | C10.597.606.150 C23.888.592.604.150 |
||
compartment syndrome | disease | ischemia | Human disease | C05.651.180 C14.907.303 |
Compartment syndrome | |
Complete androgen insensitivity syndrome | disease | androgen insensitivity syndrome | C12.706.316.096.500 C13.351.875.253.096.500 C16.131.939.316.096.500 C16.320.322.061 C19.391.119.096.500 |
|||
complex regional pain syndrome | disease health problem neurological disorder |
autonomic nervous system disease | Human disease | C10.177.195 C10.668.829.250 |
Complex regional pain syndrome | |
conductive hearing loss | disease | deafness | C09.218.458.341.562 C10.597.751.418.341.562 C23.888.592.763.393.341.562 |
|||
congenital central hypoventilation syndrome | disease | autonomic nervous system disease | Human disease | C08.618.085.852.800 C10.886.425.800.750.800 |
Central hypoventilation syndrome | |
congenital cystic adenomatoid malformation | disease developmental defect during embryogenesis |
lung disease respiratory malformation rare genetic respiratory disease non-syndromic respiratory or mediastinal malformation |
congenital disorder of respiratory system | C08.381.150 C08.695.290 C16.131.740.290 |
Congenital cystic adenomatoid malformation | |
congenital diaphragmatic hernia | disease Designated intractable/rare diseases developmental defect during embryogenesis |
diaphragm disease diaphragmatic hernia birth defect rare genetic developmental defect during embryogenesis rare genetic respiratory disease |
diaphragm disease characterized by the lack of development of all or part of the diaphragm, which results in an abnormal opening that allows the stomach and intestines to move into the chest cavity and crowd the heart and lungs | C23.300.707.500 | Congenital diaphragmatic hernia | |
congenital disorder of glycosylation | disease | carbohydrate metabolic disorder | carbohydrate metabolic disorder that involves deficient or defective glycosylation of a variety of tissue proteins and/or lipids | C16.320.565.202.125 C18.452.648.202.125 |
||
congenital erythropoietic porphyria | disease | porphyria Erythropoietic porphyria skin disease rare constitutional hemolytic anemia due to an enzyme disorder |
congenital human disease | C16.320.850.738 C17.800.827.738 C18.452.811.250 |
||
congenital heart disease | disease developmental defect during embryogenesis |
heart disease birth defect cardiovascular abnormality rare genetic cardiac disease genetic disease rare genetic developmental defect during embryogenesis |
cardiovascular disease | C14.240.400 C14.280.400 C16.131.240.400 |
Congenital diseases and disorders of the heart | |
congenital hypothyroidism | disease | hypothyroidism | hypothyroidism that is present at birth | C05.116.099.343.347 C05.116.132.256 C16.320.240.625 C19.297.155 C19.874.482.281 |
Congenital hypothyroidism | |
conjoined twins | disease | identical twins Diseases in Twins |
identical twins joined in utero | C16.131.085.806 | Conjoined twins | |
Conn's syndrome | disease | hyperaldosteronism adrenal adenoma adrenal gland disease |
adrenal adenoma characterized by over production of aldosterone | C19.053.800.604 | Primary aldosteronism | |
connective tissue disease | disease | musculoskeletal disorder skin and connective tissue diseases |
musculoskeletal system disease that affects tissues such as skin, tendons, and cartilage | C17.300 | Connective tissue diseases | |
constipation | disease | bowel dysfunction | bowel dysfunction that is characterized by infrequent or difficult evacuation of feces. | C23.888.821.150 | Constipation | |
contact dermatitis | disease | dermatitis eczema |
Human disease | C17.800.174.255 C17.800.815.255 |
Contact dermatitis | |
contagious pustular dermatitis | disease infectious disease |
viral infectious disease skin disease |
Human disease | C02.256.743.193 C22.836.259 |
Orf (animal disease) | |
cor pulmonale | disease | congestive heart failure | congestive heart failure that involves a failure of the right side of the heart and is characterized by an enlargement of the right ventricle of the heart as a response to increased resistance or high blood pressure in the lungs | C14.280.832 | Pulmonary heart disease | |
corneal neovascularization | disease | keratitis Neovascularization |
Human disease | C11.204.290 | Corneal neovascularization | |
corneal ulcer | disease | keratitis corneal disease |
Area of epithelial tissue loss from corneal surface; associated with inflammatory cells in the cornea and anterior chamber | C01.539.375.177 C11.204.564.225 C11.294.177 |
Corneal ulcer | |
Cornelia de Lange syndrome | disease | genetic disease | genetic disease that is characterized by slow growth before and after birth, intellectual disability that is usually severe to profound, skeletal abnormalities involving the arms and hands, and distinctive facial features | C10.597.606.643.210 C16.131.077.272 C16.131.260.210 C16.320.180.210 |
Cornelia de Lange syndrome | |
coronary artery disease | disease | artery disease cardiovascular disease |
artery disease characterized by plaque building up along the inner walls of the arteries of the heart resulting in a narrowing of the arteries and a reduced blood supply to the cardiac muscles | C14.280.647.250.260 C14.907.137.126.339 C14.907.585.250.260 C14.280.647.250 C14.907.585.250 C14.280.647 C14.907.585 |
Coronary artery disease | |
coronary thrombosis | disease | coronary artery disease thrombosis arterial thrombosis |
Human disease | C14.280.647.250.290 C14.907.355.830.220 C14.907.585.250.290 |
||
cortical blindness | disease | visual cortex disease cerebral visual impairment |
Human disease | C10.597.751.941.162.250 C11.966.075.250 C23.888.592.763.941.162.250 |
||
Costello syndrome | disease Designated intractable/rare diseases developmental defect during embryogenesis |
autosomal dominant disease rare genetic syndromic intellectual disability polymalformative genetic syndrome with increased risk of developing cancer dermis elastic tissue disorder hypertrophic cardiomyopathy Moyamoya syndrome Noonan syndrome and Noonan-related syndrome multiple congenital anomalies/dysmorphic syndrome-intellectual disability malformation syndrome with skin/mucosae involvement |
syndrome characterized by craniofacial dysmorphology, cardiac defects, mild mental retardation, and high birth weight followed by a failure to thrive and developmental delays | C05.660.207.219 C16.131.077.256 C16.320.185 |
Costello syndrome | |
Cowden disease | disease | autosomal dominant disease multiple hamartoma syndrome |
inherited disorder causing tumor-like growth and increased cancer risk | C04.445.435 C04.651.435 C04.700.435 C16.320.700.435 |
Cowden syndrome | |
cowpox | disease infectious disease |
viral infectious disease | Human disease | C02.256.743.175 | Cowpox | |
Coxa valga | disease | hip dysplasia | C05.116.214.750.500 C05.116.327 C23.300.970.374.500 |
Coxa valga | ||
Coxa vara | disease | hip dysplasia bone anteversion genetic disease |
Hip deformity in which the femoral neck leans forward resulting in a decrease in the angle between femoral neck and its shaft. It may be congenital often syndromic, acquired, or developmental. | C05.116.214.500.500 C23.300.970.249.500 |
Coxa vara | |
craniopharyngioma | disease | central nervous system organ benign neoplasm | Human disease | C04.557.465.625.200 C04.557.580.625.200 |
Craniopharyngiomas | |
craniosynostosis | disease | synostosis rare disease craniofacial disease |
synostosis that results in premature fusion located in skull | C05.116.099.370.894.232 C05.660.207.240 C05.660.906.364 C16.131.621.207.240 C16.131.621.906.364 |
Craniosynostosis | |
CREST syndrome | disease | syndrome limited scleroderma |
syndrome characterized by calcinosis, Raynaud's phenomeno, esophageal dysmotility, sclerodactyly and telangiectasia | C06.405.117.119.500.204 C14.907.617.812.500 C14.907.823.225 C17.300.799.801.500 C17.800.784.801.500 C18.452.174.130.204 |
CREST syndrome | |
Cri-Du-Chat syndrome | disease | chromosomal deletion syndrome autosomal deletion syndrome |
Human disease | C10.597.606.643.180 C16.131.077.262 C16.131.260.190 C16.320.180.190 |
Cri du chat syndrome | |
Crigler-Najjar syndrome | disease | bilirubin metabolic disorder | bilirubin metabolic disorder that involves a build up of bilirubin as bilirubin is not being broken down as a result of a lack or deficiency of the enzyme uridine diphosphate glycosyltransferase (UGT) | C16.320.565.300.281 C18.452.648.300.281 |
||
Crimean-Congo hemorrhagic fever | disease infectious disease |
viral infectious disease rare skin disease Skin infection |
viral disease | C02.081.885.430 C02.782.147.444 C02.782.417.412 |
||
critical illness polyneuropathy | disease | inflammatory and toxic neuropathy polyneuropathy |
Human disease | C10.668.829.800 | ||
Cronkhite-Canada syndrome | disease Designated intractable/rare diseases developmental defect during embryogenesis |
stomach disease polyposis gastric hamartomatous polyp inherited digestive tract tumor hamartoma of skin appendage inherited skin tumor |
Human disease | C06.405.469.578 | ||
croup | disease infectious disease |
respiratory system disease acute laryngitis |
respiratory condition that is usually triggered by an acute viral infection of the upper airway | C08.360.535.365 C09.400.535.365 |
Croup | |
Crouzon syndrome | disease developmental defect during embryogenesis |
craniosynostosis craniostenosis associated with a strabismus syndromic craniosynostosis |
congenital disorder of digestive system | C05.116.099.370.231 C05.660.207.231 C16.131.621.207.231 |
Crouzon syndrome | |
cryoglobulinemia | disease | type IV hypersensitivity | hypersensitivity reaction type IV disease that involves large amounts of cryoglobulins in the blood which become thick or gel-like in cold temperatures | C14.907.454.140 C15.378.147.780.243 C15.378.463.515.140 C20.683.780.250 |
Cryoglobulinemia | |
Cryopyrin-associated periodic syndrome | disease Designated intractable/rare diseases |
Periodic fever syndrome | syndrome | C16.320.382.500 C17.800.827.368.500 |
||
cryptococcosis | disease infectious disease |
opportunistic mycosis fungal infectious disease immune system disease |
opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii. | C01.703.248 | Cryptococcosis | |
cryptogenic organizing pneumonia | disease infectious disease |
idiopathic interstitial pneumonia | Human disease | C08.127.446.135.140.200 C08.381.483.487.249 C08.381.495.146.135.140.200 |
Cryptogenic organizing pneumonia | |
cryptorchidism | disease | birth defect testicular disease male reproductive system disease genetic disease |
Human disease | C12.294.829.258 C12.706.258 C16.131.939.258 C19.391.829.258 |
Cryptorchidism | |
cryptosporidiosis | disease infectious disease |
coccidiosis intestinal disease Intestinal parasite |
Human disease | C03.432.269 C03.701.688.235 C03.752.250.269 C03.752.625.235 C06.405.469.452.269 C22.674.710.235 |
Cryptosporidiosis | |
Cushing's syndrome | disease | adrenal gland hyperfunction that is caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland | C19.053.800.367 | Cushing's syndrome | ||
Cutaneous larva migrans | disease infectious disease |
parasitic helminthiasis infectious disease parasitic skin disease |
C03.335.508.523 C03.858.424 C17.800.838.775.424 |
Cutaneous larva migrans | ||
cyst | disease | lesion | closed sac growth on the body | C04.182 C23.300.306 |
Cysts | |
cystadenoma | disease | adenoma | adenoma that is a cystic | C04.557.470.035.320 C04.557.470.590.485 |
Mucinous cystoadenoma of the ovary | |
cystic fibrosis | disease | autosomal recessive disease lung disease genetic biliary tract disease genetic pancreatic disease rare genetic respiratory disease rare male fertility disorder with obstructive azoospermia rare genetic disorder with obstructive azoospermia |
autosomal recessive disease that is characterized by the buildup of thick, sticky mucus that can damage many organs. | C06.689.202 C08.381.187 C16.320.190 C16.614.213 |
Cystic fibrosis | |
cystic lymphangioma | disease | lymphangioma Cystic lymphatic malformation |
Human disease | C04.557.375.450.450 | Cystic hygroma | |
cysticercosis | disease infectious disease |
taeniasis eye disease muscle tissue disease heart disease skin disease intestinal disease |
Human helminthiasis | C03.335.190.902.185 | Cysticercosis | |
cystinosis | disease | lysosomal storage disease inborn disorder of lysosomal amino acid transport |
A lysosomal storage disease characterized by the abnormal accumulation of cystine in the lysosomes. It follows an autosomal recessive inheritance pattern and has material basis in mutations in the CTNS gene, located on chromosome 17. | C16.320.565.595.377 C18.452.648.595.377 |
Cystinosis | |
cystinuria | disease | amino acid metabolic disorder | amino acid metabolic disorder that involves the formation of cystine stones in the kidneys, ureter, and bladder | C12.777.419.815.885.250 C13.351.968.419.815.885.250 C16.320.565.861.885.250 C18.452.648.861.885.250 |
||
cystitis | disease | bladder disease inflammation inflammatory disease |
human Disease | C12.777.829.495 C13.351.968.829.495 |
Cystitis | |
cystoisosporiasis | disease infectious disease |
coccidiosis | coccidiosis that involves infection of the epithelial cells of the small intestine with Cystoisospora belli, which results in nonbloody diarrhea with crampy abdominal pain, malabsorption and weight loss | C03.752.250.410 | Isosporiasis | |
dacryoadenitis | disease | lacrimal apparatus disease | Human disease | C11.496.221 | ||
dacryocystitis | disease | acute inflammation of lacrimal passage | Human disease | C11.496.221 | Dacryocystitis | |
Dandy-Walker syndrome | disease developmental defect during embryogenesis |
cerebellar disease rare genetic developmental defect during embryogenesis cystic malformation of the posterior fossa genetic nervous system disorder malformation of the cerebellar vermis |
congenital disorder of nervous system | C10.228.140.252.300 C10.228.140.602.500 C10.500.205 C16.131.666.205 |
Dandy–Walker syndrome | |
De Quervain disease | disease arthropathy |
occupational disease arthropathy stenosing tenosynovitis |
human disease | C05.651.869.816.200 | De Quervain syndrome | |
decubitus ulcer | disease | chronic ulcer of skin | Decubitus ulcer is a chronic ulcer of skin where the ulcer is an ulceration of tissue deprived of adequate blood supply by prolonged pressure | C17.800.893.665 | Pressure ulcers | |
delayed sleep phase disorder | disease | sleep disorder obsolete chronobiology disease circadian rhythm sleep disorder |
chronic mismatch between a person's normal daily rhythm, compared to other people and societal norms | C10.281 | ||
delirium tremens | disease | alcohol withdrawal syndrome | human disease | C10.720.112.200 C25.723.705.150.200 C25.775.100.087.193.200 C25.775.835.250 |
Delirium tremens | |
dementia | disease | cognitive disorder | long-term brain disorders causing personality changes and impaired memory, reasoning, and normal function | C10.228.140.380 | Dementia | |
demyelinating disease | disease | neurological disorder neurodegeneration |
type of neurological disease where the myelin sheath of neurons is damaged | C10.314 | Demyelinating diseases | |
dengue fever | disease | viral infectious disease | tropical disease caused by the dengue virus, transmitted by mosquito | C02.081.270 C02.782.350.250.214 C02.782.417.214 |
Dengue | |
dental caries | disease | teeth hard tissue disease | disease involving breakdown of teeth | C07.793.720.210 | Dental caries | |
dental fluorosis | disease | tooth disease | Human disease | C07.793.330 | Dental fluorosis | |
dentatorubral-pallidoluysian atrophy | disease | autosomal dominant cerebellar ataxia autosomal dominant cerebellar ataxia type IV Huntington disease-like syndrome |
congenital disorder of nervous system | C10.228.140.490.250.650 | ||
Dentine hypersensitivity | disease | tooth disease teeth hard tissue disease |
Human disease | C07.793.266 | Dentistry | |
dentinogenesis imperfecta | disease | tooth disease | Human disease | C07.650.800.270 C07.793.700.270 C16.131.850.800.270 |
Dentinogenesis imperfecta | |
Denys-Drash syndrome | disease developmental defect during embryogenesis |
autosomal dominant disease nephroblastoma pseudohermaphroditism primary glomerular disease syndrome with disorder of sex development of gynecological interest polymalformative genetic syndrome with increased risk of developing cancer syndrome with 46,XY disorder of sex development |
Human disease | C04.557.435.595.220 C04.588.945.947.535.585.220 C04.700.635.220 C12.706.316.096.562 C12.758.820.750.585.220 C12.777.419.473.585.220 C13.351.875.253.096.562 C13.351.937.820.535.585.220 C13.351.968.419.473.585.220 C16.131.939.316.096.562 C16.320.700.642.220 C19.391.119.096.562 |
||
dermatitis | disease | skin disease | skin disease | C17.800.174 | Dermatitis | |
dermatitis herpetiformis | disease | autoimmune disease of skin and connective tissue bullous skin disease pemphigoid |
Human disease | C17.800.174.360 C17.800.865.360 C20.111.318 |
Dermatitis herpetiformis | |
dermatofibrosarcoma protuberans | disease | fibrosarcoma inherited soft tissue tumor rare skin tumor or hamartoma rare genetic dermis disorder skin sarcoma |
A fibrosarcoma that is located in the dermis laryer of the skin and that begins as a hard nodule and grows slowly. | C04.557.450.565.590.350.320 C04.557.450.795.350.320 |
Dermatofibrosarcoma protuberans | |
dermatomyositis | disease | polymyositis myositis skin disease |
myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness | C05.651.594.819.500 C10.668.491.562.575.500 C17.300.250 C17.800.185 |
Dermatomyositis | |
dermoid cyst | disease | cystic teratoma | Elf disease | C04.182.201 C04.557.465.910.250 |
Dermoid cyst | |
deuteranopia | disease | congenital color blindness color blindness red–green color blindness |
Human disease | C10.597.751.941.256 C11.966.256 C23.888.592.763.941.256 |
||
dextrocardia | disease | congenital heart disease | rare congenital defect in which the apex of the heart is located on the right side of the body | C14.240.400.280 C14.280.400.280 C16.131.240.400.280 C16.131.810.250 |
Dextrocardia | |
diabetes insipidus | disease | kidney disease polyuric-polydipsic syndrome |
Human disease | C12.777.419.135 C13.351.968.419.135 C19.700.159 |
Diabetes insipidus | |
diabetic angiopathy | disease | arterial occlusive disease complications of diabetes mellitus |
Human disease | C14.907.320 C19.246.099.500 |
Diabetic angiopathy | |
diabetic ketoacidosis | disease | complications of diabetes mellitus type 2 diabetes mellitus |
potentially life-threatening complication in people with diabetes mellitus | C18.452.076.176.652.500 C18.452.394.750.535 C19.246.099.812 |
||
diabetic retinopathy | disease | retinal vascular disease complications of diabetes mellitus diabetic angiopathy |
Human disease | C11.768.257 C14.907.320.382 C19.246.099.500.382 |
Diabetic retinopathy | |
Diamond-Blackfan anemia | disease | erythroblastopenia congenital hypoplastic anemia |
rare disease | C15.378.071.085.080.090 C15.378.071.750.500 C15.378.190.196.080.090 C16.320.077.090 |
||
dicrocoeliasis | disease infectious disease |
parasitic helminthiasis infectious disease distomatosis |
A parasitic helminthiasis infectious disease that involves parasitic infection of the bile ducts of the liver by Dicrocoelium dendriticum. | C03.335.865.224 | ||
Diffuse esophageal spasm | disease | esophageal disease Esophageal spasm |
C06.405.117.119.500.450 | Diffuse esophageal spasm | ||
diffuse idiopathic skeletal hyperostosis | disease developmental defect during embryogenesis |
calcinosis spinal disease developmental anomaly of metabolic origin dysostosis with predominant vertebral and costal involvement |
calcinosis that is the calcification or a bony hardening of ligaments in areas where they attach to your spine | C05.116.540.410 C05.116.900.815.651 |
Diffuse idiopathic skeletal hyperostosis | |
DiGeorge syndrome | disease | chromosomal deletion syndrome | T cell deficiency disease that is the result of a large deletion of chromosome 22 which includes the DGS gene needed for development of the thymus and related glands with subsequent lack of T-cell production | C05.660.207.103.500 C14.240.400.021.500 C14.280.400.044.500 C15.604.451.249.500 C16.131.077.019.500 C16.131.240.400.021.500 C16.131.260.019.500 C16.131.482.249.500 C16.131.621.207.103.500 C16.320.180.019.500 C19.642.482.500.500 |
DiGeorge Syndrome | |
dilated cardiomyopathy | disease | intrinsic cardiomyopathy | intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently | C14.280.195.160 C14.280.238.070 |
Dilated cardiomyopathy | |
diphtheria | disease infectious disease |
primary bacterial infectious disease bacterial infectious disease |
Infectious disease | C01.252.410.040.246 C01.252.410.040.246.388 |
Diphtheria | |
dirofilariasis | disease infectious disease |
filariasis parasitic helminthiasis infectious disease nematode infection zoonosis lung disease skin disease parasitic skin disease rare skin disease |
Human disease | C03.335.349.320 C03.335.508.700.750.361.290 C03.701.377.320 C22.674.377.320 |
||
disseminated intravascular coagulation | disease | thrombophilia | pathological process characterized by the widespread activation of the clotting cascade that results in the formation of blood clots in the small blood vessels throughout the body | C15.378.100.220 C15.378.463.250 C15.378.925.220 |
Disseminated intravascular coagulation | |
diverticulitis | disease | intestinal disease diverticular disease inflammatory disease |
digestive disease caused by an inflammation of a herniating pouch (diverticulum) within the wall of the intestine, most often colon | C01.539.463.298 C06.405.205.298 |
Diverticulitis | |
double outlet right ventricle | disease | ventricular septal defect congenital heart disease cyanotic heart defect |
Human disease, Congenital Heart Disease | C14.240.400.915.300 C14.280.400.915.300 C16.131.240.400.915.300 |
||
dracunculiasis | disease infectious disease |
nematode infection parasitic helminthiasis infectious disease filariasis |
Human helminthiasis | C03.335.508.700.750.299 | Dracunculus medinensis | |
Drusen | disease | degeneration of macula and posterior pole | Human disease | C11.768.585.585 | Drusen | |
Duane retraction syndrome | disease | strabismus | Human disease | C10.292.562.250 C11.270.235 C11.590.224 C16.320.290.235 |
Duane syndrome | |
Dubin-Johnson syndrome | disease | bilirubin metabolic disorder rare metabolic liver disease |
Human disease | C16.320.565.300.764 C16.614.451.500.250 C18.452.648.300.764 |
||
Duchenne muscular dystrophy | disease | muscular dystrophy myopathy with eye involvement qualitative or quantitative defects of dystrophin Duchenne and Becker muscular dystrophy |
Duchenne muscular dystrophy (DMD) is a neuromuscular disease characterized by rapidly progressive muscle weakness and wasting due to degeneration of skeletal, smooth and cardiac muscle | C05.651.534.500.300 C10.668.491.175.500.300 C16.320.322.562 C16.320.577.300 |
Duchenne muscular dystrophy | |
dumping syndrome | disease | postgastrectomy syndrome | Human disease | C06.405.748.630.310 C23.550.767.812.500 |
||
duodenitis | disease | intestinal disease | Human disease | C06.405.205.462.249 C06.405.469.275.600 C06.405.469.326.750 |
||
Dupuytren's contracture | disease | fibromatosis contracture superficial fibromatosis |
A superficial fibromatosis arising from the soft tissue of the palm. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern. It predominantly affects adult males. | C04.557.450.565.590.340.173 C05.651.197.270 C17.300.270 |
Dupuytren's contracture | |
dysarthria | disease | motor speech disorder | disglosia | C10.597.606.150.500.800.150.200 C23.888.592.604.150.500.800.150.200 |
||
dyscalculia | disease | learning disability Mathematical anxiety |
difficulty in learning or comprehending arithmetic | C10.597.606.150.550.099 C23.888.592.604.150.550.099 |
Dyscalculia | |
dysentery | disease | gastroenteritis intestinal infectious disease waterborne disease |
inflammation of the intestine causing diarrhea with blood | C06.405.205.331 C06.405.469.300 |
||
dysgerminoma | disease | germ cell cancer malignant germ cell tumor |
germ cell cancer that derives from cells that give rise to egg cells | C04.557.465.330.300 | ||
dysgraphia | disease | writing disorder learning disability |
writing disorder that involves a deficiency in the ability to write where the writing is distorted or incorrect, spelling difficulty, poor handwriting or trouble putting thoughts on paper | C10.597.606.150.500.050 C23.888.592.604.150.500.050 |
Dysgraphia | |
dyskinesia of esophagus | disease | esophageal disease Esophageal motility disorder |
human disease | C06.405.117.119.500 | ||
dyslexia | disease learning disability |
reading disorder language disorder learning disability |
reading/writing disorder | C10.597.606.150.500.300 C10.597.606.150.550.200 C23.888.592.604.150.500.300 C23.888.592.604.150.550.200 |
Dyslexia | |
dysmenorrhea | disease | menstrual disorder pelvic pain |
C23.550.568.750 C23.888.592.612.944.500 |
Dysmenorrhea | ||
dysostosis | disease developmental defect during embryogenesis |
bone development disease | bone development disease that results in defective ossification of located in bone | C05.116.099.370 | ||
dyspepsia | disease | functional gastric disease | Human disease | C23.888.821.236 | ||
dysplasia | disease | congenital abnormality | abnormal development, at macroscopic or microscopical level | C04.697.098.500 C23.550.727.098.500 |
||
dystonia | disease | movement disorder rare genetic dystonia |
neurological movement disorder | C10.228.662.300 C10.597.350.300 C23.888.592.350.300 |
Dystonia | |
Ebstein anomaly | disease developmental defect during embryogenesis |
tricuspid valve disease congenital heart disease cyanotic heart defect rare genetic developmental defect during embryogenesis aortic disease genetic cardiac malformation congenital tricuspid malformation rare genetic vascular disease |
tricuspid valve disease that is a congenital heart defect in which the septal leaflet of the tricuspid valve is displaced towards the apex of the right ventricle of the heart | C14.240.400.395 C14.280.400.395 C16.131.240.400.395 |
Ebstein's anomaly | |
echinococcosis | disease infectious disease |
tapeworm infection zoonosis parasitic helminthiasis infectious disease |
parasitic disease of tapeworms of the Echinococcus type | C03.335.190.396 | Echinococcosis | |
Echolalia | disease | speech disorder | speech disorder that involves the automatic repetition of vocalizations made by another person | C10.597.606.150.500.800.300 C23.888.592.604.150.500.800.300 |
||
eclampsia | disease | pre-eclampsia | pre-eclampsia characterized by the presence of seizures | C13.703.395.124 | Eclampsia | |
ecthyma | disease | impetigo | Human disease | C01.252.410.890.210 C01.252.825.210 C01.539.800.720.210 C17.800.695.210 C17.800.838.765.210 |
Ecthyma | |
Ectopia cordis | disease developmental defect during embryogenesis |
congenital malformation in which the heart is abnormally located either partially or totally outside of the thorax | C14.240.400.422 C16.131.240.400.422 |
|||
Ectopia lentis | disease | disorder of lens | C11.250.300 C11.510.598.373 C16.131.384.405 |
Ectopia lentis | ||
ectopic pregnancy | disease | female reproductive system disease Human Pregnancy |
female reproductive system disease characterized by the implantation of the embryo outside the uterine cavity | C13.703.733 | Ectopic pregnancy | |
ectropion | disease | eyelid disease | Human disease | C11.338.362 | Ectropion | |
egg allergy | disease | food allergy health effects of eggs |
food allergy that is an allergy or hypersensitivity to dietary substances from the yolk or whites of eggs, causing an overreaction of the immune system which may lead to severe physical symptoms | C20.543.480.370.150 | ||
Ehlers-Danlos syndrome | disease Designated intractable/rare diseases |
collagen disease | rare disease | C14.907.454.240 C15.378.463.515.240 C16.131.831.428 C16.320.850.260 C17.300.200.310 C17.800.804.428 C17.800.827.260 |
Ehlers-Danlos syndrome | |
Eisenmenger's syndrome | disease | congenital heart disease cyanotic heart defect pulmonary arterial hypertension associated with congenital heart disease |
fetal heart defect | C14.240.400.450 C14.280.400.450 C16.131.240.400.450 |
Eisenmenger's syndrome | |
Ellis-Van Creveld syndrome | disease developmental defect during embryogenesis |
autosomal recessive disease rare syndrome with cardiac malformations rare abdominal surgical disease syndromic renal or urinary tract malformation |
Human disease | C05.116.099.708.327 C16.131.077.350.398 C16.131.831.350.398 C16.320.850.250.398 C17.800.804.350.398 C17.800.827.250.398 |
Ellis–van Creveld syndrome | |
embryonal carcinoma | disease | embryonal cancer extragonadal germ cell cancer extragonadal non-dysgerminomatous germ cell tumor |
embryonal cancer that is a type of germ cell tumour that is located in the ovaries or located in the testes | C04.557.465.200 | Embryonal carcinoma | |
Emery-Dreifuss muscular dystrophy | disease | muscular dystrophy | muscular dystrophy that chiefly affects muscles used for movement (skeletal) and heart (cardiac) muscle | C05.651.534.500.350 C10.668.491.175.500.350 C16.320.322.625 C16.320.577.350 |
||
empty sella syndrome | disease | pituitary gland disease | endocrine disease | C10.228.140.617.738.200 C19.700.320 |
Empty sella syndrome | |
empyema | disease infectious disease |
gathering of pus within a naturally existing anatomical cavity | C01.539.830.305 C23.550.470.756.305 |
Empyemas | ||
encephalitis | disease | brain disease brain inflammatory disease |
brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms | C10.228.140.430 | Encephalitis | |
encephalitozoonosis | disease infectious disease |
microsporidiosis | Human disease | C01.703.617.300 | ||
encephalomalacia | disease | brain disease | Human disease | C10.228.140.461 | ||
encephalomyelitis | disease | central nervous system disease inflammatory disease |
Human disease | C10.228.228.291 C10.228.440 |
||
endemic goiter | disease | goiter nutritional deficiency disease |
Human disease | C19.874.283.300 | ||
endocarditis | disease | endocardium disease inflammation of heart layer |
endocardium disease characterized by inflammation of the endocardium of the heart chambers and valves | C14.280.282 | Endocarditis | |
endolymphatic hydrops | disease head and neck disease |
oedema peripheral vertigo |
human disease | C09.218.568.217 | ||
endometrial cancer | disease | uterine cancer uterine corpus cancer endometriosis |
uterine cancer that is located in tissues lining the uterus | C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200 |
Endometrial cancer | |
Endometrial hyperplasia | disease | C13.351.500.852.228 | ||||
endometriosis | disease | female reproductive system disease | female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body | C13.351.500.163 | Endometriosis | |
endometriosis of uterus | disease | endometriosis uterine disease |
medical condition characterized by the presence of glandular tissue in muscle | C13.351.500.852.113 | Adenomyosis of the uterus | |
endometritis | disease | endometrial disease | inflammation of inner lining of uterus | C13.351.500.056.750.249 C13.351.500.852.299 |
Endometritis | |
endophthalmitis | disease | globe disease eye inflammation |
globe disease that is characterized by inflammation of the inside of the eye | C01.539.375.265 C11.294.265 |
||
enophthalmos | disease | orbital disease | Human disease | C11.675.319 | ||
enterobiasis | disease infectious disease |
nematode infection anthroponotic disease parasitic helminthiasis infectious disease |
Human worm infection | C03.335.508.700.550.550 C03.335.508.700.550.550.375 |
Enterobius vermicularis | |
entropion | disease | eyelid disease | Human disease | C11.338.443 | Entropion | |
eosinophilia | disease | leukocyte disease | Human disease | C15.378.553.231 C15.378.553.231.549 |
||
eosinophilic granuloma | disease | Langerhans cell histiocytosis in childhood and adulthood | C05.116.391 C08.381.483.375.500 C15.378.553.231.348 C15.604.250.400.360 C23.550.382.250 |
Eosinophilic granuloma | ||
ependymoma | disease | tumor that arises from the ependyma, a tissue of the central nervous system | C04.557.465.625.600.380.290 C04.557.470.670.380.290 C04.557.580.625.600.380.290 |
Ependymal tumors | ||
epidemic pleurodynia | disease infectious disease |
viral infectious disease muscle tissue disease |
Human disease | C02.782.687.359.213.737 | ||
epidemic typhus | disease | typhus | Human disease | C01.252.400.780.790.805 | Epidemic Typhus | |
epidermodysplasia verruciformis | disease | autosomal recessive disease viral infectious disease skin disease immune deficiency with skin involvement other immunodeficiency syndromes due to defects in innate immunity |
Human disease | C02.256.650.810.345 C02.825.810.260 C02.928.914.345 C17.800.838.790.810.260 |
Epidermodysplasia verruciformis | |
epidermolysis bullosa | disease Designated intractable/rare diseases |
vesiculobullous skin disease | Human disease | C16.131.831.493 C16.320.850.275 C17.800.804.493 C17.800.827.275 C17.800.865.410 |
Epidermolysis bullosa | |
epididymitis | disease infectious disease |
male reproductive system disease infectious disease inflammatory disease |
Human disease | C12.294.199 | Epididymitis | |
epiglottitis | disease infectious disease |
upper respiratory tract disease supraglottitis inflammatory disease |
Human disease | C08.730.798.200 | Epiglottitis | |
epispadias | disease developmental defect during embryogenesis |
penile disease bladder exstrophy-epispadias-cloacal exstrophy complex |
congenital disorder of urinary system | C12.706.374 C12.777.767.374 C13.351.875.374 C13.351.968.767.374 C16.131.939.374 |
Epispadias | |
epulis | disease | gingival overgrowth | Human disease | C07.465.714.258 | Epulis | |
Erdheim-Chester disease | disease | non-Langerhans-cell histiocytosis granulomatous autoinflammatory syndrome histiocytic and dendritic cell cancer connective tissue neoplasm immune system disease |
rare disease | C15.604.250.410.224 | Erdheim–Chester disease | |
erethism | disease | C10.720.475.600 C25.723.647.500 |
||||
erysipelas | disease | dermatitis streptococcal infection |
human disease | C01.252.410.890.328 C01.252.825.260 C01.539.800.720.260 C17.800.838.765.260 |
Erysipelas | |
erysipeloid | disease | primary bacterial infectious disease Erysipelothrix infectious disease |
Human disease | C01.252.410.334.329 | ||
erythema infectiosum | disease infectious disease |
viral exanthem parvovirus infectious disease viral infectious disease Skin infection |
Human disease | C02.256.700.300 C02.825.260 C17.800.229.335 C17.800.838.790.260 |
Parvovirus | |
erythema multiforme | disease | skin disease erythema |
skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness | C17.800.229.400 C17.800.865.475 |
Erythema multiforme | |
erythema nodosum | disease | Reactive neutrophilic dermatoses | skin disease | C17.800.174.600.375 C17.800.229.413 C20.543.206.380.375 C25.100.468.380.375 |
Erythema nodosum | |
erythrasma | disease | pyoderma | Human disease | C01.252.410.040.246.430 C01.252.825.320 C01.539.800.720.320 C17.800.838.765.320 |
Erythrasma | |
erythroderma | disease symptom |
skin disease | C17.800.174.318 C17.800.815.318 |
|||
erythromelalgia | disease | arterial occlusive disease vascular skin disease autosomal dominant hereditary sensory and autonomic neuropathy rare genetic skin vascular disorder unclassified genetic skin disorder |
Human disease | C14.907.617.500 | Erythromelalgia | |
erythropoietic protoporphyria | disease | acute porphyria Erythropoietic porphyria porphyria |
acute porphyria characterized by a deficiency in the enzyme ferrochelatase, leading to abnormally high levels of protoporphyrin in the tissue | C06.552.830.812 C16.320.850.742.812 C17.800.827.742.812 C18.452.811.400.812 |
Erythropoietic protoporphyria | |
esophageal atresia | disease thoracic disease |
esophageal disease atresia birth defect |
congenital disorder of digestive system | C06.198.330 C06.405.117.260 C16.131.314.330 |
Oesophageal atresia | |
esophageal cancer | disease | gastrointestinal system cancer esophageal disease |
gastrointestinal system cancer that is located in the esophagus | C04.588.274.476.205 C04.588.443.353 C06.301.371.205 C06.405.117.430 C06.405.249.205 |
Esophageal cancer | |
esophagitis | disease thoracic disease |
esophageal disease | inflammation of the esophagus | C06.405.117.620 C06.405.205.663 |
||
esotropia | disease | strabismus | Esotropia is a strabismus in which the eye turns inward toward the nose | C10.292.562.887.300 C11.590.810.400 |
Esotropia | |
Essential thrombocytosis | disease | myeloproliferative neoplasm | Human disease | C15.378.100.832 C15.378.140.860.800 C15.378.190.636.860.800 C15.378.463.825 |
||
essential tremor | disease | movement disorder tremor |
A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms. | C10.228.662.350 | ||
esthesioneuroblastoma | disease | blastoma head and neck cancer olfactory nerve neoplasm |
Human disease | C04.557.465.625.600.590.650.550.150 C04.557.470.670.590.650.550.150 C04.557.580.625.600.590.650.550.150 C10.292.650.200 |
||
eumycotic mycetoma | disease | dermatomycosis | Human disease | C01.252.410.040.692.606 C01.252.825.557 C01.539.800.200.500 C01.539.800.720.557 C01.703.295.522 C17.800.838.208.557 C17.800.838.765.557 |
||
euthyroid sick syndrome | disease | thyroid gland disease | Secondary allostasis of thyroid function in fetal life, starving and in critical illness | C19.874.255 | ||
Ewing's sarcoma | disease | sarcoma bone cancer Ewing family of tumor |
bone cancer that has material basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm | C04.557.450.565.575.650.800 C04.557.450.795.620.800 C04.557.465.625.600.590.650 C04.557.470.670.590.650 C04.557.580.625.600.590.650 |
Ewing's sarcoma | |
exanthema subitum | disease | viral infectious disease Roseolovirus infectious disease |
Human disease | C02.256.466.850.290 C02.825.290 C17.800.257.335 C17.800.838.790.290 |
Roseola | |
excessive tearing | disease | lacrimal apparatus disease | Human disease | C11.496 | ||
exocrine pancreatic insufficiency | disease | pancreas disease | Human disease | C06.689.276 | ||
exophthalmos | disease clinical sign |
eye disease | eye disease that is characterized by a bulging of the eye anteriorly out of the orbit | C11.675.349 | Exophthalmos | |
exostosis | disease | hyperostosis | hyperostosis that involves formation of new bone on the surface of preexisting bone | C05.116.540.310 | Exostoses | |
exotropia | disease | strabismus | Human disease | C10.292.562.887.650 C11.590.810.440 |
Exotropia | |
experimental autoimmune encephalomyelitis | disease | encephalomyelitis | C10.114.703.300 C10.228.140.695.562.250 C10.314.350.250 C20.111.258.625.300 |
Experimental autoimmune encephalomyelitis | ||
expressive aphasia | disease | acute aphasia | C10.597.606.150.500.800.100.100 C23.888.592.604.150.500.800.100.100 |
|||
Fabry disease | disease developmental defect during embryogenesis |
sphingolipidosis developmental anomaly of metabolic origin rare genetic skin vascular disorder rare genetic epilepsy syndromic dyslipidemia vascular skin disease hypertrophic cardiomyopathy sphingolipidosis with epilepsy syndromic lymphedema nephropathy secondary to a storage or other metabolic disease cataract associated with a metabolic disease metabolic disease with corneal opacity lysosomal disease with restrictive cardiomyopathy lysosomal disease with hypertrophic cardiomyopathy rare hereditary metabolic disease with peripheral neuropathy syndrome associated with hypertrophic cardiomyopathy |
Human disease | C10.228.140.163.100.435.825.200 C10.228.140.300.275.374 C14.907.253.329.374 C16.320.322.124 C16.320.565.189.435.825.200 C16.320.565.398.641.803.300 C16.320.565.595.554.825.200 C18.452.132.100.435.825.200 C18.452.584.687.803.300 C18.452.648.189.435.825.200 C18.452.648.398.641.803.300 C18.452.648.595.554.825.200 |
Fabry disease | |
facioscapulohumeral muscular dystrophy | disease | muscular dystrophy | An autosomal dominant disorder affecting the skeletal muscles of the face, scapula, and upper arm. Patients present with muscle weakness in these anatomic areas. The muscle weakness eventually spreads to other skeletal muscles as well. | C05.651.534.500.400 C10.668.491.175.500.400 C16.320.577.400 |
||
factitious disorder | disease | mental disorder | disease of mental health where symptoms are deliberately produced, feigned or exaggerated in order to falsely demonstrate the presence of an illness | F03.875.375 | ||
factor XI deficiency | disease | autosomal genetic disease hemophilia coagulation factor deficiency rare hemorrhagic disorder due to a constitutional coagulation factors defect |
Human disease | C15.378.100.100.325 C15.378.100.141.325 C15.378.463.325 C16.320.099.325 |
||
factor XIII deficiency | disease | inherited blood coagulation disease rare hemorrhagic disorder due to a constitutional coagulation factors defect |
Human disease | C15.378.100.100.335 C15.378.100.141.335 C15.378.463.335 C16.320.099.335 |
||
familial adenomatous polyposis | disease | autosomal dominant disease polyposis |
autosomal dominant disease that is has material basis in mutations in the APC gene and involves formation of numerous polyps in the epithelium of the large intestine which are initially benign and later transform into colon cancer | C04.557.470.035.215.100 C04.588.274.476.411.307.089 C04.700.100 C06.301.371.411.307.090 C06.405.249.411.307.090 C06.405.469.158.356.090 C06.405.469.491.307.090 C06.405.469.578.249 C16.320.700.100 |
Familial adenomatous polyposis | |
Familial cold urticaria | disease | Cryopyrin-associated periodic syndrome Cold urticaria primary immunodeficiency disease |
primary immunodeficiency disease characterized by recurrent episodes of maculopapular skin rash triggered by exposure to cold associated with low-grade fever, general malaise, eye redness and arthralgia/myalgia | C16.320.382.500 C17.800.827.368.500 |
||
familial combined hyperlipidemia | disease | familial hyperlipidemia mixed hyperlipidemia |
Human disease | C16.320.565.398.450 C18.452.584.500.500.438 C18.452.648.398.450 |
||
familial Mediterranean fever | disease Designated intractable/rare diseases |
autoimmune disease Urticarial syndromes |
Human disease | C16.320.382.625 | ||
Fanconi anemia | disease | congenital hypoplastic anemia | Human disease | C15.378.071.085.080.280 C15.378.190.196.080.280 C16.320.077.280 C18.452.284.280 |
Fanconi anemia | |
Fanconi syndrome | disease | renal tubular transport disease | renal tubular transport disease of the proximal renal tubes characterized by glucosuria, phosphaturia, generalized aminoaciduria and HCO3 wasting | C12.777.419.815.450 C13.351.968.419.815.450 C16.320.565.861.450 C18.452.648.861.450 |
||
Farber lipogranulomatosis | disease genetic disease |
lipid storage disease | Human disease | C10.228.140.163.100.435.825.250 C16.320.565.189.435.825.250 C16.320.565.398.641.803.325 C16.320.565.595.554.825.250 C18.452.132.100.435.825.250 C18.452.584.687.803.325 C18.452.648.189.435.825.250 C18.452.648.398.641.803.325 C18.452.648.595.554.825.250 |
||
farmer's lung | disease | extrinsic allergic alveolitis | An extrinsic allergic alveolitis which is induced by the inhalation of spores (Aspergillus sp and thermophilic actinomycetes) in dust from moldy hay or straw. It is characterized by sudden onset, fever, cough, expectoration, and breathlessness. | C08.381.483.125.365 C08.674.055.365 C20.543.480.680.075.365 C24.080.365 |
||
fasciitis | disease | connective tissue disease | Inflammation process in fascia | C05.321 | ||
fasciolopsiasis | disease | parasitic helminthiasis infectious disease | A parasitic helminthiasis infectious disease that involves parasitic infection of the intestine by Fasciolopsis buski. The symptoms include diarrhea, abdominal pain, fever, ascites, anasarca and intestinal obstruction. | C03.335.865 | ||
fasciolosis | disease infectious disease |
distomatosis parasitic helminthiasis infectious disease |
human disease | C03.335.865.354 C03.518.424 C06.552.664.424 |
Fascioliasis | |
fatal familial insomnia | disease | transmissible spongiform encephalopathy rare disease inherited prion disease insomnia |
Fatal familial insomnia (FFI) is a very rare form of prion disease (see this term) characterized by subacute onset of insomnia showing as a reduced overall sleep time, autonomic dysfunction, and motor disturbances | C10.228.228.800.392 C10.574.843.512 C10.886.425.800.800.400 |
||
favism | disease | glucose-6-phosphate dehydrogenase deficiency | glucosephosphate dehydrogenase deficiency characterized by a hemolytic reaction to consumption of broad beans | C15.378.071.141.150.480.370 C15.378.071.141.370 C16.320.070.480.370 C25.723.415.341 C25.723.756.375 |
||
fecal incontinence | disease | impairment of continence | inability to refrain from defecation | C06.405.469.860.300 | ||
Felty's syndrome | disease arthropathy |
syndrome rare bone disease acquired neutropenia rare rheumatologic disease |
syndrome that results in rheumatoid arthritis, splenomegaly and neutropenia | C05.550.114.154.389 C05.799.114.389 C17.300.775.099.389 C20.111.199.389 |
||
fetal erythroblastosis | disease | neonatal alloimmune disease microcytic anemia hematological disease of fetus and newborn |
Human disease | C13.703.277.060 C15.378.295 C16.300.060 C16.614.304 C20.306 |
Hemolytic disease of the newborn | |
fibrillary astrocytoma | disease | brain tumor astrocytoma |
astrocytoma that is characterized as a low grade astrocytoma and has material basis in neoplastic astrocytes | C04.557.465.625.600.380.080 C04.557.470.670.380.080 C04.557.580.625.600.380.080 |
||
fibrodysplasia ossificans progressiva | disease | connective tissue disease genetic disease Heterotopic ossification |
extremely rare connective tissue disease | C05.651.594.638 | Fibrodysplasia ossificans progressiva | |
fibromyalgia | disease | myositis chronic pain syndrome |
A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation. | C05.651.324 C05.799.321 C10.668.491.425 |
Fibromyalgia | |
fibrosarcoma | disease | connective tissue neoplasm | connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern | C04.557.450.565.590.350 C04.557.450.795.350 C04.557.450.565.590 |
||
fibrous dysplasia | disease | bone remodeling disease | bone remodeling disease that results in the destruction of normal bone and replacing it with fibrous bone tissue | C05.116.099.708.375 | Fibrous dysplasia | |
filarial elephantiasis | disease | filariasis skin disease |
tropical helminthiasis | C03.335.508.700.750.361.350 C15.604.496.490 |
Elephantiasis | |
filariasis | disease infectious disease |
nematode infection parasitic helminthiasis infectious disease |
parasitic disease caused by a family of nematode worms | C03.335.508.700.750.361 | Filariasis | |
fistula | disease | symptom | abnormal connection between two hollow spaces (technically, two epithelialized surfaces), such as blood vessels, intestines, or other hollow organs | C23.300.575 | Fistulae | |
Flail chest | disease | C26.891.315 | Flail chest | |||
flat feet problems | disease | foot deformity | human foot arch that is very low | C05.330.488.655.250 C05.330.495.681.250 C05.660.585.512.380.813.250 C16.131.621.585.512.500.681.250 |
Flat feet | |
focal hand dystonia | disease | focal dystonia occupational disease |
focal dystonia that affects a single muscle or small group of muscles in the hand resulting from involuntary muscular contractions | C10.228.662.300 | ||
focal segmental glomerulosclerosis | disease | glomerulosclerosis nephrotic syndrome |
kidney disease | C12.777.419.570.363.660 C13.351.968.419.570.363.640 |
Focal segmental glomerulosclerosis | |
follicular lymphoma | disease | B-cell lymphoma | non-Hodgkin lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts). | C04.557.386.480.350 C15.604.515.569.480.350 C20.683.515.761.480.350 |
Follicular lymphoma | |
folliculitis | disease | dermatitis hair disease |
Human disease | C17.800.329.500 | Folliculitis | |
food allergy | disease | food hypersensitivity gastrointestinal allergy |
hypersensitivity reaction type I disease that is an abnormal response to a food, triggered by the body's immune system | C20.543.480.370 | Food allergy | |
Foster-Kennedy syndrome | disease | Papilledema | Human disease | C10.292.700 C11.640 |
||
Fox-Fordyce disease | disease | sweat gland disease | Human disease | C17.800.946.492.285 | ||
fragile X syndrome | disease | X-linked mental retardation overgrowth syndrome X-linked disease |
congenital disorder of nervous system | C10.597.606.643.455.500 C16.131.260.830.300 C16.320.180.830.300 C16.320.322.500.500 C16.320.400.525.500 |
Fragile X syndrome | |
Fraser syndrome | disease head and neck disease developmental defect during embryogenesis |
Cryptophthalmos autosomal recessive disease syndromic genetic deafness syndromic renal or urinary tract malformation syndromic developmental defect of the eye syndromic anorectal malformation multiple congenital anomalies/dysmorphic syndrome without intellectual disability |
Fraser syndrome is a rare clinical entity including as main characteristics cryptophthalmos and syndactyly | C05.116.099.370.894.819.428 C05.660.585.800.428 C05.660.906.819.428 C11.250.390 C12.706.410 C13.351.875.397 C16.131.077.371 C16.131.384.442 C16.131.621.585.800.428 C16.131.621.906.819.428 C16.131.939.410 |
Fraser syndrome | |
freemartinism | disease | sex differentiation disease | Human disease | C12.706.316.795.124 C13.351.875.253.795.124 C16.131.939.316.795.124 C19.391.119.795.124 C22.196.339 |
||
Frey syndrome | disease | autonomic nervous system disease | Human disease | C10.177.825 C17.800.946.350.843 |
Frey's syndrome | |
Friedreich ataxia | disease | autosomal recessive cerebellar ataxia autosomal recessive degenerative and progressive cerebellar ataxia |
Human disease | C10.228.140.252.700.150 C10.228.854.787.200 C10.574.500.825.200 C16.320.400.780.200 C18.452.660.300 |
||
Froelich syndrome | disease | Hypothalamic disease | hypothalamic disease that is characterized by endocrine dysfunction of the hypothalamic gland resulting in delayed puberty, small testes, and obesity | C10.228.140.617 | Adiposogenital dystrophy | |
frostbite | disease | cold injury | medical condition where localized damage is caused to skin and other tissues due to freezing | C26.212.500 C26.417 |
Frostbite | |
Fuchs' endothelial dystrophy | disease | corneal endothelial dystrophy | corneal dystrophy characterized by accumulation of focal outgrowths (guttae) and thickening of Descemet's membrane, leading to corneal edema and loss of vision | C11.204.236.438 C11.270.162.438 C16.320.290.162.410 |
Fuchs' dystrophy | |
fucosidosis | disease developmental defect during embryogenesis |
lysosomal storage disease rare genetic developmental defect during embryogenesis hypertrophic cardiomyopathy oligosaccharidosis lysosomal storage disease with skeletal involvement lysosomal disease with hypertrophic cardiomyopathy |
Human disease | C10.228.140.163.100.435.295 C16.320.565.189.435.295 C16.320.565.202.303 C16.320.565.595.554.295 C18.452.132.100.435.295 C18.452.648.189.435.295 C18.452.648.202.303 C18.452.648.595.554.295 |
||
fungal infectious disease | disease | infectious disease Bacterial Infections and Mycoses |
fungal infection of animals, including humans | C01.703 | Diseases and disorders due to fungi | |
gait abnormality | disease | movement disorder | C10.597.404 C23.888.592.413 |
|||
galactosemia | disease | carbohydrate metabolic disorder | carbohydrate metabolic disorder that involves a defect in galactose metabolism resulting in toxic levels of galactose 1-phosphate in various tissues | C10.228.140.163.100.320 C16.320.565.189.320 C16.320.565.202.355 C18.452.132.100.320 C18.452.648.189.320 C18.452.648.202.355 |
||
gallbladder cancer | disease | biliary tract cancer gallbladder disease |
biliary tract cancer that is located in the gallbladder | C04.588.274.120.401 C06.130.320.401 C06.130.564.401 C06.301.120.401 |
Gallbladder cancer | |
gamma chain deficiency | disease | severe combined immunodeficiency T+ B+ severe combined immunodeficiency |
Human disease | C16.320.322.968 C16.614.815.500 C20.673.815.500 |
||
ganglioglioma | disease | cell type benign neoplasm | cell type benign neoplasm that has material basis in glial-type cells | C04.557.465.625.600.380.350 C04.557.470.670.380.350 C04.557.580.625.600.380.350 |
Ganglioglioma | |
ganglioneuroma | disease | autonomic nervous system neoplasm | Human disease | C04.557.465.625.600.355 C04.557.470.670.355 C04.557.580.625.600.355 |
Ganglioneuroma | |
gangliosidosis | disease | sphingolipidosis rare genetic epilepsy rare dyslipidemia sphingolipidosis with epilepsy |
Human disease | C10.228.140.163.100.435.825.300 C16.320.565.189.435.825.300 C16.320.565.398.641.803.350 C16.320.565.595.554.825.300 C18.452.132.100.435.825.300 C18.452.584.687.803.350 C18.452.648.189.435.825.300 C18.452.648.398.641.803.350 C18.452.648.595.554.825.300 |
||
Gardner's syndrome | disease | congenital disorder of digestive system | C04.557.470.035.215.100.500 C04.588.274.476.411.307.089.393 C04.700.100.392 C06.301.371.411.307.090.500 C06.405.249.411.307.090.500 C06.405.469.158.356.090.500 C06.405.469.491.307.090.500 C06.405.469.578.249.393 C16.131.077.393 C16.320.700.100.393 |
Gardner's syndrome | ||
gas gangrene | disease infectious disease |
commensal bacterial infectious disease muscle tissue disease bacterial skin disease |
disease for all sorts of living things | C01.252.410.222.440 | Gas gangrene | |
gastric antral vascular ectasia | disease | capillary disease Ectasia vascular ectasia |
Human disease | C06.405.748.280 C14.907.075.280 |
||
gastric mucosal hypertrophy | disease | gastritis rare gastroesophageal disease genetic disease rare genetic gastroenterological disease |
Human disease | C06.405.205.697.410 C06.405.748.398.410 |
Ménétrier's disease | |
gastrinoma | disease | neuroendocrine tumor | neuroendocrine tumor that results in an overproduction of gastric acid | C04.557.470.200.025.290.500 C04.588.274.761.500.124 C04.588.322.475.500.124 C06.301.761.500.124 C06.689.667.500.124 C19.344.421.500.124 |
Gastrinoma | |
gastritis | disease | stomach disease | stomach disease that is an inflammation of the lining of the stomach. | C06.405.205.697 C06.405.748.398 |
Gastritis | |
gastroenteritis | disease | gastrointestinal system disease | medical condition characterized by inflammation of the stomach and/or small intestine | C06.405.205 | Gastroenteritis | |
gastroenterocolitis | disease | disease characterized by inflammation of the stomach, small intestines, and colon | C02.782.600.550.200.400 C22.905.469 |
|||
gastroesophageal reflux disease | disease | gastrointestinal system disease esophageal disease genetic disease stomach disease |
disease caused by stomach acid coming up from the stomach into the esophagus | C06.405.117.119.500.484 | Gastroesophageal reflux disease | |
gastrointestinal stromal tumor | disease | gastrointestinal system cancer Stromal tumor rare genetic intestinal disease inherited digestive tract tumor mesenchymal tumor of small intestine |
Human disease | C04.557.450.565.370 C06.301.371.308 C06.405.249.308 |
Gastrointestinal stromal tumors | |
gastroparesis | disease | functional gastric disease | Human disease | C06.405.748.543 C23.888.592.636.263 |
||
gastroschisis | disease developmental defect during embryogenesis |
birth defect Abdominal wall defect rare genetic developmental defect during embryogenesis primary short bowel syndrome non-syndromic diaphragmatic or abdominal wall malformation |
Human disease | C05.660.417 C16.131.621.417 C23.300.707.374.500 |
Gastroschisis | |
Gaucher's disease | disease | sphingolipidosis | human disease characterized by deficiency of the enzyme glucocerebrosidase which results in the accumulation of harmful quantities of the glycolipid glucocerebroside throughout the body | C10.228.140.163.100.435.825.400 C16.320.565.189.435.825.400 C16.320.565.398.641.803.441 C16.320.565.595.554.825.400 C18.452.132.100.435.825.400 C18.452.584.687.803.441 C18.452.648.189.435.825.400 C18.452.648.398.641.803.441 C18.452.648.595.554.825.400 |
||
genetic disease | disease | hereditary disorder disease |
disease that has material basis in genetic variations in the human genome | C16.320 | Genetic diseases and disorders | |
geniculate herpes zoster | disease | herpes zoster poliomyelitis facial nerve disease |
Human disease | C02.256.466.423.733 C07.465.299.750 C09.218.513 C10.292.319.750 |
Ramsay Hunt syndrome type II | |
genu varum | disease | knee disorder varus deformity |
O-knees | C05.116.511 | Genu varum | |
geographic tongue | disease | inflammation tongue disease atrophic glossitis |
atrophic glossitis that is characterized as an inflammatory condition of the mucous membrane of the tongue, usually on the dorsal surface | C07.465.910.363.447 | Geographic tongue | |
germinoma | disease | germ cell cancer | A germ cell cancer that lacks histologic differentiation. It usually refers to a tumor in the brain. | C04.557.465.330 | Germinoma | |
Gerstmann syndrome | disease | neurological disorder | nervous system disease that results from damage located in left parietal lobe, has symptom agraphia, has symptom acalculia, has symptom finger agnosia | C10.597.606.762.100.300 C23.888.592.604.764.100.300 |
||
Gerstmann-Straussler-Scheinker syndrome | disease | transmissible spongiform encephalopathy inherited prion disease |
prion disease characterized by adult onset of memory loss, dementia, ataxia, and pathologic deposition of amyloid-like plaques in the brain | C10.228.228.800.350 C10.574.500.425 C10.574.843.400 C16.320.400.350 |
Gerstmann–Sträussler–Scheinker syndrome | |
gestational diabetes | disease | diabetes mellitus complication of pregnancy, childbirth and the puerperium diabetes mellitus and pregnancy |
condition in which a woman without diabetes develops high blood sugar levels during pregnancy | C13.703.170 C18.452.394.750.448 C19.246.200 |
||
gestational trophoblastic neoplasm | disease | trophoblastic neoplasm | Human disease | C04.557.465.955.416 C04.850.908.416 C13.703.720.949.416 C04.557.465.955.416.812 C04.850.908.416.750 C13.703.720.949.416.875 |
Hydatidiform moles | |
Giant condyloma acuminatum | disease | C02.256.650.810.217.500 C02.800.801.220.500 C02.825.810.110.500 C02.928.914.217.500 C04.557.470.200.450.500 C04.557.470.700.450.500 C17.800.838.790.810.110.500 |
||||
giardiasis | disease | parasitic protozoa infectious disease | parasitic disease caused by Giardia lamblia | C03.432.481 C03.752.400 C06.405.469.452.481 |
Giardiasis | |
gigantism | disease | tall stature | Human disease | C05.116.099.492 C05.116.132.479 C19.700.355.528 |
Gigantism | |
Gilbert syndrome | disease | bilirubin metabolic disorder | metabolic disorder | C16.320.565.300.528 C18.452.648.300.528 |
||
Gilles de la Tourette syndrome | disease | tic disorder genetic disease rare genetic movement disorder |
congenital disorder of nervous system | C10.228.140.079.898 C10.228.662.825.800 C10.574.500.850 C16.320.400.820 |
Tourette syndrome | |
gingivitis | disease | symptom gingival disease |
Human disease | C07.465.714.258.480 | Gingivitis | |
Gitelman syndrome | disease | renal tubular transport disease inherited renal tubular disease |
Human disease | C12.777.419.815.491 C13.351.968.419.815.491 C16.320.565.861.491 C18.452.648.861.491 |
Gitelman syndrome | |
glanders | disease infectious disease |
primary bacterial infectious disease | Human disease | C01.252.400.170.400 C22.488.409 |
Glanders | |
Glanzmann's thrombasthenia | disease | blood platelet disease inherited blood coagulation disease rare hemorrhagic disorder due to a qualitative platelet defect |
Human disease | C15.378.100.100.820 C15.378.140.810 C15.378.463.810 C16.320.099.820 |
||
glaucoma | disease | eye disease | eye disease that is characterized by an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function | C11.525.381 | Glaucoma | |
glioblastoma multiforme | disease | astrocytoma | Human disease | C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335 |
Glioblastoma | |
glioma | disease | cell type cancer | a type of tumor that starts in the brain or spine | C04.557.465.625.600.380 C04.557.470.670.380 C04.557.580.625.600.380 |
Gliomas | |
gliomatosis cerebri | disease | brain cancer | Human disease | C04.557.465.625.600 C04.557.470.670 C04.557.580.625.600 |
||
gliosarcoma | disease | glioblastoma multiforme | Human disease | C04.557.465.625.600.380.400 C04.557.470.670.380.400 C04.557.580.625.600.380.400 |
||
glomerulonephritis | disease | Sida por cojer mucho glomerulopathy |
nephritis that causes inflammation of the glomeruli located in kidney | C12.777.419.570.363 C13.351.968.419.570.363 |
Glomerulonephritis | |
glossitis | disease | tongue disease inflammatory disease |
Human disease | C07.465.910.363 | Glossitis | |
glucagonoma | disease | C04.557.470.200.025.290.750 C04.588.274.761.500.249 C04.588.322.475.500.249 C06.301.761.500.249 C06.689.667.500.249 C19.344.421.500.249 |
||||
glucose-6-phosphate dehydrogenase deficiency | disease | carbohydrate metabolic disorder | carbohydrate metabolic disorder that is characterised by abnormally low levels of glucose-6-phosphate dehydrogenase (abbreviated G6PD or G6PDH) | C15.378.071.141.150.480 C16.320.070.480 C16.320.565.202.402 C18.452.648.202.402 |
||
glycogen storage disease | disease | glycogen metabolism disorder overload disease carbohydrate metabolic disorder |
glycogen metabolism disorder that has material basis in enzymes deficiencies necessary in the processing of glycogen synthesis or breakdown within muscles, liver, and other cell types | C16.320.565.202.449 C18.452.648.202.449 |
Glycogen storage disease | |
glycogen storage disease I | disease | glycogen storage disease | rare disease | C16.320.565.202.449.448 C18.452.648.202.449.448 |
||
glycogen storage disease II | disease | glycogen storage disease hypertrophic cardiomyopathy muscular glycogenosis lysosomal disease with restrictive cardiomyopathy lysosomal disease with hypertrophic cardiomyopathy glycogen storage disease with hypertrophic cardiomyopathy lysosomal glycogen storage disease |
autosomal recessive metabolic disorder | C10.228.140.163.100.435.340 C16.320.565.189.435.340 C16.320.565.202.449.500 C16.320.565.595.554.340 C18.452.132.100.435.340 C18.452.648.189.435.340 C18.452.648.202.449.500 C18.452.648.595.554.340 |
Glycogen storage disease type II | |
glycogen storage disease III | disease | glycogen storage disease | Human disease | C16.320.565.202.449.520 C18.452.648.202.449.520 |
||
glycogen storage disease IV | disease | glycogen storage disease | Human disease | C16.320.565.202.449.540 C18.452.648.202.449.540 |
||
glycogen storage disease V | disease | glycogen storage disease muscular glycogenosis |
Human disease | C16.320.565.202.449.560 C18.452.648.202.449.560 |
||
glycogen storage disease VI | disease | glycogen storage disease rare metabolic liver disease |
Glycogen storage disease | C16.320.565.202.449.580 C18.452.648.202.449.580 |
||
glycoproteinosis | disease | lysosomal storage disease | endocrine disease | C05.116.198.371 C10.228.140.163.100.435.590 C16.320.565.189.435.590 C16.320.565.202.670 C16.320.565.595.554.590 C18.452.132.100.435.590 C18.452.648.189.435.590 C18.452.648.202.670 C18.452.648.595.554.590 |
Glycoprotein metabolism disorders | |
goiter | disease | thyroid gland disease | swelling of the thyroid gland | C19.874.283 | Goiters | |
Goldenhar syndrome | disease head and neck disease developmental defect during embryogenesis |
syndrome Hemifacial microsomia skull cancer cornea cancer bulbar conjunctival dermoid or conjunctival dermolipoma syndromic corneal dystrophy lens shape anomaly syndromic palpebral coloboma syndromic developmental defect of the eye Pierre robin syndrome associated with branchial archs anomalies oculo-auriculo-vertebral spectrum |
A syndrome that is characterized by incomplete development of the ear, nose, soft palate, lip, and mandible. It is associated with anomalous development of the first branchial arch and second branchial arch. | C05.116.099.370.231.576.410 C05.660.207.231.576.410 C16.131.621.207.231.576.410 |
||
gonadal dysgenesis | disease | hypogonadism | hypogonadism that is characterized by a progressive loss of germ cells on the developing gonads of an embryo | C12.706.316.309 C13.351.875.253.309 C16.131.939.316.309 C19.391.119.309 |
||
gonorrhea | disease | primary bacterial infectious disease gonococcal infectious diseases |
sexually transmitted infection | C01.252.400.625.391 C01.252.810.401 C01.539.778.281.401 C12.294.668.281.401 C13.351.500.711.281.401 |
Gonorrhea | |
Goodpasture syndrome | disease | autoimmune disease secondary glomerular disease secondary interstitial lung disease in childhood and adulthood associated with a systemic disease predominantly small-vessel vasculitis autoimmune vasculitis |
hypersensitivity reaction type II disease that is characterized by glomerulonephritis located in kidney and hemorrhaging located in lung | C08.381.483.156 C12.777.419.570.363.304 C13.351.968.419.570.363.304 C20.111.190 |
||
Gorham's disease | disease | syndrome Osteolysis |
A syndrome that is characterized by bone loss (osteolysis) which is often associated with swelling or abnormal blood vessel growth (angiomatous proliferation). Bone loss can occur in just one bone or spread to soft tissue and adjacent bones. | C05.116.099.736 C05.116.264.579.704 |
Gorham's disease | |
gout | disease | arthritis genetic disease crystal arthropathy disease of metabolism |
condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals | C05.550.114.423 C05.550.354.500 C05.799.414 C16.320.565.798.368 C18.452.648.798.368 C05.550.114.423.410 C05.550.354.500.500 C05.799.414.410 C16.320.565.798.368.410 C18.452.648.798.368.410 |
Gout | |
Gradenigo's syndrome | disease | disease | C01.539.160.495.750 C05.116.165.495.500 C09.218.705.663.841 |
|||
granular cell tumor | disease | skin benign neoplasm | Human disease | C04.557.450.590.350 | Granular cell tumor | |
Granuloma | disease | C15.604.515.292 C23.550.382 |
Granuloma | |||
granuloma annulare | disease | dermatitis necrobiotic disorders |
Human disease | C17.300.200.495.380 C17.800.550.380 C23.550.382.375 |
Granuloma annulare | |
granuloma inguinale | disease infectious disease |
primary bacterial infectious disease bacterial sexually transmitted disease |
Human disease | C01.252.400.310.416 C01.252.810.451 C01.252.825.360 C01.539.778.281.451 C01.539.800.720.360 C12.294.668.281.451 C13.351.500.711.281.451 C17.800.838.765.360 |
Donovanosis | |
Guillain–Barré Syndrome | disease | autoimmune disease of peripheral nervous system immune system disease rare neuroinflammatory or neuroimmunological disease acute and subacute inflammatory demyelinating polyneuropathy |
autoimmune disease that causes the immune system to attack part of the peripheral nervous system | C10.114.750.100 C10.314.750.450 C10.668.829.350 C10.668.829.800.750.300 C20.111.258.750.400 |
Guillain–Barré syndrome | |
Gulf War syndrome | disease | syndrome | syndrome affecting returning military veterans and civilian workers of the Gulf War | C24.653 | ||
gynatresia | disease | female reproductive system disease atresia |
Human disease | C13.351.500.320 | ||
gynecomastia | disease | sex differentiation disease | Human disease | C17.800.090.875 | Gynecomastia | |
Hailey-Hailey disease | disease | pemphigus | Human disease | C16.320.850.700 C17.800.827.700 C17.800.865.858 |
Hailey–Hailey disease | |
hairy cell leukemia | disease | chronic lymphocytic leukemia | chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope | C04.557.337.415 C15.604.515.553 C20.683.515.517 |
Hairy cell leukemia | |
hairy tongue | disease | tongue disease | Human disease | C07.465.910.791 | Black hairy tongue | |
Hajdu-Cheney syndrome | disease | autosomal dominant disease | rare disease | C05.116.099.052 C05.116.264.579.052 C05.116.099.052.400 C05.116.264.579.052.400 C16.131.621.445 C16.320.355 |
||
Hallermann-Streiff syndrome | disease developmental defect during embryogenesis |
syndrome Slender bone dysplasia congenital absence of the eyebrow/eyelashes ectodermal malformation syndrome associated with ocular features craniofacial anomaly with cataract multiple congenital anomalies/dysmorphic syndrome-variable intellectual disability syndrome malformation syndrome with short stature rare genetic syndromic intellectual disability |
congenital disorder | C05.116.099.370.231.427 C05.660.207.231.427 C16.131.621.207.231.427 |
||
hallux rigidus | disease | foot deformity | disease | C05.330.488.310 C05.550.450 |
Hallux rigidus | |
hamartoma | disease | A non cancerous growth made up of an abnormal mixture of cells and tissues normally found in the area of the body. | C04.445 | Hamartomas | ||
Hartnup disease | disease | amino acid metabolic disorder Amino acid transport disorder neurometabolic disease Photodermatosis nephropathy secondary to a storage or other metabolic disease disorder of neutral amino acid transport genetic photodermatosis |
Human disease | C10.228.140.163.100.355 C12.777.419.815.885.457 C13.351.968.419.815.885.625 C16.320.565.151.355 C16.320.565.189.355 C16.320.565.861.885.457 C18.452.132.100.355 C18.452.648.151.355 C18.452.648.189.355 |
||
head and neck cancer | disease | organ system cancer head neoplasm |
organ system cancer that arises in the head or neck region (including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx) | C04.588.443 | Head and neck cancer | |
heart cancer | disease | cardiovascular cancer Primary tumors of the heart heart disease thoracic cancer |
cardiovascular cancer located in the heart | C04.588.894.309 C14.280.459 |
||
heart disease | disease | cardiovascular disease | cardiovascular system disease that involves the heart | C14.280 | Diseases and disorders of the heart | |
heart failure | disease | cardiovascular disease | condition in which the heart is unable to provide sufficient pump action | C14.280.434 | Heart failure | |
heart valve disease | disease | heart disease | disease in the valves of the heart | C14.280.484 C14.280.484.400 |
Diseases and disorders of the heart valves | |
heat illness | disease | hyperthermia | condition caused by the failure of body to dissipate heat in an excessively hot environment | C26.522.500 | ||
HELLP syndrome | disease | severe pre-eclampsia | severe pre-eclampsia characterized by hemolysis, elevated liver enzyme and low platelet count | C13.703.395.186 | ||
hemangioblastoma | disease | hemangioma rare nervous system tumor |
tumor of the central nervous system that originates from the vascular system | C04.557.645.375.380.370 | Hemangioblastoma | |
hemangioma | disease | cell type benign neoplasm angioma vascular tumor |
cell type benign neoplasm that has physical basis in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood | C04.557.645.375 | Skin hemangioma | |
hemarthrosis | disease arthropathy |
arthropathy arthropathy associated with hematological disorder |
Human disease | C05.550.459 C23.550.414.794 |
Hemarthrosis | |
hematocele of tunica vaginalis testis | disease | male reproductive system disease | Human disease | C12.294.287 C23.550.414.817 |
Hematocele | |
hematopoietic system diseases | disease | symptom disease of anatomical entity |
disorder which primarily affects the blood | C15.378 | Diseases and disorders of the blood | |
Hemiplegia | disease | paralysis central nervous system disease |
paralysis of the arm, leg, and trunk on the same side of the body | C10.597.622.295 C23.888.592.636.312 |
||
hemoglobin C | disease | hemoglobinopathy rare constitutional hemolytic anemia |
Human disease | C15.378.071.141.150.490 C15.378.420.463 C16.320.070.490 C16.320.365.463 |
||
hemoglobinopathy | disease | congenital hemolytic anemia genetic disease hemolytic anemia |
Human disease | C15.378.420 C16.320.365 |
||
hemoglobinuria | disease | proteinuria hemolytic anemia |
Human disease | C12.777.934.734.634 C13.351.968.934.734.634 C23.888.942.750.634 |
||
hemolytic anemia | disease | anemia normocytic anemia |
form of anemia due to hemolysis | C15.378.071.141 | Hemolytic diseases and disorders | |
hemolytic-uremic syndrome | disease | kidney disease | Human disease | C12.777.419.936.463 C13.351.968.419.936.463 C15.378.071.141.610 C15.378.140.855.925.500 |
||
hemophagocytic lymphohistiocytosis | disease | lymphatic system disease | Human disease | C15.604.250.410.575 | Hemophagocytic lymphohistiocytosis | |
hemopneumothorax | disease | pneumothorax hemothorax |
medical term describing the combination of two conditions: pneumothorax, or air in the chest cavity, and hemothorax (also called hæmothorax), or blood in the chest cavity | C08.528.338 C23.550.414.904.500 |
||
hemorrhagic disease | disease | blood coagulation disease | Human disease | C15.378.463 | ||
Henoch-Schoenlein purpura | disease | hypersensitivity vasculitis nonthrombocytopenic purpura |
Human disease | C14.907.940.777 C15.378.100.802.375 C15.378.463.515.580 C20.543.520.600 C23.550.414.950.375 C23.888.885.687.375 |
Henoch–Schönlein purpura | |
hepatic encephalopathy | disease | brain disease | brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood | C06.552.308.500.356 C10.228.140.163.360 C18.452.132.360 |
||
hepatic vein thrombosis | disease | hepatic vascular disease venous thrombosis |
Human disease | C06.552.347 C14.907.355.830.925.275 |
Budd–Chiari syndrome | |
hepatitis | disease | liver disease | inflammation of the liver tissue | C06.552.380 C06.552.380.350 |
Hepatitis | |
hepatitis A | disease infectious disease |
viral infectious disease viral hepatitis Skin infection |
acute infectious disease of the liver | C02.440.420 C02.782.687.359.500 C06.552.380.705.422 |
Hepatitis A | |
hepatitis C | disease infectious disease |
viral infectious disease viral hepatitis Skin infection |
human viral infection | C02.440.440 C02.782.350.350 C06.552.380.705.440 C02.440.440.120 C02.782.350.350.120 C06.552.380.350.120 C06.552.380.705.440.120 |
Hepatitis C | |
hepatitis D | disease infectious disease |
viral infectious disease viral hepatitis post-viral disorder rare hepatic disease rare skin disease hepatitis B |
Human disease | C02.440.450 C02.782.450 C06.552.380.705.450 |
||
hepatitis E | disease infectious disease |
viral infectious disease Hepeviridae infectious disease viral hepatitis Skin infection |
Human disease | C02.440.470 C02.782.455 C06.552.380.705.470 |
Hepatitis E virus | |
hepatoblastoma | disease | liver cancer | Human disease | C04.557.435.380 | Hepatoblastoma | |
hepatocellular adenoma | disease | adenoma liver neoplasm |
human disease | C04.557.470.035.120 C04.588.274.623.040 C06.301.623.040 C06.552.697.040 |
||
hepatocellular carcinoma | disease | liver carcinoma | liver carcinoma that has material basis in undifferentiated hepatocytes | C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160 |
Hepatocellular carcinoma | |
hepatoerythropoietic porphyria | disease | acute porphyria Erythropoietic porphyria |
Human disease | C06.552.830.437 C16.320.850.742.437 C17.800.827.742.437 C18.452.811.400.437 |
||
hepatopulmonary syndrome | disease | liver disease | Human disease | C06.552.455 C08.381.385 |
||
hepatorenal syndrome | disease | acute kidney injury liver disease |
Human disease | C06.552.465 C12.777.419.291 C13.351.968.419.291 |
Hepatorenal syndrome | |
hereditary angioedema | disease | angioedema | human disease | C14.907.079.500 C16.320.078 C17.800.862.945.066.500 C20.543.480.904.066.500 |
Hereditary angioedema | |
hereditary coproporphyria | disease | acute porphyria | Human disease | C06.552.830.074 C16.320.850.742.074 C17.800.827.742.074 C18.452.811.400.074 |
||
hereditary fructose intolerance syndrome | disease | carbohydrate metabolic disorder nephropathy secondary to a storage or other metabolic disease disorder of carbohydrate absorption and transport disorder of fructose metabolism metabolic disease with intestinal involvement rare metabolic liver disease congenital intestinal transport defect |
Human disease | C16.320.565.202.251.271 C18.452.648.202.251.271 |
||
hereditary hemorrhagic telangiectasia | disease | autosomal dominant disease | autosomal dominant disease characterized by tarteriovenous malformations that lack intervening capillaries and result in direct connections between arteries and veins | C14.907.454.900 C14.907.823.780 C15.378.463.515.900 C16.131.240.850.968 |
Hereditary hemorrhagic telangiectasia | |
hereditary lymphedema | disease | lymphedema Primary lymphedema |
lymphedema commonly located in legs, caused by congenital abnormalities in the lymphatic system | C15.604.496 | ||
hereditary multiple exostoses | disease | exostosis | exostosis that has material basis in a mutation on the genes EXT1, EXT2 and EXT3 which results in multiple bony spurs throughout a child's growth | C04.557.450.565.575.610.615.325 C04.700.330 C05.116.099.708.670.615.325 C05.116.540.310.500 C16.320.700.330 |
Hereditary multiple exostoses | |
hereditary spastic paraplegia | disease | paraplegia genetic neurodegenerative disease |
Hereditary spastic paraplegias (HSP) comprise a genetically and clinically heterogeneous group of neurodegenerative disorders characterized by progressive spasticity and hyperreflexia of the lower limbs | C10.500.300.820 C10.574.500.495.820 C10.668.829.800.300.820 C16.131.666.300.820 C16.320.400.375.820 |
||
hereditary spherocytosis | disease | congenital hemolytic anemia spherocytosis |
congenital hemolytic anemia characterized by the production of red blood cells with a sphere shape, rather than the normal biconcave disk shape | C15.378.071.141.150.785 C16.320.070.785 |
||
Hermansky-Pudlak syndrome | disease | autosomal recessive disease | rare disease | C11.270.040.545.400 C15.378.100.100.515 C15.378.100.685.400 C15.378.140.735.400 C15.378.463.735.400 C16.320.099.515 C16.320.290.040.100.400 C16.320.565.100.102.100.400 C16.320.850.080.100.400 C17.800.621.440.102.100.400 C17.800.827.080.100.400 C18.452.648.100.102.100.400 |
||
herpangina | disease infectious disease |
viral infectious disease coxsackievirus infectious disease mouth disease |
Human disease | C02.782.687.359.213.466 C02.782.687.359.347.500 |
Herpangina | |
herpes simplex virus keratitis | disease health problem |
keratitis herpes simplex Herpesviridae infectious disease |
keratitis that has material basis in herpes simplex type infection | C02.256.466.382.465.450 C02.325.465.450 C11.204.564.425.450 C11.294.800.475.450 C02.256.466.382.465 C02.325.465 C11.204.564.425 C11.294.800.475 |
Herpetic simplex keratitis | |
herpes zoster | disease infectious disease |
viral infectious disease Skin infection varicella zoster infection post-viral disorder |
human disease caused by varicella zoster | C02.256.466.423 | Herpes zoster | |
hiatus hernia | disease hern |
abdominal hernia stomach disease genetic disease |
congenital disorder of digestive system | C23.300.707.500.467 | Hiatal hernia | |
hidradenitis suppurativa | disease | hidradenitis | Human disease | C01.252.825.420 C01.539.800.720.420 C01.539.830.499 C17.800.838.765.420 C17.800.946.315.320 |
Hidradenitis suppurativa | |
hidrocystoma | disease | apocrine sweat gland neoplasm benign neoplasm of sweat gland |
Human disease | C04.557.470.035.175.375 C04.557.470.550.175.375 |
||
high pressure neurological syndrome | disease | central nervous system disease diving disorder |
neurological and physiological disorder experienced by divers | C10.228.566 C24.410 |
||
hip dysplasia | disease | developmental dislocation of joint genetic disease |
human disease | C05.660.449 C16.131.621.449 |
Hip dysplasia | |
Hirschsprung's disease | disease | megacolon intestinal dysganglionosis |
congenital disorder of digestive system | C06.198.439 C06.405.469.158.701.439 C16.131.314.439 |
Hirschsprung's disease | |
hirsutism | disease | hypertricosis virilism |
hair growth on a woman, generally causing a full beard to grow (see bearded lady) | C17.800.329.750 C23.888.971.468 |
||
histiocytosis | disease | lymphatic system disease | lymphatic system disease that is characterized by an excessive number of histiocytes | C15.604.250 | Histiocytoses | |
histoplasmosis | disease | primary systemic mycosis genetic disease |
human disease | C01.703.450 | Histoplasmosis | |
Hodgkin's lymphoma | disease | lymphoma | lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell | C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355 |
Hodgkin's lymphoma | |
holoprosencephaly | disease | cephalic disorder | congenital disorder of nervous system | C05.660.207.410 C10.500.034.875 C16.131.077.410 C16.131.260.380 C16.131.621.207.410 C16.131.666.034.875 C16.320.180.380 |
Holoprosencephaly | |
homocystinuria | disease | amino acid metabolic disorder sulfuraminoacidemia |
amino acid metabolic disorder that involves an accumulation of homocysteine in the serum and an increased excretion of homocysteine in the urine | C10.228.140.163.100.365 C16.320.565.100.480.500 C16.320.565.189.365 C17.300.428 C18.452.132.100.365 C18.452.648.100.480.500 C18.452.648.189.365 |
Homocystinuria | |
hordeolum | disease | eyelid disease blepharitis |
an infection of an oil gland in the eyelid. This results in a red tender bump at the edge of the eyelid. The outside or the inside of the eyelid can be affected | C01.252.354.400 C01.539.375.354.400 C11.294.354.400 C11.338.648 |
Stye | |
Horner's syndrome | disease | autonomic neuropathy | Human disease | C10.177.350 C10.597.690.362.500 C11.710.528.500 C23.888.592.708.362.500 |
Horner's syndrome | |
hospital-acquired infection | disease | infection | C01.539.248 C23.550.291.875.500 |
|||
Huntington disease | disease Designated intractable/rare diseases |
neurodegeneration Huntington disease and related disorders eye degenerative disease genetic neurodegenerative disease with dementia |
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia | C10.228.140.079.545 C10.228.140.380.278 C10.228.662.262.249.750 C10.574.500.497 C16.320.400.430 F03.087.250.400 F03.087.400.390 |
Huntington's disease | |
hydrocele | disease | male reproductive system disease | Human disease | C12.294.882 | Hydrocele | |
hydrocephalus | disease | cerebellar degeneration intracranial hypertension |
disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain | C10.228.140.602 | Hydrocephalus | |
hydronephrosis | disease | urinary tract obstruction kidney disease |
Human disease | C12.777.419.307 C13.351.968.419.307 |
Hydronephrosis | |
hydrophthalmos | disease | primary congenital glaucoma | Human disease | C11.250.480 C11.525.381.407.480 C16.131.384.480 C16.614.438 |
||
hyperaldosteronism | disease | adrenal gland hyperfunction | adrenal gland hyperfunction disease that results in the overproduction of aldosterone by the adrenal glands | C19.053.800.367 C19.053.800.604 |
Hyperaldosteronism | |
hyperargininemia | disease | urea cycle disorder | urea cycle disorder that involves arginase deficiency resulting in elevated levels of plasma arginine | C10.228.140.163.100.937.500 C16.320.565.100.940.500 C16.320.565.189.937.500 C18.452.132.100.937.437 C18.452.648.100.940.437 C18.452.648.189.937.437 |
||
hypercalcemia | disease | calcium metabolism disease | Human disease | C18.452.174.451 C18.452.950.340 |
Hypercalcemia | |
hyperglycemia | disease | glucose metabolism disease | Human disease | C18.452.394.952 | Hyperglycemia | |
hyperhomocysteinemia | disease | amino acid metabolic disorder sulfuraminoacidemia |
amino acid metabolic disorder that involves an abnormally large level of homocysteine in the blood | C16.320.565.100.480 C18.452.603.378 C18.452.648.100.480 C18.654.521.500.133.699.418 |
||
hyperlipidemia | disease | lipid metabolism disorder | abnormally elevated levels of any or all lipids and/or lipoproteins in the blood | C18.452.584.500.500 | Hyperlipidemias | |
hypermobility syndrome | disease | arthropathy | Human disease | C05.550.521 | Hypermobility | |
hyperopia | disease | refractive error | human eye system | C11.744.479 | Hyperopia | |
hyperostosis | disease | bone remodeling disease | bone remodeling disease that results in an abnormal growth of located in bone | C05.116.540 | Hyperostosis | |
hyperparathyroidism | disease | parathyroid gland disease | endocrine disease | C19.642.355 | Hyperparathyroidism | |
hyperphosphatemia | disease | phosphorus metabolism disease | Human disease | C18.452.750.199 | Hyperphosphatemia | |
hyperplasia | disease | hypertrophy | increase in the amount of organic tissue that results from cell proliferation | C23.550.444 | Hyperplasia | |
hyperprolactinemia | disease | acquired metabolic disease rare hypothalamic or pituitary disease rare genetic hypothalamic or pituitary disease rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin rare male infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin genetic nervous system disorder |
acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood | C13.703.844.506.389.500 C17.800.090.937.439.500 C10.228.140.617.738.250.450 C19.700.355.600 |
||
hypersomnia | disease | sleep disorder | excessive sleep | C10.886.425.800.200 | ||
hypertensive emergency | disease | hypertension Hypertensive crisis |
Human disease | C14.907.489.330 | ||
hypertensive retinopathy | disease | retinal disease | Human disease | C11.768.346 C14.907.489.815 |
Hypertensive retinopathy | |
hypertricosis | disease | hair disease rare epidermal disease genetic hair anomaly |
hair disease characterized by hair growth that is abnormal in quantity or location | C17.800.329.875 | Hypertrichosis | |
hypertriglyceridemia | disease | inherited metabolic disorder hyperlipidemia disease of metabolism |
the most abundant fatty molecule in most organisms | C18.452.584.500.500.851 | ||
hypertrophic cardiomyopathy | disease Designated intractable/rare diseases |
cardiomyopathy intrinsic cardiomyopathy |
disease in which a portion of the myocardium (heart muscle) is hypertrophic (enlarged) without any obvious cause, creating functional impairment of the heart. | C14.280.238.100 C14.280.484.150.070.160 C14.280.238.100.500 C14.280.484.150.070.160.500 C16.320.160 |
Hypertrophic cardiomyopathy | |
hypertrophy | disease | increase in the volume of an organ or tissue due to the enlargement of its component cells | C23.300.775 | Hypertrophy | ||
hypocalcaemia | disease | calcium metabolism disease | C18.452.174.509 C18.452.950.509 |
Hypocalcemia | ||
hypoglycemia | disease abnormally low value |
endocrine pancreas disease glucose metabolism disease |
when blood sugar decreases to below normal levels | C18.452.394.984 | Hypoglycemia | |
hypogonadism | disease | gonadal disease | endocrine disease | C19.391.482 | Hypogonadism | |
hypohidrotic ectodermal dysplasia | disease | Clouston syndrome bone disease |
Human disease | C16.131.077.350.198 C16.131.831.350.198 C16.320.322.116 C16.320.850.250.198 C17.800.804.350.198 C17.800.827.250.198 |
Hypohidrotic ectodermal dysplasia | |
hypokalemia | disease | mineral metabolism disease potassium deficiency |
Human disease | C18.452.950.565 | Hypokalemia | |
hypokalemic periodic paralysis | disease channelopathy |
periodic paralysis | Human disease | C05.651.701.450 C10.668.491.650.450 C16.320.565.618.711.550 C18.452.648.618.711.550 |
||
Hyponatremia | disease abnormally low value |
Hyponatremia | C18.452.950.620 | Hyponatraemia | ||
hypoparathyroidism | disease Designated intractable/rare diseases |
parathyroid gland disease | endocrine disease | C19.642.482 | ||
hypopharynx cancer | disease | carcinoma pharyngeal cancer bone cancer |
pharynx cancer that is located in the hypopharynx | C04.588.443.665.710.485 C07.550.745.436 C09.647.710.485 C09.775.549.485 |
Hypopharyngeal cancer | |
hypophosphatasia | disease | autosomal dominant disease | Human disease | C16.320.565.618.482 C18.452.648.618.482 |
||
hypophosphatemia | disease | phosphorus metabolism disease | Human disease | C18.452.750.400 | Hypophosphatemia | |
hypopituitarism | disease | pituitary gland disease | pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland | C10.228.140.617.738.300 C19.700.482 |
||
hypoplastic left heart syndrome | disease Designated intractable/rare diseases |
congenital heart disease cyanotic heart defect |
congenital heart disease characterized by abnormal development of the left-sided structures of the heart | C14.240.400.625 C14.280.400.625 C16.131.240.400.625 |
Hypoplastic left heart syndrome | |
hypospadias | disease | birth defect | congenital disorder of urinary system | C12.294.494.400 C12.706.516 C13.351.875.466 C16.131.939.516 |
Hypospadias | |
hypothermia | disease | condition in which core temperature drops below the required temperature for normal metabolism and body functions | C23.888.119.565 | Hypothermia | ||
hypotrichosis | disease | hair disease | hair disease that is characterized by sparse hair on the scalp resulting from abnormal hair follicle development and has material basis in mutations in proteins involved in hair growth, division or proliferation of cells within hair follicles | C17.800.329.937 | ||
hypovolemia | disease | low blood volume | C23.550.455 | |||
hypoxia | disease | condition in which the body or a region of the body is deprived of adequate oxygen supply at the tissue level | C23.888.852.079 | |||
idiopathic interstitial pneumonia | disease | pneumonia interstitial lung disease |
pneumonia located in the lung parenchyma of unknown cause | C08.381.765 C08.381.483.487 |
||
IgA glomerulonephritis | disease | glomerulonephritis | glomerulonephritis characterized by build up of IgA antibody in the glomerulus | C12.777.419.570.363.608 C13.351.968.419.570.363.608 C20.111.525 |
||
ileus | disease | intestinal obstruction | Human disease | C06.405.469.531.492 | Ileus | |
immunoglobulin A deficiency | disease | selective immunoglobulin deficiency disease B cell deficiency |
dysgammaglobulinemia characterized by a deficiency of immunoglobulin A | C15.378.147.333.500 C20.673.430.500 |
||
imperforate anus | disease | birth defect atresia anus disease |
congenital disorder of digestive system | C06.198.050 C16.131.314.094 |
Imperforate anus | |
impotence | disease | sexual dysfunction | Human disease | C12.294.644.486 | Erectile dysfunction | |
in situ carcinoma | disease | pre-malignant neoplasm | carcinoma that is an early development defined by the absence of invasion of surrounding tissues | C04.557.470.200.240 | Carcinoma in situ | |
inappropriate ADH syndrome | disease | pituitary gland disease | endocrine disease | C10.228.140.617.738.320 C18.452.950.626 C19.700.490 |
Syndrome of inappropriate antidiuretic hormone secretion | |
inclusion body myositis | disease Designated intractable/rare diseases |
myositis | myositis that is characterized by slowly progressive weakness and wasting of both distal and proximal muscles, most apparent in the muscles of the arms and legs that can occur in a sporadic or hereditary forms | C05.651.594.600 C10.668.491.562.500 |
||
inclusion-cell disease | disease developmental defect during embryogenesis |
lysosomal storage disease mucolipidosis rare genetic developmental defect during embryogenesis lysosomal storage disease with skeletal involvement |
Human disease | C05.116.198.371 C10.228.140.163.100.435.590 C16.320.565.189.435.590 C16.320.565.202.670 C16.320.565.595.554.590 C18.452.132.100.435.590 C18.452.648.189.435.590 C18.452.648.202.670 C18.452.648.595.554.590 |
||
incontinentia pigmenti achromians | disease | skin disease | Human disease | C17.800.621 C23.550.755 |
||
infant respiratory distress syndrome | disease health problem |
respiratory failure Respiratory Distress Syndrome, Newborn |
Human disease | C08.381.842.475 C08.618.842.475 C16.614.521.563.475 |
||
infectious mononucleosis | disease infectious disease |
viral infectious disease Epstein–Barr virus infection |
viral infectious disease that results in inflammation, located in pharynx, has material basis in Human herpesvirus 4 and has symptom fever, has symptom fatigue, has symptom lymphadenopathy, and has symptom splenomegaly | C02.256.466.313.400 C15.378.553.381 C15.604.515.516 C20.683.515.515 |
Infectious mononucleosis | |
infertility | disease | reproductive system disease | inability of a person, animal or plant to reproduce by natural means that is no intervention of contraceptive techniques | C12.294.365 C13.351.500.365 |
Infertility | |
inflammatory bowel disease | disease | intestinal disease immune system disease |
intestinal disease characterized by inflammation located in all parts of digestive tract | C06.405.205.731 C06.405.469.432 |
||
inguinal hernia | disease | intestinal disease | intestinal disease characterized by a protrusion of abdominal cavity contests through the inguinal canal | C23.300.707.374.875 | Inguinal hernia | |
inherited metabolic disorder | disease | genetic disease rare disease disease of metabolism |
class of disease including endocrine diseases, nutritional diseases and metabolic diseases | C16.320.565 C18.452.648 |
Inborn errors of metabolism | |
insomnia | disease | sleep disorder | inability to sleep | C10.886.425.800.800 | Insomnia | |
insulinoma | disease | adenoma | adenoma that is located in the pancreas and is characterized by overproduction of insulin | C04.557.470.035.100.852 C04.588.274.761.249.500 C04.588.322.475.249.500 C06.301.761.249.500 C06.689.667.249.500 C19.344.421.249.500 C04.557.470.035.100 C04.588.274.761.249 C04.588.322.475.249 C06.301.761.249 C06.689.667.249 C19.344.421.249 |
Insulinoma | |
intellectual disability | disease | specific developmental disorder cognitive deficit |
generalized neurodevelopmental disorder | C10.597.606.643 C23.888.592.604.646 |
Intellectual disability | |
internuclear ophthalmoplegia | disease | ophthalmoplegia strabismus |
Human disease | C10.228.758 C10.292.562 C11.590 |
||
interstitial cystitis | disease | cystitis | chronic inflammatory condition of the submucosal and muscular layers of the bladder | C12.777.829.495.500 C13.351.968.829.495.500 |
||
interstitial lung disease | disease | lung disease pneumonitis alveolar lung disease connective tissue disease |
group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs) | C08.381.483 | Interstitial lung diseases | |
interstitial nephritis | disease | Sida por cojer mucho | type of nephritis affecting the interstitium of the kidneys surrounding the tubules | C12.777.419.570.643 C13.351.968.419.570.643 |
||
intestinal volvulus | disease | intestinal obstruction | Human disease | C06.405.469.531.568 C23.300.970.500 |
Volvulus | |
intracranial aneurysm | disease | aneurysm cerebrovascular disease cerebral arterial disease |
cerebrovascular disorder | C10.228.140.300.510.600 C14.907.055.635 C14.907.253.560.300 |
Cerebral aneurysms | |
intracranial sinus thrombosis | disease | venous thrombosis intracranial thrombosis |
presence of acute thrombosis (a blood clot) in the dural venous sinuses, which drain blood from the brain. | C10.228.140.300.525.425.500 C14.907.253.566.350.500 C14.907.355.590.213.350.500 |
Cerebral venous sinus thrombosis | |
intrauterine growth restriction | disease | poor growth of fetus in mother's womb during pregnancy | C13.703.277.370 C16.300.390 C23.550.393.450 |
|||
intussusception | disease | intestinal obstruction genetic disease |
Human disease | C06.405.469.531.577 | Intussusception | |
invasive lobular carcinoma | disease | breast lobular carcinoma invasive breast carcinoma |
Human disease | C04.557.470.200.025.305 C04.557.470.615.305 C04.588.180.437 C17.800.090.500.437 |
Histopathology of invasive lobular carcinoma (ILC) | |
iridocyclitis | disease health problem |
anterior uveitis ciliary body disease iritis |
Human disease | C11.941.375.360 C11.941.879.780.880.400 |
||
iron deficiency anemia | disease | microcytic anemia deficiency anemia nutritional deficiency disease iron deficiency hypochromic anemia |
anemia caused by a lack of iron | C15.378.071.196.300 C18.452.565.100 |
Iron-deficiency anemia | |
iron overload | disease | iron metabolism disease overload disease metal metabolism disorder |
human disease | C18.452.565.500 | Hemochromatosis | |
irritable bowel syndrome | disease | syndrome functional colonic disease |
syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause | C06.405.469.158.272.608 | Irritable bowel syndrome | |
irritant dermatitis | disease | contact dermatitis | Human disease | C17.800.174.255.400 C17.800.815.255.400 |
Irritant contact dermatitis | |
ischaemic heart disease | disease | heart disease | C14.280.647 C14.907.585 |
|||
ischemia | disease | vascular disease | restriction in blood supply to tissues, causing a shortage of oxygen and glucose | C23.550.513 C14.280.647.124 C14.907.585.124 |
Ischemia | |
ischemic colitis | disease | colitis | colitis caused by inadequate blood supply to the colon | C06.405.205.265.115 C06.405.469.158.188.115 C14.907.286 |
Ischemic colitis | |
Japanese encephalitis | disease infectious disease |
horse disease brain disease viral infectious disease infectious disease with epilepsy |
Human disease | C02.081.343.345 C02.182.525.300.250 C02.290.310.280 C02.782.310.345 C02.782.350.250.300 C10.228.140.430.520.750.300.400 C10.228.228.245.340.300.400 C10.228.228.399.750.300.400 |
Japanese encephalitis | |
jet lag | disease | circadian misalignment | physiological condition | C10.281.440 C10.886.425.200.500 C10.281 |
||
joint effusion | disease arthropathy |
arthropathy | effusion of watery liquid into the cavity of a joint | C05.550.509 | ||
juvenile myoclonic epilepsy | disease | adolescence-adult electroclinical syndrome Idiopathic generalized epilepsy |
adolescence-adult electroclinical syndrome that is characterized by brief, involuntary twitching of a muscle or a group of muscles (myoclonus) early in the morning with onset between 12 and 18 years | C10.228.140.490.250.670 | ||
juvenile neuronal ceroid lipofuscinosis | disease | neuronal ceroid lipofuscinosis | extremely rare and fatal autosomal recessive neurodegenerative disorder in humans | C10.574.500.550 C16.320.400.600 C16.320.565.398.641.509 C18.452.584.687.509 C18.452.648.398.641.509 |
Batten disease | |
juvenile rheumatoid arthritis | disease arthropathy |
rheumatoid arthritis childhood arthritis polyarticular arthritis |
rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint | C05.550.114.122 C05.799.056 C17.300.775.049 C20.111.198 |
||
Kallmann syndrome | disease | hypogonadotropic hypogonadism | A form of hypogonadotropic hypogonadism which is also accompanied by a total lack or partial loss in the sense of smell. The condition affects both males and females and causes a failure in puberty and infertility. | C12.706.316.096.750 C13.351.875.253.096.750 C16.131.939.316.096.750 C16.320.467 C19.391.119.096.750 C19.391.482.600 |
||
Kaposi's sarcoma | disease infectious disease |
connective tissue neoplasm human herpesvirus 8-related disorder |
connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8) | C02.256.466.860 C04.557.450.795.850 C04.557.645.750 |
Kaposi's sarcoma | |
Kawasaki disease | disease | lymphadenitis immune system disease predominantly medium-vessel vasculitis |
Human disease in which blood vessels throughout the body become inflamed | C14.907.940.560 C15.604.560 C17.800.862.560 |
Kawasaki disease | |
Kennedy disease | disease Designated intractable/rare diseases |
spinal muscular atrophy nervous system heredodegenerative disease rare male infertility due to testicular endocrine disorder bulbospinal muscular atrophy of adult |
Kennedy's disease, also known as bulbospinal muscular atrophy (BSMA), is a rare X-linked recessive motor neuron disease characterized by proximal and bulbar muscle wasting | C10.228.854.468.399 C10.574.500.175 C10.574.562.500.374 C10.668.467.500.186 C16.320.322.076 |
||
keratitis | disease | corneal disease eye inflammation inflammatory disease |
corneal disease that is characterized by inflammation of the cornea. | C11.204.564 | Keratitis | |
keratoacanthoma | disease | skin squamous cell carcinoma | Human disease | C17.800.417 | ||
keratoconjunctivitis | disease | eye disease keratitis conjunctivitis |
Human disease | C11.187.183.394 C11.204.564.585 |
||
keratoconjunctivitis sicca | disease | dry eye syndrome keratoconjunctivitis |
Human disease | C11.187.183.394.550 C11.204.564.585.630 C11.496.260.394 |
Dry eye syndrome | |
keratoconus | disease | corneal disease rare genetic eye disease |
corneal disease characterized by structural changes within the cornea causing it to thin and change, leading to a protruding conical shape | C11.204.627 | Keratoconus | |
keratosis follicularis | disease | keratosis | Human disease | C16.320.850.190 C17.800.428.275 C17.800.827.190 |
Darier's disease | |
kernicterus | disease | brain disease | congenital disorder of nervous system | C10.228.140.163.480 C15.378.295.502 C16.614.304.502 C18.452.132.480 C20.306.502 C23.550.429.750 |
Kernicterus | |
kidney disease | disease health problem |
urinary system disease | a urinary system disease that is located in the kidney | C12.777.419 C13.351.968.419 |
Kidney diseases | |
kidney failure | disease | urinary system disease kidney disease impaired renal function disease |
disease where the kidneys fail to adequately filter waste products from the blood | C12.777.419.780 C13.351.968.419.780 |
||
Klatskin's tumor | disease | intrahepatic cholangiocarcinoma | Human disease | C04.557.470.200.025.450.500 | ||
Kleine-Levin syndrome | disease syndrome |
hypersomnia genetic nervous system disorder |
recurrent hypersomnia that is characterized by recurring periods of excessive amounts of sleep and altered behavior | C10.886.425.800.200.500 | ||
Klinefelter's syndrome | disease developmental defect during embryogenesis |
chromosomal disease sex chromosome disorder X chromosome number anomaly with male phenotype male infertility due to gonadal dysgenesis sex chromosome disorder of sex development chromosomal anomaly with epilepsy as a major feature |
Human disease | C12.706.316.795.500 C13.351.875.253.795.500 C16.131.260.830.835.500 C16.131.939.316.795.500 C16.320.180.830.835.500 C19.391.119.795.500 C19.391.482.629 |
Klinefelter's syndrome | |
Klippel-Feil syndrome | disease | birth defect spinal disease |
physical disorder that has material basis in abnormal segmentation of the vertebra during fetal development which results in fusion located in cervical vertebra | C05.116.099.370.535 C05.660.551 C16.131.621.551 |
Klippel–Feil syndrome | |
Klippel–Trénaunay–Weber syndrome | disease | overgrowth syndrome syndrome |
syndrome that is characterized by large cutaneous hemangiomata with hypertrophy of the related bones and soft tissues | C14.907.077.410 | Klippel–Trénaunay syndrome | |
Kluver-Bucy syndrome | disease | impulse control disorder | Human disease | C10.228.140.380.326 | ||
Knee osteoarthritis | disease arthropathy |
osteoarthritis knee disorder |
C05.550.114.606.500 C05.799.613.500 |
Knee osteoarthritis | ||
Korsakoff's syndrome | disease | nutritional deficiency disease Wernicke encephalopathy Effects of alcohol on memory |
mental illness caused by a lack of thiamine in the brain | C10.597.606.525.400 C10.720.112.100.500 C23.888.592.604.529.400 C25.723.705.150.100.500 C25.775.100.087.193.100.500 |
Korsakoff's syndrome | |
Krabbe disease | disease | sphingolipidosis nervous system heredodegenerative disease eye degenerative disease |
Krabbe disease is a lysosomal disorder that affects the white matter of the central and peripheral nervous systems. It includes infantile, late-infantile/juvenile and adult forms. | C10.228.140.163.100.362.500 C10.228.140.163.100.435.825.590 C10.228.140.695.625.500 C10.314.400.500 C16.320.565.189.362.500 C16.320.565.189.435.825.590 C16.320.565.398.641.803.585 C16.320.565.595.554.825.590 C18.452.132.100.362.500 C18.452.132.100.435.825.590 C18.452.584.687.803.585 C18.452.648.189.362.500 C18.452.648.189.435.825.590 C18.452.648.398.641.803.585 C18.452.648.595.554.825.590 |
||
Krukenberg carcinoma | disease secondary neoplasm |
ovary epithelial cancer ovarian metastasis metastatic carcinoma ovary adenocarcinoma signet ring cell adenocarcinoma |
Human disease | C04.557.470.200.025.415.410 C04.557.470.590.415.410 |
Krukenberg tumor | |
kuru | disease | transmissible spongiform encephalopathy human prion disease |
Human disease | C10.228.228.800.435 C10.574.843.625 |
Kuru (disease) | |
kwashiorkor | disease | protein-energy malnutrition | Human disease | C18.654.521.719.500 | Kwashiorkor | |
Kyasanur forest disease | disease infectious disease |
viral infectious disease tick-borne disease viral hemorrhagic fever |
Human disease | C02.081.885.475 C02.782.350.250.635 C02.782.417.475 |
||
kyphosis | disease | spinal disease Spinal curvature |
human disease | C05.116.900.800.500 | Kyphosis | |
lactic acidosis | disease | acidosis metabolic acidosis |
acquired metabolic disease that has material basis in low pH in body tissues and blood accompanied by the buildup of lactate especially D-lactate | C18.452.076.176.180 | Lactic acidosis | |
lactose intolerance | disease | carbohydrate metabolic disorder | Human disease | C06.405.469.637.506 C16.320.565.202.589 C18.452.603.506 C18.452.648.202.589 |
Lactose intolerance | |
Lafora disease | disease | neurodegeneration Progressive myoclonus epilepsy genetic neurodegenerative disease progressive epilepsy and/or ataxia with myoclonus as a major feature |
Lafora disease (LD) is a rare, inherited, severe, progressive myoclonic epilepsy characterized by myoclonus and/or generalized seizures, visual hallucinations (partial occipital seizures), and progressive neurological decline | C10.228.140.490.250.650.500 C10.574.500.529 C16.320.400.480 |
||
Lambert-Eaton myasthenic syndrome | disease | neuromuscular junction disease channelopathy immune-mediated acquired neuromuscular junction disease paraneoplastic neurologic syndrome |
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune, presynaptic disorder of neuromuscular transmission characterized by fluctuating muscle weakness and autonomic dysfunction frequently associated with small-cell lung cancer (SCLC) | C04.588.614.550.225 C04.730.856.225 C10.114.468 C10.574.781.500 C10.668.758.450 C20.111.258.350 |
||
Landau–Kleffner syndrome | disease | childhood electroclinical syndrome | Human disease | C10.228.140.490.535 | ||
Langerhans-cell histiocytosis | disease | histiocytosis | disease involving clonal proliferation of Langerhans cells | C08.381.483.375 C15.604.250.400 |
Langerhans cell histiocytosis | |
Laron syndrome | disease | autosomal recessive disease Growth hormone insensitivity syndrome |
Laron syndrome is a congenital disorder characterized by marked short stature associated with normal or high serum growth hormone (GH) and low serum insulin-like growth factor-1 (IGF-I) levels which fail to rise after exogenous GH administration | C05.116.099.343.679 C16.320.240.750 C19.297.656 |
||
laryngeal cancer | disease | head and neck cancer carcinoma laryngeal disease respiratory system cancer |
respiratory system cancer that is located in the larynx | C04.588.443.665.481 C08.360.369 C08.785.481 C09.400.369 C09.647.481 |
Laryngeal cancer | |
laryngitis | disease | laryngeal disease inflammatory disease |
inflammation of the larynx | C08.360.535 C08.730.368 C09.400.535 |
Laryngitis | |
Lassa fever | disease infectious disease |
viral infectious disease arenavirus hemorrhagic fever |
viral disease | C02.782.082.545 C02.782.417.505 |
||
lateral medullary syndrome | disease | brain stem infarction | Human disease | C10.228.140.300.150.477.100.500 C10.228.140.300.775.200.100.500 C14.907.253.092.477.100.500 C14.907.253.855.200.100.500 |
Lateral medullary syndrome | |
latex allergy | disease | type I hypersensitivity | hypersensitivity reaction type I disease triggered by latex | C20.543.600 | ||
learning disability | disease | specific developmental disorder | specific developmental disorder that involves difficulty in scholastic skills such as reading, writing, spelling, reasoning, recalling and/or organizing information resulting from the brain's inability to receive and process information | C10.597.606.150.550 C23.888.592.604.150.550 |
Learning disabilities | |
Leber congenital amaurosis | disease | retinal disease | retinal disease that is characterized by nystagmus, sluggish or no pupillary responses, and severe vision loss or blindness | C11.270.516 C11.768.364 |
Leber's congenital amaurosis | |
Leber hereditary optic neuropathy | disease Designated intractable/rare diseases developmental defect during embryogenesis |
optic nerve disease hereditary optic atrophy genetic peripheral neuropathy mitochondrial disease with eye involvement hereditary optic neuropathy mitochondrial disease with dilated cardiomyopathy mitochondrial disease with hypertrophic cardiomyopathy mitochondrial oxidative phosphorylation disorder due to a point mutation of mitochondrial DNA |
Human disease | C10.292.700.225.500.400 C10.574.500.662.400 C11.270.564.400 C11.640.451.451.400 C16.320.290.564.400 C16.320.400.630.400 C18.452.660.670 |
Leber's hereditary optic neuropathy | |
left ventricular noncompaction | disease | intrinsic cardiomyopathy cardiomyopathy |
intrinsic cardiomyopathy characterized by distinctive (spongy) morphological appearance of the LV myocardium | C14.240.400.660 C14.280.238.281.500 C14.280.400.660 C16.131.077.477 C16.131.240.400.655 C16.320.322.370 |
Left ventricular non-compaction | |
Legg-Calve-Perthes disease | disease | osteochondrosis osteonecrosis type 2 collagen-related bone disorder osteochondrosis of genetic origin |
osteochondrosis that results in death and fracture located in hip joint | C05.116.852.175.570 | Legg–Calvé–Perthes disease | |
legionnaires' disease | disease infectious disease |
legionellosis atypical pneumonia bacterial pneumonia rare respiratory disease |
legionellosis that is characterized by severe form of infection producing pneumonia. Symptoms include fever, chills, and cough. | C01.252.400.500.501 C08.730.382.380 |
Legionnaires' disease | |
Leigh disease | disease | mitochondrial disease | A mitochondrial metabolism disease characterized by progressive loss of mental and movement abilities. Symptoms usually begin between ages of three months and two years and include loss of appetite, vomiting, irritability and seizure activity. | C10.228.140.163.100.412 C16.320.565.189.412 C16.320.565.202.810.444 C18.452.132.100.412 C18.452.648.189.412 C18.452.648.202.810.444 C18.452.660.520 |
||
leiomyosarcoma | disease | smooth muscle cancer | malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis | C04.557.450.590.455 C04.557.450.795.455 |
Leiomyosarcoma | |
leishmaniasis | disease | parasitic protozoa infectious disease | disease caused by parasites of the Leishmania type | C03.752.300.500 C03.858.560 C17.800.838.775.560 |
Leishmaniasis | |
Lemierre's syndrome | disease | commensal bacterial infectious disease Fusobacterium infectious disease |
Human disease: infectious thrombophlebitis of the internal jugular vein | C01.252.400.388.350 | ||
Lennox-Gastaut syndrome | disease Designated intractable/rare diseases |
childhood electroclinical syndrome | a childhood-onset epilepsy with triad of signs including frequent seizures of multiple types, an abnormal EEG pattern of less than 2.5 Hz slow spike wave activity, and moderate to severe intellectual impairment | C10.228.140.490.583 C16.320.495 |
||
LEOPARD syndrome | disease | autosomal dominant disease | Human disease | C05.660.207.525 C14.240.400.695 C14.280.400.695 C14.280.484.716.525 C16.131.077.525 C16.131.240.400.685 C16.131.621.207.525 C17.800.621.430.530.550.525 |
LEOPARD syndrome | |
leptospirosis | disease | primary bacterial infectious disease spirochetal diseases |
Human disease | C01.252.400.511 C01.252.847.511 C01.252.400.511.739 C01.252.847.511.739 |
Leptospirosis | |
Lesch-Nyhan syndrome | disease | inborn errors of purine–pyrimidine metabolism | rare disease | C10.228.140.163.100.425 C10.597.606.643.455.625 C16.320.322.500.625 C16.320.400.525.625 C16.320.565.189.425 C16.320.565.798.594 C18.452.132.100.425 C18.452.648.189.425 C18.452.648.798.594 |
||
leukocyte-adhesion deficiency syndrome | disease | autosomal recessive disease | Human disease | C20.673.600 | ||
leukopenia | disease | leukocyte disease cytopenia |
decrease in the number of white blood cells | C15.378.553.546 | ||
leukorrhea | disease | vaginal discharge | type of vaginal discharge | C13.351.500.894.700.500 | ||
Lewy body dementia | disease | synucleinopathy dementia Lewy body dementia |
type of dementia | C10.228.140.079.862.400 C10.228.140.380.422 C10.228.662.600.200 C10.574.531 |
Dementia with Lewy bodies | |
Li-Fraumeni syndrome | disease | autosomal dominant disease disease with Cushing syndrome as a major feature inherited nervous system cancer-predisposing syndrome rare genetic endocrine disease genetic nervous system disorder hereditary cancers |
autosomal dominant disease characterized by increases risk of developing several types of cancer, including breast cancer, osteosarcomata and soft tissue sarcomata | C04.700.600 C16.320.700.600 C18.452.284.520 |
||
lice infestation | disease infectious disease |
parasitic ectoparasitic infectious disease | parasitic ectoparasitic infectious disease that involves infestation of lice, which are blood-feeding ectoparasitic insects of the order Phthiraptera | C03.858.211.465 C17.800.838.775.580 |
Pediculus humanus capitis | |
lichen planus | disease | lichen disease | lichen disease that is located in skin, located in tongue or located in oral mucosa, which presents itself in the form of papules, lesions or rashes | C17.800.859.475.560 | Lichen planus | |
Liddle syndrome | disease | renal tubular transport disease Pseudohyperaldosteronism genetic hypertension |
Human disease | C12.777.419.815.683 C13.351.968.419.815.683 C16.320.565.861.698 C18.452.648.861.698 |
||
limb-girdle muscular dystrophy | disease | muscular dystrophy progressive muscular dystrophy |
muscular dystrophy characterized by weakening of the muscles of the hip and shoulders which comprise the limb girdle muscles | C05.651.534.500.280 C10.668.491.175.500.149 C16.320.577.280 |
||
linitis plastica | disease | gastric diffuse adenocarcinoma | Human disease | C04.557.470.200.025.095.410 | Linitis plastica | |
Lipedema | disease | lymphatic system disease | C17.300.451 | |||
lipid metabolism disorder | disease | inherited metabolic disorder | An inherited acute metabolic disorder that involves the creation and degradation of lipids. | C16.320.565.398 C18.452.584.562 C18.452.648.398 C18.452.584 C18.452.584.500 |
||
lipodystrophy | disease | connective tissue disease disease of metabolism |
Human disease | C17.800.849.391 C18.452.584.625 C18.452.880.391 |
||
lipoid nephrosis | disease | nephrotic syndrome glomerulonephritis |
Human disease | C12.777.419.630.477 C13.351.968.419.630.477 |
Minimal change disease | |
lipoma | disease | cell type benign neoplasm adipose tissue neoplasm |
cell type benign neoplasm that is composed of lipocytes | C04.557.450.550 C04.557.450.550.400 |
Lipoma | |
lipomatosis | disease | skin disease | Human disease | C17.800.463 C18.452.584.718 |
Lipomatosis | |
liposarcoma | disease | lipomatous cancer | lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum | C04.557.450.550.420 C04.557.450.795.465 |
Liposarcoma | |
lissencephaly | disease developmental defect during embryogenesis |
cephalic disorder Neuronal migration disorder syndrome with a central nervous system malformation as major feature cerebral malformation with epilepsy rare genetic developmental defect during embryogenesis rare genetic syndromic intellectual disability |
congenital disorder of nervous system | C10.500.507.450.499 C16.131.666.507.450.499 |
Lissencephaly | |
listeriosis | disease infectious disease |
primary bacterial infectious disease bacterial infectious disease |
bacterial infection | C01.252.410.514 | Listeriosis | |
Livedo reticularis | disease | Blanch Livedo |
C14.907.617.625 C17.800.862.355 C23.888.885.437 |
|||
liver cancer | disease | gastrointestinal system cancer liver tumor endocrine gland cancer liver disease rare hepatic and biliary tract tumor liver neoplasm |
gastrointestinal system cancer, located in the liver | C04.588.274.623 C06.301.623 C06.552.697 |
Liver cancer | |
liver cirrhosis | disease | liver disease | long-term disease of the liver | C06.552.630 | Cirrhosis | |
liver disease | disease | hepatobiliary disease endocrine system disease |
Human disease | C06.552 | Diseases and disorders of liver | |
liver failure | disease clinical sign |
C06.552.308.500 C06.552.308 |
||||
locked-in syndrome | disease | neurological disorder | nervous system disease that is characterized by complete paralysis of all voluntary muscles except for the ones that control the movements of the eyes | C10.597.622.760 C23.888.592.636.786 |
||
loiasis | disease infectious disease |
filariasis parasitic helminthiasis infectious disease eye disease skin disease parasitic skin disease rare skin disease |
Human disease | C03.335.508.700.750.361.518 | Loa loa filariasis | |
long QT syndrome | disease | heart arrhythmia intrinsic cardiomyopathy QT interval prolonged |
rare congenital and inherited or acquired heart condition in which delayed repolarization of the heart following a heartbeat increases the risk of episodes of torsades de pointes | C14.280.067.565 C16.131.240.400.715 C23.550.073.547 C14.280.067.565.720 C16.131.240.400.715.720 C23.550.073.547.720 |
||
lordosis | disease | Spinal curvature | C05.116.900.800.750 | Lordosis | ||
louping ill | disease infectious disease |
viral infectious disease tick-borne disease animal disease |
Human disease | C02.782.350.250.650 C22.836.435 |
Louping ill | |
low compliance bladder | disease | bladder disease | Human disease | C12.777.829.866 C13.351.968.829.813 C23.888.942.343.780 |
||
Lown-Ganong-Levine syndrome | disease | syndrome pre-excitation syndrome genetic cardiac rhythm disease |
syndrome that involves pre-excitation of the ventricles due to an accessory pathway providing an abnormal electrical communication from the atria to the ventricles | C14.280.067.780.560 | ||
Ludwig's angina | disease infectious disease |
cellulitis mouth disease |
Human disease | C01.539.535 C07.465.433 |
Ludwig's angina | |
lung abscess | disease thoracic disease |
lung disease abscess |
lung disease characterized by microbial infection which causes a type of liquefactive necrosis of the pulmonary tissue and formation of cavities containing necrotic debris or fluid | C01.539.830.025.490 C08.381.450 C08.730.407 |
Lung abscess | |
lupus nephritis | disease | glomerulonephritis | lupus nephritis | C12.777.419.570.363.680 C13.351.968.419.570.363.680 C17.300.480.680 C20.111.590.560 |
Lupus nephritis | |
Lyme disease | disease | primary bacterial infectious disease borreliosis |
Human disease | C01.252.400.155.569 C01.252.400.825.480 C01.252.847.193.569 C01.252.200.450 C01.252.400.155.569.600 C01.252.400.825.480.700 C01.252.847.193.569.600 C10.228.228.180.437 |
Borreliosis | |
lymphangioleiomyomatosis | disease | lung disease rare genetic respiratory disease primary interstitial lung disease specific to adulthood rare tumor |
Human disease | C04.557.375.460.465 C04.557.450.692.500 C15.604.515.562.465 C20.683.515.710.465 |
Lymphangioleiomyomatosis | |
lymphangioma | disease | cell type benign neoplasm lymphatic abnormality rare lymphatic system malformation |
Human disease | C04.557.375.450 | Lymphangiomas | |
lymphangitis | disease infectious disease |
lymphatic system disease immune system disease streptococcal infection bacterial infectious disease |
Human disease | C15.604.406 | Lymphangitis | |
lymphedema | disease | lymphatic system disease | Human disease | C15.604.496 | Lymphedema | |
lymphocele | disease | lymphatic system disease | Human disease | C04.182.430 C15.604.510 |
||
lymphocytic choriomeningitis | disease | viral meningitis Arenaviridae infectious disease brain disease viral infectious disease |
Human disease | C02.182.550.500 C02.782.082.580 C10.228.228.245.500.500 C10.228.614.400.500 |
||
lymphogranuloma venereum | disease sexually transmitted infection infectious disease |
commensal bacterial infectious disease granuloma inguinale chlamydia infection |
Human disease | C01.252.400.210.210.490 C01.252.810.301.490 C01.539.778.281.301.490 C12.294.668.281.301.490 C13.351.500.711.281.301.490 |
Lymphogranuloma venereum | |
lymphoma | disease | hematologic cancer lymphatic system cancer lymphoma and pseudolymphoma |
hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs | C04.557.386 C15.604.515.569 C20.683.515.761 |
Lymphomas | |
lymphopenia | disease | leukopenia | leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood | C15.378.553.546.605 C20.673.627 |
||
Lynch syndrome | disease | autosomal dominant disease | Human disease | C04.588.274.476.411.307.190 C04.700.250 C06.301.371.411.307.190 C06.405.249.411.307.190 C06.405.469.158.356.190 C06.405.469.491.307.190 C16.320.700.250 C18.452.284.255 |
||
lysosomal storage disease | disease | inherited metabolic disorder overload disease |
inherited metabolic disorder that involve an abnormal accumulation of substances inside the lysosome resulting from defects in lysosomal function | C16.320.565.595 C18.452.648.595 |
Lysosomal storage diseases | |
macular holes | disease | retinal disease retinal perforation |
Human disease | C11.768.740 | Macular hole | |
macular retinal edema | disease | retinal edema | Human disease | C11.768.585.439.245 | Macular edema | |
Maffucci syndrome | disease | syndrome Ollier disease |
syndrome characterized by the presence of multiple enchondromas (benign growths of cartilage) associated with multiple cavernous hemangiomas and phleboliths | C05.116.099.708.338 | ||
Malakoplakia | disease | Xanthogranulomatous inflammation intestinal disease |
Malakoplakia is a chronic multisystem granulomatous inflammatory disease characterized by the presence of single or multiple soft plaques on various organs of the body | C23.550.548 | ||
malaria | disease | parasitic protozoa infectious disease vector-borne disease |
mosquito-transmitted disease | C03.752.530 | Malaria | |
male infertility | disease | male reproductive system disease infertility |
Human disease | C12.294.365.700 | Male infertility | |
malignant histiocytosis | disease | histiocytosis | Human disease | C04.557.227 C15.604.250.390 |
||
malignant hyperthermia | disease | genetic disease muscular channelopathy rare disease with malignant hyperthermia peripheral nervous system disease |
genetic disease that is characterized by a drastic and uncontrolled increase in skeletal muscle oxidative metabolism, which overwhelms the body's capacity to supply oxygen, remove carbon dioxide, and regulate body temperature | C23.550.505.700 C23.550.767.600 |
||
malignant peripheral nerve sheath tumor | disease | Nerve sheath tumor | Human disease | C04.557.465.625.650.595 C04.557.580.600.610.595 C04.557.580.625.650.595 |
Malignant peripheral nerve sheath tumor | |
Mallory–Weiss syndrome | disease | esophageal disease | C06.405.117.468.524 | |||
MALT lymphoma | disease | marginal zone B-cell lymphoma | non-Hodgkin lymphoma that has material basis in mucosal tissue involved in antibody production | C04.557.386.480.150.570 C15.604.515.569.480.150.570 C20.683.515.761.480.150.570 |
||
mammary Paget's disease | disease | breast adenocarcinoma | Human disease | C04.557.470.200.240.187.500 C04.557.470.615.275.625 |
Paget's disease of the breast | |
mantle cell lymphoma | disease | B-cell lymphoma aggressive B-cell non-Hodgkin lymphoma |
B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles | C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525 |
Mantle cell lymphoma | |
maple syrup urine disease | disease Designated intractable/rare diseases |
organic acidemia | Human disease | C10.228.140.163.100.520 C16.320.565.100.608 C16.320.565.189.520 C18.452.132.100.520 C18.452.648.100.608 C18.452.648.189.520 |
||
marantic endocarditis | disease thoracic disease |
endocarditis thrombosis |
endocarditis that results from the deposition of small sterile vegetations on valve leaflets | C14.280.282.703 | ||
marasmus | disease | protein-energy malnutrition | form of severe malnutrition characterized by energy deficiency | C18.654.521.500.708.626 | Marasmus | |
Marburg hemorrhagic fever | disease infectious disease |
viral infectious disease Filoviridae infectious disease |
Human disease | C02.782.417.560 C02.782.580.250.500 C22.735.500.500 |
||
Marfan syndrome | disease Designated intractable/rare diseases |
marfanoid connective tissue disease eye disease |
genetic disorder of the connective tissue | C05.116.099.674 C14.240.400.725 C14.280.400.725 C16.131.077.550 C16.131.240.400.720 C16.320.540 C17.300.500 |
Marfan syndrome | |
mastitis | disease | breast disease breastfeeding difficulties inflammatory disease reproductive system disease |
inflammation of the breast | C13.703.844.603 C17.800.090.968 |
Mastitis in animals | |
mastocytosis | disease | leukocyte disease | a rare mast cell activation disorder of both children and adults caused by the presence of too many mast cells | C04.557.450.565.465 C17.800.508 |
Mastocytosis | |
mastoiditis | disease | bone inflammation disease middle ear disease |
middle ear disease characterized by an inflammation of the mucosal lining of the mastoid antrum and the mastoid air cell system inside the mastoid process | C01.539.160.495.500 C05.116.165.495.249 C09.218.705.663.652 |
Mastoiditis | |
maturity-onset diabetes of the young | disease | diabetes mellitus genetic disease |
genetic disease that has material basis in mutations in the MODY genes disrupting insulin production | C18.452.394.750.149 C19.246.300 |
||
measles | disease infectious disease |
viral infectious disease Morbillivirus infectious disease |
viral disease affecting humans | C02.782.580.600.500.500 | Measles | |
Meckel's diverticulum | disease | birth defect genetic disease |
congenital disorder of digestive system | C06.198.859 C16.131.314.556 C23.300.415.750 |
Meckel's diverticulum | |
meconium aspiration syndrome | disease | lung disease perinatal respiratory disorder |
Human disease | C08.381.520.687 C08.618.580 C13.703.277.785 C16.300.580 C16.614.580 |
Meconium aspiration syndrome | |
mediastinitis | disease | connective tissue disease mediastinal disease inflammatory disease |
inflammatory process affecting the mediastinum | C08.846.187.790 | ||
Medulloblastoma | disease | infratentorial cancer embryonal tumor of neuroepithelial tissue |
infratentorial cancer that is located in the lower part of the brain and is a type of primitive neuroectodermal tumor | C04.557.465.625.600.380.515 C04.557.465.625.600.590.500 C04.557.470.670.380.515 C04.557.470.670.590.500 C04.557.580.625.600.380.515 C04.557.580.625.600.590.500 C04.557.465.625.600.590 C04.557.470.670.590 C04.557.580.625.600.590 |
Medulloblastoma | |
megacolon | disease | colonic disease | colonic disease that is characterized by an abnormal dilation of the colon | C06.405.469.158.701 | ||
megaesophagus | disease | esophageal disease | abnormal dilation of the esophagus not due to obstruction | C06.405.117.119.500.432 | ||
meibomian cyst | disease | blepharitis internal hordeolum |
blepharitis that is characterized as a cyst in the eyelid that is caused by inflammation of a blocked meibomian gland, usually on the upper eyelid | C04.182.197 C11.338.300 |
Chalazion | |
Meige syndrome | disease | cranio-facial dystonia focal, segmental or multifocal dystonia |
cranio-facial dystonia that is accompanied by blepharospasm | C10.228.140.079.590 C10.228.662.300.500 |
Meige's syndrome | |
melanoma | disease | skin cancer cell type cancer |
malignant neoplasm originating from melanocytes | C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510 |
Melanoma | |
melioidosis | disease infectious disease |
primary bacterial infectious disease bacterial infectious disease |
Human disease | C01.252.400.170.531 | Melioidosis | |
Melkersson-Rosenthal syndrome | disease | facial nerve disease cheilitis genetic peripheral neuropathy skin disease |
Human disease | C07.465.299.800 C07.465.466 C10.292.319.800 |
||
melorheostosis | disease developmental defect during embryogenesis |
osteosclerosis | osteosclerosis that has material basis in a mutation of the LEMD3 gene which results in a hyperdense bony cortex | C05.116.099.708.702.593 | ||
membranous glomerulonephritis | disease | glomerulonephritis lupus nephritis |
Human disease | C12.777.419.570.363.625 C13.351.968.419.570.363.625 C20.111.535 |
||
Meniere's disease | disease head and neck disease |
endolymphatic hydrops genetic otorhinolaryngologic disease genetic disease genetic nervous system disorder |
disorder of the inner ear | C09.218.568.217.500 | ||
meningioma | disease | central nervous system cancer rare nervous system tumor |
central nervous system cancer that are manifested in the central nervous system and arise from the arachnoid "cap" cells of the arachnoid villi in the meninges | C04.557.580.520 C04.557.645.520 C04.588.614.250.580.500 C10.551.240.500.500 C04.588.614.250.580 C10.551.240.500 |
Meningioma | |
meningitis | disease | central nervous system disease encephalomyelitis |
inflammation of membranes around the brain and spinal cord | C10.228.228.507 C10.228.566 |
Meningitis | |
Menkes disease | disease Designated intractable/rare diseases |
hair disease metal metabolism disorder copper metabolism disease syndromic neurometabolic disease with X-linked intellectual disability rare genetic epilepsy disorder of copper metabolism syndromic hair shaft abnormality eyebrow/eyelashes structural anomaly rare epidermal disease metal transport or utilization disorder with epilepsy |
Human disease | C10.228.140.163.100.540 C10.597.606.643.455.687 C16.320.322.500.687 C16.320.400.525.687 C16.320.565.189.540 C16.320.565.618.590 C17.800.329.968 C18.452.132.100.540 C18.452.648.189.540 C18.452.648.618.590 |
Menkes disease | |
mercury poisoning | disease | metal poisoning chemical hazard rare intoxication |
poisoning caused by mercury chemicals | C25.723.647 | ||
Merkel cell carcinoma | disease | skin carcinoma | Human disease | C02.256.721.150 C02.928.216 C04.557.465.625.650.240.325 C04.557.470.200.025.370.325 C04.557.580.625.650.240.325 |
Merkel cell carcinoma | |
MERRF syndrome | disease developmental defect during embryogenesis |
mitochondrial encephalomyopathy mitochondrial oxidative phosphorylation disorder due to a point mutation of mitochondrial DNA neurometabolic disease mitochondrial disease with epilepsy mitochondrial disease with peripheral neuropathy syndrome associated with hypertrophic cardiomyopathy mitochondrial disease with eye involvement mitochondrial disease with hypertrophic cardiomyopathy mitochondrial disease with dilated cardiomyopathy |
mitochondrial disease | C05.651.460.620.530 C10.228.140.163.100.545 C10.228.140.490.250.650.700 C10.668.491.500.500.550 C16.320.565.189.545 C18.452.132.100.545 C18.452.648.189.545 C18.452.660.560.620.530 |
||
metabolic syndrome | disease | abdominal obesity-metabolic syndrome | a clustering of medical conditions (giving a total of 16 possible combinations giving the syndrome) | C18.452.394.968.500.570 C18.452.625 |
Metabolic syndrome | |
metachromatic leukodystrophy | disease | sphingolipidosis rare hereditary metabolic disease with peripheral neuropathy rare genetic epilepsy unclassified primitive or secondary maculopathy metabolic disease with dementia hereditary retinal dystrophy rare dyslipidemia neurometabolic disease sphingolipidosis with epilepsy |
sphingolipidosis characterized by the accumulation of sulfatides in cells, especially the myelin producing cells of the nervous system | C10.228.140.163.100.362.550 C10.228.140.163.100.435.825.850.500 C10.228.140.695.625.550 C10.314.400.550 C16.320.565.189.362.550 C16.320.565.189.435.825.850.500 C16.320.565.398.641.803.925.500 C16.320.565.595.554.825.850.500 C18.452.132.100.362.550 C18.452.132.100.435.825.850.500 C18.452.584.687.803.925.500 C18.452.648.189.362.550 C18.452.648.189.435.825.850.500 C18.452.648.398.641.803.925.500 C18.452.648.595.554.825.850.500 |
Metachromatic leukodystrophy | |
Methemoglobinemia | disease | hemoglobinopathy | Human disease | C15.378.619 | ||
microcephaly | disease | cephalic disorder malformation of cortical development, Group I |
medical condition in which the brain does not develop properly resulting in a smaller than normal head | C05.660.207.620 C10.500.507.400.500 C16.131.621.207.620 C16.131.666.507.400.500 |
Microcephaly | |
microphthalmia | disease | eye disease eye abnormalities |
eye disease where one or both eyeballs are abnormally small | C11.250.566 C16.131.384.666 |
Microphthalmia | |
Microscopic polyangiitis | disease | arterial occlusive disease anti-neutrophil cytoplasmic antibody-associated vasculitis systemic inflammatory disease associated with an acquired peripheral neuropathy secondary glomerular disease |
Microscopic polyangiitis (MPA) is an inflammatory, necrotizing, systemic vasculitis that affects predominantly small vessels (i.e. small arteries, arterioles, capillaries, venules) in multiple organs. | C10.228.140.300.275.600 C14.907.253.329.600 C14.907.940.897.249.500 C20.111.193.750 |
||
microsporidiosis | disease infectious disease |
opportunistic mycosis immune system disease fungal infectious disease |
opportunistic mycosis that results in systemic fungal infection in immunocompromised people, has material basis in Microsporidia phylum members | C01.703.617 | Microsporidiosis | |
microtia | disease | congenital physical abnormalitie pinna disease |
C09.218.235 C16.131.287 |
Microtia | ||
Middle cerebral artery syndrome | disease | cerebral arterial disease cerebral infarction cerebral artery occlusion |
Human disease | C10.228.140.300.150.477.200.450 C10.228.140.300.510.200.387 C10.228.140.300.775.200.200.450 C14.907.253.092.477.200.450 C14.907.253.560.200.387 C14.907.253.855.200.200.450 |
||
migraine | disease | brain disease | brain disease characterized by recurrent headaches on one side | C10.228.140.546.399.750 | Migraine | |
Mikulicz disease | disease head and neck disease |
lacrimal apparatus disease benign lymphoepithelial lesion of salivary gland autoimmune disease of eyes, ear, nose and throat genetic otorhinolaryngologic disease rare genetic immune disease autoimmune disease of the nervous system IgG4-related disease |
Human disease | C07.465.815.355 | ||
miliaria | disease | sweat gland disease | Human disease | C17.800.946.492 | Miliaria (disease) | |
milk allergy | disease | food allergy | type of food allergy caused by milk | C20.543.480.370.500 | ||
Miller Fisher syndrome | disease | Guillain–Barré Syndrome regional variant of Guillain-Barre syndrome |
A Guillain-Barre syndrome that manifests as a descending paralysis. It usually affects the eye muscles first and presents with the triad of ophthalmoplegia, ataxia, and areflexia. | C10.114.750.100.500 C10.228.140.252.500 C10.292.562.350 C10.314.750.450.500 C10.668.829.350.500 C10.668.829.800.750.300.500 C11.590.312 C20.111.258.750.400.500 |
||
mitochondrial disease | disease developmental defect during embryogenesis |
inherited metabolic disorder mitochondrial developmental anomaly of metabolic origin inborn disorder of energy metabolism |
inherited disorder that involves mitochondrial dysfunction | C18.452.660 | Mitochondrial diseases | |
mitral valve insufficiency | disease | mitral valve disease | disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood | C14.280.484.461 | Mitral valve insufficiency | |
mitral valve prolapse | disease | mitral valve disease heart valve prolapse |
mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole | C14.280.484.400.500 | Mitral valve prolapse | |
mitral valve stenosis | disease | mitral valve disease | mitral valve disease that is characterized by the narrowing of the orifice of the mitral valve of the heart | C14.280.484.517 | Mitral valve stenosis | |
mixed connective tissue disease | disease Designated intractable/rare diseases |
collagen disease overlap syndrome secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease rare rheumatologic disease secondary glomerular disease systemic inflammatory disease associated with an acquired peripheral neuropathy immune system disease |
collagen disease that is considered an overlap of three diseases, systemic lupus erythematosus, scleroderma, and polymyositis with very high titers of circulating antinuclear antibody to a ribonucleoprotein antigen | C17.300.540 | ||
Mobius syndrome | disease head and neck disease developmental defect during embryogenesis |
facial nerve disease cranial nerve and nuclear aplasia syndrome with a symptomatic strabismus nuclear oculomotor paralysis multiple congenital anomalies/dysmorphic syndrome-variable intellectual disability syndrome branchial arch or oral-acral syndrome paralytic facial malformation genetic peripheral neuropathy |
rare disease | C07.465.299.825 C10.292.319.825 C16.131.077.578 C16.614.595 |
Möbius syndrome | |
molluscum contagiosum | disease infectious disease |
viral infectious disease viral skin disease |
viral infection of the skin | C02.256.743.611 C02.825.550 C17.800.838.790.550 |
Molluscum contagiosum | |
Monckeberg arteriosclerosis | disease | arteriosclerosis vascular calcification |
Human pathology | C18.452.174.130.780.500 | Monckeberg's arteriosclerosis | |
Mongolian spot | disease medical finding |
skin disease | benign, flat, congenital birthmark | C04.557.665.560.615.530 | Mongolian spot | |
monilethrix | disease | autosomal dominant disease hair disease isolated genetic hair shaft abnormality |
Human disease | C16.131.077.592 C16.320.850.647 C17.800.329.984 C17.800.827.602 |
||
monkeypox | disease | viral infectious disease | viral disease | C02.256.743.615 C22.735.750 C22.795.600 |
||
motion sickness | disease head and neck disease |
inner ear disease genetic nervous system disorder genetic otorhinolaryngologic disease genetic disease |
condition in which a disagreement exists between visually perceived movement and the vestibular system's sense of movement | C23.888.571 | Motion sickness | |
Moyamoya disease | disease Designated intractable/rare diseases |
cerebral arterial disease | A cerebral arterial disease characterized by constriction of certain arteries at the base of the brain. Blood flow is blocked by the constriction and also by blood clots. | C10.228.140.300.200.600 C10.228.140.300.510.200.737 C14.907.137.615 C14.907.253.123.620 C14.907.253.560.200.737 |
||
Muckle-Wells syndrome | disease | Cryopyrin-associated periodic syndrome autosomal dominant disease Urticarial syndromes secondary glomerular disease rare genetic renal disease |
Human disease | C16.320.382.500 C17.800.827.368.500 |
||
mucocele of salivary gland | disease | salivary gland disease Mucous cyst of the oral mucosa |
Human disease | C04.182.766 C07.465.780 |
Ranula | |
mucopolysaccharidosis | disease developmental defect during embryogenesis |
lysosomal storage disease rare genetic developmental defect during embryogenesis rare disease with glaucoma as a major feature developmental anomaly of metabolic origin |
lysosomal storage disease that involves the accumulation of glycosaminoglycans in the tissues and their excretion in the urine | C16.320.565.202.715 C16.320.565.595.600 C17.300.550.575 C18.452.648.202.715 C18.452.648.595.600 |
Mucopolysaccharidoses | |
mucopolysaccharidosis I | disease | mucopolysaccharidosis | Lysosomal storage disease | C16.320.565.202.715.640 C16.320.565.595.600.640 C17.300.550.575.640 C18.452.648.202.715.640 C18.452.648.595.600.640 |
Hurler syndrome | |
mucopolysaccharidosis II | disease developmental defect during embryogenesis |
mucopolysaccharidosis syndromic neurometabolic disease with X-linked intellectual disability mucopolysaccharidosis with skin involvement hypertrophic cardiomyopathy lysosomal storage disease with skeletal involvement ptosis syndrome associated with hypertrophic cardiomyopathy lysosomal disease with hypertrophic cardiomyopathy |
mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme iduronate sulfatase | C10.597.606.643.455.750 C16.320.322.500.750 C16.320.400.525.750 C16.320.565.202.715.645 C16.320.565.595.600.645 C17.300.550.575.645 C18.452.648.202.715.645 C18.452.648.595.600.645 |
||
mucopolysaccharidosis VI | disease developmental defect during embryogenesis |
mucopolysaccharidosis lysosomal storage disease with skeletal involvement metabolic disease with corneal opacity |
Lysosomal storage disease | C16.320.565.202.715.670 C16.320.565.595.600.670 C17.300.550.575.670 C18.452.648.202.715.670 C18.452.648.595.600.670 |
||
Muir-Torre syndrome | disease head and neck disease |
Lynch syndrome rare skin tumor or hamartoma palpebral sebaceous gland tumor benign tumor of palpebral epidermis benign neoplasm of sebaceous gland |
Human disease | C04.588.805.578.500 C04.700.250.500.500 C16.320.700.250.500.500 C17.800.794.712.500 C17.800.827.610 C17.800.882.712.500 |
||
multidrug-resistant tuberculosis | disease infectious disease |
tuberculosis MDR bacteria |
tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs | C01.252.410.040.552.846.775 | ||
multiple acyl-CoA dehydrogenase deficiency | disease | inherited metabolic disorder acyl-CoA dehydrogenase deficiency fatty acid oxidation and ketogenesis disorder with hypertrophic cardiomyopathy |
Human disease | C16.320.565.100.614 C18.452.648.100.614 C18.452.660.612 |
||
multiple chemical sensitivity | disease questionable disease |
syndrome | rare disease | C20.543.312.500 C21.223.500 |
||
multiple endocrine neoplasia | disease | Endocrine gland neoplasm | Human disease | C04.588.322.400 C04.651.600 C04.700.630 C16.320.700.630 C19.344.400 |
Multiple endocrine neoplasia | |
multiple endocrine neoplasia type 2A | disease | autosomal dominant disease multiple endocrine neoplasia catecholamine-producing tumor inherited renal tumor |
autosomal dominant disease characterized by medullary carcinoma of the thyroid, pheochromocytoma, hyperparathyroidism, and occasionally cutaneous lichen amyloidosis | C04.588.322.400.505 C04.651.600.505 C04.700.630.505 C16.320.700.630.505 C19.344.400.505 |
||
multiple endocrine neoplasia type 2B | disease | autosomal dominant disease multiple endocrine neoplasia inherited renal tumor catecholamine-producing tumor |
autosomal dominant disease characterized by medullary thyroid carcinoma, pheochromocytoma, multiple mucosal neuromas and intestinal ganglioneuromas, and often a marfanoid habitus and other skeletal abnormalities | C04.588.322.400.510 C04.651.600.510 C04.700.630.510 C16.320.700.630.510 C19.344.400.510 |
||
multiple epiphyseal dysplasia | disease genetic disease developmental defect during embryogenesis |
osteochondrodysplasia | An osteochondrodysplasia that has material basis in defective cartilage mineralization into bone which results in irregular ossification centers of the located in hip or located in knee. The disease has symptom fatigue, has symptom joint pain. | C05.116.099.708 C16.320.728 |
||
multiple myeloma | disease | myeloid neoplasm leukocyte disease |
A myeloid neoplasm that is located in the plasma cells in bone marrow. | C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650 |
Multiple myeloma | |
multiple system atrophy | disease Designated intractable/rare diseases |
synucleinopathy neurodegeneration |
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure (cardiovascular and/or urinary), parkinsonism, cerebellar impairment and corticospinal signs with a median survival of 6-9 years | C10.177.575.550.750 C10.228.140.079.612.700 C10.228.662.550.700 C10.574.625.700 C14.907.514.741 C10.177.575.550 C10.228.140.079.612 C10.228.662.550 C10.574.625 |
Multiple system atrophy | |
mumps | disease | Mumps virus infectious disease herpangina salivary gland disease |
Human disease caused by paramyxovirus | C02.782.580.600.680.500 C07.465.815.470.800.630 |
Mumps | |
Munchausen by proxy | disease | factitious disorder child abuse |
behavioral disorder in which an adult fakes an illness in (mostly) a child or other proxy(s) | F03.875.375.800 | ||
muscular dystrophy | disease Designated intractable/rare diseases |
myopathy genetic peripheral neuropathy |
myopathy characterized by progressive skeletal muscle weakness degeneration | C05.651.534.500 C10.668.491.175.500 C16.320.577 |
Muscular dystrophies | |
mutism | disease health problem |
speech disorder | inability to speak | C10.597.606.150.500.800.500 C23.888.592.604.150.500.800.500 |
||
mycosis fungoides | disease | cutaneous T cell lymphoma rare disease mycosis fungoides and variants |
Human disease | C04.557.386.480.750.800.550 C15.604.515.569.480.750.800.550 C20.683.515.761.480.750.800.550 |
||
myelitis | disease | spinal cord disease | spinal cord disease that is characterized by inflammation of the white matter or gray matter of the spinal cord | C10.228.228.618 C10.228.854.525 |
||
myelodysplastic syndrome | disease | bone marrow cancer neoplastic syndrome |
diverse collection of hematological (blood-related) medical conditions that involve ineffective production of the myeloid class of blood cells | C04.834.770 C15.378.800 C15.378.190.625 |
Myelodysplastic syndrome | |
myelofibrosis | disease | myeloid neoplasm acquired aplastic anemia rare genetic immune disease |
myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue | C15.378.190.636.765 | ||
myiasis | disease infectious disease |
parasitic ectoparasitic infectious disease rare skin disease |
parasitic ectoparasitic infectious disease that is caused by parasitic dipterous fly larvae (maggots) feeding on the host's necrotic or living tissue | C03.858.211.503 | Myiasis | |
myocardial infarction | disease | coronary artery disease | interruption of blood supply to a part of the heart | C14.280.647.500 C14.907.585.500 |
Myocardial infarction | |
myocarditis | disease | extrinsic cardiomyopathy myocardial disorder inflammation of heart layer |
extrinsic cardiomyopathy that is characterized as an inflammation of the heart muscle | C14.280.238.625 | Myocarditis | |
myofascial pain syndrome | disease | myopathy | Human disease | C05.651.550 | ||
myoglobinuria | disease | myopathy | myopathy that is characterized by an increased urinary excretion of myoglobin | C05.651.807.628 | ||
myoma | disease | muscle benign neoplasm uterine benign neoplasm |
Human disease | C04.557.450.590.540 | Uterine fibroids | |
myopathy | disease | muscle tissue disease | muscular disease in which the muscle fibers do not function resulting in muscular weakness | C05.651 C10.668.491 |
Diseases and disorders of the muscular system | |
myopia | disease | refractive error visual impairment |
problem with distance vision | C11.744.636 | Myopia | |
myositis | disease | myopathy inflammation |
myopathy characterized by muscle inflammation | C05.651.594 C10.668.491.562 |
||
myotonia congenita | disease | muscle tissue disease channelopathy |
muscle tissue disease that is characterised by slow muscle relaxation associated with hyperexcitation of the muscle fibres | C05.651.662.500 C10.574.500.545 C10.668.491.606.500 C16.320.400.540 |
||
myotonic dystrophy type 1 | disease | myotonic disease hypertrophic cardiomyopathy organic brain syndrome ptosis myopathy with eye involvement syndrome associated with hypertrophic cardiomyopathy musculoskeletal disease with cataract Hypergonadotropic hypogonadism |
Human disease | C05.651.534.500.500 C05.651.662.750 C10.574.500.547 C10.668.491.175.500.500 C10.668.491.606.750 C16.320.400.542 C16.320.577.500 |
Myotonic dystrophy | |
myxedema | disease | hypothyroidism mucinosis |
Human disease | C17.300.550.590 C19.874.482.638 |
Myxedema | |
myxoma | disease | cancer | myxoid tumor of primitive connective tissue | C04.557.450.565.550 | Myxoma | |
narcolepsy | disease | sleep disorder | sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work | C10.886.425.800.200.750 | Narcolepsy | |
nasopharynx carcinoma | disease head and neck disease |
carcinoma pharyngeal cancer nasopharyngeal disease respiratory system cancer |
common cancer originating in the nasopharynx | C04.588.443.665.710.650 C07.550.350.650 C07.550.745.650 C09.647.710.650 C09.775.350.650 C09.775.549.650 |
Nasopharynx cancer | |
necrobiosis lipoidica | disease | skin disease Diabetic dermadrome necrobiotic disorders |
Human disease | C17.300.200.495.545 C17.800.550.545 C17.800.849.495 C18.452.880.495 |
Necrobiosis lipoidica | |
necrotizing fasciitis | disease | fasciitis necrosis |
Human disease | C01.252.825.340 C05.321.550 |
Necrotizing fasciitis | |
necrotizing ulcerative gingivitis | disease | gingivitis | Human disease | C01.252.400.388.350.400 C01.539.424 C07.465.714.258.480.446 |
Acute necrotizing ulcerative gingivitis | |
Nelson syndrome | disease head and neck disease |
adrenal cortex disease functioning pituitary adenoma |
Human disease | C04.588.322.609.145.500 C10.228.140.617.738.675.149.500 C19.344.609.145.500 C19.700.734.145.500 |
||
nemaline myopathy | disease | congenital structural myopathy non-dystrophic myopathy |
congenital structural myopathy characterized by generally non-progressive muscle weakness of varying severity | C05.651.575.290 C10.668.491.550.290 |
||
neonatal jaundice | disease | pigmentation disease | pigmentation disease characterized by a high level of bilirubin in the blood, causing a yellowing of the skin and other tissues of a newborn infant | C16.614.451.500 C23.550.429.249.500 C16.614.451 C23.550.429.249 |
Neonatal jaundice | |
nephroblastoma | disease | kidney cancer | rare disease | C04.557.435.595 C04.588.945.947.535.585 C04.700.635 C12.758.820.750.585 C12.777.419.473.585 C13.351.937.820.535.585 C13.351.968.419.473.585 C16.320.700.642 |
Wilms' tumor | |
nephrocalcinosis | disease | calcinosis kidney disease |
Human disease | C12.777.419.590 C13.351.968.419.590 C18.452.174.130.560 |
||
nephrosclerosis | disease | renal hypertension | Human disease | C12.777.419.610 C13.351.968.419.610 |
||
nephrotic syndrome | disease | nephrosis | Human disease | C12.777.419.630.643 C13.351.968.419.630.643 |
||
nerve compression syndrome | disease | peripheral nervous system disease | Human disease | C10.668.829.550 | ||
Nesidioblastosis | disease | carbohydrate metabolic disorder Hyperinsulinemic hypoglycemia |
carbohydrate metabolic disorder that involves low blood glucose resulting from an excess of insulin | C06.689.150.500 C16.614.200.500 C18.452.394.968.250.500 C18.452.394.984.200.500 |
||
neural tube defect | disease developmental defect during embryogenesis |
birth defect Congenital vertebral anomaly rare genetic developmental defect during embryogenesis genetic nervous system disorder |
congenital disorder of nervous system | C10.500.680 C16.131.666.680 |
||
neurilemmoma | disease | neuroma | Human disease | C04.557.465.625.650.595 C04.557.580.600.610.595 C04.557.580.625.650.595 |
||
neuroacanthocytosis | disease Designated intractable/rare diseases |
neurodegeneration genetic neurodegenerative disease with dementia Huntington disease-like syndrome |
Neuroacanthocytosis (NA) syndromes are a group of genetic diseases characterized by the association of red blood cell acanthocytosis (deformed erythrocytes with spike-like protrusions) and progressive degeneration of the basal ganglia | C10.228.662.262.249.937 C16.320.400.550 |
||
neuroblastoma | disease | autonomic nervous system neoplasm | An autonomic nervous system neoplasm that is derived from immature nerve cells. | C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550 |
Neuroblastoma | |
neurodegeneration | disease | central nervous system disease degenerative disease |
central nervous system disease | C10.574 | Neurodegenerative diseases and disorders | |
neurodermatitis | disease | dermatitis lichen disease |
Human disease | C17.800.174.660 C17.800.815.660 |
Lichen simplex chronicus | |
neuroendocrine tumor | disease | endocrine gland cancer rare disease |
endocrine gland cancer that has material basis in neuroendocrine cells | C04.557.465.625.650 C04.557.580.625.650 |
Neuroendocrine tumors | |
neurofibroma | disease | Nerve sheath tumor | Human disease | C04.557.580.600.580 C10.551.775.500.750 C10.668.829.725.500.600 |
Neurofibroma | |
neurofibromatosis | disease | autosomal dominant disease peripheral nervous system neoplasm overgrowth syndrome |
human disease | C04.557.465.625.650.595.610.500 C04.557.580.600.580.590.655 C04.557.580.600.610.595.610.500 C04.700.645.655 C09.218.807.800.675.500 C09.647.675.500 C10.292.225.750.500 C10.292.910.600.500 C10.562.600.750 C10.574.500.549.700 C16.320.400.560.700 C16.320.700.645.655 C04.557.580.600.580.590.650 C04.700.645.650 C10.562.600.500 C10.574.500.549.400 C10.668.829.675 C16.320.400.560.400 C16.320.700.645.650 C04.557.580.600.580.590 C04.700.645 C10.562.600 C10.574.500.549 C16.320.400.560 C16.320.700.645 |
Neurofibromatosis | |
neurofibromatosis type II | disease Designated intractable/rare diseases |
neurofibromatosis | type of neurofibromatosis disease | C04.557.465.625.650.595.610.500 C04.557.580.600.580.590.655 C04.557.580.600.610.595.610.500 C04.700.645.655 C09.218.807.800.675.500 C09.647.675.500 C10.292.225.750.500 C10.292.910.600.500 C10.562.600.750 C10.574.500.549.700 C16.320.400.560.700 C16.320.700.645.655 |
Neurofibromatosis type 2 | |
neurogenic arthropathy | disease | arthropathy | Human disease | C05.550.186 | Neuropathic arthropathy | |
neuroleptic malignant syndrome | disease health problem |
neurological disorder adverse drug reaction rare disease with malignant hyperthermia |
nervous systm disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers | C10.228.140.079.737 C10.720.737 C25.723.705.600 |
||
neuroma | disease | nervous system benign neoplasm | nervous system benign neoplasm that is characterized as a nerve tissue tumor | C04.557.580.600.610 | Neuroma | |
neuromyelitis optica | disease | autoimmune disease of central nervous system spinal cord disease autoimmune disease of peripheral nervous system optic nerve disease neurodegeneration multiple sclerosis eye degenerative disease immune system disease multiple sclerosis variant rare acquired eye disease |
Neuromyelitis optica (NMO) and NMO spectrum disorders are inflammatory demyelinating diseases of the central nervous system characterized mainly by attacks of uni- or bilateral optic neuritis (ON) and acute myelitis | C10.114.375.600.500 C10.114.375.800 C10.292.700.550.500 C10.314.350.600.500 C10.314.350.800 C11.640.576.695 C20.111.258.250.550.500 C20.111.258.250.775 |
Multiple sclerosis | |
neutropenia | disease | agranulocytosis | abnormally low concentration of neutrophils in the blood | C15.378.553.546.184.564 | ||
nevoid basal cell carcinoma syndrome | disease | autosomal dominant disease | an autosomal dominant condition that can cause unusual facial appearances and a predisposition for basal-cell carcinoma | C04.182.089.530.690.150 C04.557.470.200.165.150 C04.557.470.565.165.150 C04.700.175 C05.116.099.105 C05.500.470.690.150 C07.320.450.670.130 C16.131.077.130 C16.320.700.175 |
||
Niemann-Pick disease | disease | sphingolipidosis non-Langerhans-cell histiocytosis |
rare disease | C10.228.140.163.100.435.825.700 C15.604.250.410.625 C16.320.565.189.435.825.700 C16.320.565.398.641.803.730 C16.320.565.595.554.825.700 C18.452.132.100.435.825.700 C18.452.584.687.803.730 C18.452.648.189.435.825.700 C18.452.648.398.641.803.730 C18.452.648.595.554.825.700 |
Niemann–Pick disease | |
night blindness | disease | eye disease retinal disease vision disorder |
condition making it difficult or impossible to see in relatively low light | C11.966.671 | ||
Nijmegen breakage syndrome | disease developmental defect during embryogenesis |
autosomal recessive disease rare genetic inherited tumor multiple congenital anomalies/dysmorphic syndrome without intellectual disability developmental anomaly of metabolic origin DNA repair defect other than combined T-cell and B-cell immunodeficiencies rare genetic developmental defect during embryogenesis polymalformative genetic syndrome with increased risk of developing cancer |
Human disease | C18.452.284.600 | ||
nocardiosis | disease infectious disease |
opportunistic bacterial infectious disease bacterial infectious disease |
Human disease | C01.252.410.040.692 | Nocardiosis | |
nocturnal enuresis | disease | enuresis | disease | C12.777.934.284.500 C13.351.968.934.252.500 |
||
nodding disease | disease rare disease |
disease | C10.228.140.490.375.525 | |||
noma | disease infectious disease |
ulcerative stomatitis aphthous stomatitis bacterial infectious disease |
Human disease | C07.465.604 | Noma (disease) | |
nominal aphasia | disease | aphasia | type of aphasia that causes problems with recalling words or names | C10.597.606.150.500.090 C23.888.592.604.150.500.090 |
||
Non-alcoholic fatty liver disease | disease | fatty liver disease | fatty liver disease characterized by the storing of excess fat in liver cells which is is not caused by heavy alcohol use | C06.552.241.519 | ||
non-Hodgkin lymphoma | disease | lymphoma neoplasm hematopoietic system diseases |
cancer of lymph in humans | C04.557.386.480 C15.604.515.569.480 C20.683.515.761.480 |
Hematologic neoplasms | |
Noonan syndrome | disease Designated intractable/rare diseases |
rare disease syndrome |
syndrome that is characterized by mildly unusual facial features, short stature, heart defects, bleeding problems, skeletal malformations, and many other signs and symptoms | C05.660.207.690 C14.240.400.787 C14.280.400.787 C16.131.240.400.784 C16.131.621.207.690 C17.300.690 |
Noonan syndrome | |
normal pressure hydrocephalus | disease | communicating hydrocephalus genetic neurodegenerative disease genetic dementia |
Human disease | C10.228.140.602.750 | Normal pressure hydrocephalus | |
nutrition disorder | disease | acquired metabolic disease nutritional and metabolic diseases |
disease that results from excessive or inadequate intake of food and nutrients | C18.654 | Nutritional diseases and disorders | |
nutritional deficiency disease | disease | nutrition disorder | Human disease | C18.654.521.500 | Diseases and disorders due to nutritional deficiencies | |
ochronosis | disease | connective tissue disease | Human disease | C23.550.744 | Ochronosis | |
ocular albinism type 1 | disease | ocular albinism | C11.270.040.090 C16.320.290.040.090 C16.320.565.100.102.090 C16.320.850.080.090 C17.800.621.440.102.090 C17.800.827.080.090 C18.452.648.100.102.090 |
|||
oculocerebrorenal syndrome | disease developmental defect during embryogenesis |
X-linked disease developmental anomaly of metabolic origin syndromic neurometabolic disease with X-linked intellectual disability inherited renal tubular disease Amino acid transport disorder rare renal tubular disease renal disease with cataract rare disease with glaucoma as a major feature metabolic disease with cataract syndromic developmental defect of the eye |
Human disease | C10.228.140.163.100.640 C12.777.419.815.720 C13.351.968.419.815.720 C16.131.077.662 C16.320.322.750 C16.320.565.151.600 C16.320.565.189.640 C16.320.565.861.750 C16.320.709 C18.452.132.100.640 C18.452.648.151.600 C18.452.648.189.640 C18.452.648.861.750 |
||
oculocutaneous albinism | disease Wikimedia disambiguation page |
autosomal recessive disease albinism |
autosomal recessive disease characterized by abnormal pigmentation of the skin, hair and eyes | C11.270.040.545 C16.320.290.040.100 C16.320.565.100.102.100 C16.320.850.080.100 C17.800.621.440.102.100 C17.800.827.080.100 C18.452.648.100.102.100 |
||
oculomotor nerve paralysis | disease | third cranial nerve disease paralytic squint |
Human disease | C10.292.562.700 C11.590.436 |
Oculomotor nerve palsy | |
oligodendroglioma | disease | glioma | Human disease | C04.557.465.625.600.380.590 C04.557.470.670.380.590 C04.557.580.625.600.380.590 |
Oligodendroglioma | |
oligohydramnios | disease | placenta disease | placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion | C13.703.560 | ||
Oligomenorrhea | disease | menstrual disorder | C23.550.568.937 | |||
Omphalocele | disease | birth defect Abdominal wall defect |
physical disorder characterized by a defect in the development of the abdominal wall muscles, resulting in the intestines, liver and other organs to remain outside of the abdomen in a sac | C16.614.378 C23.300.707.374.937.500 |
Omphalocele | |
onchocerciasis | disease | filariasis parasitic helminthiasis infectious disease |
Human helminthiasis | C03.335.508.700.750.361.699 C03.858.650 C17.800.838.775.690 |
Onchocerciasis | |
onychomycosis | disease | fungal infectious disease nail disease |
Human and animal disease | C01.539.800.200.720.550 C01.703.295.872.458 C17.800.529.550 C17.800.838.208.883.458 |
Onychomycosis | |
ophthalmoplegia | disease | ocular motility disease | Human disease | C10.292.562.750 C10.597.622.447 C11.590.472 C23.888.592.636.447 |
Ophthalmoparesis | |
opisthorchiasis | disease infectious disease |
parasitic helminthiasis infectious disease distomatosis |
Human helminthiasis | C03.335.865.685 | ||
Opportunistic infection | disease | superinfection | C01.539.597 C02.597 C03.684 |
Opportunistic infections | ||
optic neuritis | disease | optic nerve disease eye disease encephalomyelitis |
optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision | C10.292.700.550 C11.640.576 |
||
oral cavity cancer | disease | gastrointestinal system cancer mouth disease |
gastrointestinal system cancer that is located in the oral cavity | C04.588.443.591 C07.465.565 |
Oral cancer | |
oral hairy leukoplakia | disease | mouth disease leukoplakia |
mouth disease characterized by a white patch on the lateral sides of the tongue with a corrugated or hairy appearance; caused by Epstein-Barr virus | C02.256.466.313.500 C04.588.443.591.545.500 C04.834.512.513.500 C07.465.565.545.500 C23.300.816.513.500 |
||
orbital cellulitis | disease health problem infectious disease |
acute orbital inflammation cellulitis |
Human disease | C11.675.387 C17.300.185.500 |
||
orchitis | disease | testicular disease inflammatory disease |
inflammation of the testes | C12.294.829.493 C19.391.829.493 |
Orchitis | |
ornithosis | disease animal disease infectious disease |
primary bacterial infectious disease Chlamydophila infectious disease |
Human disease | C01.252.400.210.250.600 | Psittacosis | |
oromandibular dystonia | disease | focal dystonia lingual-facial-buccal dyskinesia focal, segmental or multifocal dystonia |
focal dystonia that is characterized by distortions of the mouth and tongue. | C10.228.662 | ||
oropharynx cancer | disease head and neck disease |
pharyngeal cancer carcinoma neoplasm of oropharynx |
pharynx cancer that is located in the oropharynx | A03.556.750 | ||
Osgood-Schlatter's disease Mohamed disease | disease | bone inflammation disease knee disorder |
osteochondrosis | C05.116.821 | Osgood–Schlatter disease | |
osteitis fibrosa | disease | bone resorption disease | bone resorption disease that has material basis in hyperparathyroidism which results in hyperactivity in osteoclasts, deformity, and loss of mass located in bone | C05.116.132.684 | ||
osteoblastoma | disease | bone benign neoplasm | Human disease | C04.557.450.565.575.600 | ||
osteochondritis dissecans | disease | ischemic bone disease | ischemic bone disease that results_in necrosis located_in epiphysis. | C05.116.791 C05.182.520 C17.300.182.520 C05.116.791.668 |
Osteochondritis dissecans | |
osteochondrosis | disease | ischemic bone disease | ischemic bone disease that results in necrosis followed by regrowth in children and teens located in bone | C05.116.821 | Osteochondrosis | |
osteogenesis imperfecta | disease | osteochondrodysplasia | osteochondrodysplasia that has material basis in a deficiency in type-I collagen which results in brittle bones and defective connective tissue | C05.116.099.708.685 C16.320.737 C17.300.200.540 |
Osteogenesis imperfecta | |
osteoid osteoma | disease | osteoma inherited syndrome with bone tumors as a major feature |
C04.557.450.565.575.625.625 | Osteoid osteoma | ||
osteomalacia | disease | bone remodeling disease | bone remodeling disease that has material basis in a vitamin D deficiency which results in softening located in bone | C05.116.198.816.640 C18.452.104.816.640 C18.452.174.845.640 C18.654.521.500.133.770.734.640 |
||
osteomyelitis | disease | bone inflammation disease | bone inflammation disease that has material basis in infection located in bone or located in bone marrow | C01.539.160.495 C05.116.165.495 |
Osteomyelitis | |
osteonecrosis | disease | necrosis ischemic bone disease |
bone death caused when the bone no longer receives blood supply | C05.116.852 C23.550.717.732 |
Aseptic osteonecrosis | |
osteopetrosis | disease | osteosclerosis | inherited disorder | C05.116.099.708.702.678 | Osteopetrosis | |
osteophyte | disease | exostosis | C05.116.540.310.800 | Osteophyte | ||
osteopoikilosis | disease | osteosclerosis | osteosclerosis that results in numerous bone islands located in skeleton | C05.116.099.708.702.685 C17.300.705 |
Osteopoikilosis | |
osteoporosis | disease | bone resorption disease | bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength | C05.116.198.579 C18.452.104.579 C05.116.198.579.610 C18.452.104.579.610 |
Osteoporosis | |
osteosarcoma | disease | bone cancer sarcoma |
bone cancer that is located in bone that has material basis in cells of mesenchymal origin | C04.557.450.565.575.650 C04.557.450.795.620 C04.557.450.565.575 |
Osteosarcoma | |
osteosclerosis | disease | bone remodeling disease | bone remodeling disease that results in abnormal elevated bone density or mass | C05.116.099.708.702 | ||
otitis externa | disease head and neck disease infectious disease |
external ear disease ear infection post-infectious disorder |
An external ear disease that involves inflammation of the outer ear and ear canal. It can be caused by active bacterial or fungal infections. | C09.218.705.496 | Otitis externa | |
otitis media | disease head and neck disease |
middle ear disease inflammatory disease |
otitis which involves inflammation of the middle ear | C09.218.705.663 | Otitis media | |
otomycosis | disease | otitis externa cutaneous mycosis |
Human disease | C01.703.658 C09.218.736 |
||
otosclerosis | disease | inner ear disease | otitis interna characterized by an abnormal bone growth in the middle ear | C09.218.768 | ||
ovarian Brenner tumor | disease | ovarian benign neoplasm | ovarian benign neoplasm that has material basis in the surface epithelium of the ovary | C04.557.450.565.590.595.150 C04.557.470.625.150 C13.351.500.056.630.705.265 C13.351.937.418.685.265 C19.391.630.705.265 |
Brenner tumour | |
ovarian cancer | disease | female reproductive organ cancer ovarian tumor ovarian disease endocrine gland cancer rare genetic endocrine disease inherited gynecological tumor |
female reproductive organ cancer that is located_in the ovary. | C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705 |
Ovarian cancer | |
ovarian cyst | disease | ovarian disease ovarian tumor |
fluid-filled sac in the ovary | C04.182.612 C13.351.500.056.630.580 C19.391.630.580 |
Ovarian cysts | |
ovarian hyperstimulation syndrome | disease | ovarian disease rare genetic endocrine disease rare genetic gynecological and obstetrical diseases rare non-malformative uterine adnexal disease |
Human disease | C13.351.500.056.630.642 C19.391.630.642 |
||
oxyphilic adenoma | disease | endocrine organ benign neoplasm oncocytic neoplasm benign epithelial neoplasm |
Human disease | C04.557.470.035.140 | Oncocytoma | |
Pancoast tumor | disease | lung cancer | Human disease | C04.588.894.797.520.734 C08.381.540.734 C08.785.520.734 |
||
pancreatic cancer | disease | endocrine gland cancer pancreas disease pancreatic tumor gastrointestinal system cancer |
endocrine gland cancer located in the pancreas | C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421 |
Pancreatic cancer | |
pancreatitis | disease | pancreas disease inflammatory disease |
Human disease | C06.689.750 | Pancreatitis | |
pancytopenia | disease | anemia | Human disease | C15.378.700 | ||
panniculitis | disease | fibromyalgia dermatomyositis connective tissue disease |
Inflammation of the subcutaneous adipose tissue | C17.300.710 C17.800.566 |
||
panophthalmitis | disease infectious disease |
scleritis purulent endophthalmitis |
Human disease | C01.252.354.900.675 C01.539.375.354.900.675 C01.539.375.450.900.675 C01.703.343.900.675 C11.294.354.900.675 C11.294.450.900.675 C11.941.879.960.580 |
||
pantothenate kinase-associated neurodegeneration | disease | neurodegeneration with brain iron accumulation neuroacanthocytosis nervous system heredodegenerative disease eye degenerative disease |
A neurodegeneration with brain iron accumulation that has_material_basis_in autosomal recessive inheritance of mutation in the PANK2 gene on chromosome 20p13. | C10.228.140.079.800 C10.228.140.744.320 C10.228.662.575 C10.574.500.700 C16.320.400.650 |
||
Papilledema | disease | optic nerve disease | Human disease | C10.292.700.900 C11.640.710 |
Papilledema | |
papilloma | disease | cell type benign neoplasm | cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue | C04.557.470.700.600 | Papillomas | |
Papillomatosis | disease | disease | C04.557.470.700.600 | |||
paracoccidioidomycosis | disease infectious disease |
primary systemic mycosis cutaneous mycosis bone disease lymph node disease lung disease cellulitis fungal infectious disease |
primary systemic mycosis that results in systemic fungal infection located in mucosa, located in lymph nodes, located in bone, located in skin or located in lungs, has material basis in Paracoccidioides brasiliensis | C01.703.700 | Paracoccidioidomycosis | |
paraganglioma | disease | neuroendocrine tumor | Human disease | C04.557.465.625.650.700 C04.557.580.625.650.700 |
Paraganglioma | |
parakeratosis | disease | keratinization characterized by the retention of nuclei in the stratum corneum | C17.800.428.736 | |||
parametritis | disease | pelvic inflammatory diseases inflammatory disease uterine disease |
Human disease | C13.351.500.056.750.750 | ||
paraneoplastic syndrome | disease | C04.730 | ||||
paraphimosis | disease | phimosis | Human disease | C12.294.494.684.587 | Paraphimosis | |
paraplegia | disease | central nervous system disease paralysis |
impairment in motor or sensory function of the lower extremities | C10.597.622.669 C23.888.592.636.637 |
||
parasitic helminthiasis infectious disease | disease infectious disease |
parasitic infectious diseases | macroparasitic disease in which a part of the body is infected with parasitic worms | C03.335 | Helminthiases | |
parasitic infectious diseases | disease infectious disease |
infectious disease | infectious disease caused or transmitted by a parasite | C03 | Parasitic diseases | |
parasitic protozoa infectious disease | disease | parasitic infectious diseases | parasitic disease caused by a protozoan | C03.752 | ||
paratyphoid fever | disease infectious disease |
primary bacterial infectious disease Salmonella infectious disease salmonellosis |
Human disease | C01.252.400.310.821.438 | ||
parkinsonian syndrome | disease | extrapyramidal symptoms movement disorder |
symptoms that resemble Parkinson's disease | C10.228.140.079.862.800 C10.228.662.600.700 C10.228.140.079.862 C10.228.662.600 |
Parkinson's disease | |
parotitis | disease | parotid disease inflammatory disease |
parotid disease characterized by the inflammation of one or both parotid glands | C07.465.815.470.800 C07.465.815.793.500 |
||
paroxysmal nocturnal hemoglobinuria | disease Designated intractable/rare diseases |
hemoglobinuria | Human disease | C15.378.071.141.560 C15.378.190.625.460 |
||
Parry–Romberg syndrome | disease | facial nerve disease brain inflammatory disease inflammatory and autoimmune disease with epilepsy genetic peripheral neuropathy rare genetic epilepsy |
a rare disease characterized by progressive shrinkage and degeneration of the tissues beneath the skin, usually on only one side of the face (hemifacial atrophy) but occasionally extending to other parts of the body | C07.465.284 C07.465.299.375 C10.292.319.375 |
Parry–Romberg syndrome | |
Pathologic fracture | disease | bone fracture | C26.404.374 | Pathologic fractures | ||
Pelger-Huet anomaly | disease | autosomal dominant disease leukocyte disease |
Human disease | C15.378.553.696 C16.320.784 |
||
Pelizaeus-Merzbacher disease | disease | hypomyelinating leukodystrophy nervous system heredodegenerative disease eye degenerative disease |
hypomyelinating leukodystrophy characterized by impaired myelin formation, nystagmus, spastic quadriplegia, ataxia, and developmental delay that has material basis in mutation in the PLP1 gene on chromosome Xq22 | C10.228.140.163.100.362.775 C10.228.140.695.625.775 C10.314.400.775 C16.320.322.906 C16.320.565.189.362.775 C18.452.132.100.362.775 C18.452.648.189.362.775 |
||
pellagra | disease | nutritional deficiency disease other acquired skin disease skin disease |
Human disease | C18.654.521.500.133.699.529 | Pellagra | |
pelvic inflammatory diseases | disease | female reproductive system disease | infection of uterus, fallopian tubes, ovaries or the inner surface of pelvis | C01.539.635.500 C13.351.500.056.750 |
Pelvic inflammatory disease | |
pemphigus | disease Designated intractable/rare diseases |
bullous skin disease | Human disease | C17.800.865.716 C20.111.736 |
Pemphigus | |
penile cancer | disease | penile disease male reproductive organ cancer |
human disease | C04.588.945.440.715 C12.294.260.500 C12.294.494.591 C12.758.409.500 |
Penile cancer | |
peptic esophagitis | disease | peptic ulcer disease esophagitis gastroesophageal reflux disease |
Human disease | C06.405.117.620.420 C06.405.205.663.420 C06.405.469.275.800.523 |
||
peptic ulcer disease | disease | gastrointestinal system disease | Ulcer of an area of the gastrointestinal tract | C06.405.469.275.800 C06.405.748.586 |
Peptic ulcers | |
periapical periodontitis | disease | inflammation periodontitis dental pulp disease periapical disease |
Human disease | C07.320.830.700 C07.465.714.306.700 C07.465.714.533.487 |
||
pericardial effusion | disease | pericardium disease | pericardium disease that is characterized by an abnormal accumulation of fluid in the pericardial cavity | C14.280.695 | Pericardial effusion | |
pericarditis | disease | pericardium disease inflammation inflammatory disease heart disease |
pericardium disease that is characterized by an inflammation of the pericardium and has symptom chest pain | C14.280.720 | Pericarditis | |
pericoronitis | disease | gingival disease | Human disease | C07.465.714.258.771 | Pericoronitis | |
perineurioma | disease | Nerve sheath tumor | Human disease | C04.557.580.600 C10.551.775.500 C10.668.829.725.500 |
||
periodic paralysis | disease | myopathy metal metabolism disorder |
Human disease | C05.651.701 C10.668.491.650 C16.320.565.618.711 C18.452.648.618.711 |
||
periodontal disease | disease | tooth disease jaw disease |
Human disease | C07.465.714 | ||
periodontitis | disease | periodontal disease | Human disease | C07.465.714.533 | Periodontitis | |
periostitis | disease | connective tissue disease inflammatory disease bone disease |
human disease | C01.539.160.595 C05.116.165.595 |
||
peripheral artery disease | disease | artery disease | artery disease characterized by build up of plaque in the arteries that carry blood to your head, organs, and limbs | C14.907.137.126.307.500 C14.907.617.671 |
Peripheral vascular diseases | |
peritoneal carcinoma | disease | gastrointestinal system cancer peritoneal neoplasm |
carcinoma that is located in the inside of the abdomen | C04.588.033.513 C04.588.274.780 C06.301.780 C06.844.620 |
||
peritonitis | disease | gastrointestinal system disease intraabdominal infection inflammatory disease |
inflammation of the peritoneum, the lining of the inner wall of the abdomen | C01.539.463.600 C06.844.640 |
Peritonitis | |
Peritonsillar abscess | disease | Human disease | C01.539.830.025.675 C07.550.781.750.500 C08.730.561.750.500 C09.775.649.750.500 |
Peritonsillar abscess | ||
periventricular leukomalacia | disease | encephalomalacia | Human disease | C10.228.140.300.700 C10.228.140.461.550 C14.907.253.612 C16.614.521.450 |
||
pernicious anemia | disease | deficiency anemia nutritional deficiency disease vitamin B12 deficiency anemia |
Human disease | C15.378.071.252.196.500 C18.654.521.500.133.699.923.280 |
||
pertussis | disease | commensal bacterial infectious disease | human disease caused by the bacteria Bordetella pertussis | C01.252.400.143 C01.252.400.143.740 C01.539.739.969 C08.730.969 |
Pertussis | |
petechia | disease | C15.378.100.802 C23.550.414.950 C23.888.885.687 |
Petechiae | |||
petrositis | disease | osteomyelitis | osteomyelitis that has material basis in infection located in petrous part of temporal bone | C01.539.160.495.750 C05.116.165.495.500 C09.218.705.663.841 |
||
Peutz-Jeghers syndrome | disease | intestinal disease | Human disease | C04.700.705 C06.405.469.578.750 C16.320.700.705 C17.800.621.430.530.550.625 |
Peutz–Jeghers syndrome | |
Peyronie's disease | disease | penile disease fibromatosis |
Human disease | C12.294.494.508 C17.300.715 |
Peyronie's disease | |
Pfeiffer syndrome | disease | acrocephalosyndactylia | acrocephalosyndactylia that has material basis in mutations in the FGFR1 and FGFR2 gene which results in premature fusion located in skull | C05.116.099.370.894.232.015 C05.116.099.370.894.819.100 C05.660.207.240.100 C05.660.585.800.100 C05.660.906.364.100 C05.660.906.819.100 C16.131.621.207.240.100 C16.131.621.585.800.100 C16.131.621.906.364.100 C16.131.621.906.819.100 |
Pfeiffer syndrome | |
phaeochromocytoma | disease | neuroendocrine tumor cell type benign neoplasm |
type of neuroendocrine tumor | C04.557.465.625.650.700.725 C04.557.580.625.650.700.725 |
Pheochromocytoma | |
phakomatosis | disease | Multisystem disorders that involve the ectodermal structures like central nervous system, skin and eyes. | C10.562 C16.131.077.350.712 C16.131.831.350.712 C16.320.850.250.712 C17.800.804.350.712 C17.800.827.250.712 |
Phakomatoses | ||
phenylketonuria | disease | amino acid metabolic disorder enzymopathy hyperphenylalaninemia |
amino acid metabolic disorder that is characterized by a mutation in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional | C10.228.140.163.100.687 C16.320.565.100.766 C16.320.565.189.687 C18.452.132.100.687 C18.452.648.100.766 C18.452.648.189.687 C10.228.140.163.100.687.500 C13.703.575 C16.320.565.100.766.500 C16.320.565.189.687.500 C18.452.132.100.687.500 C18.452.648.100.766.500 C18.452.648.189.687.500 |
||
phimosis | disease | penile disease | A condition in which there is constriction in the tip of the foreskin resulting in inability to fully retract the foreskin over the glans penis. Causes include balanoposthitis, balanitis xerotica obliterans, and untreated diabetes. | C12.294.494.684 | Phimosis | |
phlebitis | disease | vein disorder venous thromboembolism |
vein disease that is characterized by inflammation of a vein | C14.907.617.718 C14.907.940.740 |
||
Phlebotomus fever | disease infectious disease |
viral infectious disease | Human disease | C02.081.700 C02.782.147.700 |
||
phosphofructokinase deficiency | disease | glycogen storage disease muscular glycogenosis hemolytic anemia due to a disorder of glycolytic enzymes disorder of glycolysis |
Human disease | C05.651.534.500.149 C10.668.491.175.500.112 C16.320.565.202.449.600 C16.320.577.149 C18.452.648.202.449.600 |
Phosphofructokinase deficiency | |
photosensitivity disease | disease | dermatitis Photodermatosis |
Human disease | C17.800.600 | ||
pica disease | disease | eating disorder | eating disorder that is characterized by an appetite for non-nutritive substances or food ingredients | C23.888.821.825 | ||
piebaldism | disease | autosomal dominant disease pigmentation disorder with eye involvement, excluding albinism eyebrow/eyelashes pigmentation anomaly rare genetic developmental defect during embryogenesis hypopigmentation of the skin |
Human disease | C16.320.290.040.600 C16.320.565.100.102.600 C16.320.850.080.600 C17.800.621.440.102.600 C17.800.827.080.600 C18.452.648.100.102.600 |
Piebaldism | |
Pierre Robin syndrome | disease | sequence first arch syndrome |
C05.500.460.606 C05.660.207.540.460.606 C07.320.440.606 C07.650.500.460.606 C16.131.621.207.540.460.606 C16.131.850.500.460.606 |
|||
pigeon toe | disease | foot deformity | a condition which causes the toes to point inward when walking | C05.330.711 | Pigeon-toed | |
pilomatrixoma | disease | hair follicle neoplasm rare genetic epidermal disorder rare skin tumor or hamartoma |
Human disease | C04.557.470.565.625 | Pilomatricoma | |
pilonidal cyst | disease | genetic disease | hair-containing cyst or sinus, occurring chiefly in the coccygeal region | C04.182.710 | Sinus pilonidalis | |
Pinealoblastoma | disease | Pinealoma | pineal gland neoplasm located in the brain | C04.557.465.625.600.657 C04.557.470.670.657 C04.557.580.625.600.657 C04.588.614.250.195.766 C10.228.140.211.788 C10.551.240.250.625 |
||
Pinealoma | disease | endocrine gland cancer thalamic disease brain cancer |
endocrine gland located in the pineal gland located in the brain | C04.557.465.625.600.657 C04.557.470.670.657 C04.557.580.625.600.657 C04.588.614.250.195.766 C10.228.140.211.788 C10.551.240.250.625 |
||
pinguecula | disease | conjunctival degeneration | Human disease | C11.187.631 | Pinguecula | |
pinta disease | disease | treponematosis primary bacterial infectious disease |
Human disease | C01.252.400.840.558 C01.252.825.630 C01.252.847.840.558 C01.539.800.720.630 C17.800.838.765.630 |
Pinta (disease) | |
pituitary adenoma | disease | endocrine organ benign neoplasm pituitary gland disease adenoma |
Human disease | C04.588.322.609 C04.588.614.250.195.885.500.600 C10.228.140.211.885.500.600 C10.228.140.617.477.600 C10.228.140.617.738.675 C10.551.240.250.700.500.500 C19.344.609 C19.700.734 |
Pituitary adenoma | |
pituitary apoplexy | disease | pituitary infarct acquired pituitary hormone deficiency |
Human disease | C10.228.140.300.535.625 C10.228.140.617.738.350 C14.907.253.573.600 C19.700.725 |
||
pityriasis rosea | disease | psoriasis | Human disease | C17.800.859.600.675 | Pityriasis rosea | |
pityriasis rubra pilaris | disease | psoriasis Erythrokeratodermia |
Human disease | C17.800.859.600.685 | ||
pityriasis versicolor | disease infectious disease |
superficial mycosis Skin infection |
condition characterized by a rash on the trunk and proximal extremities | C01.539.800.200.860 C01.703.295.936 C17.800.838.208.941 |
Tinea versicolor | |
placenta accreta | disease | placenta disease | placenta disease that is characterized by an abnormally deep attachment of the placenta, through the endometrium and into the myometrium | C13.703.420.643 C13.703.590.609 |
Placenta accreta | |
placenta praevia | disease | placenta disease | placenta disease that is characterized by placenta attachment to the uterine wall close to or covering the cervix | C13.703.420.714 C13.703.590.734 |
Placenta previa | |
placental abruption | disease | placenta disease | placenta disease that is characterized by separation of the placental lining from the uterus of the mother | C13.703.039.339 C13.703.420.078 C13.703.590.132 |
Placental abruption | |
placental insufficiency | disease | placenta disease complication of pregnancy, childbirth and the puerperium |
placenta disease that is characterized by insufficient blood flow to the placenta during pregnancy | C13.703.590.800 | ||
plague | disease | primary bacterial infectious disease yersiniosis |
Dangerous human disease | C01.252.400.310.980.745 | Plague | |
plantar fascial fibromatosis | disease | connective tissue disease foot disease fibromatosis |
non-malignant thickening of the feet's deep connective tissue | C04.557.450.565.590.340.705 C05.360.375 C05.651.197.369 C17.300.349 C17.800.321.063 |
Plantar fibromatosis | |
pleural empyema | disease | pleural disease empyema pleural effusion lung disease |
empyema (an accumulation of pus) in the pleural cavity that can develop when bacteria invade the pleural space, usually in the context of a pneumonia | C01.539.739.484 C01.539.830.305.310 C08.528.240 C08.730.265 |
Pleural empyema | |
pneumoconiosis | disease | occupational disease interstitial lung disease |
interstitial lung disease that is caused by the inhalation of dust | C08.381.483.581 C08.381.520.702 C24.800 |
Pneumoconiosis | |
pneumoperitoneum | disease | C06.844.670 | Pneumoperitoneum | |||
pneumothorax | disease | pleural disease | an abnormal collection of air in the pleural space that causes an uncoupling of the lung from the chest wall | C08.528.778 | Pneumothorax | |
Poland syndrome | disease developmental defect during embryogenesis |
birth defect syndromic breast hypoplasia/aplasia rare genetic gynecological and obstetrical diseases syndrome with brachydactyly |
Human disease | C05.116.099.370.894.819.756 C05.660.585.800.756 C05.660.906.819.756 C16.131.621.585.800.756 C16.131.621.906.819.756 |
Poland syndrome | |
polyarteritis nodosa | disease Designated intractable/rare diseases |
vasculitis | Human disease | C14.907.940.090.720 C14.907.940.897.500 C17.800.862.625 |
||
polycystic ovary syndrome | disease | syndrome endocrine system disease genetic disease |
syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight | C04.182.612.765 C13.351.500.056.630.580.765 C19.391.630.580.765 |
Polycystic ovary syndrome | |
polycythemia | disease | bone marrow disease immune system disease rare bone disease |
Human disease | C15.378.738 | Polycythemias | |
polycythemia vera | disease | polycythemia | Human disease | C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500 |
Polycythemia vera | |
polydactyly | disease developmental defect during embryogenesis |
birth defect congenital limb deformities non-syndromic polydactyly, syndactyly and/or hyperphalangy |
Physical anomaly | C05.660.585.600 C16.131.621.585.600 |
Polydactyly | |
polyhydramnios | disease | placenta disease | placenta disease that is characterized by an excess of amniotic fluid in the amniotic sac | C13.703.610 | Polyhydramnios | |
polymyalgia rheumatica | disease | myopathy collagen disease rare rheumatologic disease immune system disease |
human disease | C05.651.742 C05.799.720 C17.300.775.720 |
||
polyneuropathy | disease | peripheral nervous system disease | peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain | C10.668.829.800 | ||
pompholyx | disease | sweat gland disease | Human disease | C17.800.174.620.300 C17.800.815.620.300 C17.800.865.385 |
Dyshidrosis | |
porencephaly | disease | brain disease Central nervous system cyst Malformations of Cortical Development, Group III |
congenital disorder of nervous system characterized by cysts or cavities within the cerebral hemisphere. | C05.660.207.620.500 C10.500.507.500.625 C16.131.621.207.620.500 C16.131.666.507.500.625 |
Porencephaly | |
porphyria | disease Designated intractable/rare diseases |
inherited metabolic disorder inborn disorder of porphyrin and haem metabolism genetic photodermatosis metabolic disease with skin involvement Photodermatosis nephropathy secondary to a storage or other metabolic disease |
An inherited metabolic disorder that involves certain enzymes in the heme bio-synthetic pathway resulting in the overproduction and accumulation of porphyrins. | C18.452.811 | Porphyrias | |
porphyria cutanea tarda | disease | acute porphyria porphyria |
acute porphyria characterized by painful, blistering skin lesions that develop on sun-exposed skin | C06.552.830.250 C16.320.850.742.250 C17.800.827.742.250 C18.452.811.400.250 |
||
portal hypertension | disease | hepatic vascular disease | hypertension in the hepatic portal system, which are the portal vein and its branches, which drain from most of the intestines to the liver | C06.552.494 | Portal hypertension | |
Post-polio syndrome | disease infectious disease |
poliomyelitis | Human disease | C02.782.687.359.764.650 C05.651.534.750 C10.228.228.618.750.750 C10.228.854.525.850.750 C10.574.827 C10.668.491.175.750 C10.668.864.500 |
||
post-thrombotic syndrome | disease | venous insufficiency | venous insufficiency that is characterized by aching pain, heaviness, swelling, cramps, itching, or tingling in the affected limb and is a chronic complication of deep venous thrombosis | C14.907.617.718.760 C14.907.952.760 C14.907.355.830.925.462 C14.907.952.880 |
||
postcholecystectomy syndrome | disease | biliary tract disease bladder disease |
Human disease | C06.130.825 C23.550.767.775 |
||
postoperative nausea and vomiting | disease | adverse reactions to anesthesia nausea |
C23.550.767.859 C23.888.821.712.700 C23.888.821.937.059 |
|||
postpartum depression | disease | endogenous depression puerperal disorder mental disorder complicating pregnancy, childbirth, or the puerperium |
endogenous depression that involves intense, sustained and sometimes disabling depression experienced by women after giving birth | C13.703.844.253 | ||
Postural orthostatic tachycardia syndrome | disease | autonomic nervous system disease orthostatic intolerance heart conduction disease |
symptoms: difficulty with digestion, migraines, stroke like symptoms, difficulty breathing, chest pain, eye throbbing | C10.177.575.600.625 | ||
Prader-Willi syndrome | disease | chromosomal disease syndrome |
Genetic disorder | C10.597.606.643.690 C16.131.077.730 C16.131.260.700 C16.320.180.700 C18.654.726.500.740 |
Prader-Willi syndrome | |
pre-malignant neoplasm | disease | disease of cellular proliferation Q17321238 |
cellular proliferation that results in abnormal growths in the body, which do not invade or destroy the surrounding tissue, but in time will transform into a cancer | C04.834 | ||
Precocious puberty | disease | disorder of puberty | Human disease | C19.391.693 | ||
premature contraction | disease | heart arrhythmia Ectopic beat |
C14.280.067.325 C23.550.073.325 |
|||
premature ejaculation | disease | psychosexual disorder ejaculatory dysfunction |
Human disease | C12.294.644.743 | ||
premature ovarian failure | disease | ovarian disease Poor ovarian reserve |
ovarian disease where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40 | C13.351.500.056.630.750 C19.391.630.750 |
||
premenstrual tension | disease | female reproductive system disease | symptoms that occur before a woman's period | C23.550.568.968 | Premenstrual syndrome | |
presbyopia | disease | eye accommodation disease refractive error |
medical condition associated with aging of the eye | C11.744.786 | Presbyopia | |
preterm birth | disease | obstetric labor complication parturition |
birth at less than a specified gestational age | C13.703.420.491.500 | Incubators (neonatal) | |
priapism | disease | arterial occlusive disease penile disease |
peripheral vascular disease characterized by blood trapped in the penis that is unable to drain. | C12.294.494.786 | ||
primary biliary cirrhosis | disease | autoimmune disease of urogenital tract liver cirrhosis |
liver cirrhosis characterized by chronic and slow progressive destruction of intrahepatic bile ducts | C06.130.120.135.250.250 C06.552.150.250 C06.552.630.400 |
Primary biliary cirrhosis | |
primary ciliary dyskinesia | disease | ciliopathy | ciliopathy that is characterized by impaired function of the cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear) and fallopian tube | C08.200 C09.150 C16.131.077.245.500 C16.320.184.500 |
Primary ciliary dyskinesia | |
Primary polydipsia | disease | polydipsia eating disorder |
Dry mouth and excessive fluid consumption in the absence of physiological stimuli to drink | C23.550.759.500 C23.888.663.500 |
||
Prinzmetal's angina | disease | angina pectoris coronary disease coronary artery vasospasm |
cardiac chest pain at rest that occurs in cycles | C10.597.617.192.500.150.150 C14.280.647.187.150.150 C14.907.585.187.150.500 C23.888.592.612.233.500.150.150 |
||
proctitis | disease | rectal disease inflammatory disease |
Human disease | C06.405.205.865 C06.405.469.860.622 |
||
Prodrome | disease | part of disease | C23.888.672 | |||
progeria | disease developmental defect during embryogenesis |
autosomal recessive disease progeroid syndrome disease malformation syndrome with skin/mucosae involvement primary osteolysis |
Human disease | C16.320.565.753 C18.452.648.753 |
Progeria | |
progressive multifocal leukoencephalopathy | disease Designated intractable/rare diseases infectious disease |
viral infectious disease Polyomavirus infectious disease infectious encephalitis |
viral disease affecting human brains | C02.182.525.500 C02.256.721.500 C02.290.575 C02.839.550 C10.228.140.430.520.750.500 C10.228.140.695.750 C10.228.228.245.340.500 C10.228.228.399.750.500 C10.314.450 |
Progressive multifocal leukoencephalopathy | |
progressive supranuclear palsy | disease Designated intractable/rare diseases |
movement disorder frontotemporal degeneration with dementia genetic neurodegenerative disease with dementia eye degenerative disease |
Progressive supranuclear palsy (PSP) is a rare late-onset neurodegenerative disease characterized by supranuclear gaze palsy, postural instability, progressive rigidity, and mild dementia | C10.228.140.079.882 C10.228.662.700 C10.292.562.750.500 C10.574.945.500 C10.597.622.447.690 C11.590.472.500 C23.888.592.636.447.690 |
Progressive supranuclear palsy | |
prolactinoma | disease head and neck disease |
functioning pituitary adenoma genetic nervous system disorder rare male infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin prolactin producing pituitary tumor rare genetic endocrine disease inherited gynecological tumor rare genetic bone disease |
Human disease | C04.557.470.035.625 C04.588.322.609.792 C10.228.140.617.738.675.800 C19.344.609.792 C19.700.734.792 |
||
prolapse of female genital organ | disease | female reproductive system disease | portion of the vaginal canal protruding from the opening of the vagina | C23.300.842.624 | Female genital prolapse | |
prolymphocytic leukemia | disease | lymphoid leukemia chronic lymphocytic leukemia chronic leukemia |
Human disease | C04.557.337.428.565 C15.604.515.560.550 C20.683.515.528.565 |
||
prosopagnosia | disease | cognitive disorder associative agnosia agnosia |
cognitive disorder which impairs the ability to recognise faces | C10.597.606.762.100.650 C23.888.592.604.764.100.650 |
||
prostate cancer | disease | male reproductive organ cancer prostate disease |
male reproductive cancer | C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750 |
Prostatic adenocarcinoma | |
prostatitis | disease | prostate disease inflammatory disease |
Human disease | C12.294.565.750 | Prostatitis | |
protein C deficiency | disease | inherited blood coagulation disease | Human disease | C15.378.100.100.690 C15.378.147.880 C15.378.925.795 C16.320.099.690 |
||
protein-losing enteropathy | disease | intestinal disease genetic disease |
Human disease | C06.405.469.818 | ||
proteinuria | disease | kidney disease urinalysis |
presence of an excess of serum proteins in the urine | C12.777.934.734 C13.351.968.934.734 C23.888.942.750 |
||
Proteus syndrome | disease head and neck disease developmental defect during embryogenesis |
birth defect multiple hamartoma syndrome head and neck cancer brain cancer rare genetic vascular tumor complex vascular malformation with associated anomalies rare nervous system tumor syndrome or malformation associated with head and neck malformations neurocutaneous syndrome with epilepsy rare genetic skin vascular disorder rare genetic bone disease skull cancer overgrowth syndrome |
A human disease characterized by an overgrowth of skin, bones, muscles, fatty tissues, and blood and lymphatic vessels. | C04.445.435.500 C04.651.435.500 C05.116.099.750 C05.660.585.620 C16.131.077.740 C16.131.621.585.620 |
||
Prune belly syndrome | disease developmental defect during embryogenesis |
urinary system disease syndrome fetal lower urinary tract obstruction syndromic renal or urinary tract malformation syndromic urogenital tract malformation |
congenital disorder of urinary system | C16.131.077.745 | Prune belly syndrome | |
Pseudarthrosis | disease | C26.404.468.627 | Pseudarthrosis | |||
pseudobulbar palsy | disease | brain disease motor neuron disease |
Human disease | C10.597.622.714 C23.888.592.636.711 |
||
pseudohermaphroditism | disease | sex differentiation disease | Human disease | C12.706.316 C13.351.875.253 C16.131.939.316 C19.391.119 |
Pseudohermaphroditism | |
pseudohypoaldosteronism | disease | renal tubular transport disease | Human disease | C12.777.419.815.770 C13.351.968.419.815.770 C16.320.565.861.770 C18.452.648.861.770 |
||
pseudohypoparathyroidism | disease Designated intractable/rare diseases |
metal metabolism disorder | human disease | C05.116.198.709 C16.320.565.618.815 C18.452.104.709 C18.452.174.766 C18.452.648.618.815 |
Pseudohypoparathyroidism | |
pseudolymphoma | disease | benign neoplasm lymphoma and pseudolymphoma |
a benign nepolasm that resembles a malignant lymphoma | C15.604.613 | ||
pseudomyxoma peritonei | disease colonic disease |
appendix cancer peritoneal neoplasm primary peritoneal tumor mucinous adenocarcinoma of the appendix |
appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis | C04.557.470.590.782 | ||
pseudopseudohypoparathyroidism | disease developmental defect during embryogenesis |
pseudohypoparathyroidism pseudohypoparathyroidism with Albright hereditary osteodystrophy |
human disease | C05.116.198.709.628 C16.320.565.618.815.815 C18.452.104.709.628 C18.452.174.766.815 C18.452.648.618.815.815 |
||
pseudotumor cerebri | disease | intracranial hypertension cerebrovascular disease |
Human disease | C10.228.140.631.750 | ||
pseudoxanthoma elasticum | disease Designated intractable/rare diseases developmental defect during embryogenesis |
autosomal recessive disease connective tissue disease genetic central nervous system and retinal vascular disease rare central nervous system and retinal vascular disease dermis elastic tissue disorder familial restrictive cardiomyopathy connective tissue disease with eye involvement malformation syndrome with skin/mucosae involvement rare developmental defect with connective tissue involvement pseudoxanthoma elasticum (inherited or acquired) genetic hypertension |
Human disease | C14.907.454.530 C15.378.463.515.530 C16.131.831.766 C16.320.850.750 C17.300.766 C17.800.804.766 C17.800.827.750 |
||
psoriasis | disease | skin disease | Human disease | C17.800.859.675 | Psoriasis | |
psoriatic arthritis | disease | arthritis syndrome |
syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis | C05.116.900.853.625.800.424 C05.550.114.145 C05.550.114.865.800.424 C17.800.859.675.175 |
Psoriatic arthritis | |
pterygium | disease head and neck disease |
pinguecula corneal disease conjunctival disease benign conjunctival neoplasm benign neoplasm of cornea |
Human disease | C11.187.781 | Pterygium (conjunctiva) | |
ptosis | disease | eye disease eyelid disease |
eye disease characterized by the drooping or falling of the upper or lower eyelid | C11.338.204 | Ptosis (eyelid) | |
Pudendal nerve entrapment | disease | neuropathic pain nerve compression syndrome acquired peripheral neuropathy neuralgia |
Pudendal neuralgia (PN) is a chronic neuropathic pain, aggravated by sitting and for which no organic cause can be found by imaging studies. It is often associated with pelvic dysfunction. | C10.597.617.682.737 C10.668.829.550.650 C10.668.829.600.737 C23.888.592.612.664.737 |
||
pulmonary alveolar proteinosis | disease | lung disease alveolar lung disease |
lung disease that is characterized by abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange | C08.381.719 | Pulmonary alveolar proteinosis | |
pulmonary edema | disease | respiratory failure | fluid accumulation in the air spaces and parenchyma of the lungs | C08.381.742 | Pulmonary edema | |
pulmonary embolism | disease | artery disease | blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body | C08.381.746 C14.907.355.350.700 |
Pulmonary embolism | |
pulmonary emphysema | disease | respiratory system disease chronic obstructive pulmonary disease |
Human disease | C08.381.495.389.750 | Pulmonary emphysema | |
pulmonary hypertension | disease | hypertension | hypertension characterized by an increase of blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries | C08.381.423 | Pulmonary hypertension | |
pulmonary valve stenosis | disease | pulmonary valve disease congenital heart disease |
Human disease | C14.280.484.716 C14.280.955.750 |
Pulmonary valve stenosis | |
pulpitis | disease infectious disease |
dental pulp disease | Human disease | C07.793.237.820 | ||
pure red-cell aplasia | disease | aplastic anemia erythroblastopenia |
Human disease | C15.378.071.750 | ||
purpura | disease | hemorrhagic disease | Human disease | C15.378.100.802 C23.550.414.950 C23.888.885.687 |
Purpura (dermatology) | |
pycnodysostosis | disease developmental defect during embryogenesis |
osteochondrodysplasia developmental anomaly of metabolic origin |
osteochondrodysplasia that has material basis in a mutation in the CTSK gene which results in dwarfism, brittle bones, osteopetrosis, shortening of the distal phalanges | C05.116.099.708.779 C16.320.565.595.800 C16.320.812 C18.452.648.595.800 |
||
pyelonephritis | disease infectious disease |
pyelitis urinary tract infection |
Human disease | C12.777.419.570.643.790 C12.777.419.570.821.717 C13.351.968.419.570.643.790 C13.351.968.419.570.821.717 |
Pyelonephritis | |
pyloric stenosis | disease | gastric outlet obstruction | congenital disorder of digestive system | C06.405.748.340.690 | Pyloric stenosis | |
pyoderma | disease | dermatitis | Pyoderma is a skin infectious disease where the infection is pyogenic causing the formation of pus | C17.800.695 | ||
pyoderma gangrenosum | disease | pyoderma Reactive neutrophilic dermatoses pyogenic autoinflammatory syndrome rare skin disease autoinflammatory syndrome with skin involvement |
Human disease | C17.800.695.675 C17.800.862.675 C17.800.893.675 |
Pyoderma gangrenosum | |
pyometritis | disease | metritis uterine disease |
Human disease | C13.351.500.852.544 | ||
pyomyositis | disease infectious disease |
myositis bacterial infectious disease |
Human disease | C01.539.830.767 C05.651.594.909 C10.668.491.562.787 |
||
pyuria | disease | urinary system disease | Human disease | C01.539.895.719 C12.777.892.719 C13.351.968.892.719 |
Pyuria | |
Q fever | disease | primary bacterial infectious disease | disease caused by infection with Coxiella burnetii, a bacterium that affects humans and other animals; the most common manifestation is flu-like symptoms; the name Q stands for “query”, so named when the pathogen was unknown | C01.252.400.755 | Q fever | |
radial neuropathy | disease | mononeuropathy brachial plexus neuropathy |
Human disease | C10.668.829.500.650 | ||
radiation burn | disease | burn dermatitis |
damage to the skin or other biological tissue caused by exposure to radiation | C17.800.174.826 C26.733.804 |
Radiation burns | |
radiculopathy | disease | polyradiculopathy nerve root and plexus disorder |
Human disease | C10.668.829.820 | ||
Raynaud disease | disease | arterial occlusive disease | Human disease | C14.907.617.812 | ||
reactive arthritis | disease arthropathy |
arthritis rare rheumatologic disease rare bone disease |
arthritis that is an autoimmune disease which develops due to an infection located elsewhere in the body | C01.539.100.500 C05.116.900.853.625.800.637 C05.550.114.099.500 C05.550.114.865.800.637 |
Reactive arthritis | |
receptive aphasia | disease | acute aphasia | C10.597.606.150.500.800.100.166 C23.888.592.604.150.500.800.100.166 |
|||
red color blindness | disease | dichromacy color blindness red–green color blindness |
Human disease | C10.597.751.941.256 C11.966.256 C23.888.592.763.941.256 |
||
refractive error | disease | eye disease visual impairment vision disorder rare genetic eye disease |
cause of vision problems | C11.744 | ||
relapsing fever borreliosis | disease infectious disease |
primary bacterial infectious disease borreliosis bacterial infectious disease |
primary bacterial infectious disease that results in infection, has material basis in Borrelia, which is transmitted by tick or transmitted by body louse | C01.252.400.155.644 C01.252.400.825.750 C01.252.847.193.644 |
Relapsing fever | |
relapsing polychondritis | disease Designated intractable/rare diseases arthropathy |
chondromalacia immune system disease Autoimmune connective tissue disorder secondary glomerular disease |
Human disease | C05.182.531 C17.300.182.531 |
||
REM sleep behavior disorder | disease | sleep disorder | sleep disorder that involves abnormal behavior including the acting out of violent or dramatic dreams during the sleep phase with rapid eye movement | C10.886.659.633.700 | ||
renal artery obstruction | disease | renal artery disease | narrowing of one of the renal arteries, most often caused by atherosclerosis or fibromuscular dysplasia | C12.777.419.775 C13.351.968.419.775 C14.907.137.727 |
Renal artery stenosis | |
renal cell carcinoma | disease | renal carcinoma | renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney | C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160 |
Renal cell carcinomas | |
renal glycosuria | disease | renal tubular transport disease glucose transport disorder nephropathy secondary to a storage or other metabolic disease |
Human disease | C12.777.419.815.532 C12.777.934.363.450 C13.351.968.419.815.532 C13.351.968.934.363.450 C16.320.565.861.532 C18.452.394.937.450 C18.452.648.861.532 |
||
renal osteodystrophy | disease | impaired renal function disease chronic kidney disease-mineral and bone disorder |
Human disease | C05.116.198.816.750 C12.777.419.795 C13.351.968.419.795 C18.452.104.816.750 C18.452.174.845.750 C18.654.521.500.133.770.734.750 C19.642.355.480.500 |
||
renal tubular acidosis | disease | renal tubular transport disease | renal tubular transport disease characterized by excess levels of acid in the blood, due to a failure of the kidneys to appropriately acidify the urine | C12.777.419.815.093 C13.351.968.419.815.093 C16.320.565.861.093 C18.452.076.176.210 C18.452.648.861.093 |
||
respiratory failure | disease | lung disease | inadequate gas exchange by the respiratory system | C08.618.846 | ||
restless legs syndrome | disease | central nervous system disease | central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them | C10.803 C10.886.425.800.700 C10.886.659.634 |
Restless leg syndrome | |
restrictive cardiomyopathy | disease Designated intractable/rare diseases |
intrinsic cardiomyopathy | form of cardiomyopathy in which the walls are rigid,and the heart is restricted from stretching and filling with blood properly | C14.280.238.160 | ||
retinal detachment | disease | retinal disease rare genetic eye disease genetic disease |
Human disease | C11.768.648 | Retinal detachment | |
retinal disease | disease | eye disease | eye disease that is located in the retina | C11.768 | Retinopathy | |
retinitis | disease | retinal disease | Human disease | C11.768.773 | ||
retinitis pigmentosa | disease Designated intractable/rare diseases |
retinal degeneration | retinal degeneration characterized by the gradual deterioration of the photoreceptors or the retinal pigment epithelium of the retina leading to progressive sight loss | C11.270.684 C11.768.585.658.500 C16.320.290.684 |
Retinitis pigmentosa | |
retinoblastoma | disease | retinal cell cancer | retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives from the tissues of the retina | C04.557.465.625.600.725 C04.557.470.670.725 C04.557.580.625.600.725 C04.588.364.818.760 C11.319.475.760 C11.768.717.760 |
Retinoblastoma | |
retinopathy of prematurity | disease | retinal disease premature infant disease |
Human disease | C11.768.836 C16.614.521.731 |
Retinopathy of prematurity | |
retinoschisis | disease | retinal degeneration retinoschisis and retinal cysts |
Human disease | C11.768.585.865 | ||
retrognathism | disease Wikimedia disambiguation page |
malocclusion | C05.500.460.827 C05.660.207.540.460.827 C07.320.440.827 C07.320.610.827 C07.650.500.460.827 C16.131.621.207.540.460.827 C16.131.850.500.460.827 |
Retrognathism | ||
retrograde amnesia | disease | amnesia | loss of memory of events that in occurred before the onset of amnesiac condition | C10.597.606.525.100.150 C23.888.592.604.529.100.150 |
||
Retroverted uterus | disease | C13.351.500.852.952 C23.300.970.750 |
||||
Rett syndrome | disease Designated intractable/rare diseases |
pervasive developmental disorder neurological disorder |
Human disease | C10.597.606.643.455.937 C16.320.322.500.937 C16.320.400.525.937 |
||
Reye syndrome | disease | syndrome brain disease systemic disease |
A syndrome characterized by acute brain damage and liver function problems. It has been associated with aspirin consumption by children with viral illness, although it also occurs in the absence of aspirin use. | C06.552.241.649 C10.228.140.163.780 C18.452.132.780 |
Reye's syndrome | |
rhabdomyosarcoma | disease | skeletal muscle cancer | skeletal muscle cancer that arise from skeletal muscle progenitors | C04.557.450.590.550.660 C04.557.450.795.550.660 |
Rhabdomyosarcoma | |
rheumatic fever | disease | bacterial infectious disease | inflammatory disease that can involve the heart, joints, skin, and brain | C01.252.410.890.731 C05.550.114.843 C05.799.825 |
Rheumatic fever | |
rheumatoid arthritis | disease | arthritis autoimmune disease chronic condition collagen disease Felty's syndrome |
An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint. | C05.550.114.154 C05.799.114 C17.300.775.099 C20.111.199 |
Rheumatoid arthritis | |
Rheumatoid nodule | disease arthropathy |
rheumatoid arthritis polyarticular arthritis |
a particular variant of polyarthritis associated with early manifestations of palindromic rheumatism, radiologic subchondral bone cysts, and subcutaneous rheumatoid nodules | C05.550.114.154.683 C05.799.114.683 C17.300.775.099.683 |
Rheumatoid nodule | |
rhinitis | disease infectious disease |
nasal cavity disease tracheitis bacterial infectious disease infectious disease of the nervous system rare respiratory disease |
irritation and inflammation of the mucous membrane inside the nose | C08.460.799 C08.730.674 C09.603.799 |
||
rickets | disease | bone remodeling disease | human disease | C05.116.198.816 C18.452.104.816 C18.452.174.845 C18.654.521.500.133.770.734 |
Rickets | |
rickettsialpox | disease | spotted fever | Human disease | C01.252.400.780 | ||
Rift Valley fever | disease infectious disease |
viral infectious disease | Human disease | C02.081.810 C02.407.810 C02.782.147.810 C02.782.417.762 C06.552.380.315.430.812 C22.467.435.812 |
Rift Valley fever virus | |
ring chromosome | disease developmental defect during embryogenesis |
chromosome abnormality autosomal monosomy |
chromosome whose arms fused into a ring | C23.550.210.760 | ||
Ritter's disease | disease | commensal bacterial infectious disease staphylococcal infection skin disease |
Human disease | C01.252.410.868.820.770 C01.252.825.770.770 C01.539.800.720.770.770 C17.800.838.765.770.770 |
Staphylococcal scalded skin syndrome | |
Rocky Mountain spotted fever | disease infectious disease |
spotted fever | Human disease | C01.252.400.780.790.700 C01.252.400.825.775 |
Rocky Mountain spotted fever | |
rosacea | disease | skin disease | long-term human skin disease | C17.800.716 | Rosacea (disease) | |
Rothmund-Thomson syndrome | disease developmental defect during embryogenesis |
DNA repair-deficiency disorder skin disease Photodermatosis hereditary cancers rare genetic developmental defect during embryogenesis hereditary poikiloderma ectodermal malformation syndrome associated with ocular features dentocutaneous disease with cataract progeroid syndrome genetic photodermatosis |
human disease | C16.131.831.775 C16.320.850.765 C16.614.760 C17.800.804.775 C17.800.827.775 C18.452.284.760 |
Rothmund–Thomson syndrome | |
rubella | disease infectious disease |
viral infectious disease Rubella virus infectious disease |
Human viral disease | C02.782.930.700.700 | Rubella | |
Rubinstein-Taybi syndrome | disease Designated intractable/rare diseases |
autosomal dominant disease | rare disease | C05.116.099.370.797 C05.660.207.850 C10.597.606.643.700 C16.131.077.804 C16.131.260.790 C16.131.621.207.850 C16.320.180.790 |
Rubinstein-Taybi syndrome | |
sacroiliitis | disease | inflammation | inflammation of pelvis | C05.550.114.854 | Sacroiliitis | |
salmonellosis | disease infectious disease |
Salmonella infectious disease primary bacterial infectious disease bacterial infectious disease |
infection caused by Salmonella bacteria | C01.252.400.310.821.606 C25.723.415.738 |
Salmonellosis | |
salpingitis | disease | fallopian tube disease inflammatory disease |
infection and inflammation in the fallopian tubes | C13.351.500.056.390.890 C13.351.500.056.750.875 |
Salpingitis | |
Salter–Harris fracture | disease | bone fracture | C05.116.359.336.875 C26.289.336.875 C26.404.026.500 |
Salter–Harris fracture | ||
Sandhoff disease | disease | GM2 gangliosidosis eye degenerative disease |
Sandhoff disease is a lysosomal storage disorder from the GM2 gangliosidosis family and is characterised by central nervous system degeneration | C10.228.140.163.100.435.825.300.300.249 C16.320.565.189.435.825.300.300.249 C16.320.565.398.641.803.350.300.700 C16.320.565.595.554.825.300.300.800 C18.452.132.100.435.825.300.300.249 C18.452.584.687.803.350.300.700 C18.452.648.189.435.825.300.300.249 C18.452.648.398.641.803.350.300.700 C18.452.648.595.554.825.300.300.800 |
||
SAPHO syndrome | disease | syndrome autoinflammatory syndrome with skin involvement pyogenic autoinflammatory syndrome |
Human disease | C05.116.099.708.025 | ||
sarcoidosis | disease Designated intractable/rare diseases |
type IV hypersensitivity | hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs | C15.604.515.827 | Sarcoidosis | |
scabies | disease infectious disease |
Acarodermatitis acariasis skin infection |
Human disease | C03.858.211.480.708 C17.800.838.775.800 |
Scabies | |
scarlet fever | disease infectious disease |
upper respiratory tract disease streptococcal infection |
infectious disease | C01.252.410.890.823 | Scarlet fever | |
Scheuermann's disease | disease | osteochondrosis kyphosis spinal osteochondrosis osteochondrosis of genetic origin |
osteochondrosis that results in abnormal bone growth and curvature located in thoracic vertebral column | C05.116.821.500.500 C05.116.900.800.500.500 C05.116.900.808.500 |
Scheuermann's disease | |
Schimmelpenning syndrome | disease head and neck disease developmental defect during embryogenesis |
syndrome phakomatosis epidermal nevus benign conjunctival neoplasm malformation syndrome with hamartosis bulbar conjunctival dermoid or conjunctival dermolipoma palpebral nevus |
A neurocutaneous syndrome with anomalies of the central nervous system, ocular system, skeletal system, cardiovascular system, and genitourinary system. A triad of sebaceous nevi, seizures, and mental retardation. | C04.557.665.560.700 C10.562.700 C16.131.077.633 |
||
schistosomiasis | disease | trematode infection parasitic helminthiasis infectious disease |
Human disease | C03.335.865.859 | Schistosoma | |
Schizencephaly | disease developmental defect during embryogenesis |
Malformations of Cortical Development, Group III Encephaloclastic disorder cerebral malformation with epilepsy |
a rare birth defect characterized by abnormal clefts lined with grey matter that form the ependyma of the cerebral ventricles to the pia mater. | C10.500.507 C16.131.666.507 C10.500.507.500.750 C16.131.666.507.500.750 |
Schizencephaly | |
Schnitzler syndrome | disease | type IV hypersensitivity autoimmune urticaria unexplained periodic fever syndrome |
Human disease | C20.683.780.640.700 | ||
scleritis | disease | scleral disease | Human disease | C11.790.500 | Scleritis | |
scleroderma | disease | rheumatic disease collagen disease |
rheumatic disease and collagen disease that involves the abnormal growth of connective tissue, which supports the skin and internal organs | C17.300.787 C17.800.767 |
Systemic sclerosis | |
sclerosing hemangioma | disease fibrous histiocytoma |
hemangioma | Human disease | C04.557.450.565.590.425.350 | Benign fibrous histiocytoma | |
scoliosis | disease | bone structure disease spinal disease Spinal curvature |
spinal medical condition | C05.116.900.800.875 | Scoliosis | |
scotoma | disease | Anopsia eye disease |
Human disease | C10.597.751.941.811 C11.966.811 C23.888.592.763.941.811 |
Scotoma | |
scrub typhus | disease infectious disease |
typhus | Human disease | C01.252.400.780.850 | ||
scurvy | disease | nutritional deficiency disease ascorbic acid deficiency deficiency |
human disease | C14.907.454.800 C15.378.463.515.800 C18.654.521.500.133.115.661 |
Scurvy | |
seborrheic infantile dermatitis | disease | seborrhoeic dermatitis | Human disease | C17.800.174.146 C17.800.738.353 |
Cradle cap | |
seborrheic keratosis | disease | keratosis | Human disease | C17.800.428.580 | Seborrheic keratosis | |
seborrhoeic dermatitis | disease | dermatitis | long-term skin disorder | C17.800.174.580 C17.800.794.230 C17.800.815.580 C17.800.859.350 |
Seborrhoeic dermatitis | |
secondary hypertrophic osteoarthropathy | disease | arthropathy | Human disease | C05.116.758 C05.550.684 |
Hypertrophic osteoarthropathy | |
seminoma | disease | germ cell cancer | germinoma that has material basis in cells that make sperm and eggs | C04.557.465.330.800 | Testicular seminoma | |
sensorineural hearing loss | disease | deafness inner ear disease |
Human disease | C09.218.458.341.887.432 C09.218.807.186.432 C10.228.140.068.432 C10.597.751.418.341.887.432 C23.888.592.763.393.341.887.432 C09.218.458.341.812 C10.597.751.418.341.812 C23.888.592.763.393.341.812 C09.218.458.341.887 C10.597.751.418.341.887 C23.888.592.763.393.341.887 |
||
septic arthritis | disease arthropathy |
arthritis | arthritis that involves infection by a pathogen located in joint | C01.539.100 C05.550.114.099 |
Septic arthritis | |
septic shock | disease | circulatory shock | Septic shock is a serious medical condition that occurs when sepsis, which is organ injury or damage in response to infection, leads to dangerously low blood pressure | C01.539.757.800 C23.550.470.790.500.800 C23.550.835.900.712 |
||
Sertoli cell-only syndrome | disease | male infertility | Human disease | C12.294.365.700.754 | ||
severe acute respiratory syndrome | disease | viral infectious disease | viral respiratory disease | C02.782.600.550.200.750 C08.730.730 |
SARS | |
severe combined immunodeficiency | disease | combined immunodeficiency | combined T cell and B cell immunodeficiency that is caused by a defect in several genes encoding for B and T lymphocytes resulting in individuals with non-functional immune systems | C16.614.815 C18.452.284.800 C20.673.815 |
||
sexual dysfunction | disease | sexual disorder psychosexual disorder |
Human disease | C12.294.644 C13.351.500.665 |
Sexual disorders | |
Sezary's disease | disease | cutaneous T cell lymphoma aggressive primary cutaneous T-cell lymphoma |
Human disease | C04.557.386.480.750.800.775 C15.604.515.569.480.750.800.775 C15.604.515.841 C20.683.515.761.480.750.800.775 C20.683.515.920 |
Sézary's disease | |
Sheehan's syndrome | disease | puerperal disorder necrosis of pituitary Simmonds' cachexia hypopituitarism |
human disease | C10.228.140.617.738.300 C19.700.482 |
||
shigellosis | disease infectious disease |
primary bacterial infectious disease colonic disease intestinal disease bacterial infectious disease |
Human disease | C01.252.400.310.229 C06.405.205.331.479 C06.405.469.300.479 |
||
short bowel syndrome | disease | intestinal disease | Human disease | C06.405.469.637.832 C23.550.767.882 |
||
shoulder impingement syndrome | disease arthropathy |
arthropathy | Human disease | C05.550.840 C26.803.500 |
Subacromial impingement | |
sialadenitis | disease | salivary gland disease artery disease lymphadenitis |
Human disease | C07.465.815.793 | ||
sialolithiasis | disease | salivary gland disease calculus |
Human disease | C07.465.815.497.500 C23.300.175.700.500 C07.465.815.497 C23.300.175.700 C07.465.815.497.325 C23.300.175.700.325 |
Sialolithiasis | |
sick building syndrome | disease | extrinsic allergic alveolitis rare allergic respiratory disease |
Human disease | C20.543.312.750 C21.223.750 |
||
sick sinus syndrome | disease | sinoatrial node disease bradycardia |
group of abnormal heart rhythms (arrhythmias) presumably caused by a malfunction of the sinus node, the heart's primary pacemaker | C14.280.067.093.249 C14.280.067.558.536 C23.550.073.093.249 C23.550.073.425.440 |
||
sickle-cell disease | disease | hematopoietic system diseases autosomal recessive disease hemoglobinopathy rare constitutional hemolytic anemia |
type of hereditary blood disorder | C15.378.071.141.150.150 C15.378.420.155 C16.320.070.150 C16.320.365.155 C15.378.071.141.150.150.440 C15.378.420.155.440 C16.320.070.150.440 C16.320.365.155.440 |
Sickle-cell anemia | |
Sida por cojer mucho | disease | kidney disease | inflammation of the kidneys | C12.777.419.570 C13.351.968.419.570 |
Nephritis | |
siderosis | disease | pneumoconiosis | Human disease | C08.381.483.581.750 C08.381.520.702.750 C24.800.773 |
||
signet ring cell adenocarcinoma | disease | adenocarcinoma | adenocarcinoma that derives from epithelial cells originating in glandular tissue, which have signet ring appearance | C04.557.470.200.025.415 C04.557.470.590.415 |
Signet ring cell carcinoma | |
silicosis | disease | pneumoconiosis | pneumoconiosis that is an inflammation and scarring of the uper lobes of the lungs causing nodular lesions resulting from inhalation of silica, quartz or slate particles | C08.381.483.581.760 C08.381.520.702.760 C24.800.834 |
Silicosis | |
Silver-Russell syndrome | disease developmental defect during embryogenesis |
chromosomal disease primordial dwarfism rare genetic inherited tumor multiple congenital anomalies/dysmorphic syndrome-variable intellectual disability syndrome malformation syndrome with short stature polymalformative genetic syndrome with increased risk of developing cancer |
growth disorder | C05.660.207.925 C16.131.077.855 C16.131.260.870 C16.320.180.870 C16.320.240.937 |
Silver–Russell syndrome | |
sinusitis | disease | paranasal sinus disease inflammatory disease |
Human disease | C08.460.692.752 C08.730.749 C09.603.692.752 |
Sinusitis | |
situs inversus | disease | visceral heterotaxy state of physical system |
congenital condition in which the major visceral organs are reversed or mirrored from their normal positions (the normal arrangement of internal organs is known as situs solitus while situs inversus is generally the mirror image of situs solitus) | C16.131.810 | Situs inversus | |
Sjögren's syndrome | disease | autoimmune disease autoimmune disease of exocrine system |
hypersensitivity reaction type II disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva | C05.550.114.154.774 C05.799.114.774 C07.465.815.929.669 C11.496.260.719 C17.300.775.099.774 C20.111.199.774 |
Sjögren's syndrome | |
skin cancer | disease | integumentary system cancer tumor of the skin skin disease |
class of skin illnesses, tumor or cancer of the skin | C04.588.805 C17.800.882 |
Skin cancers | |
skin disease | disease | integumentary system disease skin and connective tissue diseases |
class of disorder that affects skin, hair or nails | C16.320.850 C17.800.827 C17.800 |
Diseases and disorders of the skin | |
sleep apnea | disease | sleep disorder apnea |
sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep | C08.618.085.852 C10.886.425.800.750 |
Sleep apnea | |
sleep paralysis | disease | phenomenon | C10.886.659.633.800 | |||
sleeping sickness | disease | trypanosomiasis | parasitic disease | C03.752.300.900.719 | African trypanosomiasis | |
sleepwalking | disease | parasomnia | phenomenon of combined sleep and wakefulness | C10.886.659.635.700 | Sleepwalking | |
Sly syndrome | disease developmental defect during embryogenesis |
mucopolysaccharidosis lysosomal storage disease with skeletal involvement |
mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme beta-glucuronidase resulting in the inability to degrade glucuronic acid-containing glycosaminoglycans | C16.320.565.202.715.675 C16.320.565.595.600.675 C17.300.550.575.675 C18.452.648.202.715.675 C18.452.648.595.600.675 |
||
small cell carcinoma | disease | carcinoma | type of carcinoma that commonly arises within lung and sometime other body sites | C04.557.470.200.380 | Small-cell carcinoma | |
Smith-Lemli-Opitz syndrome | disease developmental defect during embryogenesis |
lipid metabolism disorder syndrome sterol biosynthesis disorder syndromic renal or urinary tract malformation dysostosis with limb and face anomalies as a major feature syndrome with limb duplication, polydactyly, syndactyly, and/or hyperphalangy craniofacial anomaly with cataract metabolic disease with cataract ptosis syndromic epicanthus 46,XY disorder of sex development due to a cholesterol synthesis defect malformation syndrome with short stature multiple congenital anomalies/dysmorphic syndrome-intellectual disability syndromic developmental defect of the eye syndromic neurometabolic disease with non-X-linked intellectual disability syndromic dyslipidemia |
an inborn error of cholesterol synthesis. It is an autosomal recessive, multiple malformation syndrome caused by a mutation in the enzyme 7-Dehydrocholesterol reductase, or DHCR7. | C16.131.077.860 C16.320.565.398.850 C16.320.565.925.875 C18.452.584.500.937 C18.452.648.398.850 C18.452.648.925.875 |
||
Sneddon syndrome | disease | artery disease vascular skin disease autoimmune disease of skin and connective tissue Autoimmune connective tissue disorder autoimmune disease of the nervous system rare genetic skin vascular disorder rare genetic immune disease genetic nervous system disorder rare central nervous system and retinal vascular disease other acquired skin disease genetic systemic or rheumatologic disease |
Human disease | C10.228.140.300.750 C14.907.253.774 C17.800.862.775 |
||
sodoku | disease | primary bacterial infectious disease | Human disease | C01.252.400.771 | ||
soft-tissue sarcoma | disease | soft tissue disorder | human disease | C04.557.450 | ||
somatostatinoma | disease | neuroendocrine tumor pancreatic neuroendocrine tumor G1 |
Human disease | C04.557.465.625.650.240.695 C04.557.470.200.025.370.695 C04.588.274.761.500.500 C04.588.322.475.500.500 C06.301.761.500.500 C06.689.667.500.500 C19.344.421.500.500 |
||
Sotos syndrome | disease developmental defect during embryogenesis |
autosomal recessive disease overgrowth syndrome |
autosomal recessive disease that occurs rarely and is characterized by excessive physical growth during the first 2 to 3 years of life | C16.131.077.889 C16.131.260.905 C16.320.180.905 |
||
space motion sickness | disease head and neck disease |
motion sickness | Human disease | C23.888.571.800 | ||
speech disorder | disease | communication disorder | communication disorder that involves difficulty with the act of speech production. | C10.597.606.150.500.800 C23.888.592.604.150.500.800 |
Speech impediments | |
spermatic cord torsion | disease | testicular disease organ torsion genetic disease |
Human disease | C12.294.693 | ||
spermatocele | disease | male reproductive system disease epididymal cyst |
Human disease | C12.294.731 C23.300.306.750 |
Spermatocele | |
spina bifida | disease | neural tube defect | congenital disorder of nervous system | C10.500.680.800 C16.131.666.680.800 |
Spina bifida | |
spinal disc herniation | disease | Intervertebral disc disorder | disease | C05.116.900.307 C23.300.707.952 |
Spinal disc herniation | |
spinal muscular atrophy | disease Designated intractable/rare diseases |
motor neuron disease spinal muscular atrophy |
rare congenital neuromuscular disorder | C10.228.854.468 C10.574.562.500 C10.668.467.500 |
Spinal muscular atrophy | |
spinal stenosis | disease | bone deterioration disease | bone deterioration disease that has material basis in bony spurs, disc degeneration, or thickened ligaments which results in narrowing located in spinal cord | C05.116.900.825 | Spinal stenosis | |
splenic infarction | disease | splenic disease | condition in which oxygen supply to the spleen is interrupted | C14.907.795 C15.604.744.617 |
Splenic infarction | |
Splenomegaly | disease | splenic disease | C23.300.775.750 | Splenomegaly | ||
spondylitis | disease arthropathy |
spondyloarthropathy Intervertebral disc disorder inflammatory disease bone disease |
inflammation of the vertebra | C01.539.160.762 C05.116.165.762 C05.116.900.853 |
Spondylitis | |
spondylolisthesis | disease | bone structure disease genetic disease |
bone structure disease that has material basis in displacement located in set of vertebrae | C05.116.900.938.500.500 | Spondylolisthesis | |
spondylolysis | disease | bone structure disease | bone structure disease that involves a defect located in lumbar vertebral column. | C05.116.900.938.500 | Spondylolysis | |
spondylosis | disease | bone structure disease | degenerative osteoarthritis of the joints between the center of the spinal vertebrae and/or neural foramina | C05.116.900.938 | Spondylosis | |
sporotrichosis | disease infectious disease |
primary systemic mycosis subcutaneous mycosis fungal infectious disease |
primary systemic mycosis that results in a systemic fungal infection, has material basis in Sporothrix schenckii in animals and humans and results in formation of red papule at the site of inoculation | C01.539.800.200.675 C01.703.295.675 C17.800.838.208.675 |
Sporotrichosis | |
squamous cell carcinoma | disease | Q3542023 carcinoma |
carcinoma that derives from squamous epithelial cells | C04.557.470.200.400 C04.557.470.700.400 C04.557.470.700 |
Squamous-cell carcinomas | |
St. Louis encephalitis | disease infectious disease |
viral infectious disease infectious disease with epilepsy |
Human disease | C02.081.343.350 C02.182.525.300.300 C02.290.310.406 C02.782.310.350 C02.782.350.250.450 C10.228.140.430.520.750.300.550 C10.228.228.245.340.300.550 C10.228.228.399.750.300.550 |
||
status asthmaticus | disease | asthma | type of asthma | C08.127.108.880 C08.674.095.880 C20.543.480.680.095.880 |
||
status epilepticus | disease | epilepsy | Human disease | C10.228.140.490.690 | ||
steatorrhea busuk | disease | intestinal disease | Human disease | C06.405.469.637.887 C18.452.603.887 |
||
Stevens-Johnson syndrome | disease | skin disease erythema |
Disease | C07.465.864.500 C17.800.174.600.900 C17.800.229.400.683 C17.800.865.475.683 C20.543.206.380.900 C25.100.468.380.900 |
Stevens–Johnson syndrome | |
Stiff-Person syndrome | disease | movement disorder | movement disease that is of unknown etiology characterized by progressive rigidity | C10.114.812 C10.228.854.790 C10.668.900 C20.111.258.850 |
Stiff person syndrome | |
stomach cancer | disease | gastrointestinal system cancer stomach disease |
gastrointestinal system cancer that is located in the stomach | C04.588.274.476.767 C06.301.371.767 C06.405.249.767 C06.405.748.789 |
Stomach cancer | |
stomach disease | disease | gastrointestinal system disease | gastrointestinal system disease that is located in the stomach. | C06.405.748 | Diseases and disorders of the stomach | |
stomatitis | disease | mouth disease inflammation Mucositis inflammatory disease |
inflammation of the mouth and lips | C07.465.864 | Stomatitis | |
strabismus | disease | ocular motility disease hyperopia |
Human disease | C10.292.562.887 C11.590.810 |
Strabismus | |
stupor | disease | altered level of consciousness | disease | C10.597.606.358.800.500 C23.888.592.604.359.800.500 |
||
stuttering | disease | articulation disorder speech disorder |
articulation disorder characterized by involuntary sound repetition and disruption or blocking of speech | C10.597.606.150.500.800.750 C23.888.592.604.150.500.800.750 |
Stuttering | |
subarachnoid hemorrhage | disease | intracranial hemorrhage brain disease |
bleeding into the subarachnoid space | C10.228.140.300.535.800 C14.907.253.573.800 C23.550.414.913.850 |
Subarachnoid hemorrhage | |
subclavian steal syndrome | disease | syndrome | constellation of signs and symptoms that arise from retrograde (reversed) blood flow in the vertebral artery or the internal thoracic artery, due to a proximal stenosis (narrowing) and/or occlusion of the subclavian artery | C10.228.140.300.150.956.700 C14.907.253.092.956.700 C14.280.647.250.647 C14.907.585.250.647 C23.550.767.115 |
Subclavian steal syndrome | |
subependymal giant cell astrocytoma | disease | fibrillary astrocytoma subependymal glioma |
low-grade astrocytic brain tumor (astrocytoma) that arises within the ventricles of the brain | C04.557.465.625.600.380.080 C04.557.470.670.380.080 C04.557.580.625.600.380.080 |
||
substance dependence | disease | substance-related disorder addiction |
substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance. | C25.775 | Substance dependence | |
sudden infant death syndrome | disease | syndrome sudden cardiac death infant death genetic disease |
syndrome that is characterized by the sudden death of an infant that is not predicted by medical history and remains unexplained after a thorough forensic autopsy and detailed death scene investigation. | C23.550.260.322.625 C23.550.260.657.500 |
Sudden infant death syndrome | |
sulfhemoglobinemia | disease | blood protein disease | Human disease | C15.378.896 | ||
superior mesenteric artery syndrome | disease | duodenal obstruction artery disease syndrome aortic disease |
Human disease | C06.405.469.275.395.890 | Superior mesenteric artery syndrome | |
sweating sickness | disease | C23.888.119.344.672 | Sweating sickness | |||
syndactyly | disease | synostosis | synostosis that results in the fusion of two or more digits | C05.116.099.370.894.819 C05.660.585.800 C05.660.906.819 C16.131.621.585.800 C16.131.621.906.819 |
Syndactyly | |
syndrome | disease | physiological condition disease |
association of several clinically recognizable features | C23.550.288.500 | Syndromes | |
synostosis | disease | dysostosis | dysostosis that results in abnormal fusing of adjacent bones | C05.116.099.370.894 C05.660.906 C16.131.621.906 |
Synostosis | |
synovitis | disease | connective tissue disease | connective tissue disease that results in inflammation located in synovial membrane that lines a synovial joint which causes pain and swelling | C05.550.870 | ||
syringomyelia | disease Designated intractable/rare diseases |
spinal cord disease syrinx |
congenital disorder of nervous system | C10.228.854.833 | Syringomyelia | |
systemic lupus erythematosus | disease Designated intractable/rare diseases |
lupus erythematosus rheumatic disease |
inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart. | C17.300.480 C20.111.590 |
Systemic lupus erythematosus | |
Takayasu's arteritis | disease Designated intractable/rare diseases |
syndrome artery disease secondary glomerular disease predominantly large-vessel vasculitis |
syndrome that involves inflammation of the aorta that carries blood from the heart to the rest of the body | C14.907.109.239 C14.907.109.239.650 C14.907.940.090.800 C17.800.862.875 |
Takayasu arteritis | |
Tangier disease | disease | hypolipoproteinemia neurometabolic disease Hypoalphalipoproteinemia rare hereditary metabolic disease with peripheral neuropathy rare hereditary systemic disease with peripheral neuropathy |
Human disease | C10.668.829.800.875 C16.320.565.398.500.330.750 C18.452.584.500.875.330.750 C18.452.648.398.500.330.750 |
Tangier disease | |
tarsal tunnel syndrome | disease | tibial neuropathy | Human disease | C10.668.829.500.700.800 C10.668.829.550.800 |
||
Tay-Sachs disease | disease | lysosomal storage disease GM2 gangliosidosis eye degenerative disease |
GM2 gangliosidosis, variant B or Tay-Sachs disease is marked by accumulation of G2 gangliosides due to hexosaminidase A deficiency | C10.228.140.163.100.435.825.300.300.500 C16.320.565.189.435.825.300.300.500 C16.320.565.398.641.803.350.300.850 C16.320.565.595.554.825.300.300.840 C18.452.132.100.435.825.300.300.500 C18.452.584.687.803.350.300.850 C18.452.648.189.435.825.300.300.500 C18.452.648.398.641.803.350.300.850 C18.452.648.595.554.825.300.300.840 |
Tay–Sachs disease | |
Telangiectasia | disease | arterial occlusive disease | Human disease | C14.907.823 | Telangiectasia | |
temporal arteritis | disease Designated intractable/rare diseases |
central nervous system vasculitis predominantly large-vessel vasculitis secondary glomerular disease |
Human disease | C10.114.875.700 C10.228.140.300.850.500 C14.907.253.946.700 C14.907.940.090.530 C14.907.940.907.700 C17.800.862.252 C20.111.258.962.800 |
||
temporal lobe epilepsy | disease | focal epilepsy | Human disease | C10.228.140.490.360.290 | ||
tendinitis | disease | myositis tendinopathy |
Human disease | C05.651.869 C26.874.800 |
||
tenosynovitis | disease health problem arthropathy |
arthropathy tendinitis synovitis tendon sheath disorder |
human disease | C05.651.869.870 | ||
teratoma | disease | germ cell and embryonal cancer | germ cell and embryonal cancer that is an encapsulated tumor with tissue or organ components resembling normal derivatives of all three germ layers | C04.557.465.910 | Teratoma | |
testicular cancer | disease | male reproductive organ cancer endocrine gland cancer testicular disease |
male reproductive system cancer that is located in the testicles | C04.588.322.762 C04.588.945.440.915 C12.294.260.937 C12.758.409.937 C19.344.762 C19.391.829.782 |
Testicular cancer | |
tetany | disease clinical sign |
medical sign consisting of the involuntary contraction of muscles | C10.597.613.875 C18.452.174.509.700 C23.888.592.608.875 |
Tetany (medical sign) | ||
tethered spinal cord syndrome | disease developmental defect during embryogenesis |
spinal cord disease malformation of the neurenteric canal, spinal cord and column |
Human disease | C10.500.680.800 C16.131.666.680.800 |
||
tetralogy of Fallot | disease Designated intractable/rare diseases developmental defect during embryogenesis |
congenital heart disease cyanotic heart defect rare genetic developmental defect during embryogenesis genetic disease rare genetic cardiac disease |
congenital heart defect that is present at birth. Symptoms include episodes of bluish color to the skin embryology includes the displacement of the inphondibulor septem anterio superiorly | C14.240.400.849 C14.280.400.849 C16.131.240.400.849 |
Tetralogy of Fallot | |
tetraplegia | disease | central nervous system disease | paralysis of all four limbs and torso | C10.597.622.760 C23.888.592.636.786 |
||
thalassemia | disease | autosomal recessive disease hemoglobinopathy |
Human disease | C15.378.071.141.150.875 C15.378.420.826 C16.320.070.875 C16.320.365.826 |
Thalassemia | |
thanatophoric dysplasia | disease developmental defect during embryogenesis |
osteochondrodysplasia FGFR3-related chondrodysplasia primary bone dysplasia with micromelia |
osteochondrodysplasia that results in short arms and legs with excess folds of skin | C05.116.099.343.110.500 C05.116.099.708.017.500 C05.660.585.984 C16.131.621.585.984 C16.320.240.500.500 C16.614.890 |
Thanatophoric dysplasia | |
theileriasis | disease infectious disease |
parasitic protozoa infectious disease | parasitic protozoa infectious disease that involves infection of humans and cattle caused by a genus of parasitic protozoa Theileria, which is transmitted by ixodid ticks | C03.701.688.735 C03.752.625.735 C03.752.875.850 C22.196.831 C22.674.710.735 |
||
Thoracic Outlet Syndrome | disease | vascular disease rare surgical thoracic disease |
vascular disease that is characterized by compression at the superior thoracic outlet resulting from excess pressure placed on a neurovascular bundle passing between the anterior scalene and middle scalene muscles | C10.668.829.550.850 C14.907.863 |
||
thromboangiitis obliterans | disease Designated intractable/rare diseases |
arterial occlusive disease predominantly medium-vessel vasculitis secondary glomerular disease |
Human disease | C14.907.137.870 C14.907.940.905 |
Thromboangiitis obliterans | |
thrombocytopenia | disease | blood platelet disease clinical sign |
A blood platelet disease characterized by a low platelet count in the blood. | C15.378.140.855 | ||
thrombogavitis | disease | blood platelet disease | blood platelet disease that is characterized by the presence of high platelet counts in the blood | C15.378.140.860 C15.378.190.636.860 |
||
thrombophilia | disease | blood coagulation disease | Human disease | C15.378.925 | ||
thrombophlebitis | disease | phlebitis | phlebitis that results from a blood clot in the vessel | C14.907.355.830.925.770 C14.907.617.718.788 C14.907.940.740.910 |
||
thrombosis | disease | hematopoietic system diseases vascular disease vascular occlusion embolism and thrombosis |
vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system | C14.907.355.830 | Thrombosis | |
thrombotic thrombocytopenic purpura | disease Designated intractable/rare diseases |
thrombophilia thrombocytopenic purpura rare thrombotic disorder due to a platelet anomaly thrombotic microangiopathy |
Human disease | C15.378.100.802.687.680 C15.378.140.855.925.750.680 C15.378.925.850 C23.550.414.950.687.680 C23.888.885.687.687.680 |
Thrombotic thrombocytopenic purpura | |
thymoma | disease | thymus cancer | A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus. | C04.557.435.850 C04.588.894.949.500 C15.604.861.800 |
Thymoma | |
thyroid cancer | disease | endocrine gland cancer thyroid gland disease |
endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage | C04.588.322.894 C04.588.443.915 C19.344.894 C19.874.788 |
Thyroid cancer | |
thyroid hormone resistance syndrome | disease | hypothyroidism | Human disease | C19.874.410.500 | ||
tic disorder | disease | specific developmental disorder motor disorder |
specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity | C10.228.662.825 | ||
tick-borne encephalitis | disease infectious disease |
viral infectious disease infectious disease with epilepsy tick-borne disease |
viral infectious disease involving the central nervous system | C02.081.343.360 C02.081.885.400 C02.182.525.300.350 C02.290.310.530 C02.782.310.360 C02.782.350.250.500 C10.228.140.430.520.750.300.775 C10.228.228.245.340.300.775 C10.228.228.399.750.300.775 |
Tick-borne encephalitis | |
tinea capitis | disease infectious disease |
dermatophytosis | Human disease | C01.539.800.200.720.730 C01.703.295.872.541 C17.800.738.708 C17.800.838.208.883.558 |
Tinea capitis | |
tinea favosa | disease infectious disease |
tinea capitis skin infection |
Human disease | C01.539.800.200.720.730.740 C01.703.295.872.541.500 C17.800.738.708.708 C17.800.838.208.883.558.708 |
Favus | |
Todd's paresis | disease | C10.597.622 C23.888.592.636 |
||||
tolosa-hunt syndrome | disease | ocular motility disease genetic peripheral neuropathy rare strabismus and restriction syndrome nuclear oculomotor paralysis |
Human disease | C10.292.562.900 C11.590.905 |
Tolosa–Hunt syndrome | |
tonsillitis | disease | upper respiratory tract disease | Human disease | C07.550.781.750 C08.730.561.750 C09.775.649.750 |
Tonsillitis | |
tooth agenesis | disease | tooth disease | tooth disease characterized by failure to develop on or more missing teeth | C07.650.800.100 C07.793.700.100 C16.131.850.800.100 |
Hypodontia | |
toothache | disease | pain | medical condition | C07.793.929 C10.597.617.203.500 C23.888.592.612.330.500 |
Toothache | |
Torticollis | disease | dystonic condition defined by an abnormal, asymmetrical head or neck position, which may be due to a variety of causes | C10.228.662.300.750 C10.597.350.300.800 C23.888.592.350.300.800 |
Torticollis | ||
toxic megacolon | disease | megacolon | Human disease | C06.405.469.158.701.591 | Toxic megacolon | |
toxic shock syndrome | disease | commensal bacterial infectious disease | Human disease | C01.539.757.800 C23.550.470.790.500.800 C23.550.835.900.712 |
||
toxocariasis | disease | parasitic helminthiasis infectious disease nematode infection zoonosis liver disease eye disease lung disease brain disease muscle tissue disease heart disease |
Human disease | C03.335.508.523.780 C03.335.508.700.100.868.420 C03.335.349.868 C03.335.508.700.100.868 C03.701.377.868 C22.674.377.868 |
||
toxoplasmosis | disease infectious disease |
coccidiosis zoonosis |
parasitic human disease | C03.752.250.800 | Toxoplasma | |
tracheitis | disease infectious disease |
tracheal disease inflammatory disease |
inflammation of the trachea | C08.730.848 C08.907.763 |
||
tracheomalacia | disease head and neck disease developmental defect during embryogenesis |
tracheal disease genetic otorhinolaryngological malformation rare genetic respiratory disease non-syndromic respiratory or mediastinal malformation tracheal anomaly respiratory malformation |
tracheal disease | C05.182.895.500 C08.907.796.500 C16.131.621.953.500 C17.300.182.895.500 |
Tracheomalacia | |
trachoma | disease | commensal bacterial infectious disease eye disease |
Human disease | C01.252.354.225.800 C01.252.400.210.210.800 C01.539.375.354.220.800 C11.187.183.220.889 C11.204.813 C11.294.354.220.800 |
Trachoma | |
transient cerebral ischemia | disease | brain ischemia | neurological dysfunctio by transient ischemia | C10.228.140.300.150.836 C14.907.253.092.836 |
||
transient tic disorder | disease | tic disorder | tic disorder that consists of multiple motor and/or phonic tics with duration of at least 4 weeks, but less than 12 months | C10.228.662.825 | ||
transmissible spongiform encephalopathy | disease Designated intractable/rare diseases |
brain disease | brain disease that is characterized by brain damage resulting from the abnormal folding, clumping and accumulation of cellular proteins in the brain induced by prion proteins | C10.228.228.800 C10.574.843 |
Transmissible spongiform encephalopathies | |
transposition of great vessels | disease thoracic disease |
congenital heart disease | group of congenital heart defects involving an abnormal spatial arrangement of any of the great vessels: superior and/or inferior venae cavae, pulmonary artery, pulmonary veins, and aorta | C14.240.400.915 C14.280.400.915 C16.131.240.400.915 |
Transposition of the great vessels | |
Treacher Collins syndrome | disease | autosomal dominant disease first arch syndrome |
Human disease | C05.116.099.370.231.576 C05.660.207.231.576 C16.131.621.207.231.576 |
Treacher Collins syndrome | |
trench fever | disease infectious disease |
bartonellosis bacterial infectious disease |
Human disease | C01.252.400.126.100.800 | ||
trichinosis | disease | nematode infection zoonosis parasitic helminthiasis infectious disease |
parasitic disease due to invasion by Trichinella spp. | C03.335.508.100.275.882 | Trichinosis | |
trichomoniasis | disease | parasitic protozoa infectious disease | parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively | C03.752.890 | Trichomoniasis | |
tricuspid atresia | disease Designated intractable/rare diseases developmental defect during embryogenesis |
congenital heart disease cyanotic heart defect tricuspid valve disease genetic disease rare genetic cardiac disease congenital tricuspid malformation rare genetic developmental defect during embryogenesis |
A tricuspid valve disease characterized by a missing or abnormally developed tricuspid heart value at birth. | C14.240.400.920 C14.280.400.920 C14.280.484.845 C16.131.240.400.920 |
Tricuspid atresia | |
Tricuspid insufficiency | disease | tricuspid valve disease | A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal. | C14.280.484.856 | Tricuspid valve insufficiency | |
trigeminal neuralgia | disease | trigeminal nerve disease facial neuralgia |
neuropathic disorder | C07.465.299.625.500.700 C10.292.319.625.700.700 |
||
tropical spastic paraparesis | disease infectious disease |
viral infectious disease spinal cord disease genetic nervous system disorder infectious disease of the nervous system |
Human disease | C02.782.815.200.470.710 C10.228.228.618.500 C10.228.854.525.700 |
||
tropical sprue | disease | intestinal disease | Human disease | C06.405.469.637.850 C18.452.603.850 |
||
Tuberous sclerosis | disease | autosomal dominant disease phakomatosis malformation of cortical development, Group I |
a rare multisystem genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, liver, eyes, lungs, and skin. | C04.445.810 C04.651.800 C04.700.632 C10.500.507.400.750 C10.562.850 C10.574.500.865 C16.131.666.507.400.750 C16.320.400.880 C16.320.700.636 |
Tuberous sclerosis | |
tularemia | disease | primary bacterial infectious disease | primary bacterial infectious disease that has material basis in Francisella tularensis, which is transmitted by dog tick bite (Dermacentor variabilis), transmitted by deer flies (Chrysops sp) or transmitted by contact with infected animal tissues. | C01.252.400.939 | Tularemia | |
tungiasis | disease infectious disease |
parasitic ectoparasitic infectious disease Pulicosis rare skin disease |
Human disease | C03.858.211.250.800 | ||
Turner syndrome | disease | gonadal dysgenesis sex chromosome disorder |
Human disease | C12.706.316.309.872 C12.706.316.795.750 C13.351.875.253.309.872 C13.351.875.253.795.750 C14.240.400.980 C14.280.400.980 C16.131.240.400.970 C16.131.260.830.835.750 C16.131.939.316.309.872 C16.131.939.316.795.750 C16.320.180.830.835.750 C19.391.119.309.872 C19.391.119.795.750 |
Turner syndrome | |
twin-to-twin transfusion syndrome | disease | neonatal anemia Diseases in Twins anemia immune system disease |
Human disease | C15.378.071.363.344 C16.614.053.344 |
||
type 1 diabetes mellitus | disease | diabetes mellitus | form of diabetes mellitus | C18.452.394.750.124 C19.246.267 C20.111.327 |
Diabetes mellitus type 1 | |
typhoid fever | disease | primary bacterial infectious disease Salmonella infectious disease |
A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics. | C01.252.400.310.821.873 | Typhoid fever | |
typhus | disease | primary bacterial infectious disease rickettsiosis |
group of infectious diseases | C01.252.400.780.790.800 C01.252.400.780.790.805 |
Typhus | |
tyrosinemia | disease | amino acid metabolic disorder inborn disorder of phenylalanin or tyrosine metabolism |
amino acid metabolic disorder that involves impaired break down of the amino acid tyrosine | C10.228.140.163.100.875 C16.320.565.100.880 C16.320.565.189.875 C18.452.132.100.875 C18.452.648.100.880 C18.452.648.189.875 |
||
tyrosinemia type I | disease | tyrosinemia | tyrosinemia that has material basis in deficiency of the enzyme fumarylacetoacetate hydrolase resulting in an increase in fumarylacetoacetate which inhibits previous steps in tyrosine degradation leading to an accumulation of tyrosine in the body | C10.228.140.163.100.875 C16.320.565.100.880 C16.320.565.189.875 C18.452.132.100.875 C18.452.648.100.880 C18.452.648.189.875 |
||
unstable angina | disease | coronary artery disease angina pectoris |
type of angina pectoris that is irregular. It is also classified as a type of acute coronary syndrome | C10.597.617.192.500.150 C14.280.647.187.150 C14.907.585.187.150 C23.888.592.612.233.500.150 |
||
urea cycle disorder | disease | amino acid metabolic disorder | amino acid metabolic disorder that involves a deficiency of one of the enzymes in the urea cycle which is responsible for removing ammonia from the blood stream | C10.228.140.163.100.937 C16.320.565.100.940 C16.320.565.189.937 C18.452.132.100.937 C18.452.648.100.940 C18.452.648.189.937 |
||
ureterocele | disease | ureteral disease genetic disease bladder disease |
Human disease | C12.777.725.876 C13.351.968.725.876 |
Ureteroceles | |
urethral stricture | disease | urethral obstruction | Human disease | C12.777.767.700.700 C13.351.968.767.700.700 |
Urethral stricture | |
urethritis | disease infectious disease |
urethral disease inflammatory disease urinary tract infection |
Inflammation of the urethra | C12.777.767.851 C13.351.968.767.851 |
Urethritis | |
urinary incontinence | disease | impairment of continence urination disorder |
uncontrolled leakage of urine | C12.777.934.852 C13.351.968.934.814 C23.888.942.343.800 |
Urinary incontinence | |
urolithiasis | disease | urinary system disease urolithiasis |
Urolithiasis | C12.777.967.500 C13.351.968.967.500 C23.300.175.850 C12.777.967 C13.351.968.967 |
Lithiasis | |
urticaria | disease | skin disease | skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis | C17.800.862.945 C20.543.480.904 |
Urticaria | |
Usher syndrome | disease | autosomal recessive disease | syndrome characterized by a combination of hearing loss and visual impairment | C09.218.458.341.186.500.500 C09.218.458.341.887.886 C10.597.751.418.341.186.500.500 C10.597.751.418.341.887.886 C10.597.751.941.162.625.500 C11.768.585.658.500.813 C11.966.075.375.500 C16.131.077.299.500 C16.320.290.684.500 C23.888.592.763.393.341.887.886 |
||
uterine cancer | disease | female reproductive organ cancer uterine disease |
female reproductive organ cancer that is located in the uterus | C04.588.945.418.948 C13.351.500.852.762 C13.351.937.418.875 |
Uterine cancer | |
uterine fibroid | disease | uterine benign neoplasm leiomyoma fibroma |
uterine benign neoplasm derived from the smooth muscle layer of the uterus | C04.557.450.590.450 | Uterine fibroids | |
uveitis | disease | uveal disease eye inflammation inflammatory disease |
Human disease | C11.941.879 | Uveitis | |
uveoparotid fever | disease | sarcoidosis Uveoparotitis |
Human disease | C15.604.515.827.865 | ||
vaginal cancer | disease | female reproductive organ cancer vaginal disease |
female reproductive system cancer that is located in the vagina | C04.588.945.418.955 C13.351.500.894.834 C13.351.937.418.937 |
Vaginal cancer | |
vaginal discharge | disease | vaginal disease body fluid |
fluid that comes out of the vagina | C13.351.500.894.700 | Vaginal discharge | |
vaginitis | disease | vaginal disease | Human disease | C13.351.500.894.906 | Vaginitis | |
varicocele | disease | pelvic varices | abnormal enlargement of the pampiniform venous plexus in the scrotum | C12.294.936 C14.907.903 |
Varicocele | |
varicose veins | disease | vein disorder | vein disease that is characterized by swollen, twisted veins visible just under the surface of the skin | C14.907.927 | Varicose veins | |
variegate porphyria | disease | acute porphyria porphyria acute hepatic porphyria |
Human disease | C06.552.830.625 C16.320.850.742.625 C17.800.827.742.625 C18.452.811.400.625 |
||
vascular dementia | disease | dementia | dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain | C10.228.140.300.400 C10.228.140.300.510.800.500 C10.228.140.380.230 C10.228.140.695.500 C14.907.137.126.372.500 C14.907.253.560.350.500 C10.228.140.300.150.477.200.199 C10.228.140.300.400.408 C10.228.140.300.775.200.200.199 C10.228.140.380.230.250 C14.907.253.092.477.200.199 C14.907.253.855.200.200.199 |
Vascular dementia | |
vascular disease | disease | cardiovascular disease | cardiovascular system disease that primarily affects the blood vessels | C14.907.055 C14.907 C10.228.854.785 C14.907.790 C10.228.854.785.650 C14.907.790.550 |
Vascular diseases | |
vascular malformation | disease | vascular anomaly vascular disease |
disease | C14.240.850 C16.131.240.850 |
||
vasculitis | disease | vascular disease angiitis |
vascular disease that is characterized by inflammation of the blood vessels | C14.907.940 | Vasculitis | |
Venous ulcer | disease | wound ulcer of lower limbs |
C17.800.893.592 C14.907.927.730 C17.800.893.592.730 |
Venous ulcer | ||
ventricular fibrillation | disease thoracic disease |
tachycardia ventricular dyssynchrony |
disorganized electrical activity in the ventricles. It is a type of cardiac arrhythmia Ventricular fibrillation results in cardiac arrest | C14.280.067.922 C23.550.073.922 |
Ventricular fibrillation | |
ventricular septal defect | disease | heart septal defect | heart septal defect characterized by an opening in the interventricular septum, causing a shunt between ventricles | C14.240.400.560.540 C14.280.400.560.540 C16.131.240.400.560.540 |
Ventricular septal defect | |
vesicoureteral reflux | disease | ureteral disease | ureteral disease characterized by backward flow of urine from the urinary bladder into the ureter | C12.777.829.920 C13.351.968.829.920 |
Vesicoureteral reflux | |
vestibular neuronitis | disease | vestibulocochlear nerve disease | Human disease | C09.218.807.800.837 C10.292.910.850 |
||
vibration white finger | disease | occupational disease | C10.668.829.380 C14.907.440 C24.400 |
|||
VIPoma | disease | neuroendocrine tumor | Human disease | C04.557.465.625.650.240.847 C04.557.470.200.025.370.847 C04.588.274.761.500.750 C04.588.322.475.500.750 C06.301.761.500.750 C06.689.667.500.750 C19.344.421.500.750 |
||
viral hepatitis | disease | hepatitis viral infectious disease |
hepatitis that involves viral infection causing inflammation of the liver | C02.407 C06.552.380.315.430 C22.467.435 C02.440 C06.552.380.705 |
Viral hepatitis | |
viral infectious disease | disease infectious disease |
infectious disease rare infectious disease |
Human, animal or plant disease resulting from a viral infection | C02.081 | Viral diseases | |
visceral heterotaxy | disease | birth defect | rare disease | C14.240.400.592 C14.280.400.592 C15.604.744.146 C16.131.077.401 C16.131.240.400.592 |
||
visual verbal agnosia | disease | reading disorder agnosia |
An agnosia that is a loss of the ability to comprehending the meaning of written words. | C10.597.606.150.500.300 C10.597.606.150.550.200 C23.888.592.604.150.500.300 C23.888.592.604.150.550.200 C10.597.606.150.500.300.200 C10.597.606.150.550.200.500 C23.888.592.604.150.500.300.200 C23.888.592.604.150.550.200.500 |
||
vitelliform macular dystrophy | disease | macular degeneration | A macular degeneration that can cause progressive vision loss, it is characterized by the disruption of cells in a small area near the center of the retina, the macula. | C11.768.585.439.433 C16.320.290.763 |
||
vitiligo | disease | autoimmune disease autoimmune disease of skin and connective tissue |
hypersensitivity reaction type II disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes. | C17.800.621.440.895 | Vitiligo | |
vitreous detachment | disease | vitreous disease Vitreoretinopathy |
condition of the eye in which the vitreous membrane separates from the retina | C11.980 | ||
Vitreous hemorrhage | disease | intraocular hemorrhage vitreous disease |
C11.290.960 C23.550.414.756.887 |
Vitreous hemorrhage | ||
Vogt–Koyanagi–Harada syndrome | disease head and neck disease |
autoimmune disease panuveitis genetic otorhinolaryngologic disease eyebrow/eyelashes pigmentation anomaly autoimmune disease of skin and connective tissue autoimmune uveitis rare genetic immune disease rare neuroinflammatory or neuroimmunological disease |
multisystem disease | C10.114.843 C11.941.879.980 C20.111.258.925 |
Vogt–Koyanagi–Harada disease | |
Volkmann's contracture | disease | connective tissue disease | Human disease | C05.550.323.734 C05.651.180.531 C05.651.197.734 C14.907.303.531 |
||
von Hippel-Lindau disease | disease head and neck disease developmental defect during embryogenesis |
hemangioblastoma multiple polyglandular tumor syndromic developmental defect of the eye inherited nervous system cancer-predisposing syndrome genetic central nervous system and retinal vascular disease inherited renal tumor hereditary eye tumor rare central nervous system and retinal vascular disease catecholamine-producing tumor familial cystic renal disease malformation syndrome with hamartosis rare disease with glaucoma as a major feature |
a rare genetic disorder characterized by visceral cysts and benign tumors in multiple organ systems with potential for subsequent malignant change. | C10.562.925 C14.907.077.925 |
Von Hippel-Lindau disease | |
von Willebrand's disease | disease | inherited blood coagulation disease | Human disease | C15.378.100.100.900 C15.378.100.141.900 C15.378.140.900 C15.378.463.920 C16.320.099.920 |
||
vulvitis | disease | vulvar disease inflammatory disease |
vulva disease | C13.351.500.944.902 | ||
vulvovaginal candidiasis | disease infectious disease |
candidiasis vulvovaginitis |
excessive growth of yeast in the vagina that results in irritation | C01.703.160.190 C13.351.500.894.906.820.500 C13.351.500.944.902.737.500 |
Vaginal yeast infection | |
Waardenburg's syndrome | disease | autosomal dominant disease genetic deafness |
autosomal disease characterized by varying degrees of deafness, minor defects in structures arising from the neural crest and pigmentation anomalies of the hair, the skin and/or the iris of both eyes | C16.131.077.938 | Waardenburg syndrome | |
WAGR syndrome | disease developmental defect during embryogenesis |
chromosomal deletion syndrome rare disease with glaucoma as a major feature syndromic obesity syndrome with disorder of sex development of gynecological interest partial deletion of the short arm of chromosome 11 polymalformative genetic syndrome with increased risk of developing cancer syndromic renal or urinary tract malformation syndrome with 46,XY disorder of sex development syndromic aniridia |
Human disease | C04.557.435.595.950 C04.588.945.947.535.585.950 C04.700.635.950 C10.597.606.643.969 C11.250.060.950 C11.270.060.950 C11.941.375.060.950 C12.706.316.096.875 C12.758.820.750.585.950 C12.777.419.473.585.950 C13.351.875.253.096.875 C13.351.937.820.535.585.950 C13.351.968.419.473.585.950 C16.131.260.940 C16.131.384.079.950 C16.131.939.316.096.875 C16.320.180.940 C16.320.290.078.950 C16.320.700.642.950 C19.391.119.096.875 |
||
Waldenström's macroglobulinemia | disease | B-cell lymphoma | B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells | C04.557.595.925 C14.907.454.960 C15.378.147.780.925 C15.378.463.515.960 C15.604.515.925 C20.683.780.925 |
||
Walker–Warburg syndrome | disease | congenital muscular dystrophy autosomal recessive |
a rare form of autosomal recessive congenital muscular dystrophy. | C10.500.507.450.499.249.500 C11.270.881 C16.131.666.507.450.499.249.500 C16.320.577.750 |
||
Waterhouse-Friderichsen syndrome | disease | adrenal gland disease Adrenal crisis |
adrenal gland disease that is characterized by failure of the adrenal gland due to bleeding into the gland | C01.252.200.500.550.800 C01.252.400.625.549.449.800 C10.228.228.180.500.750.500 C10.228.614.280.505.904 C15.378.100.802.843 C15.378.463.950 C19.053.500.740 C23.550.414.950.843 C23.888.885.687.843 |
Waterhouse–Friderichsen syndrome | |
Wegener's granulomatosis | disease | autoimmune disease anti-neutrophil cytoplasmic antibody-associated vasculitis kidney disease lung disease skin disease inflammatory and autoimmune disease with epilepsy immune system disease secondary glomerular disease systemic inflammatory disease associated with an acquired peripheral neuropathy |
autoimmune disease affecting blood vessels in the lungs, kidneys, and skin | C08.381.483.950 C14.907.940.897.249.750 C20.111.193.875 |
Wegener's granulomatosis | |
Werner syndrome | disease Designated intractable/rare diseases developmental defect during embryogenesis |
autosomal recessive disease progeroid syndrome ectodermal malformation syndrome associated with ocular features hereditary poikiloderma malformation syndrome with skin/mucosae involvement polymalformative genetic syndrome with increased risk of developing cancer |
Human disease. Common in 1 in 2 children. Death is inevitable. | C16.320.925 C18.452.284.960 |
||
West syndrome | disease | infancy electroclinical syndrome | A severe epilepsy syndrome with triad of infantile spasms, an interictal electroencephalogram (EEG) pattern termed hypsarrhythmia, and mental retardation. | C10.228.140.490.375.760 | ||
Whipple disease | disease infectious disease |
intestinal disease bacterial infectious disease rare disease with myoclonus as a major feature infectious disease of the nervous system |
Human disease | C01.252.410.040.137.631 C06.405.469.637.925 C18.452.603.925 |
Whipple's disease | |
Williams-Beuren syndrome | disease developmental defect during embryogenesis |
chromosomal deletion syndrome supravalvular aortic stenosis syndromic developmental defect of the eye multiple congenital anomalies/dysmorphic syndrome-intellectual disability malformation syndrome with short stature genetic hypertension partial deletion of the long arm of chromosome 7 rare syndrome with cardiac malformations rare abdominal surgical disease rare genetic syndromic intellectual disability organic brain syndrome syndromic epicanthus motor stereotypies |
neurodevelopmental disorder | C10.597.606.643.970 C14.280.484.150.535.960 C16.131.260.970 C16.320.180.970 |
Williams syndrome | |
Wilson disease | disease Designated intractable/rare diseases |
liver disease metal metabolism disorder copper metabolism disease organic brain syndrome rare hereditary metabolic disease with peripheral neuropathy metabolic disease with cataract metabolic disease with corneal opacity supranuclear oculomotor palsy disorder of copper metabolism tremor rare genetic tremor disorder rare metabolic liver disease metal transport or utilization disorder with epilepsy rare genetic epilepsy neurometabolic disease rare disorder with dystonia and other neurologic or systemic manifestation nephropathy secondary to a storage or other metabolic disease |
Human disease | C06.552.413 C10.228.140.079.493 C10.228.140.163.100.360 C10.228.662.400 C10.574.500.487 C16.320.400.361 C16.320.565.189.360 C16.320.565.618.403 C18.452.132.100.360 C18.452.648.189.360 C18.452.648.618.403 |
Wilson's disease | |
Wiskott-Aldrich syndrome | disease | X-linked disease polymalformative genetic syndrome with increased risk of developing cancer immune deficiency with skin involvement skin disease syndrome with combined immunodeficiency combined immunodeficiency dense granule disease |
rare disease | C15.378.100.100.970 C15.378.463.960 C15.378.553.546.605.900 C16.320.099.970 C16.320.322.937 C20.673.627.900 |
||
Wolf-Hirschhorn syndrome | disease | chromosomal deletion syndrome | chromosome abnormality | C16.131.077.944 C16.131.260.985 C16.320.180.985 |
Wolf–Hirschhorn syndrome | |
Wolff-Parkinson-White syndrome | disease | pre-excitation syndrome heart conduction disease genetic disease |
disorder due to a specific type of problem with the electrical system of the heart which has resulted in symptoms | C14.280.067.780.977 C16.131.240.400.980 |
Wolff–Parkinson–White syndrome | |
Wolfram syndrome | disease Designated intractable/rare diseases |
genetic disease syndrome hereditary optic atrophy |
Human disease | C09.218.458.341.186.500.750 C10.292.700.225.500.980 C10.574.500.662.980 C10.597.751.418.341.186.500.750 C10.597.751.941.162.625.750 C11.270.564.980 C11.640.451.451.980 C11.966.075.375.750 C12.777.419.135.875 C13.351.968.419.135.875 C16.131.077.299.750 C16.320.290.564.980 C16.320.400.630.980 C18.452.394.750.124.960 C19.246.267.960 C19.700.159.875 |
Wolfram syndrome | |
X-linked hypophosphatemic rickets | disease | rickets familial hypophosphatemia |
Human disease | C05.116.198.816.875.500 C12.777.419.815.647.500 C13.351.968.419.815.647.500 C16.320.565.618.544.500 C16.320.565.861.647.500 C18.452.104.816.875.500 C18.452.174.845.875.500 C18.452.648.618.544.500 C18.452.648.861.647.500 C18.452.750.400.500.500 C18.452.750.400.750.500 C18.654.521.500.133.770.734.875.500 |
||
xeroderma pigmentosum | disease Designated intractable/rare diseases |
autosomal recessive disease autosomal recessive cerebellar ataxia due to a DNA repair defect |
autosomal recessive disease that is characterized by a deficiency in the ability to repair ultraviolet damage that has material basis in autosomal recessive inheritance of DNA repair | C04.834.867 C16.131.831.936 C16.320.850.970 C17.800.600.925 C17.800.621.936 C17.800.804.936 C17.800.827.970 C18.452.284.975 |
Xeroderma pigmentosum | |
xerophthalmia | disease | conjunctival degeneration dry eye syndrome |
Human disease | C11.187.810 C11.496.260.892 |
Xerophthalmia | |
XY gonadal dysgenesis | disease | gonadal dysgenesis | gonadal dysgenesis that is characterized by a normal 46,XY karyotype along with a progressive loss of germ cells on the developing gonads of an embryo | C12.706.316.096.687 C12.706.316.309.388 C13.351.875.253.096.687 C13.351.875.253.309.388 C16.131.939.316.096.687 C16.131.939.316.309.388 C19.391.119.096.687 C19.391.119.309.388 C12.706.316.096 C13.351.875.253.096 C16.131.939.316.096 C19.391.119.096 |
||
XYY syndrome | disease developmental defect during embryogenesis |
sex chromosome disorder Y chromosome number anomaly |
C23.550.210.024.500 C23.550.210.815.970 |
XYY syndrome | ||
yaws | disease infectious disease |
primary bacterial infectious disease treponematosis bone disease cellulitis |
Human disease: tropical infection of the skin, bones and joints caused by the spirochete bacterium Treponema pallidum pertenue | C01.252.400.840.892 C01.252.825.910 C01.252.847.840.892 C01.539.800.720.910 C17.800.838.765.910 |
Yaws | |
yellow fever | disease infectious disease |
viral infectious disease rare skin disease arbovirosis Skin infection |
viral disease | C02.081.980 C02.782.350.250.980 C02.782.417.881 |
Yellow fever | |
yellow nail syndrome | disease | syndrome nail disease skin disease primary lymphedema with associated anomalies rare genetic respiratory disease syndromic lymphedema rare genetic skin vascular disorder syndromic nail anomaly primary interstitial lung disease specific to childhood due to alveolar vascular disorder |
Human disease | C16.320.962 C17.800.529.819 C17.800.621.968 C23.300.820.500 |
Yellow nail syndrome | |
Zellweger syndrome | disease | peroxisomal disease Zellweger spectrum disorder eye degenerative disease |
congenital disorder of nervous system | C06.552.970 C10.228.140.163.100.968 C12.777.419.978 C13.351.968.419.978 C16.131.077.970 C16.320.565.189.968 C16.320.565.663.970 C18.452.132.100.968 C18.452.648.189.968 C18.452.648.663.970 |
||
Zollinger-Ellison syndrome | disease | syndrome | syndrome that is haracterized by the development of a one or more tumors (gastrinoma) in the pancreas, duodenum, or both that secrete excessive levels of gastrin, a hormone that stimulates production of acid by the stomach | C04.730.713.988 C06.301.371.883 C06.405.249.883 C06.405.469.275.800.924 C06.405.469.965 C06.405.748.586.924 C06.405.748.947 |
Zollinger–Ellison syndrome |
dural venous sinuses
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
cavernous sinus | dural venous sinuses | A07.231.908.224 | Cavernous sinus | |||
Inferior sagittal sinus | dural venous sinuses | A07.231.908.224 | ||||
Occipital sinus | dural venous sinuses | A07.231.908.224 | ||||
Sigmoid sinus | dural venous sinuses | A07.231.908.224 | ||||
Superior petrosal sinus | dural venous sinuses | A07.231.908.224 | ||||
superior sagittal sinus | dural venous sinuses | A07.231.908.224 | ||||
Transverse sinuses | dural venous sinuses | A07.231.908.224 |
embryonic structure
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
foramen ovale | embryonic structure | In the fetal heart allows blood to enter the left atrium from the right atrium. | A07.541.459.500 | Foramen ovale | ||
metencephalon | embryonic structure brain region |
secondary cerebral vesicle | A08.186.211.132.810.428 | Metencephalon | ||
myelencephalon | embryonic structure brain region |
secondary cerebral vesicle | posterior region of the embryonic hindbrain | A08.186.211.132.810.406 | ||
rhombencephalon | embryonic structure brain region |
primary cerebral vesicle | A08.186.211.132.810 | Rhombencephalon |
eye disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Aphakia | eye disease | disorder of lens | C11.510.103 | |||
conjunctivitis | eye disease disease eye inflammation |
eye disease disease conjunctival disease inflammatory disease |
inflammation of the outermost layer of the eye and the inner surface of the eyelids | C11.187.183 | Conjunctivitis |
facial feature
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
cheek | facial feature | anatomical region facial feature |
part of the head | A01.456.505.173 | Cheeks | |
forehead | facial feature | facial feature | area of the head between the eyebrows and the hairline | A01.456.505.580 | Foreheads |
flat bone
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
frontal bone | flat bone | bone | bone in the human skull | A02.835.232.781.375 | Frontal bones | |
rib | flat bone | bone | long curved bone surrounding the chest | A02.835.232.904.567 | Ribs (skeleton) | |
sternum | flat bone | flat bone in the middle front part of the rib cage | A02.835.232.904.766 | Sternum |
food ingredient
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Dietary Sucrose | food ingredient | Nutritive Sweeteners sugar |
Sucrose present in the diet. It is added to food and drinks as a sweetener | D27.720.372.300.353.609.750.250 | ||
high fructose corn syrup | food ingredient sweetener syrup |
corn syrup Nutritive Sweeteners |
processed corn syrup | D27.720.372.300.353.609.750.500 | ||
vitamin | food ingredient | organic compound Micronutrients |
organic compound and a vital nutrient that an organism requires in limited amounts | D27.505.696.377.605.600 | Vitamins |
government program
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Medicare | government program publicly funded health care health insurance in the United States |
United States single-payer national social insurance program | N03.219.521.346.506.564.663 N03.219.521.576.343.840 N03.706.615.696 |
Medicare (United States) | ||
Medicare Part D | government program | N03.219.521.576.343.575.500 N03.219.521.576.343.840.938 N03.706.615.752 |
group of chemical substances
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
cephalosporin antibiotic | group of chemical substances | chemical compound cephem antibiotic |
class of pharmaceutical drugs | D02.065.589.099.249 D02.886.665.074 D03.633.100.300.249 |
Cephalosporin antibiotics | |
glucocorticoid | group of chemical substances | chemical substance corticosteroid hormone |
class of corticosteroids | D27.505.696.399.472.488 | Glucocorticoids |
gyrus
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
dentate gyrus | gyrus | A08.186.211.577.405.200 | Dentate gyrus | |||
parahippocampal gyrus | gyrus | A08.186.211.577.710 | Parahippocampal gyrus |
head and neck disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Laryngomalacia | head and neck disease developmental defect during embryogenesis |
laryngeal disease genetic otorhinolaryngological malformation larynx anomaly |
congenital disorder of upper respiratory system | C05.182.310 C08.360.563 C09.400.563 C16.131.621.568 C17.300.182.310 |
Laryngomalacia | |
macroglossia | head and neck disease developmental defect during embryogenesis |
tongue disease rare head and neck malformation genetic head and neck malformation rare maxillo-facial surgical disease |
enlargement of the tongue | C07.465.910.460 | Macroglossia |
health problem
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Acute generalized exanthematous pustulosis | health problem | pustulosis adverse drug reaction toxic dermatosis |
widespread acute rash characterized by fever and multiple small pustules on a reddish background | C17.800.174.600.174 C20.543.206.380.174 C25.100.468.380.174 |
||
Femoral acetabular impingement | health problem | skeletal disease | C05.550.384 C23.550.347 |
Femoroacetabular impingement | ||
Perioral dermatitis | health problem | skin disease | C17.800.174.550 C17.800.271.250 |
Perioral dermatitis | ||
progressive disease | health problem | disease | C23.550.291.656 | |||
tinnitus | health problem | hearing disorder | perception of sound within the human ear ("ringing of the ears") when no external sound is present | C09.218.458.670 C10.597.751.418.670 C23.888.592.763.393.670 |
Tinnitus | |
tympanosclerosis | health problem disease |
tympanic membrane disease | Human disease | C09.218.636 | Tympanosclerosis |
hereditary disorder
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Becker myotonia | hereditary disorder | myotonia congenita | C05.651.662.500 C10.574.500.545 C10.668.491.606.500 C16.320.400.540 |
|||
hereditary cancers | hereditary disorder | cancer causes of cancer genetic disease rare genetic disease neoplastic syndrome |
Human disease | C04.700 C16.320.700 |
Hereditary cancers |
horse disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Covering sickness | horse disease | trypanosomiasis | horses disease | C03.701.688.367 C03.752.300.900.226 C03.752.625.367 C22.674.710.367 |
Covering sickness | |
lameness | horse disease | limp animal disease |
departure from the normal gait in animals | C22.510 |
infectious disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
bluetongue disease | infectious disease | animal disease sheep disease |
type of disease that afflicts ruminants | C02.081.125 C02.782.791.315 C22.836.120 |
Bluetongue disease | |
Intestinal parasite | infectious disease | parasitic infectious diseases intestinal disease |
Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS. | C03.432 C06.405.469.452 |
||
Meningococcal disease | infectious disease | gram-negative bacterial infection | Human disease | C01.252.400.625.549 | Meningococcal infections | |
swine vesicular disease | infectious disease | infectious disease swine disease |
Human disease | C02.782.687.359.855 C22.905.850 |
||
zoonosis | infectious disease | vector-borne disease animal disease |
infectious disease that is transmitted between species (sometimes by a vector) from animals other than humans to humans or from humans to other animals | C01.908 C02.968 C03.908 C22.969 |
Zoonoses |
ink blot test
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Holtzman Inkblot Test | ink blot test | projective personality test | F04.711.647.622.341.387 | |||
Rorschach test | ink blot test projective test |
Psychological test in which subjects' perceptions of inkblots are recorded and analyzed using psychological interpretation and/or complex algorithims | F04.711.647.622.341.736 | Rorschach inkblots |
joint
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Atlanto-axial joint | joint | intervertebral joint joints of the neck |
articulation between the cervical atlas and the axis | A02.835.583.097 | Atlanto-axial joint | |
Atlanto-occipital joint | joint | joints of the neck | articulation between the occiptal bone and the cervical atlas | A02.835.583.101 | ||
shoulder joint | joint | A02.835.583.748 | Glenohumeral joint | |||
Sternoclavicular articulation | joint | A02.835.583.781 | Sternoclavicular joint | |||
temporomandibular joint | joint | A02.835.583.861 | Temporomandibular joint | |||
wrist | joint | part of the arm between the lower arm and the hand | A02.835.583.405.930 | Wrists | ||
Zygapophysial joint | joint | intervertebral joint | A02.835.583.979 |
medical finding
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
bradycardia | medical finding | heart arrhythmia finding of heart rate |
heart rate that is below the normal range | C14.280.067.319 C23.550.073.300 |
Bradycardia | |
hyperbilirubinemia | medical finding | disease of metabolism | medical condition | C23.550.429 |
medical specialty
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
blood substitute | medical specialty | surgery Hematologic Agents |
Substances that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs | D27.505.954.502.140 | ||
forensic medicine | medical specialty | forensic science legal medicine |
branch of medicine that deals with application of medical knowledge to aid in the administration and furthering of justice. | H02.403.330 I01.198.780.937 |
Forensic medicine | |
forensic psychiatry | medical specialty | medical specialty | F04.096.544.335 H02.403.690.208 I01.198.780.937.469 I01.880.604.583.310 N03.706.535.351 |
|||
psychiatry | medical specialty | medicine | medical specialty devoted to the study, diagnosis, treatment, and prevention, of mental disorders | F04.096.544 H02.403.690 |
Psychiatry |
muscle
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
deltoid muscle | muscle | human shoulder muscle | A02.633.567.300 | Deltoid muscle | ||
intercostal muscle | muscle | A02.633.567.900.500 | Intercostal muscles | |||
Lateral pterygoid muscle | muscle | A02.633.567.600.700 | Lateral pterygoid muscles | |||
Medial pterygoid muscle | muscle | A02.633.567.600.700 | Medial pterygoid muscles | |||
pectoralis major | muscle | main human chest muscle | A02.633.567.775 | Pectoralis major muscle | ||
Psoas major muscle | muscle | long fusiform muscle located on the side of the lumbar region of the vertebral column and brim of the lesser pelvis | A02.633.567.825 | Psoas major muscles | ||
Psoas minor muscle | muscle | long, slender skeletal muscle located anterior to the psoas major muscle | A02.633.567.825 | Psoas minor muscles | ||
quadriceps femoris muscle | muscle | human leg muscle | A02.633.567.850 | Quadriceps femoris muscles | ||
rectus abdominis muscle | muscle | paired muscle running vertically on each side of the anterior wall of the human (of some other mammals) abdomen | A02.633.567.050.800 | Rectus abdominis muscle | ||
stylopharyngeus muscle | muscle | A02.633.567.800 | Stylopharyngeus muscles |
neurological disorder
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
brain abscess | neurological disorder | intracranial abscess | C01.395.250 C01.539.830.025.160 C10.228.140.116 C10.228.228.090 |
Brain abscesses | ||
cerebellar disease | neurological disorder disease |
brain disease | Human disease | C10.228.140.252 |
neuropsychological test
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Luria-Nebraska neuropsychological battery | neuropsychological test | F04.711.513.300 | ||||
Trail Making Test | neuropsychological test | F04.711.513.838 |
organ
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
human heart | organ | heart human organ |
human organ | A07.541 | Human heart | |
mesentery | organ | human organ | A01.047.025.600.451 | Mesentery |
physiological finding
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
deficiency | physiological finding | nutrition disorder nutritional deficiency disease |
Human disease | C18.654.521.500.133 | Diseases and disorders due to vitamin deficiencies | |
magnesium deficiency | physiological finding | disorder of magnesium metabolism mineral deficiency nutritional deficiency disease |
human disease | C18.654.521.500.439 |
protein family
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Gliadin | protein family | prolamin | class of proteins | D12.776.765.725.500.500.400 | Gliadin | |
gluten | protein family adhesive |
protein | protein composite found in wheat and related grains, including barley and rye | D12.776.765.725.500.500 | Gluten | |
prolamin | protein family | protein | D12.776.765.725.500 | |||
Zein seed storage protein | protein family | prolamin | InterPro Family | D12.776.765.725.500.750 |
rare disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Anti-NMDA receptor encephalitis | rare disease | encephalitis | rare disease | C04.588.614.550.112 C04.730.856.112 C10.228.140.430.124 C10.574.781.249 C20.111.258.124 |
||
Arnold-Chiari malformation | rare disease | rare disease | C10.500.680.291 C16.131.666.680.291 |
Chiari malformation | ||
Castleman's disease | rare disease disease |
Lymphoproliferative disorders | lymphoproliferative syndrome characterized by one or more enlarged lymph nodes containing cells with hyaline-vascular, plasmacytic, or mixed appearance microscopically | C15.604.515.245 C20.683.515.250 |
Castleman's disease | |
congenital insensitivity to pain with anhidrosis | rare disease Designated intractable/rare diseases |
hereditary sensory neuropathy absence of pain sensation anhidrosis |
rare disease | C10.500.310 C10.574.500.496 C10.668.829.800.175 C16.131.666.310 C16.320.400.415 |
Congenital insensitivity to pain with anhidrosis | |
Degos disease | rare disease | rare disease | C14.907.137.520 C14.907.940.530 C17.800.862.457 |
Degos disease | ||
Dejerine–Sottas disease | rare disease | Charcot–Marie–Tooth disease | rare disease | C10.500.300 C10.574.500.495 C10.668.829.800.300 C16.131.666.300 C16.320.400.375 |
||
Ectodermal dysplasia | rare disease | Human disease | C16.131.077.350 C16.131.831.350 C16.320.850.250 C17.800.804.350 C17.800.827.250 |
Ectodermal dysplasia | ||
ichthyosis | rare disease disease |
skin disease rare epidermal disease |
skin disease in which dry, scaly skin accumulates | C16.131.831.512 C16.614.492 C17.800.428.333 C17.800.804.512 |
Ichthyosis | |
Idiopathic CD4+ lymphocytopenia | rare disease | rare disease | C15.378.553.546.605.800 C20.673.627.800 |
|||
Jacobsen syndrome | rare disease developmental defect during embryogenesis |
syndromic constitutional thrombocytopenia ptosis partial deletion of the long arm of chromosome 11 |
Jacobsen syndrome is a multiple congenital anomaly/mental retardation (MCA/MR) contiguous gene syndrome caused by partial deletion of the long arm of chromosome 11 | C15.378.140.855.440 C16.131.260.440 C16.320.180.440 |
Jacobsen syndrome | |
Kashin–Beck disease | rare disease | osteochondrodysplasia | chronic, endemic osteochondropathy | C05.116.099.708.534 | Kashin–Beck disease | |
McCune–Albright syndrome | rare disease | rare disease | C05.116.099.708.375.381 | |||
Morquio Syndrome | rare disease disease |
mucopolysaccharidosis | Rare Disease | C16.320.565.202.715.655 C16.320.565.595.600.655 C17.300.550.575.655 C18.452.648.202.715.655 C18.452.648.595.600.655 |
||
Mucolipidosis type IV | rare disease developmental defect during embryogenesis |
mucolipidosis rare genetic epilepsy lysosomal disease with epilepsy metabolic disease with corneal opacity unclassified primitive or secondary maculopathy hereditary retinal dystrophy rare genetic developmental defect during embryogenesis |
Lysosomal storage disease | C05.116.198.371 C10.228.140.163.100.435.590 C16.320.565.189.435.590 C16.320.565.202.670 C16.320.565.595.554.590 C18.452.132.100.435.590 C18.452.648.189.435.590 C18.452.648.202.670 C18.452.648.595.554.590 |
||
Opsoclonus myoclonus syndrome | rare disease | paraneoplastic neurologic syndrome rare disease with myoclonus as a major feature rare acquired eye disease brain inflammatory disease |
rare disease | C04.588.614.550.600 C04.730.856.596 C10.228.758.500 C10.292.562.831 C10.574.781.662 C10.597.350.500.500 C11.590.725 |
||
Rotor syndrome | rare disease | bilirubin metabolic disorder rare metabolic liver disease |
rare disease | C16.320.565.300 C18.452.648.300 |
||
Sanfilippo syndrome | rare disease disease |
mucopolysaccharidosis | mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme resulting in incomplete breakdown of the heparan sulfate sugar chain | C16.320.565.202.715.650 C16.320.565.595.600.650 C17.300.550.575.650 C18.452.648.202.715.650 C18.452.648.595.600.650 |
Sanfilippo syndrome | |
slipped capital femoral epiphysis | rare disease | chondropathy genetic disease |
rare disease | C05.116.099.708.928 C05.116.425.500 |
Slipped capital femoral epiphysis | |
Sturge–Weber syndrome | rare disease head and neck disease developmental defect during embryogenesis |
phakomatosis overgrowth syndrome cerebral diseases of vascular origin with epilepsy neurocutaneous syndrome with epilepsy syndrome or malformation associated with head and neck malformations skull cancer brain cancer rare capillary malformation with associated anomalies palpebral tumor with a vascular malformation rare genetic vascular tumor conjunctival cancer conjunctival hemangioma or hemolymphangioma rare disease with glaucoma as a major feature neurovascular malformation syndromic developmental defect of the eye |
a rare congenital neurological and skin disorder associated with port-wine stains of the face, glaucoma, seizures, mental retardation, and ipsilateral leptomeningeal angioma (cerebral malformations and tumors). | C04.557.645.375.850 C10.562.800 C14.907.077.850 |
Sturge–Weber syndrome | |
Tarlov cyst | rare disease | neurological disorder | Perineural (or Tarlov) cysts are cerebrospinal fluid-filled nerve root cysts most commonly found at the sacral level of the spine, although they can be found in any section of the spine, which can cause progressively painful radiculopathy | C04.182.872 C10.668.829.900 |
Tarlov cyst | |
trisomy 9 | rare disease | trisomy | partial or complete triplication of chromosome 9 | C23.550.210.050.750 C23.550.210.182.500 |
||
X-linked adrenoleukodystrophy | rare disease disease Designated intractable/rare diseases |
leukodystrophy nervous system heredodegenerative disease |
X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder resulting in cerebral demyelination, axonal dysfunction in the spinal cord leading to spastic paraplegia, adrenal insufficiency and in some cases testicular insufficiency | C10.114.375.112 C10.228.140.400 C10.228.140.695.562.112 C10.314.350.112 C20.111.258.250.175 C10.228.140.163.100.084 C10.228.140.163.100.362.250 C10.228.140.695.625.250 C10.314.400.250 C10.597.606.643.455.124 C16.320.322.500.124 C16.320.400.525.124 C16.320.565.189.084 C16.320.565.189.362.250 C16.320.565.663.100 C18.452.132.100.084 C18.452.132.100.362.250 C18.452.648.189.084 C18.452.648.189.362.250 C18.452.648.663.100 C19.053.500.270 |
Adrenoleukodystrophy |
sexually transmitted infection
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Adult T-cell leukemia/lymphoma | sexually transmitted infection disease |
T-cell leukemia | Human disease | C04.557.337.428.580.100 C15.604.515.560.575.100 C20.683.515.528.582.100 |
||
Syphilitic aortitis | sexually transmitted infection | aortitis syphilis |
inflammation of the aorta | C01.252.400.840.744.657 C01.252.847.840.744.657 C01.539.190.500 C14.260.500 |
sheep disease
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
ovine pulmonary adenocarcinoma | sheep disease cancer in animals |
sheep disease | Animal disease | C02.782.815.725 C02.928.740 C04.557.470.200.025.715 C22.836.715 |
||
scrapie | sheep disease disease |
transmissible spongiform encephalopathy | disease that affects sheep and goats | C10.228.228.800.717 C10.574.843.850 C22.836.799 |
Scrapie |
state of the United States
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
North Carolina | state of the United States | state of the United States of America | Z01.107.567.875.075.475 Z01.107.567.875.750.530 |
North Carolina | ||
South Carolina | state of the United States | state of the United States of America | Z01.107.567.875.075.662 Z01.107.567.875.750.700 |
South Carolina | ||
Virginia | state of the United States | state of the United States of America | Z01.107.567.875.075.837 Z01.107.567.875.750.870 |
Virginia |
symptom
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
angina pectoris | symptom | coronary disease | chest pain due to ischemia of the heart muscle | C10.597.617.192.500 C14.280.647.187 C14.907.585.187 C23.888.592.612.233.500 |
Angina pectoris | |
chemical burn | symptom | occupational disease burn |
medical condition | C26.200.156 | Chemical burns | |
cyanosis | symptom | abnormal skin coloration | medical diagnosis | C23.888.248 | Cyanosis | |
erythema | symptom | flushing | symptom | C17.800.229 | Erythemas | |
heart arrhythmia | symptom medical finding |
heart disease clinical sign finding of cardiac rhythm |
group of conditions in which the heartbeat is irregular, too fast, or too slow | C14.280.067 C23.550.073 |
Cardiac arrhythmias | |
hyperpigmentation | symptom | health problem pigmentation disease |
darkening of an area of skin or nails caused by increased melanin | C17.800.621.430 | Hyperpigmentation | |
inflammation | symptom | disease | signs of activation of the immune system | C23.550.470 | Inflammation | |
intermittent claudication | symptom disease |
arteriosclerosis claudication |
symptom that describes muscle pain on mild exertion (ache, cramp, numbness or sense of fatigue) | C14.907.137.126.669 C23.888.531 |
||
necrolytic migratory erythema | symptom | erythema | C17.800.551 C23.888.885.468 |
|||
rash | symptom | clinical sign skin disease |
C17.800.257 | Diseases and disorders of the skin | ||
tachycardia | symptom medical finding |
heart arrhythmia finding of heart rate |
heart rate that exceeds the normal resting rate | C14.280.067.845 C23.550.073.845 |
Tachycardia | |
tension headache | symptom | headache | C10.228.140.546.399.875 | Tension headache | ||
tremor | symptom rhythmic process |
movement disorder | involuntary muscle contraction | C10.597.350.850 C23.888.592.350.850 |
Tremor |
syndrome
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
circulatory shock | syndrome | circulatory collapse | medical emergency characterized by decreased tissue perfusion and impaired cellular metabolism resulting from failure of circulatory system | C23.550.835 C23.550.835.888 C26.797 |
Shock (circulatory) | |
LAMB Syndrome | syndrome | C04.557.450.565.550.312 C04.588.894.309.500 C14.280.459.500 C16.131.077.229 C16.131.831.108 |
||||
NAME syndrome | syndrome | C04.557.450.565.550.312 C04.588.894.309.500 C14.280.459.500 C16.131.077.229 C16.131.831.108 |
||||
overweight | syndrome | overnutrition | having more body fat than is optimally healthy | C23.888.144.699 | Obesity |
taxon
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
Escherichia coli | taxon model organism |
Gram-negative, rod-shaped bacterium | B03.440.450.425.325.300 B03.660.250.150.180.100 |
Escherichia coli | ||
Henipavirus | taxon | genus of viruses | B04.820.455.600.650.400 | Henipavirus | ||
Morbillivirus | taxon | genus of viruses | B04.820.455.600.650.500 | Morbillivirus | ||
moringa | taxon | fast-growing, drought-resistant tree | B01.650.940.800.575.912.250.752.500 | Moringa oleifera | ||
Xylella | taxon | genus of prokaryotes | B03.440.400.425.967.950 B03.660.250.915.950 |
tissue
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
bone marrow | tissue | tissue | flexible tissue in the interior of bones | A15.382.216 | Bone marrow | |
corneal epithelium | tissue | stratified squamous epithelium | A09.371.060.217.325 |
vein
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
axillary vein | vein | A07.231.908.077 | Axillary vein | |||
azygos vein | vein | A07.231.908.106 | ||||
brachiocephalic vein | vein | A07.231.908.130 | ||||
femoral vein | vein | A07.231.908.314 | Femoral vein | |||
Great saphenous vein | vein | large, subcutaneous, superficial vein of the leg | A07.231.908.819 | |||
hepatic portal vein | vein portal vein |
A07.231.908.670.567 | Body | |||
inferior vena cava | vein | vena cava | A07.231.908.949.648 | |||
internal jugular vein | vein | jugular vein | paired vein collecting the blood from the brain, the superficial parts of the face, and the neck | A07.231.908.498 | ||
jugular vein | vein | vein | veins that bring deoxygenated blood from the head back to the heart | A07.231.908.498 | Jugular vein | |
popliteal vein | vein | A07.231.908.641 | ||||
pulmonary vein | vein umbrella term |
A07.231.908.713 | ||||
renal vein | vein | A07.231.908.752 | ||||
splenic vein | vein | A07.231.908.670.730 | ||||
subclavian vein | vein | paired large vein | A07.231.908.877 | |||
superior vena cava | vein | vena cava | A07.231.908.949.815 |
website
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
International HapMap Project | website | website | H01.158.273.180.350.162 H01.158.273.343.249.199 H01.158.273.343.350.130 H01.770.644.145.350.249 |
International HapMap Project | ||
MedlinePlus | website medical database |
online information service produced by the United States National Library of Medicine | L01.313.500.750.280.730 | MedlinePlus | ||
PubMed | website search engine medical database bibliographic database |
online database with abstracts of medical articles, hosted by US National Library of Medicine | L01.313.500.750.280.750 L01.313.500.750.300.188.300.650 L01.313.500.750.300.742.650 L01.470.750.500.650 |
PubMed |
Misc
[edit]Article | instance of | subclass of | description | MeSH Code | Commons category | image |
---|---|---|---|---|---|---|
14-alpha Demethylase Inhibitors | Steroid Synthesis Inhibitors Cytochrome P-450 Enzyme Inhibitors |
Compounds that specifically inhibit sterol 14-demethylase. A variety of azole-derived antifungal agents act through this mechanism | D27.505.696.399.450.855.100 D27.505.389.500.059 D27.505.519.389.870.100 D27.505.519.389.335.059 |
|||
5-alpha Reductase Inhibitors | Steroid Synthesis Inhibitors | Drugs that inhibit 3-oxo-5-alpha-steroid 4-dehydrogenase. They are commonly used to reduce the production of dihydrotestosterone | D27.505.519.389.870.200 D27.505.696.399.450.855.200 |
|||
5-HT2c receptor agonist | serotonin receptor agonist | Endogenous compounds and drugs that specifically stimulate serotonin 5-ht2 receptors. Included under this heading are agonists for one or more of the specific 5-ht2 receptor subtypes | D27.505.696.577.850.800.200 D27.505.519.625.850.800.200 |
|||
5-Lipoxygenase-Activating Protein Inhibitors | enzyme inhibitor | Compounds that bind to and inhibit the action of 5-lipoxygenase-activating proteins | D27.505.519.389.086 | |||
abdominal obesity | obesity clinical sign |
excessive abdominal fat around the stomach and abdomen | C18.654.726.500.697 | Abdominal obesity | ||
abdominal pregnancy | ectopic pregnancy | C13.703.733.536 | Abdominal pregnancy | |||
abortifacient Agents | Reproductive Control Agents | Chemical substances that interrupt pregnancy after implantation. | D27.505.954.705.131 D27.505.696.875.131 |
Abortifacients | ||
Abortifacient Agents, Nonsteroidal | abortifacient Agents | Non-steroidal chemical compounds with abortifacient activity. | D27.505.696.875.131.100 D27.505.954.705.131.100 |
|||
Abortifacient Agents, Steroidal | abortifacient Agents | Steroidal compounds with abortifacient activity | D27.505.696.875.131.200 D27.505.954.705.131.200 |
|||
Abuse-Deterrent Formulations | Central Nervous System Agents Sensory System Agents Physiological Effects of Drugs |
Drug formulations or delivery systems intended to discourage the abuse of controlled substances. These may include physical barriers to prevent chewing or crushing the drug; chemical barriers that prevent extraction of psychoactive ingredients; agon | D27.505.696.663.850.007 D27.505.696.034 D27.505.954.427.005 |
|||
Acaricide | zoocide pesticide |
agent that kills members of the arachnid subclass Acari | D27.720.031.700.071 D27.888.723.071 |
Acaricides | ||
ACE inhibitor | drug class | Protease inhibitor | pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure | D27.505.519.389.745.085 | ACE inhibitors | |
Acetaldehyde Dehydrogenase Inhibitors | enzyme inhibitor | Compounds that bind to and inhibit the enzymatic activity of acetaldehyde dehydrogenases | D27.505.519.389.089 | |||
Acetylcholine Release Inhibitors | Cholinergic Agents Membrane Transport Modulators |
Compounds that block release of the neurotransmitter acetylcholine | D27.505.696.577.120.069 D27.505.519.625.120.069 D27.505.519.562.061 |
|||
Acetylcholinesterase inhibitor | enzyme inhibitor Cholinergic Agents |
Drugs that inhibit cholinesterases. The neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses | D27.505.519.389.275 D27.505.519.625.120.300 D27.505.696.577.120.300 |
|||
Achilles tendon | tendon | type of tendon in the lower leg | A02.880.176 | Achilles tendon | ||
Acid Sensing Ion Channel Blockers | Sodium channel blocker | A subclass of sodium channel blockers that are specific for acid-sensing sodium channels | D27.505.519.562.750.100 | |||
Acne conglobata | acne | C17.800.030.150.500 C17.800.794.111.500 |
||||
Acromioclavicular joint | A02.835.583.032 | Acromioclavicular joints | ||||
Activated protein C resistance | thrombophilia | C15.378.100.100.037 C15.378.100.141.036 C15.378.925.050 C16.320.099.037 |
||||
acute bronchitis | bronchitis | short-term inflammation of the bronchi (large and medium-sized airways) of the lungs | C08.127.446 C08.381.495.146 C08.730.099 |
Acute bronchitis | ||
acute disease | disease | disease with a rapid onset and/or a short course | C23.550.291.125 | |||
acute radiation syndrome | intoxication | health effect of radiation | C26.733.188 | Acute radiation syndrome | ||
Adams–Stokes syndrome | brain ischemia | periodic fainting spell in which there is a periodic onset and offset of blockage of heart due to disorder of heart rhythm | C14.280.067.558.137 C23.550.073.425.025 |
|||
adenoidectomy | lymphatic ectomy | surgical removal of the adenoids | E04.580.068 | |||
Adenosine A1 Receptor Agonists | Purinergic P1 Receptor Agonists | Compounds that bind to and stimulate adenosine a1 receptors | D27.505.696.577.725.200.100.100 D27.505.519.625.725.200.100.100 |
|||
Adenosine A1 Receptor Antagonists | Purinergic P1 Receptor Antagonists | Compounds that bind to and block the stimulation of adenosine a1 receptors | D27.505.519.625.725.400.100.100 D27.505.696.577.725.400.100.100 |
|||
Adenosine A2 Receptor Agonists | Purinergic P1 Receptor Agonists | Compounds that selectively bind to and activate adenosine a2 receptors | D27.505.696.577.725.200.100.200 D27.505.519.625.725.200.100.200 |
|||
Adenosine A2 Receptor Antagonists | Purinergic P1 Receptor Antagonists | Compounds that selectively bind to and block the activation of adenosine a2 receptors | D27.505.519.625.725.400.100.200 D27.505.696.577.725.400.100.200 |
|||
Adenosine A3 Receptor Agonists | Purinergic P1 Receptor Agonists | Drugs that selectively bind to and activate adenosine a3 receptors | D27.505.519.625.725.200.100.300 D27.505.696.577.725.200.100.300 |
|||
Adenosine A3 Receptor Antagonists | Purinergic P1 Receptor Antagonists | Compounds that selectively bind to and block the activation of adenosine a3 receptors | D27.505.696.577.725.400.100.300 D27.505.519.625.725.400.100.300 |
|||
Adenosine Deaminase Inhibitors | enzyme inhibitor | Drugs that inhibit adenosine deaminase activity | D27.505.519.389.092 | |||
Adenylyl Cyclase Inhibitors | enzyme inhibitor | Compounds that bind to and inhibit the action of Adenylyl Cyclase | D27.505.519.389.108 | |||
adhesive | Specialty Uses of Chemicals process material |
material which is used for bonding of various materials | D27.720.013 | Adhesives | ||
Adjuvants, Anesthesia | Central Nervous System Agents | Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage | D27.505.954.427.010 | |||
Adjuvants, Pharmaceutic | Adjuvant Pharmaceutic Aids |
Agents that aid or increase the action of the principle drug (drug synergism) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (pharmacokinetics) in such a way as to enhance its effects | D27.720.744.064 | |||
Adrenergic Agents | neurotransmitter | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitter | D27.505.519.625.050 D27.505.696.577.050 |
|||
Adrenergic alpha-1 Receptor Agonists | Alpha-adrenergic agonist | Compounds that bind to and activate adrenergic alpha-1 receptors | D27.505.696.577.050.100.100.100 D27.505.519.625.050.100.100.100 |
|||
Adrenergic alpha-1 Receptor Antagonists | Alpha blocker | Drugs that bind to and block the activation of adrenergic alpha-1 receptors | D27.505.696.577.050.200.100.100 D27.505.519.625.050.200.100.100 |
|||
Adrenergic alpha-2 Receptor Agonists | Alpha-adrenergic agonist | Compounds that bind to and activate adrenergic alpha-2 receptors | D27.505.696.577.050.100.100.200 D27.505.519.625.050.100.100.200 |
|||
Adrenergic alpha-2 Receptor Antagonists | Alpha blocker | Drugs that bind to and block the activation of adrenergic alpha-2 receptors | D27.505.696.577.050.200.100.200 D27.505.519.625.050.200.100.200 |
|||
Adrenergic antagonist | Adrenergic Agents | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine | D27.505.519.625.050.200 D27.505.696.577.050.200 |
|||
Adrenergic beta-1 Receptor Agonists | Adrenergic beta-Agonists | Compounds that bind to and activate adrenergic beta-1 receptors | D27.505.696.577.050.100.200.100 D27.505.519.625.050.100.200.100 |
|||
Adrenergic beta-1 Receptor Antagonists | Adrenergic beta-antagonist | Drugs that bind to and block the activation of adrenergic beta-1 receptors | D27.505.696.577.050.200.200.100 D27.505.519.625.050.200.200.100 |
|||
Adrenergic beta-2 Receptor Antagonists | Adrenergic beta-antagonist | Drugs that bind to and block the activation of adrenergic beta-2 receptors | D27.505.519.625.050.200.200.200 D27.505.696.577.050.200.200.200 |
|||
Adrenergic beta-3 Receptor Agonists | Adrenergic beta-Agonists | Compounds that bind to and activate adrenergic beta-3 receptors | D27.505.696.577.050.100.200.300 D27.505.519.625.050.100.200.300 |
|||
Adrenergic beta-3 Receptor Antagonists | Adrenergic beta-antagonist | Drugs that bind to and block the activation of adrenergic beta-3 receptors | D27.505.696.577.050.200.200.300 D27.505.519.625.050.200.200.300 |
|||
Adrenergic beta-Agonists | adrenergic agonist | Drugs that selectively bind to and activate beta-adrenergic receptors. | D27.505.519.625.050.100.200 D27.505.696.577.050.100.200 |
|||
Adrenergic beta-antagonist | Adrenergic antagonist | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine h | D27.505.696.577.050.200.200 D27.505.519.625.050.200.200 |
|||
Affinity Labels | Indicators and Reagents | Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of | D27.720.470.410.080 | |||
age group | group of humans social group |
set of persons classified by age from birth (infant, newborn) to octogenarians and older (aged, 80 and over) | M01.060 | |||
ageusia | taste disorder sensory loss |
total loss of the sense of taste | C10.597.751.861.184 C23.888.592.763.861.184 |
|||
agrochemical | chemical substance Specialty Uses of Chemicals |
Chemicals used in agriculture. These include pesticides, fumigants, fertilizers, plant hormones, steroids, antibiotics, mycotoxins, etc | D27.720.031 | Agricultural chemistry | ||
Air Pollutants | Environmental Pollutants | Any substance in the air which could, if present in high enough concentration, harm humans, animals, vegetation or materials. Substances include gases; particulate matter; and volatile organic chemicals | D27.888.284.101 | |||
Air Pollutants, Occupational | Air Pollutants | Toxic air-borne matter related to work performed they are usually produced by the specific nature of the occupation | D27.888.284.101.268 | |||
Air Pollutants, Radioactive | Air Pollutants | Pollutants present in air which exhibit radioactivity | D27.888.284.101.393 | |||
albinism | disease | congenital disorder causing skin to lack pigmentation | C11.270.040 C16.320.290.040 C16.320.565.100.102 C16.320.850.080 C17.800.621.440.102 C17.800.827.080 C18.452.648.100.102 |
Albinism | ||
albuminuria | urinary system disease proteinuria |
urologic disease typically indicating kidney malfunction | C12.777.934.734.269 C13.351.968.934.734.269 C23.888.942.750.269 |
|||
Alcohol Deterrents | Central Nervous System Agents | Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism | D27.505.954.427.020 | |||
alcoholic liver disease | liver disease long-term effects of alcohol |
C06.552.645 C25.775.100.087.645 |
||||
Alkylating antineoplastic agent | alkylating agent antineoplastic |
pharmaceutical drugs | D27.505.519.124.035 D27.888.569.035.035 D27.505.954.248.150 |
Alkylating antineoplastic agents | ||
allantois | A10.615.284.147 | |||||
Alpha blocker | Adrenergic antagonist | pharmaceutical drugs, neutral antagonist of alpha-adrenergic receptors | D27.505.696.577.050.200.100 D27.505.519.625.050.200.100 |
Alpha blockers | ||
Alpha-adrenergic agonist | adrenergic agonist | Drugs that selectively bind to and activate alpha adrenergic receptors. | D27.505.696.577.050.100.100 D27.505.519.625.050.100.100 |
|||
Amaurosis fugax | Amaurosis | C10.597.751.941.162.125 C11.966.075.125 C23.888.592.763.941.162.125 |
||||
Amebicide | antiprotozoal | Agents which are destructive to amebae, especially the parasitic species causing amebiasis in man and animal | D27.505.954.122.250.100.055 | |||
Amnion | A10.615.284.277 | |||||
amniotic band syndrome | congenital abnormality | Human disease | C16.614.042 | |||
Ampholyte Mixtures | buffer solution | Such mixtures of amphoteric electrolytes or buffers that provide a continuous range of ph in an electric field; used for separating proteins by their isoelectric points, i.e., by isoelectric focusing | D27.720.470.280.060 | |||
Amylin Receptor Agonists | anti-diabetic medication mechanism of action |
Compounds that stimulate the activity of amymin receptors. Included under this heading is the endogenous form of islet amyloid polypeptide and synthetic compounds that mimic its effect | D27.505.696.422.374 D27.505.519.143 |
|||
Anabolic Agents | hormone | These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power | D27.505.696.399.472.080 | |||
Analgesics, Short-Acting | analgesic | Pain-alleviating drugs characterized by rapid action time. | D27.505.954.427.040.381 D27.505.696.663.850.014.580 |
|||
anaphylaxis | hypersensitivity | severe allergic reaction | C20.543.480.099 | Anaphylaxis | ||
Anatomy of the cerebellum | A08.186.211.132.810.428.200 | Cerebellum | ||||
androgen | sex steroid hormone |
type of sex steroid | D27.505.696.399.472.161 | Anabolic-androgenic steroids | ||
Androgen Antagonists | Hormone Antagonists | Compounds which inhibit or antagonize the biosynthesis or actions of androgens | D27.505.696.399.450.065 | |||
Androgen Receptor Antagonists | Androgen Antagonists | Compounds that bind to and inhibit the activation of androgen receptors | D27.505.696.399.450.065.249 | |||
anesthesia awareness | adverse reactions to anesthesia | C23.550.505.400 | ||||
Anesthesia dolorosa | trigeminal neuralgia | C07.465.299.625.500.349 C10.292.262.875 C10.292.319.625.700.349 C10.900.300.218.775 C26.915.300.400.825 |
||||
Anesthetics, Combined | anesthetic | The use of two or more chemicals simultaneously or sequentially to induce anesthesia. The drugs need not be in the same dosage form | D27.505.696.277.100.017 D27.505.954.427.210.100.017 |
|||
Anesthetics, Dissociative | Anesthetics, Intravenous | Intravenous anesthetics that induce a state of sedation, immobility, amnesia, and marked analgesia. Subjects may experience a strong feeling of dissociation from the environment. The condition produced is similar to neuroleptanalgesia, but is brough | D27.505.696.277.100.035.075.035 D27.505.954.427.210.100.035.075.035 |
|||
Anesthetics, General | anesthetic | Agents that induce various degrees of analgesia; depression of consciousness, circulation, and respiration; relaxation of skeletal muscle; reduction of reflex activity; and amnesia. There are two types of general anesthetics, inhalation and intraven | D27.505.696.277.100.035 D27.505.954.427.210.100.035 |
|||
Anesthetics, Inhalation | Anesthetics, General | Gases or volatile liquids that vary in the rate at which they induce anesthesia; potency; the degree of circulation, respiratory, or neuromuscular depression they produce; and analgesic effects. Inhalation anesthetics have advantages over intravenou | D27.505.954.427.210.100.035.060 D27.505.696.277.100.035.060 |
|||
Anesthetics, Intravenous | Anesthetics, General | Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulatio | D27.505.696.277.100.035.075 D27.505.954.427.210.100.035.075 |
|||
Aneugens | Mutagen | Agents which affect cell division and the mitotic spindle apparatus resulting in the loss or gain of whole chromosomes, thereby inducing an aneuploidy | D27.888.569.468.060 | |||
Angiogenesis Inducing Agents | Angiogenesis Modulating Agents | Agents that induce or stimulate physiologic angiogenesis or pathologic angiogenesis | D27.505.696.377.077.077 | |||
Angiogenesis Modulating Agents | Growth Substances | Agents that modulate the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents | D27.505.696.377.077 | |||
Angiotensin II Type 1 Receptor Blockers | Angiotensin Receptor Antagonists | Agents that antagonize angiotensin ii type 1 receptor. Included are angiotensin ii analogs such as saralasin and biphenylimidazoles such as losartan. Some are used as antihypertensive agents | D27.505.519.162.500 | |||
Angiotensin II Type 2 Receptor Blockers | Angiotensin Receptor Antagonists | Agents that antagonize the angiotensin ii type 2 receptor | D27.505.519.162.750 | |||
Angiotensin Receptor Antagonists | mechanism of action | Agents that antagonize angiotensin receptors. Many drugs in this class specifically target the angiotensin type 1 receptor | D27.505.519.162 | |||
Anion Exchange Resins | Ion Exchange Resins | High-molecular-weight insoluble polymers that contain functional cationic groups capable of undergoing exchange reactions with anions | D27.720.470.420.050 | |||
Anisocoria | pupil disease | C10.597.690.150 C11.710.090 C23.888.592.708.150 |
Anisocoria | |||
anophthalmia | agenesis microphthalmia |
C11.250.080 C16.131.384.159 |
Anophthalmia | |||
anosmia | olfaction disorder sensory loss |
the inability to smell | C10.597.751.600 C23.888.592.763.550 |
Anosmia | ||
Antacid | drugs for acid-related disorders Gastrointestinal Agents mechanism of action |
a substance which neutralizes stomach acidity, used to relieve heartburn, indigestion or an upset stomach | D27.505.954.483.080 D27.505.519.170 |
Antacids | ||
Anterior root of spinal nerve | nerve | A08.800.800.720.725 | ||||
Anti-Allergic Agents | Therapeutic Uses | Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (from ama drug evaluations annual, 1994, p475) | D27.505.954.016 | |||
Anti-Asthmatic Agents | Respiratory System Agents | Drugs that are used to treat asthma | D27.505.954.796.050 | |||
Anti-Dyskinesia Agents | Central Nervous System Agents | Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the | D27.505.954.427.090 | |||
Anti-HIV Agents | Anti-Retroviral Agents | Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. | D27.505.954.122.388.077.088 | |||
Anti-Infective Agents | Therapeutic Uses drug |
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. | D27.505.954.122 | |||
Anti-Infective Agents, Local | Anti-Infective Agents | Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. | D27.505.954.122.187 | |||
Anti-Infective Agents, Urinary | Anti-Infective Agents Renal Agents |
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. | D27.505.954.613.056 D27.505.954.122.237 |
|||
anti-inflammatory agent | drug Therapeutic Uses |
substance that reduces or suppresses inflammation | D27.505.954.158 | Anti-inflammatory agents | ||
Anti-Obesity Agents | Central Nervous System Agents | Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (niddm) to treat obesit | D27.505.954.427.140 | |||
Anti-Retroviral Agents | antiviral agent | Agents used to treat retroviridae infections | D27.505.954.122.388.077 | |||
antibiotic | drug Anti-Infective Agents antimicrobial drug |
drug used in the treatment and prevention of bacterial infections | D27.505.954.122.085 | Antibiotics | ||
Antibiotics, Antineoplastic | antineoplastic | Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. | D27.505.954.248.106 | |||
Antibiotics, Antitubercular | antituberculous drug | Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and | D27.505.954.122.085.255.135 | |||
Anticarcinogenic Agents | antineoplastic Protective Agents |
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved | D27.505.696.706.018 D27.505.954.248.125 D27.720.799.018 |
|||
Anticestodal Agents | Antiplatyhelmintic Agents | Agents used to treat tapeworm infestations in man or animals | D27.505.954.122.250.075.100.040 | |||
Anticholesteremic Agents | hypolipidemic | Substances used to lower plasma cholesterol levels | D27.505.519.186.071.202 D27.505.954.557.500.202 |
|||
anticoagulant | drug Hematologic Agents |
chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. | D27.505.954.502.119 | Anticoagulants | ||
antidepressant | drug Psychotropic Drugs |
drugs used for the treatment of major depressive disorders and other conditions | D27.505.954.427.700.122 | Antidepressants | ||
Antidepressive Agents, Second-Generation | antidepressant | A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake | D27.505.954.427.700.122.050 | |||
Antidiarrheals | Gastrointestinal Agents | Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition | D27.505.954.483.161 | |||
Antidiuretic Agents | Natriuretic Agents | Agents that reduce the excretion of urine, most notably the octapeptide vasopressins | D27.505.696.560.249 | |||
Antidiuretic Hormone Receptor Antagonists | Natriuretic Agents mechanism of action |
Endogenous compounds and drugs that inhibit or block the activity of antiduiretic hormone receptors | D27.505.696.560.311 D27.505.519.174 |
|||
antidote | drug Protective Agents |
substance which counteracts poisoning | D27.720.799.037 D27.505.696.706.037 |
Antidotes | ||
Antifibrinolytic | Hemostatics Fibrin Modulating Agents |
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders | D27.505.954.502.270.463.091 D27.505.519.421.500 |
Antifibrinolytics | ||
antifoaming agent | food additive surfactant mechanism of action |
chemical additive that reduces and hinders the formation of foam in liquids | D27.720.877.048 D27.505.519.178 |
|||
Antihyperkalemic Agents | Natriuretic Agents | Compounds used to lower excessive potassium levels in the body | D27.505.696.560.374 | |||
antimalarial | antiprotozoal | Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (from ama, drug evaluations annual, 1992, p1585) | D27.505.954.122.250.100.085 | Antimalarial agents | ||
Antimanic Agents | tranquilizer | Agents that are used to treat bipolar disorders or mania associated with other affective disorders | D27.505.696.277.950.025 D27.505.954.427.700.872.025 D27.505.954.427.210.950.025 |
|||
Antimetabolites | drug Noxae mechanism of action |
Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (from ama drug evaluations annual, 1994, p2033) | D27.888.569.042 D27.505.519.186 |
Antimetabolites | ||
Antimetabolites, Antineoplastic | Antimetabolites antineoplastic |
Antimetabolites that are useful in cancer chemotherapy | D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030 |
|||
Antimitotic Agents | antineoplastic Mitosis Modulators |
Agents that arrest cells in mitosis, most notably tubulin modulators | D27.505.954.248.147 D27.505.519.593.249 |
|||
Antimutagenic Agents | Protective Agents | Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved | D27.505.696.706.080 D27.720.799.042 |
|||
antinematodal agent | anthelmintic | Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice | D27.505.954.122.250.075.080 | |||
Antineoplastic Agents, Hormonal | antineoplastic | Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacolog | D27.505.954.248.169 | |||
Antineoplastic Agents, Immunological | antineoplastic | Antineoplastic agents containing immunological agents (e.g. Mabs). These pharmacologic preparations inhibit or prevent the proliferation of neoplasms | D27.505.954.248.384 | |||
Antineoplastic Agents, Phytogenic | antineoplastic | Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. | D27.505.954.248.179 | |||
antioxidant | food additive food ingredient Protective Agents mechanism of action |
molecule that inhibits the oxidation of other molecules | D27.505.696.706.125 D27.505.519.217 D27.720.799.047 |
Antioxidants | ||
Antiparkinson Agents | Anti-Dyskinesia Agents | Agents used in the treatment of parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists | D27.505.954.427.090.050 | |||
Antiperspirants | cosmetics | Agents that are put on the skin to reduce sweating or prevent excess sweating (hyperhidrosis) | D27.720.269.189 | |||
Antiplatyhelmintic Agents | anthelmintic | Agents used to treat cestode, trematode, or other flatworm infestations in man or animals | D27.505.954.122.250.075.100 | |||
Antisense Elements (Genetics) | Nucleic Acid Probes | Nucleic acids which hybridize to complementary sequences in other target nucleic acids causing the function of the latter to be affected | D27.720.470.530.600.150 | |||
Antisense oligonucleotide | Antisense Elements (Genetics) | Short fragments of dna or rna that are used to alter the function of target rnas or dnas to which they hybridize | D27.720.470.530.600.150.640 | |||
Antisense RNA | non-coding RNA Antisense Elements (Genetics) |
Rna molecules which hybridize to complementary sequences in either rna or dna altering the function of the latter. Endogenous antisense rnas function as regulators of gene expression by a variety of mechanisms. Synthetic antisense rnas are used to e | D27.720.470.530.600.150.760 | |||
Antisickling Agents | Hematologic Agents | Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions | D27.505.954.502.135 | |||
Antispermatogenic Agents | Contraceptive Agents, Male Noxae Physiological Effects of Drugs |
Agents, either mechanical or chemical, which destroy spermatozoa in the male genitalia and block spermatogenesis | D27.505.696.138 D27.505.696.875.360.443.068 D27.888.569.071 D27.505.954.705.360.443.068 |
|||
antistatic agent | Specialty Uses of Chemicals | compound used for treatment of materials or their surfaces in order to reduce or eliminate buildup of static electricity | D27.720.066 | |||
Antithrombins | anticoagulant Serine Proteinase Inhibitors |
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects | D27.505.954.502.119.500 D27.505.519.389.745.800.449 |
|||
Antithyroid Agents | Hormone Antagonists | Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones | D27.505.696.399.450.100 | |||
Antitreponemal Agents | antibiotic | Agents used to treat infections with bacteria of the genus treponema. This includes syphilis & yaws | D27.505.954.122.085.222 | |||
Antitrichomonal Agents | antiprotozoal | Agents used to treat trichomonas infections | D27.505.954.122.250.100.115 | |||
antituberculous drug | antibacterial antibiotic |
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs u | D27.505.954.122.085.255 | |||
anxiety | emotion | emotion characterized by an unpleasant state of inner turmoil | F01.470.132 | Anxiety | ||
Aortic body | one of several small clusters of peripheral chemoreceptors known as glomus cells, baroreceptors, and supporting cells located along the aortic arch | A08.675.650.915.500.600.050 | ||||
aphonia | voice disorder | medical condition leading to loss of voice | C08.360.940.160 C09.400.940.160 C10.597.975.100 C23.888.592.979.100 |
|||
aphrodisiac | stimulant | Chemical agents or odorants that stimulate sexual desires. (mcgraw-hill dictionary of scientific and technical terms, 4th ed) | D27.505.954.427.220.045 D27.505.696.282.045 |
Aphrodisiacs | ||
apocrine sweat gland | mostly limited to the axilla (armpits) and perianal areas in humans; they are not significant for cooling in humans, but are the sole effective sweat glands in hoofed animals, such as the camels, donkeys, horses, and cattle | A10.336.899.206 | ||||
Appetite Depressants | Anti-Obesity Agents | Agents that are used to suppress appetite | D27.505.954.427.140.155 | |||
Appetite Stimulants | stimulant | Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and aids | D27.505.954.427.220.050 D27.505.696.282.050 |
|||
arachnoid mater | leptomeninx | weblike middle layer of the three meninges | A08.186.566.166 | Arachnoid mater | ||
Area postrema | medullary structure in the brain that controls vomiting | A08.186.211.132.810.406.286 | ||||
Aromatase inhibitor | Estrogen Antagonists Steroid Synthesis Inhibitors |
medicine | D27.505.519.389.870.300 D27.505.696.399.450.855.300 D27.505.696.399.450.327.149 |
Aromatase inhibitors | ||
Aromatic Amino Acid Decarboxylase Inhibitors | Antiparkinson Agents enzyme inhibitor |
Compounds and drugs that block or inhibit the enzymatic action of aromatic amino acid decarboxylases. Pharmaceutical agents in this category are used in conjunction with levodopa in order to slow its metabolism | D27.505.519.389.124 D27.505.954.427.090.050.249 |
|||
arsenic poisoning | intoxication | C10.720.475.150 C25.723.097 |
||||
arteriole | blood vessel | small-diameter blood vessel in the microcirculation that extends and branches out from an artery and leads to capillaries. | A07.231.114.060 | |||
arteritis | angiitis | inflammation of the walls of arteries, usually as a result of infection or autoimmune response. | C14.907.940.090 | |||
artery | blood vessel | blood vessels that carry blood away from the heart | A07.231.114 | Arteries | ||
arthrosis of hip | arthropathy | osteoarthritis | C05.550.114.606.400 C05.799.613.400 |
Coxarthrosis | ||
articular cartilage | hyaline cartilage | A02.165.407.150 | ||||
Artificial tears | eye drop lubricant |
Ophthalmic solutions that include lubricants and wetting agents such as polyethylene glycol; hypromellose; glycerol; propylene glycol. They are used to treat conditions caused by deficient tear production such as dry eye syndrome | D27.505.954.578.645.500 D27.720.556.249 D27.720.752.608.500 |
|||
arytenoid cartilage | A02.165.507.083 | Arytenoid cartilages | ||||
astringent | dermatologic drug Physiological Effects of Drugs |
chemical compound that tends to shrink or constrict body tissues | D27.505.696.207 D27.505.954.444.100 |
|||
Athetosis | movement disorder | C10.597.350.110 C23.888.592.350.110 |
||||
attention | mental process | behavioral and cognitive process of selectively concentrating on a discrete aspect of information, whether deemed subjective or objective, while ignoring other perceivable information | F02.830.104.214 | Attention | ||
attentional bias | bias | F02.830.104.214.500 | ||||
Attentional blink | F02.463.593.932.145 | |||||
Auditory processing disorder | hearing disorder hearing disorder |
C09.218.807.186.094 C10.228.140.068.094 C10.597.606.762.200 C23.888.592.604.764.200 |
||||
Autonomic Agents | Peripheral Nervous System Agents | Agents affecting the function of, or mimicking the actions of, the autonomic nervous system and thereby having an effect on such processes as respiration, circulation, digestion, body temperature regulation, certain endocrine gland secretions, etc | D27.505.696.663.050 | |||
Aversive Agents | Abuse-Deterrent Formulations Pharmaceutic Aids mechanism of action |
Chemicals added to pharmacologic preparations, poisonous household goods, and other chemicals to discourage their abuse or consumption | D27.720.744.179 D27.505.519.241 D27.505.696.663.850.007.500 D27.505.954.427.005.500 D27.505.696.034.500 |
|||
bacteremia | hematopoietic system diseases bacterial infectious disease |
presence of bacteria in the blood | C01.252.100 C01.539.757.100 C23.550.470.790.500.100 |
Bacteremia | ||
Bankart lesion | shoulder problem | C26.404.625.500 C26.803.250.500 |
Bankart lesion | |||
Bartholin's gland | exocrine gland | two glands located slightly posterior and to the left and right of the opening of the vagina | A05.360.319.887.220 | |||
basal ganglia | A08.186.211.730.885.105 | Basal ganglia | ||||
basilar membrane | A09.246.631.246.125 | |||||
Behavioral game theory | E05.385 | |||||
Bender-Gestalt Test | psychological test neuropsychological test |
psychological test that assesses visual-motor functioning, developmental disorders, and neurological impairments | F04.711.513.180 F04.711.647.138 |
|||
Beta-lactamase inhibitor | chemical compound antibiotic enzyme inhibitor |
Endogenous substances and drugs that inhibit or block the activity of beta-lactamases | D27.505.954.122.085.516 D27.505.519.389.400 |
Beta-lactamase inhibitors | ||
Beta2-adrenergic agonist | Adrenergic beta-Agonists | Compounds bind to and activate adrenergic beta-2 receptors | D27.505.696.577.050.100.200.200 D27.505.519.625.050.100.200.200 |
|||
binge drinking | alcohol abuse | modern epithet for drinking alcoholic beverages with an intention of becoming intoxicated by heavy consumption of alcohol over a short period of time | C25.775.100.437 | |||
biocompatible material | Biomedical and Dental Materials | substance that has been engineered to interact with biological systems for a medical purpose | D27.720.102.130 | |||
Biomedical and Dental Materials | Specialty Uses of Chemicals | Substances used in biomedicine or dentistry predominantly for their physical, as opposed to chemical, properties. | D27.720.102 | |||
Bitemporal hemianopsia | hemianopia heteronymous hemianopsia |
C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
||||
blastocyst | embryo | A16.254.085 | Blastocyst | |||
Bleaching Agents | oxidizing agent | Chemicals that are used to oxidize pigments and thus effect whitening | D27.720.642.315 | |||
blister | Q371226 | small pocket of fluid within the upper layers of the skin | C17.800.865.187 C23.300.122 |
Blisters | ||
Blood–air barrier | A04.411.715.025 | |||||
Blowout fracture | Zygoma fracture eye adnexa disease |
C10.900.300.284.500.550 C26.404.750.684 C26.915.300.425.500.550 |
||||
body temperature | temperature vital signs |
temperature, vital sign, measurement | E01.370.600.120 | Body temperature | ||
Boerhaave syndrome | esophageal rupture | syndrome characterized by spontaneous longitudinal transmural rupture of the esophagus, usually in its distal part | C06.405.117.468 C26.348 |
Boerhaave syndrome | ||
Bone cement | Biomedical and Dental Materials | Adhesives used to fix prosthetic devices to bones and to cement bone to bone in difficult fractures. Synthetic resins are commonly used as cements. A mixture of monocalcium phosphate, monohydrate, alpha-tricalcium phosphate, and calcium carbonate wi | D27.720.102.158 | |||
Bone Density Conservation Agents | Physiological Effects of Drugs | Agents that inhibit bone resorption and/or favor bone mineralization and bone regeneration. They are used to heal bone fractures and to treat metabolic bone diseases such as osteoporosis | D27.505.696.242 | |||
bone tumor | tumor | C04.588.149 C05.116.231 |
Cancers of bone and articular cartilage | |||
brachial plexus | nerve plexus | A08.800.800.720.050 | Brachial plexus | |||
brachytherapy | radiation therapy | E02.815.150 | Brachytherapy | |||
Bradykinin B1 Receptor Antagonists | Bradykinin Receptor Antagonists | Compounds and drugs that inhibit ligand binding or cellular signaling by bradykinin b1 receptors | D27.505.519.265.249 | |||
Bradykinin B2 Receptor Antagonists | Complement Inactivating Agents Bradykinin Receptor Antagonists |
Compounds and drugs that inhibit ligand binding or cellular signaling by bradykinin b2 receptors | D27.505.519.265.500 D27.505.696.477.656.500.500 |
|||
Bradykinin Receptor Antagonists | mechanism of action | Compounds and drugs that inhibit ligand binding or cellular signaling by bradykinin receptors | D27.505.519.265 | |||
brain | animal organ | organ that serves as the center of the Nervous System in all vertebrate and most invertebrate animals | A08.186.211 | Brain | ||
brain stem | posterior part of the brain, adjoining and structurally continuous with the spinal cord | A08.186.211.132 | Brain stem | |||
brain tumor | tumor intracranial neoplasm |
type of tumor | C04.588.614.250.195 C10.228.140.211 C10.551.240.250 |
Brain neoplasms | ||
Branchial cleft cyst | branchial cleft anomalies Cutaneous columnar cyst |
C04.182.117 | Branchial cleft cyst | |||
Breech birth | Presentation | obstructed labor | C13.703.420.183 | |||
Bronchoconstrictor Agents | Autonomic Agents Respiratory System Agents |
Agents causing the narrowing of the lumen of a bronchus or bronchiole | D27.505.696.663.050.100 D27.505.954.796.170 |
|||
buffer solution | aqueous solution acidity regulator Laboratory Chemicals |
aqueous solution consisting of a mixture of a weak acid and its conjugate base, which resists pH change when a strong acid or base is added | D27.720.470.280 | Buffers (chemical) | ||
bulbourethral gland | exocrine gland | small exocrine gland in the reproductive system of many male mammals | A05.360.444.123 | Bulbourethral gland | ||
bunion | foot deformity | deformity characterized by lateral deviation of the great toe | C05.330.488.050 C05.330.610 |
Bunion | ||
buttocks | anatomical structure | two rounded portions of the anatomy, traditionally located on the posterior of various organisms | A01.378.610.100 | Buttocks | ||
Caecitis | cecal disease intraabdominal infection |
caecitis | C01.539.463.850 C06.405.205.932 C06.405.469.110.708 |
|||
calcaneus | bone short bone |
bone of the foot | A02.835.232.043.300.710.300 | Calcaneus | ||
Calcimimetic Agents | Hormone Antagonists | Small organic molecules that act as allosteric activators of the calcium sensing receptor (casr) in the parathyroid glands and other tissues. They lower the threshold for casr activation by extracellular calcium ions and diminish parathyroid hormone | D27.505.696.399.450.230 | |||
Calcineurin Inhibitors | enzyme inhibitor | Compounds that inhibit or block the phosphatase activity of calcineurin | D27.505.519.389.174 | |||
Calcium Channel Agonists | Vasoconstrictor Agents Membrane Transport Modulators |
Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-se | D27.505.519.562.124 D27.505.954.411.793.205 |
|||
calcium channel blocker | antihypertensive drug Cardiovascular Agents Membrane Transport Modulators |
several medications that disrupt the movement of calcium (Ca2+) through calcium channels | D27.505.954.411.192 D27.505.519.562.249 |
Calcium channel blockers | ||
Calcium Chelating Agents | Chelating Agents | Substances that bind to and sequester calcium ions | D27.720.832.500.204 D27.505.519.914.500.204 |
|||
Calcium Ionophores | Ionophore | Chemical agents that increase the permeability of cell membranes to calcium ions | D27.720.395.100 D27.505.519.562.374.100 |
|||
calculus | dental plaque | form of hardened dental plaque | C07.793.208.250 C23.300.175.350 |
Dental calculus | ||
call centre | centralised office used for the purpose of receiving or transmitting a large volume of requests by telephone | N02.421.297.036 | Call centres | |||
callosity | keratosis | C17.800.428.200 | ||||
canaliculitis | lacrimal apparatus disease | C11.496.221.500 | ||||
canine distemper | Morbillivirus infectious disease | species of virus | C02.782.580.600.500.285 C22.268.265 |
Canine distemper | ||
canine hip dysplasia | dog disease | hip dysplasia animal genetic disease |
A hereditary disease of the hip joints in dogs. Signs of the disease may be evident any time after 4 weeks of age. | C22.268.485 | ||
canine tooth | tooth | tooth | A14.549.167.860.200 | Canine teeth | ||
Cannabinoid Receptor Agonists | Cannabinoid Receptor Modulators | Compounds that interact with and stimulate the activity of cannabinoid receptors | D27.505.519.625.085.500 D27.505.696.399.472.188.500 |
|||
Cannabinoid receptor antagonist | Cannabinoid Receptor Modulators | Compounds that inhibit or block the activity of cannabinoid receptors | D27.505.519.625.085.750 D27.505.696.399.472.188.750 |
|||
Cannabinoid Receptor Modulators | hormone neurotransmitter |
Compounds that interact with and modulate the activity of cannabinoid receptors | D27.505.696.399.472.188 D27.505.519.625.085 |
|||
capitate bone | bone | bone of the wrist | A02.835.232.087.319.150.150 | Capitate bone | ||
Carbamoyl Phosphate Synthetase I Activators | Enzyme activator | Substances and drugs that stimulate the synthesis or increase the activity of carbamoyl phosphate synthetase i. Drugs in this class of compounds have been used to treat the genetic disorder, carbamoyl-phosphate synthase i deficiency disease | D27.505.519.374.099 | |||
carbon monoxide poisoning | intoxication chemical hazard |
death due to exposure to carbon monoxide | C25.723.455.245 | Carbon monoxide | ||
Carbonic anhydrase inhibitor | enzyme inhibitor | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrases | D27.505.519.389.200 | Carbonic anhydrase inhibitors | ||
carcinogen | causes of cancer substance Noxae |
substance, radionuclide, or radiation directly involved in causing cancer | D27.888.569.100 | Carcinogens | ||
Carcinogens, Environmental | carcinogen | Carcinogenic substances that are found in the environment | D27.888.569.100.125 | |||
Cardiac asthma | heart disease | medical diagnosis of wheezing, coughing or shortness of breath due to congestive heart failure | C08.618.326.396 C14.280.434.313 C23.888.852.371.396 |
|||
Cardioplegic Solutions | Cardiovascular Agents Pharmaceutical Solutions |
Solutions which, upon administration, will temporarily arrest cardiac activity. They are used in the performance of heart surgery | D27.505.954.411.207 D27.720.752.322 D27.505.954.578.322 |
|||
Cardiotonic Agents | Cardiovascular Agents Protective Agents |
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in | D27.505.954.411.222 D27.720.799.080 |
|||
Cardiotoxins | Noxae | Agents that have a damaging effect on the heart. Such damage can occur from alkylating agents; free radicals; or metabolites from oxidative stress and in some cases is countered by cardiotonic agents. Induction of long qt syndrome or torsades de poi | D27.888.569.142 | |||
Cardiovascular Agents | Therapeutic Uses | Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume | D27.505.954.411 | |||
Cariogenic Agents | Biomedical and Dental Materials | Substances that promote dental caries | D27.720.102.187 | |||
Cariostatic Agents | Biomedical and Dental Materials Protective Agents |
Substances that inhibit or arrest dental caries formation. (boucher's clinical dental terminology, 4th ed) | D27.505.696.706.222 D27.720.799.113 D27.720.102.223 |
|||
Caspase Inhibitors | Cysteine Proteinase Inhibitors | Endogenous and exogenous compounds and that either inhibit caspases or prevent their activation | D27.505.519.389.745.325.500 | |||
Catechol O-Methyltransferase Inhibitors | Antiparkinson Agents enzyme inhibitor |
Compounds and drugs that inhibit or block the activity of catechol o-methyltransferase enzymes. Drugs in this class are used in management of central nervous system disorders such as parkinson disease | D27.505.519.389.237 D27.505.954.427.090.050.500 |
|||
Cathartics | Gastrointestinal Agents | Agents that are used to stimulate evacuation of the bowels | D27.505.954.483.396 | |||
Cation Exchange Resins | Ion Exchange Resins | High molecular weight insoluble polymers which contain functional anionic groups that are capable of undergoing exchange reactions with cations | D27.720.470.420.275 | |||
Cauda equina | A08.800.800.720.725.150 | |||||
CCR5 Receptor Antagonists | Anti-HIV Agents mechanism of action |
Compounds and drugs that inhibit or block the activity of ccr5 receptors | D27.505.519.275 D27.505.954.122.388.077.088.104 |
|||
celiac ganglia | ganglion | part of nervous system | A08.340.315.350 | |||
Celiac plexus | A complex network of nerves (a nerve plexus) located in the abdomen. | A08.800.050.050.150 | ||||
Central gelatinous substance of spinal cord | A08.186.854.697.500.500 | |||||
Central Nervous System Agents | Therapeutic Uses | A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for tha | D27.505.954.427 | |||
Central Nervous System Depressants | Central Nervous System Agents Physiological Effects of Drugs |
A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and ant | D27.505.696.277 D27.505.954.427.210 |
|||
Central serous retinopathy | retinal disease rare acquired eye disease |
C11.768.175 | Central serous retinopathy | |||
cerebral peduncle | A08.186.211.132.659 | |||||
Cerumenolytic Agents | mechanism of action Physiological Effects of Drugs Emulsifying Agents |
Compounds that disintegrate natural waxy exudates such as ear wax | D27.505.519.295 D27.505.696.305 D27.720.877.383.500 |
|||
cervical plexus | nerve plexus | A08.800.800.720.150 | ||||
cervix | the lower part of the uterus in the human female reproductive system | A05.360.319.679.256 | Cervix uteri | |||
Charcot–Bouchard aneurysm | intracranial aneurysm | C14.907.055.817 | ||||
Chelating Agents | Sequestering Agents | Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. | D27.505.519.914.500 D27.720.832.500 |
|||
chemical database | database | L01.313.500.750.300.188.400.300 L01.470.750.750.300 |
||||
chemical warfare agent | chemical substance poison |
Chemicals that are used to cause the disturbance, disease, or death of humans during warfare | D27.720.777.300 D27.888.569.612.150 |
|||
Chilaiditi syndrome | colonic disease | C06.405.469.158.093 | Chilaiditi syndrome | |||
child abuse | occurrence abuse |
physical, sexual or emotional maltreatment or neglect of a child | I01.198.240.856.350.250 I01.880.735.900.350.250 |
Child abuse | ||
chin | facial feature | facial feature | A01.456.505.259 | Chins | ||
Chloride Channel Agonists | Membrane Transport Modulators | A class of drugs that stimulate chloride ion influx through cell membrane channels | D27.505.519.562.311 | |||
Cholagogues and Choleretics | Gastrointestinal Agents | Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic) | D27.505.954.483.508 | |||
Cholinergic Agents | drug | neurotransmitter | Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes | D27.505.519.625.120 D27.505.696.577.120 |
||
Cholinergic Agonists | Cholinergic Agents | Drugs that bind to and activate cholinergic receptors | D27.505.696.577.120.140 D27.505.519.625.120.140 |
|||
Cholinesterase Reactivators | Enzyme Reactivators Cholinergic Agents |
Drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. They are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates. | D27.505.519.405.347 D27.505.696.577.120.400 D27.505.519.625.120.400 |
|||
chorda tympani | nerve | A08.800.800.120.250.120 | ||||
Chorioallantoic membrane | A16.254.300.400 | |||||
chorion | A10.615.284.473 | |||||
choroid plexus | plexus | structure in the ventricles of the brain | A08.186.211.276.298 | Choroid plexus | ||
Chromogenic Compounds | food coloring Indicators and Reagents dye |
Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogen | D27.720.470.410.200 D27.720.233.174 |
|||
chronic bronchitis | bronchitis | Lung disease that involves excessive mucus production and is accompanied by a continuous cough | C08.127.446.567 C08.381.495.146.567 C08.381.495.389.500 C08.730.099.567 |
|||
chronic condition | disease | human health condition or disease that is persistent or otherwise long-lasting in its effects | C23.550.291.500 | |||
chronic pancreatitis | pancreatitis | Human disease | C06.689.750.830 | |||
cingulate gyrus | gyrus | A08.186.211.577.330 | Cingulate cortex | |||
Circle of Willis | circulatory anastomosis that supplies blood to the brain and surrounding structures | A07.231.114.228.351 | Circle of Willis | |||
Cisterna magna | A08.186.566.166.686.351 | |||||
clitoris | sex organ | female sex organ | A05.360.319.887.436 | Clitoris | ||
Cloaca | A13.223 | |||||
Coagulants | Hematologic Agents | Agents that cause clotting | D27.505.954.502.270 | |||
Coccidiostats | antiprotozoal | Agents useful in the treatment or prevention of coccidiosis in man or animals | D27.505.954.122.250.100.170 | |||
cochlear nerve | nerve | A08.800.800.120.910.120 | ||||
Coenurosis | zoonosis | parasitic helminthiasis infectious disease zoonosis tapeworm infection |
Helminthiasis | C03.335.190 | ||
cognitive therapy | therapy | F04.754.137.428 | Cognitive therapy | |||
coma | disorder of consciousness clinical sign |
state of unconsciousness | C10.597.606.358.800.200 C23.888.592.604.359.800.200 |
Coma | ||
Commotio cordis | cardiac arrest Traumatic cardiac arrest |
C14.280.067.441 C26.891.375.750.500 C26.974.250.875.500 |
||||
Community-acquired pneumonia | pneumonia community acquired infection |
C01.539.234 | ||||
Complement Inactivating Agents | immunosuppressive drug | Compounds that negatively regulate the cascade process of complement activation. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host | D27.505.696.477.656.500 | |||
Complementary DNA | DNA DNA Probes |
Single-stranded complementary dna synthesized from an rna template by the action of rna-dependent dna polymerase. Cdna (i.e., complementary dna, not circular dna, not c-dna) is used in a variety of molecular cloning experiments as well as serving as | D27.720.470.530.600.223.260 | |||
conduction aphasia | receptive aphasia | C10.597.606.150.500.800.100.111 C23.888.592.604.150.500.800.100.111 |
||||
connective tissue | tissue | type of biological tissue | A10.165 | Connective tissue | ||
consanguinity | property | property of being from the same kinship as another person; quality of being descended from the same ancestor as another person | G05.090.403.180 G05.180 |
Consanguinity | ||
Contact Lens Solutions | disinfectant | Sterile solutions used to clean and disinfect contact lenses | D27.720.274.150 D27.505.954.122.425.150 |
|||
Contraceptive Agents | Reproductive Control Agents | Chemical substances that prevent or reduce the probability of conception | D27.505.696.875.360 D27.505.954.705.360 |
|||
Contraceptive Agents, Female | Contraceptive Agents | Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading | D27.505.696.875.360.276 D27.505.954.705.360.276 |
|||
Contraceptive Agents, Male | Contraceptive Agents | Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading | D27.505.954.705.360.443 D27.505.696.875.360.443 |
|||
Contraceptives, Oral | Contraceptive Agents, Female | Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both | D27.505.954.705.360.276.210 D27.505.696.875.360.276.210 |
|||
Contraceptives, Oral, Combined | Contraceptives, Oral | Fixed drug combinations administered orally for contraceptive purposes | D27.505.954.705.360.276.210.100 D27.505.696.875.360.276.210.100 |
|||
Contraceptives, Oral, Hormonal | Contraceptives, Oral | Oral contraceptives which owe their effectiveness to hormonal preparations | D27.505.954.705.360.276.210.277 D27.505.696.875.360.276.210.277 |
|||
Contraceptives, Oral, Sequential | Contraceptives, Oral | Drugs administered orally and sequentially for contraceptive purposes | D27.505.696.875.360.276.210.400 D27.505.954.705.360.276.210.400 |
|||
Contraceptives, Oral, Synthetic | Contraceptives, Oral | Oral contraceptives which owe their effectiveness to synthetic preparations | D27.505.954.705.360.276.210.443 D27.505.696.875.360.276.210.443 |
|||
Contraceptives, Postcoital | Contraceptive Agents, Female | Contraceptive substances to be used after coitus. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; antimetabolites; alkaloids, and prostaglandins | D27.505.696.875.360.276.310 D27.505.954.705.360.276.310 |
|||
Contraceptives, Postcoital, Hormonal | Contraceptives, Postcoital | Postcoital contraceptives which owe their effectiveness to hormonal preparations | D27.505.954.705.360.276.310.235 D27.505.696.875.360.276.310.235 |
|||
Contraceptives, Postcoital, Synthetic | Contraceptives, Postcoital | Postcoital contraceptives which owe their effectiveness to synthetic preparations | D27.505.696.875.360.276.310.360 D27.505.954.705.360.276.310.360 |
|||
Contrast medium | Specialty Uses of Chemicals Diagnostic Uses of Chemicals |
A substance used in medical imaging to enhance the contrast of structures or fluids within the body. | D27.505.259.500 D27.720.259 |
Contrast agents | ||
Convulsant | stimulant | Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most common | D27.505.696.282.224 D27.505.954.427.220.224 |
Convulsants | ||
coronary circulation | circulation of blood in the blood vessels of the heart muscle (myocardium) | G09.330.190.163.324 | Coronary circulation | |||
Corrosive substance | Noxae Specialty Uses of Chemicals |
Strong alkaline chemicals that destroy soft body tissues resulting in a deep, penetrating type of burn, in contrast to corrosives, that result in a more superficial type of damage via chemical means or inflammation. Caustics are usually hydroxides o | D27.888.569.185 D27.720.185 |
Corrosive materials labelling | ||
Cosmeceutical | cosmetics | Cosmetics that are associated with therapeutic effects | D27.720.269.285 | |||
cosmetics | chemical substance Specialty Uses of Chemicals |
substances used to enhance the appearance or odor of the human body | D27.720.269 | Cosmetics | ||
COX-2 inhibitor | cyclooxygenase inhibitor | A subclass of cyclooxygenase inhibitors with specificity for cyclooxygenase-2 | D27.505.696.663.850.014.040.500.500.500 D27.505.954.329.030.500.500 D27.505.954.158.030.500.500 D27.505.519.389.310.500 |
COX-2 inhibitors | ||
coxis | bone | bone of the pelvis | A02.835.232.834.229 | Coccyx | ||
Cracked tooth syndrome | dental trauma Enamel infraction |
C07.793.850.750.300 C26.900.750.300 |
||||
cretinism | birth defect thyroid gland disease |
disease | C05.116.099.343.347 C05.116.132.256 C16.320.240.625 C19.297.155 C19.874.482.281 |
Cretinism | ||
cricoid cartilage | It is a signet ring shape cartilage | A02.165.507.211 | Cricoid cartilage | |||
CRISPR | repeated sequence | family of DNA sequences in bacteria, contain snippets of DNA from viruses that have attacked the bacterium, are used by the bacterium to detect and destroy DNA from further attacks by similar viruses | G02.111.570.080.708.800.325.500 G05.360.080.708.800.325.500 G05.360.340.024.850.069 |
CRISPR | ||
Cross-Linking Reagents | Indicators and Reagents | Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can | D27.720.470.410.210 | |||
Cryoprotective Agents | Protective Agents | Substances that provide protection against the harmful effects of freezing temperatures | D27.505.696.706.320 D27.720.799.180 |
|||
Culture media, conditioned | body fluid | growth medium | Cell culture growth medium retrieved from certain cultured cells | D27.720.470.305.250 | ||
Culture Media, Serum-Free | growth medium | Culture media free of serum proteins but including the minimal essential substances required for cell growth. This type of medium avoids the presence of extraneous substances that may affect cell proliferation or unwanted activation of cells | D27.720.470.305.255 | |||
cuneiform bones | set of bones in the human foot | A02.835.232.043.300.710 | Cuneiform bones | |||
cyclooxygenase inhibitor | non-steroidal anti-inflammatory drug enzyme inhibitor |
class of drug | D27.505.696.663.850.014.040.500.500 D27.505.954.329.030.500 D27.505.954.158.030.500 D27.505.519.389.310 |
|||
Cysteine Proteinase Inhibitors | Protease inhibitor | Exogenous and endogenous compounds which inhibit cysteine endopeptidases | D27.505.519.389.745.325 | |||
Cystine Depleting Agents | mechanism of action | Compounds and drugs that react with cystine and convert it into a compound that can be more easily metabolized or intracellularly transported. Drugs in this class have been used to treat cystinosis | D27.505.519.334 | |||
Cytochrome P-450 CYP1A2 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp1a2 | D27.505.389.249.120 D27.505.519.349.120 |
|||
Cytochrome P-450 CYP1A2 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp1a2 | D27.505.389.500.120 D27.505.519.389.335.120 |
|||
Cytochrome P-450 CYP2B6 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2b6 | D27.505.519.349.260 D27.505.389.249.260 |
|||
Cytochrome P-450 CYP2B6 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2b6 | D27.505.389.500.260 D27.505.519.389.335.260 |
|||
Cytochrome P-450 CYP2C19 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2c19 | D27.505.519.349.350 D27.505.389.249.350 |
|||
Cytochrome P-450 CYP2C19 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2c19 | D27.505.519.389.335.319 D27.505.389.500.319 |
|||
Cytochrome P-450 CYP2C8 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2c8 | D27.505.519.349.308 D27.505.389.249.308 |
|||
Cytochrome P-450 CYP2C8 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2c8 | D27.505.519.389.335.308 D27.505.389.500.308 |
|||
Cytochrome P-450 CYP2C9 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2c9 | D27.505.519.349.320 D27.505.389.249.320 |
|||
Cytochrome P-450 CYP2C9 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2c9 | D27.505.519.389.335.329 D27.505.389.500.315 |
|||
Cytochrome P-450 CYP2D6 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2d6 | D27.505.389.249.500 D27.505.519.349.500 |
|||
Cytochrome P-450 CYP2D6 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2d6 | D27.505.389.500.368 D27.505.519.389.335.368 |
|||
Cytochrome P-450 CYP2E1 Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp2e1 | D27.505.389.249.600 D27.505.519.349.600 |
|||
Cytochrome P-450 CYP2E1 Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp2e1 | D27.505.519.389.335.421 D27.505.389.500.421 |
|||
Cytochrome P-450 CYP3A Inducers | Cytochrome P-450 Enzyme Inducers | Drugs and compounds that induce the synthesis of cytochrome p-450 cyp3a | D27.505.389.249.700 D27.505.519.349.700 |
|||
Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 Enzyme Inhibitors | Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 cyp3a | D27.505.519.389.335.503 D27.505.389.500.503 |
|||
Cytochrome P-450 Enzyme Inducers | mechanism of action Metabolic Side Effects of Drugs and Substances |
Drugs and compounds that induce the synthesis of cytochrome p-450 enzymes | D27.505.519.349 D27.505.389.249 |
|||
Cytochrome P-450 Enzyme Inhibitors | enzyme inhibitor Metabolic Side Effects of Drugs and Substances |
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of cytochrome p-450 enzymes | D27.505.389.500 D27.505.519.389.335 |
|||
Cytostatic Agents | Noxae | Compounds that inhibit or prevent the proliferation of cells | D27.888.569.199 | |||
cytotoxin | poison Noxae |
Term for substances that have a harmful or destructive effect on a biological cell | D27.888.569.213 | |||
Cytotrophoblast | A16.254.085.162 | |||||
dangerous goods | transportable goods Modes of Toxic Action |
Dangerous goods or hazardous goods are solids, liquids, or gases that can harm people, other living organisms, property, or the environment | D27.888.426 | Dangerous goods | ||
deafblindness | deafness blindness sensation disorder decreased audio-visual performance |
condition of little or no useful sight and little or no useful hearing | C09.218.458.341.186.500 C10.597.751.418.341.186.500 C10.597.751.941.162.625 C11.966.075.375 C16.131.077.299 C23.888.592.763.393.341.186.500 C23.888.592.763.941.162.625 |
Deafblindness | ||
Decidua | A16.759.289 | |||||
decompression sickness | decompression illness | condition arising on depressurisation of the body | C26.120.248 | Decompression sickness | ||
defence mechanism | behavior psychological phenomenon |
unconscious psychological mechanism that reduces anxiety arising from unacceptable or potentially harmful stimuli | F01.393 | Ego defence mechanisms | ||
Defoliants, Chemical | herbicide | Herbicides that remove leaves from trees and growing plants. They may be either organic or inorganic. Several of the more persistent types have been used in military operations and many are toxic. (from hawley's condensed chemical dictionary, 11th e | D27.720.031.700.366.181 D27.888.723.366.181 |
|||
Degloving | Avulsion injury Soft tissue injury |
type of avulsion in which an extensive section of skin is completely torn off the underlying tissue | C26.808.500 | |||
Delayed puberty | disorder of puberty | Human disease | C19.391.690 | |||
Demulcents | anti-inflammatory agent Gastrointestinal Agents surfactant Respiratory System Agents |
Compounds that form soothing films on the surface of mucous membranes. They are generally used as agents to protect the integrity of internal epithelium | D27.720.877.156 D27.505.954.796.210 D27.505.954.483.534 D27.505.954.158.515 |
|||
dental attrition | tooth wear | C07.793.818.249 | ||||
Dental Disinfectants | disinfectant | Chemicals especially for use on instruments to destroy pathogenic organisms. (boucher, clinical dental terminology, 4th ed) | D27.505.954.122.425.300 D27.720.274.300 |
|||
Dental insurance | health insurance | N03.219.521.576.343.450 | ||||
Dental Materials | Biomedical and Dental Materials | Materials used in the production of dental bases, restorations, impressions, prostheses, etc | D27.720.102.339 | |||
Dental papilla | A14.549.167.900.720.250 | |||||
dental plaque | dental deposits | C07.793.208.377 | Dental plaque | |||
dental pulp | A14.549.167.900.260 | Pulp (tooth) | ||||
Dentifrices | cosmetics | Any preparations used for cleansing teeth; they usually contain an abrasive, detergent, binder and flavoring agent and may exist in the form of liquid, paste or powder; may also contain medicaments and caries preventives | D27.720.269.380 | |||
Dentin Desensitizing Agents | analgesic | Substances which reduce or eliminate dentinal sensitivity or the pain associated with a source of stimulus (such as touch, heat, or cold) at the orifice of exposed dentinal tubules causing the movement of tubular fluid that in turn stimulates tooth | D27.505.696.663.850.014.640 D27.505.954.427.040.437 |
|||
deodorant | Personal hygiene item | product cosmetics |
substance applied to the body to prevent body odor | D27.720.269.385 | Deodorants | |
Dermal Fillers | Biomedical and Dental Materials | Materials such as collagen or hyaluronic acid that are injected or deposited into the dermis for the purpose of skin augmentation | D27.720.102.461 | |||
dermis | layer | layer of skin between the epidermis (with which it makes up the cutis) and subcutaneous tissues, that primarily consists of dense irregular connective tissue and cushions the body from stress and strain | A17.815.180 | |||
Dermotoxins | Noxae | Specific substances elaborated by plants, microorganisms or animals that cause damage to the skin; they may be proteins or other specific factors or substances; constituents of spider, jellyfish or other venoms cause dermonecrosis and certain bacter | D27.888.569.242 | |||
detergent | chemical product surfactant cleaning product |
Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties | D27.720.877.265 | Detergents | ||
Diabetic coma | complications of diabetes mellitus coma |
C19.246.099.750 | ||||
diabetic nephropathy | kidney disease complications of diabetes mellitus |
disease | C12.777.419.192 C13.351.968.419.192 C19.246.099.875 |
Diabetic nephropathy | ||
Diagnostic Uses of Chemicals | Pharmacologic Actions | Chemicals administered to patients in order to diagnose or study the pathology of medical conditions, diseases, or syndromes. | D27.505.259 | |||
Diagonal band of Broca | A08.186.211.730.885.380 | |||||
Dialysis Solutions | Pharmaceutical Solutions | Solutions prepared for exchange across a semipermeable membrane of solutes below a molecular size determined by the cutoff threshold of the membrane material | D27.505.954.578.483 D27.720.752.483 |
|||
diaphragmatic hernia | abdominal hernia diaphragm disease |
defect or hole in the diaphragm that allows the abdominal contents to move into the chest cavity | C23.300.707.500 | Diaphragmatic hernia | ||
diaphysis | zone of long bone | A02.835.232.169 | ||||
Diastema | tooth disease | C07.650.800.320 C07.793.700.320 C16.131.850.800.320 |
Diastema (dentistry) | |||
dichromacy | color vision congenital color blindness |
C10.597.751.941.256 C11.966.256 C23.888.592.763.941.256 |
||||
differential diagnosis | diagnostic procedure | E01.171 | Differential diagnosis | |||
diffusion-tensor imaging | diffusion magnetic resonance imaging | imaging method | E01.370.350.578.750 E01.370.376.537.500 E05.629.750 |
|||
digital dermatitis | bacterial infectious disease bovine disease infectious disease |
animal disease bacterial skin disease |
cattle disease | C01.252.825.180 C01.539.800.720.180 C17.800.838.765.180 C22.214 |
||
Dipeptidyl peptidase-4 inhibitor | anti-diabetic medication Protease inhibitor |
Compounds that suppress the degradation of incretins by blocking the action of dipeptidyl-peptidase iv. This helps to correct the defective insulin and glucagon secretion characteristic of type 2 diabetes mellitus by stimulating insulin secretion an | D27.505.696.422.500 D27.505.519.389.745.335 |
Dipeptidyl peptidase-4 inhibitors | ||
diphyllobothriasis | fish disease disease infectious disease |
parasitic helminthiasis infectious disease zoonosis Q4505372 |
helminthiasis | C03.335.190.304 | ||
Diplopia | vision disorder binocular vision disease |
Human disease | C10.597.751.941.339 C11.966.339 C23.888.592.763.941.339 |
Diplopia | ||
Direct Xa inhibitor | Antithrombins | Endogenous factors and drugs that inhibit or block the activity of factor xa | D27.505.954.502.119.500.500 D27.505.519.389.745.800.449.500 |
|||
Discoid lupus erythematosus | lupus erythematosus chronic cutaneous lupus erythematosus |
C17.300.475.479 C17.800.480.479 |
Discoid lupus erythematosus | |||
disease | health problem | abnormal condition negatively affecting organisms | C | Diseases and disorders | ||
disease-modifying antirheumatic drug | Therapeutic Uses | Drugs that are used to treat rheumatoid arthritis | D27.505.954.329 | |||
disinfectant | engineering process cleaning Anti-Infective Agents Specialty Uses of Chemicals |
antimicrobial agent that is applied to non-living objects (compare: antisepsis) to reduce the number of microorganisms (unwanted germs and parasites) on them (compare:sterilization) | D27.720.274 D27.505.954.122.425 |
Disinfectants | ||
dislocated shoulder | shoulder problem | C05.116.359.750 C26.289.750 C26.803.125 |
Shoulder luxation | |||
Diuretics, Osmotic | diuretic | Compounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma | D27.505.696.560.500.453 | |||
diverticulosis | intestinal disease Diverticulum, Colon |
condition of having diverticula (outpocketings) in the wall of the intestine | C06.405.469.158.587 | Diverticulosis | ||
DNA Primers | DNA Probes | Short sequences (generally about 10 base pairs) of dna that are complementary to sequences of messenger rna and allow reverse transcriptases to start copying the adjacent sequences of mrna. Primers are used extensively in genetic and molecular biolo | D27.720.470.530.600.223.600 | |||
DNA Probes | Nucleic Acid Probes | Species- or subspecies-specific dna (including complementary dna; conserved genes, whole chromosomes, or whole genomes) used in hybridization studies in order to identify microorganisms, to measure dna-dna homologies, to group subspecies, etc. The d | D27.720.470.530.600.223 D27.505.259.750.600.223 |
|||
DNA Probes, HLA | DNA Probes | Dna probes specific for the human leukocyte antigen genes, which represent the major histocompatibility determinants in humans. The four known loci are designated as a, b, c, and d. Specific antigens are identified by a locus notation and number, e | D27.720.470.530.600.223.615 D27.505.259.750.600.223.615 |
|||
DNA Probes, HPV | DNA Probes | Dna probes specific for the identification of human papilloma virus | D27.505.259.750.600.223.620 D27.720.470.530.600.223.620 |
|||
DNA, Antisense | Antisense Elements (Genetics) | Dna that is complementary to the sense strand. (the sense strand has the same sequence as the mrna transcript. The antisense strand is the template for mrna synthesis.) synthetic antisense dnas are used to hybridize to complementary sequences in tar | D27.720.470.530.600.150.200 | |||
domestication | evolution | sustained multi-generational relationship in which one group of organisms assumes a significant degree of influence over the reproduction and care of another group to secure a more predictable supply of resources from that second group | J01.040.330 | Domesticated animals | ||
Dopamine agonist | Dopaminergic | Drugs that bind to and activate dopamine receptors | D27.505.696.577.150.151 D27.505.519.625.150.151 |
Dopamine agonists | ||
Dopamine antagonist | Dopaminergic | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therap | D27.505.696.577.150.175 D27.505.519.625.150.175 |
Dopamine antagonists | ||
Dopamine D2 Receptor Antagonists | Dopamine antagonist | Compounds and drugs that bind to and inhibit or block the activation of dopamine d2 receptors | D27.505.519.625.150.175.500 D27.505.696.577.150.175.500 |
|||
Dopamine reuptake inhibitor | Neurotransmitter Uptake Inhibitors Dopaminergic |
type of drug that acts as a reuptake inhibitor for the neurotransmitter dopamine | D27.505.696.577.150.800 D27.505.519.625.150.800 D27.505.519.625.600.220 D27.505.696.577.600.220 D27.505.519.562.437.220 |
Dopamine reuptake inhibitors | ||
Dopaminergic | neurotransmitter | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons | D27.505.696.577.150 D27.505.519.625.150 |
|||
dorsal root ganglion | A08.340.390.340 | Dorsal root ganglion | ||||
dorsomedial hypothalamic nucleus | A08.186.211.730.385.357.352.270 | |||||
drug eruption | exanthem adverse drug reaction |
adverse drug reaction of the skin | C17.800.174.600 C20.543.206.380 C25.100.468.380 |
|||
drunkenness | substance intoxication | psychological state induced by the ingestion of ethanol (alcohol) | C25.775.100.175 | Drunken people | ||
dura mater | meninx | There are 4 processes of dura mater | A08.186.566.395 | Dura mater | ||
dural venous sinuses | A07.231.908.224 | |||||
dwarfism | disease | a condition affecting a person or animal short in stature, caused by slow or delayed growth | C05.116.099.343 C16.320.240 C19.297 |
Dwarfism | ||
dye | material colourant Specialty Uses of Chemicals |
colored substance that has an affinity to the substrate to which it is being applied | D27.720.233 | Dyes | ||
dyskinesia | movement disorder | human disease | C10.228.662.262 C10.597.350 C23.888.592.350 |
|||
dysphonia | voice disorder | voice disorder | C08.360.940.490 C08.618.490 C09.400.940.490 C10.597.975.550 C23.888.592.979.550 C23.888.852.490 C08.360.940.325 C09.400.940.325 C10.597.975.325 C23.888.592.979.325 |
|||
dyssomnia | sleep disorder | broad classification of sleeping disorders involving difficulty getting to sleep, remain sleeping, or of excessive sleepiness | C10.886.425 | |||
eccrine sweat gland | sweat gland | distributed almost all over the human body, in varying densities; its water-based secretion represents a primary form of cooling in humans | A10.336.899.480 | |||
ectoderm | germ layer | A16.254.425.273 | Ectoderm | |||
Ectromelia | congenital amputation | C05.660.585.350 C16.131.621.585.350 |
||||
eczema | skin disease | cutaneous disease | C17.800.174.620 C17.800.815.620 C17.800.815 |
Eczema | ||
Edinger–Westphal nucleus | nucleus | A08.186.211.132.659.413.875.381.500 | ||||
ejaculatory duct | A05.360.444.251 | |||||
electronic health record | medical software personal health record |
a program used to document a patient's medical history on a computer | E05.318.308.940.968.249.500 E05.318.308.940.968.625.500 |
Electronic health record | ||
embolism | vascular disease | embolism and thrombosis | disease of arteries, arterioles and capillaries | C14.907.355.350 | Embolism | |
emerging infectious disease | infectious disease | C01.539.221.500 | ||||
emetic | drug Autonomic Agents Central Nervous System Agents Gastrointestinal Agents Physiological Effects of Drugs |
drug that induces vomiting | D27.505.696.663.050.225 D27.505.954.483.560 D27.505.954.427.270 D27.505.696.329 |
Emetics | ||
Emollients | dermatologic drug | Oleagenous substances used topically to soothe, soften or protect skin or mucous membranes. They are used also as vehicles for other dermatologic agents | D27.505.954.444.200 | |||
Emulsifying Agents | surfactant | Surface-active agents that induce a dispersion of undissolved material throughout a liquid | D27.720.877.383 | |||
endocrine disruptor | Modes of Toxic Action Physiological Effects of Drugs |
chemicals that can interfere with endocrine (or hormone) systems at certain doses | D27.505.696.353 D27.888.141 |
Endocrinology | ||
endoderm | germ layer | A16.254.425.407 | Endoderm | |||
endolymph | labyrinthine fluid | A12.207.270.517.324 | ||||
endometrium | mucus membrane | inner mucous membrane of the mammalian uterus | A05.360.319.679.490 | Endometrium | ||
Endoneurium | A08.800.800 | |||||
Endothelin A Receptor Antagonists | Endothelin receptor antagonist | Compounds and drugs that bind to and inhibit or block the activation of endothelin a rececptors | D27.505.519.364.500 | |||
Endothelin B Receptor Antagonists | Endothelin receptor antagonist | Compounds and drugs that bind to and inhibit or block the activation of endothelin b receptors | D27.505.519.364.750 | |||
Endothelin receptor antagonist | mechanism of action | chemical compound blocks the endotelin receptor | D27.505.519.364 | |||
Endothelium-Dependent Relaxing Factors | vasodilator agent | Paracrine substances produced by the vascular endothelium with vascular smooth muscle relaxation (vasodilation) activities. Several factors have been identified, including nitric oxide and prostacyclin | D27.505.954.411.918.500 | |||
enteritis | intestinal infectious disease inflammation |
intestinal infectious disease | C06.405.205.462 C06.405.469.326 |
|||
entorhinal cortex | brain area | A08.186.211.577.710.225 | Entorhinal cortex | |||
Environmental Pollutants | Modes of Toxic Action | Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. | D27.888.284 | |||
Enzyme activator | mechanism of action | Compounds or factors that act on a specific enzyme to increase its activity | D27.505.519.374 | |||
enzyme inhibitor | mechanism of action | molecule that binds to an enzyme and decreases its activity | D27.505.519.389 | Enzyme inhibitors | ||
Enzyme Reactivators | mechanism of action | Compounds which restore enzymatic activity by removing an inhibitory group bound to the reactive site of the enzyme | D27.505.519.405 | |||
ependymoblastoma | tumor disease |
central nervous system primitive neuroectodermal neoplasm | Human disease | C04.557.465.625.600.590 C04.557.470.670.590 C04.557.580.625.600.590 |
||
epididymis | sex organ | Epididim | A05.360.444.371 | Epididymis | ||
epiglottis | thin flap in the oesophagus | A02.165.257.625.411 | Epiglottis | |||
Epineurium | A08.800.800 | |||||
epiphysis | zone of long bone | end part of long bones | A02.835.232.251 | |||
Epithelial Sodium Channel Agonists | Sodium Channel Agonists | Compounds that either stimulate the opening or prevent closure of epithelial sodium ion channels | D27.505.519.562.625.249 | |||
Epithelial Sodium Channel Blockers | Sodium channel blocker Potassium-sparing diuretic |
A subclass of sodium channel blockers that are specific for epithelial sodium channels | D27.505.519.562.750.374 D27.505.696.560.500.726.100 |
|||
ergotism | food poisoning Mycotoxicosis |
C25.723.680.262 | Ergotism | |||
Erythema induratum | panniculitis | C01.252.410.040.552.846.583.260 C01.252.825.820.260 C01.539.800.720.820.260 C17.300.710.329 C17.800.229.329 C17.800.566.329 C17.800.838.765.820.320 |
||||
Escherichia coli O157:H7 | strain | serotype of the bacterial species Escherichia coli and is one of the Shiga toxin–producing types of E. coli | B03.440.450.425.325.300.800.250.500 B03.660.250.150.180.100.800.250.500 |
|||
estrogen | sex steroid hormone |
primary female sex hormone as well as a medication, is responsible for the development and regulation of the female reproductive system and secondary sex characteristics | D27.505.696.399.472.277 | Estrogens | ||
Estrogen Antagonists | Hormone Antagonists | Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds | D27.505.696.399.450.327 | |||
Estrogen Receptor Antagonists | Estrogen Antagonists | Compounds and drugs that bind to and block or inhibit the activation of estrogen receptors | D27.505.696.399.450.327.650 | |||
Estrogen Receptor Modulators | Hormone Antagonists | Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure | D27.505.696.399.450.360 | |||
Estrogens, Non-Steroidal | estrogen | Non-steroidal compounds with estrogenic activity | D27.505.696.399.472.277.540 | |||
excipient | chemical substance Pharmaceutical Vehicles |
substance formulated alongside the active ingredient of a medication | D27.720.744.770.419 | |||
Excitatory Amino Acid Agents | neurotransmitter | Drugs used for their actions on any aspect of excitatory amino acid neurotransmitter systems. Included are drugs that act on excitatory amino acid receptors, affect the life cycle of excitatory amino acid transmitters, or affect the survival of neur | D27.505.519.625.190 D27.505.696.577.190 |
|||
Excitatory Amino Acid Agonists | Excitatory Amino Acid Agents | Drugs that bind to and activate excitatory amino acid receptors | D27.505.696.577.190.200 D27.505.519.625.190.200 |
|||
Excitatory amino acid antagonist | Excitatory Amino Acid Agents | Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists | D27.505.696.577.190.300 D27.505.519.625.190.300 |
|||
Expectorants | Respiratory System Agents | Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here | D27.505.954.796.250 | |||
explosive material | chemical substance Specialty Uses of Chemicals |
reactive substance that contains a great amount of potential energy that can produce an explosion | D27.720.317 | Explosives | ||
Extensively drug-resistant tuberculosis | multidrug-resistant tuberculosis | C01.252.410.040.552.846.775.500 | ||||
External fixation | E07.858.442.660.430 | External fixation | ||||
extracellular matrix | cellular component | extracellular region part | A structure lying external to one or more cells, which provides structural support for cells or tissues. | A11.284.295.310 | Extracellular matrix proteins | |
eye drop | Pharmaceutical Solutions | A saline-containing liquid drug, administered through the eye. | D27.720.752.608 D27.505.954.578.645 |
Eye drops | ||
Faith healing | miracle healing |
healing through spiritual means | E02.190.901.155 | Faith healing | ||
fascia | connective tissue | layer of fibrous connective tissue that surrounds muscles, blood vessels and nerves | A02.340 | Fascia (tissue) | ||
fast food | industry | dish | food prepared and served in a small amount of time | G07.203.300.477 J02.500.477 |
Fast food | |
Fat Substitutes | food additive | Compounds used in food or in food preparation to replace dietary fats. They may be carbohydrate-, protein-, or fat-based. Fat substitutes are usually lower in calories but provide the same texture as fats | D27.720.372.300.350 | |||
Fatty Acid Synthesis Inhibitors | hypolipidemic | Compounds that interfere with fatty acid synthase resulting in a reduction of fatty acids. This is a target mechanism in humans of some antineoplastic agents and anti-obesity agents and of some anti-infective agents which interfere with cell wall an | D27.505.519.186.071.401 | |||
Fazio-Londe disease | infantile progressive bulbar palsy | a very rare inherited motor neuron disease of children and young adults | C10.574.562.300 C10.668.467.300 |
|||
febrile neutrophilic dermatosis | Reactive neutrophilic dermatoses erythema rare rheumatologic disease other acquired skin disease |
C17.800.229.800 | Febrile neutrophilic dermatosis | |||
fecal impaction | constipation intestinal obstruction |
C06.405.469.531.424 | Fecal impaction | |||
female genital mutilation | ablation Genital modification and mutilation |
controversial cultural ritual | E02.218.085.165 E04.085.165 E04.950.300.200 I01.076.201.450.199 |
Female genital mutilation | ||
female infertility | infertility | Diminished or absent ability of a female to achieve conception | C13.351.500.365.700 | |||
femoral nerve | nerve | A08.800.800.720.450.250 | Femoral nerve | |||
Fertility Agents | Reproductive Control Agents | Drugs used to increase fertility or to treat infertility | D27.505.696.875.552 D27.505.954.705.552 |
|||
Fertility Agents, Female | Fertility Agents | Compounds which increase the capacity to conceive in females | D27.505.954.705.552.344 D27.505.696.875.552.344 |
|||
Fertility Agents, Male | Fertility Agents | Compounds which increase the capacity of the male to induce conception | D27.505.954.705.552.510 D27.505.696.875.552.510 |
|||
fertilizer | use | chemical substance agrochemical |
any material of natural or synthetic origin (other than liming materials) that is applied to soils or to plant tissues (usually leaves) to supply one or more plant nutrients essential to the growth of plants | D27.720.031.400 | Fertilizers | |
Fibrin Modulating Agents | mechanism of action | Agents that affect the function of fibrin in blood coagulation. They used as coagulants for hemorrhage or anticoagulants for thrombosis | D27.505.519.421 | |||
Fibrinolytic Agents | Cardiovascular Agents Hematologic Agents Fibrin Modulating Agents |
Fibrinolysin or agents that convert plasminogen to fibrinolysin | D27.505.519.421.750 D27.505.954.411.320 D27.505.954.502.427 |
|||
fibula | bone | bone of the leg | A02.835.232.043.650.321 | Fibula (bone) | ||
Fifth metacarpal bone | A02.835.232.087.319.550 | Fifth metacarpal bone | ||||
Filaricides | antinematodal agent | Pharmacological agents destructive to nematodes in the superfamily filarioidea | D27.505.954.122.250.075.080.275 | |||
finger | digit | organ of manipulation and sensation found in the hands of humans and other primates | A01.378.800.667.430 | Fingers | ||
Fixatives | Specialty Uses of Chemicals | Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifyi | D27.720.355 | |||
Flame retardant | chemical substance Specialty Uses of Chemicals |
Materials applied to fabrics, bedding, furniture, plastics, etc. To retard their burning; many may leach out and cause allergies or other harm | D27.720.361 | Flame retardants | ||
flavoring agent | food additive Pharmaceutic Aids |
substance added to foods and medicine to improve the taste | D27.720.372.300.353 D27.720.744.294 |
|||
Fluorophore | food coloring Luminescent Agents dye |
Agents that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label othe | D27.720.470.410.505.500 D27.720.233.348 |
Fluorescent dyes | ||
Focal infection theory | disease infection |
C01.539.392 | ||||
Focal nodular hyperplasia | liver neoplasm | C06.552.270 | ||||
Folic Acid Antagonists | enzyme inhibitor | Inhibitors of the enzyme, dihydrofolate reductase (tetrahydrofolate dehydrogenase), which converts dihydrofolate (fh2) to tetrahydrofolate (fh4). They are frequently used in cancer chemotherapy. (from ama, drug evaluations annual, 1994, p2033) | D27.505.519.389.350 | |||
food additive | additive food ingredient |
substances added to food to preserve flavor or enhance its taste, appearance, or other qualities | D27.720.372.300 | Food additives | ||
food coloring | food additive dye Specialty Uses of Chemicals |
substance that imparts color when it is added to food or drink | D27.720.233.674 D27.720.372.300.355 |
Food colorings | ||
food ingredient | ingredient Specialty Uses of Chemicals |
ingredient used in food product | D27.720.372 | |||
food poisoning | intoxication | illness resulting from food that is spoiled or contaminated by pathogenic bacteria, viruses, parasites, or toxins | C25.723.415 | Foodborne illness | ||
Food Preservatives | food additive | Substances capable of inhibiting, retarding or arresting the process of fermentation, acidification or other deterioration of foods | D27.720.372.300.385 | |||
foot | anatomical structure | anatomical structure found in vertebrates | A01.378.610.250 | Feet | ||
foot-and-mouth disease | animal disease bovine disease |
infectious and sometimes fatal viral disease (only in young animals) that affects cloven-hoofed animals and caused by apthovirus which is a non enveloped, single stranded RNA (ss RNA) virus. | C02.782.687.484 C22.380 |
Foot-and-mouth disease | ||
foreskin | prepuce | retractable fold of skin which covers and protects the glans of the penis | A05.360.444.492.362 | Foreskin | ||
founder effect | phenomenon | loss of genetic variation that occurs when a new population is established by a very small number of individuals | G05.285 | Founder effect | ||
Fourier analysis | harmonic analysis | E05.377 G17.226 L01.224.800.625 |
Fourier analysis | |||
Fournier gangrene | necrotizing fasciitis | C01.252.377 C12.294.229 |
Fournier gangrene | |||
Fourth metacarpal bone | metacarpal bone | A02.835.232.087.319.550 | Fourth metacarpal bone | |||
Free Radical Scavengers | antioxidant | Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. | D27.505.519.217.500 | |||
frenulum of tongue | A14.549.885.431 | Tongue | ||||
Fungicides, Industrial | Fungicide pesticide |
Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. | D27.720.031.700.288 D27.888.723.288 |
|||
GABA Agents | neurotransmitter | Substances used for their pharmacological actions on gabaergic systems. Gabaergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function | D27.505.696.577.240 D27.505.519.625.240 |
|||
GABA agonist | GABA Agents | GABA receptor agonist medication | D27.505.696.577.240.200 D27.505.519.625.240.200 |
GABA receptor agonists | ||
GABA Antagonists | GABA Agents | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gamma-aminobutyric acid and gaba receptor agonists | D27.505.519.625.240.300 D27.505.696.577.240.300 |
|||
GABA Modulators | GABA Agents | Substances that do not act as agonists or antagonists but do affect the gamma-aminobutyric acid receptor-ionophore complex. Gaba-a receptors (receptors, gaba-a) appear to have at least three allosteric sites at which modulators act: a site at which | D27.505.519.625.240.500 D27.505.696.577.240.500 |
|||
GABA Uptake Inhibitors | Neurotransmitter Uptake Inhibitors GABA Agents |
Compounds that suppress or block the plasma membrane transport of gamma-aminobutyric acid by gaba plasma membrane transport proteins | D27.505.696.577.600.535 D27.505.519.625.600.535 D27.505.696.577.240.750 D27.505.519.562.437.535 D27.505.519.625.240.750 |
|||
GABA-A Receptor Agonists | GABA agonist | Endogenous compounds and drugs that bind to and activate gaba-a receptors | D27.505.696.577.240.200.500 D27.505.519.625.240.200.500 |
|||
GABA-A Receptor Antagonists | GABA Antagonists | Drugs that bind to but do not activate gaba-a receptors thereby blocking the actions of endogenous or exogenous gaba-a receptor agonists | D27.505.696.577.240.300.500 D27.505.519.625.240.300.500 |
|||
GABA-B Receptor Agonists | GABA agonist | Endogenous compounds and drugs that bind to and activate gaba-b receptors | D27.505.519.625.240.200.750 D27.505.696.577.240.200.750 |
|||
GABA-B Receptor Antagonists | GABA Antagonists | Drugs that bind to but do not activate gaba-b receptors thereby blocking the actions of endogenous or exogenous gaba-b receptor agonists | D27.505.696.577.240.300.750 D27.505.519.625.240.300.750 |
|||
Galactogogues | Physiological Effects of Drugs | Substances that induce lactation | D27.505.696.365 | |||
gallbladder | animal organ anatomical structure |
organ in humans and other vertebrates | A03.159.439 | Gallbladder | ||
gallstone | gallbladder disease calculus |
Human disease | C06.130.409.633 C06.130.564.332.500 C23.300.175.525 |
Gallstones | ||
Ganglionic Blockers | Autonomic Agents | Agents having as their major action the interruption of neural transmission at nicotinic receptors on postganglionic autonomic neurons. Because their actions are so broad, including blocking of sympathetic and parasympathetic systems, their therapeu | D27.505.696.663.050.340 | |||
Ganglionic Stimulants | Autonomic Agents | Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non- | D27.505.696.663.050.400 | |||
Gasotransmitters | neurotransmitter | Endogenously produced lipid-soluble gaseous molecules which function as neurotransmitters and signal mediators targeting ion channels and transporters | D27.505.519.625.270 | |||
Gastrointestinal Agents | Therapeutic Uses | Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. | D27.505.954.483 | |||
Genodermatosis | skin disease genetic disease |
skin disease that is caused by a modification of the individual's genome | C16.320.850 C17.800.827 |
Genodermatoses | ||
genomics | branch of biology | genetics computational biology |
discipline in genetics | H01.158.273.180.350 H01.158.273.343.350 |
Genomics | |
genu valgum | knee disorder valgus deformity |
C05.116.482 | Genu valgum | |||
Gingival and periodontal pocket | periodontitis | C07.465.714.258.480.360 C07.465.714.533.750 |
||||
global warming | climate change | climate change | rise in the average temperature of Earth's atmosphere and oceans since the late 19th century and its projected continuation | G16.500.240.135.374.500 | Global warming | |
glossalgia | tongue disease | C07.465.910.280 C10.597.617.217 C23.888.592.612.414 |
||||
Glossoptosis | tongue disease | C07.465.910.411 | ||||
glottis | A04.329.364 | Glottis | ||||
gluten-free diet | diet | diet that excludes gluten | E02.642.249.265 G07.203.650.240.265 |
Gluten-free diet | ||
Glycine Agents | neurotransmitter | Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function | D27.505.519.625.300 D27.505.696.577.300 |
|||
Glycoside Hydrolase Inhibitors | enzyme inhibitor anti-diabetic medication |
Compounds that inhibit or block the activity of glycoside hydrolases such as alpha-amylases and alpha-glucosidases | D27.505.696.422.249 D27.505.519.389.320 |
|||
Gout Suppressants | disease-modifying antirheumatic drug | Agents that increase uric acid excretion by the kidney (uricosuric agents), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout | D27.505.954.329.337 | |||
granulosa cell tumour | ovarian cancer | C04.557.475.750.656 C04.588.322.455.398 C13.351.500.056.630.705.398 C13.351.937.418.685.398 C19.344.410.398 C19.391.630.705.398 |
||||
Graves' ophthalmopathy | toxic diffuse goiter eye and adnexa disease |
C11.270.842 C11.675.349.500.500 C19.874.283.605.500 C19.874.397.370.500 C20.111.555.500 |
Graves' ophthalmopathy | |||
greater omentum | A01.923.047.025.600.573 | Epiploon | ||||
greenhouse effect | process | atmosopheric phenomenon | G16.500.240.135.827 N06.230.265 |
Greenhouse effect | ||
greenhouse gas | Air Pollutants | gas in an atmosphere that absorbs and emits radiation within the thermal infrared range | D27.888.284.101.696 | Greenhouse gases | ||
Growth hormone deficiency | dwarfism | Human disease | C05.116.099.343.445 C05.116.132.358 C10.228.140.617.738.300.300 C19.297.312 C19.700.482.311 |
|||
Growth Inhibitors | Growth Substances | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators) | D27.505.696.377.450 | |||
growth medium | reagent laboratory equipment liquid gel Laboratory Chemicals |
liquid or gel used for the growth of microorganisms or cells | D27.720.470.305 | Petri dishes cultures | ||
Growth Substances | Physiological Effects of Drugs | Signal molecules that are involved in the control of cell growth and differentiation | D27.505.696.377 | |||
GTP Phosphohydrolase Activators | Enzyme activator | Agents and factors that activate gtp phosphohydrolase activity | D27.505.519.374.200 | |||
Guanylyl Cyclase C Agonists | Gastrointestinal Agents Enzyme activator |
Compunds that bind to and activate guanylyl cyclase-c receptors | D27.505.519.374.400 D27.505.954.483.590 |
|||
gums | animal structure | A14.549.167.646.480 | Gingiva | |||
H1 antagonist | histamine antagonist | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate h | D27.505.696.577.375.425.400 D27.505.519.625.375.425.400 |
|||
H2 antagonist | drugs for acid-related disorders histamine antagonist |
Drugs that selectively bind to but do not activate histamine h2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth musc | D27.505.519.625.375.425.425 D27.505.696.577.375.425.425 |
H2 receptor antagonists | ||
haemorrhagic disease of the newborn | perinatal disease hematological disease of fetus and newborn blood coagulation disease |
Human disease | C15.378.100.920.360 C15.378.463.841.464 C16.614.940 C18.654.422.360 C18.654.521.500.133.912.360 |
|||
Hair Bleaching Agents | Hair Preparations Bleaching Agents |
Chemicals that are used to oxidize pigments in hair | D27.720.642.315.249 D27.720.269.430.214 |
|||
hair dye | dye Hair Preparations |
dye used as a cosmetic to change hair color either permanently or temporarily | D27.720.269.430.430 D27.720.233.837 |
|||
Hair Preparations | cosmetics | Hair grooming, cleansing and modifying products meant for topical application to hair, usually human. They include sprays, bleaches, dyes, conditioners, rinses, shampoos, nutrient lotions, etc | D27.720.269.430 | |||
hallucinogen | psychoactive drug Psychotropic Drugs Physiological Effects of Drugs |
general group of pharmacological agents | D27.505.696.388 D27.505.954.427.700.372 |
Psychedelics | ||
hallux varus | foot deformity | C05.330.612 | Hallux varus | |||
hamate bone | bone carpal bone |
bone of the wrist | A02.835.232.087.319.150.400 | Hamate bone | ||
hammer toe | foot deformity | deformity of the proximal joint of the second, third or fourth toe | C05.330.615 | Hammer toes | ||
hand | anatomical region | extremity at the end of an arm or forelimb | A01.378.800.667 | Hands | ||
hand sanitizer | essential medicine | Anti-Infective Agents, Local disinfectant |
Preparations used as alternatives or supplements to hand washing with soap and water to destroy microorganisms and prevent transmission of pathogens. The active ingredient may be ethanol; 1-propanol; or povidone-iodine in a gel, foam, or liquid solu | D27.505.954.122.425.650 D27.720.274.650 D27.505.954.122.187.500 |
Hand sanitizers | |
Hazardous waste | waste hazard |
pollutant dangerous goods |
waste that poses substantial or potential threats to public health or the environment | D27.888.426.500 | Hazardous waste | |
head | anatomical region anatomical structure |
cephalic part of an animal | A01.456 | Heads | ||
head of femur | zone of femur | A02.835.232.043.650.247.343 | ||||
health information exchange | E05.318.308.940.968.625.500.500 L01.313.500.500 L01.399.500.500 |
|||||
health information management | L01.399.500 | |||||
health insurance | insurance | insurance for medical and health care costs | N03.219.521.576.343 | Health insurance | ||
health insurance exchange | N03.219.521.576.343.918.500 | Health insurance marketplace | ||||
health maintenance organization | managed care | organization | part of the health system and the social security | N03.219.521.576.343.800.400 N03.219.521.576.343.925.400 N04.452.758.244.425 N04.590.374.410.400 |
||
hearing disorder | disability sensation disorder |
human disease | C09.218.458 C10.597.751.418 C23.888.592.763.393 |
|||
heart valve prolapse | heart valve disease | Human disease | C14.280.484.400 | |||
hemagglutinin | membrane protein Agglutinin |
substance that causes red blood cells to agglutinate | D27.505.696.477.136.377 | |||
Hemangiosarcoma | angiosarcoma | C04.557.450.795.390 C04.557.645.390 |
||||
Hematinics | Hematologic Agents | Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias | D27.505.954.502.543 | |||
Hematologic Agents | Therapeutic Uses | Drugs that act on blood and blood-forming organs and those that affect the hemostatic system | D27.505.954.502 | |||
heme | heterocyclic compound | chemical substance | metal complex of ferrous ion and porphyrin; component of hemoglobin and some other biologically important hemoproteins | D03.383.129.578.840.500.640.587 D03.633.400.909.500.640.587 D04.345.783.500.640.587 D23.767.727.640.587 |
||
hemianopia | Anopsia | decreased vision or blindness (anopsia) in half the visual field, usually on one side of the vertical midline. The most common causes of this damage are stroke, brain tumor, and trauma, and stop the fight ref. | C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
Hemianopsia | ||
Hemifacial spasm | movement disorder | C07.465.364 C10.597.613.750.400 C23.888.592.608.750.400 |
||||
Hemodialysis Solutions | Dialysis Solutions | Solutions prepared for hemodialysis. The composition of the pre-dialysis solution may be varied in order to determine the effect of solvated metabolites on anoxia, malnutrition, acid-base balance, etc. Of principal interest are the effect of the cho | D27.505.954.578.483.651 D27.720.752.483.651 |
|||
Hemolytic Agents | cytotoxin | Substances that are toxic to blood in general, including the clotting mechanism; hematotoxins may refer to the hematopoietic system | D27.888.569.213.444 | |||
Hemostatics | Coagulants | Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents | D27.505.954.502.270.463 | |||
hemothorax | pleural effusion | type of pleural effusion in which blood accumulates in the pleural cavity | C08.528.380 C23.550.414.904 |
Hemothorax | ||
Heparin Antagonists | Coagulants mechanism of action |
Coagulant substances inhibiting the anticoagulant action of heparin | D27.505.954.502.270.546 D27.505.519.452 |
|||
herbicide | phytopharmaceuticals pesticide |
chemical used to kill unwanted plants | D27.720.031.700.366 D27.888.723.366 |
Herbicides | ||
hern | disease | type of digestive system disease | C23.300.707.374.937 | Hernias | ||
heteronymous hemianopsia | hemianopia | C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
||||
Histamine agonist | histaminergic | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically | D27.505.696.577.375.400 D27.505.519.625.375.400 |
|||
histamine antagonist | histaminergic | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine h1 receptors only | D27.505.519.625.375.425 D27.505.696.577.375.425 |
Antihistamines | ||
Histamine H1 Antagonists, Non-Sedating | H1 antagonist | A class of non-sedating drugs that bind to but do not activate histamine receptors (drug inverse agonism), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differi | D27.505.519.625.375.425.400.500 D27.505.696.577.375.425.400.500 |
|||
Histamine H3 Antagonists | histamine antagonist | Drugs that selectively bind to but do not activate histamine h3 receptors. They have been used to correct sleep wake disorders and memory disorders | D27.505.696.577.375.425.712 D27.505.519.625.375.425.712 |
|||
Histone deacetylase inhibitor | enzyme inhibitor | Compounds that inhibit histone deacetylases. This class of drugs may influence gene expression by increasing the level of acetylated histones in specific chromatin domains | D27.505.519.389.360 | |||
HIV Fusion Inhibitors | Anti-HIV Agents Viral Fusion Protein Inhibitors |
Inhibitors of the fusion of hiv to host cells, preventing viral entry. This includes compounds that block attachment of hiv envelope protein gp120 to cd4 receptors | D27.505.954.122.388.077.088.209 D27.505.519.957.500 D27.505.954.122.388.538.500 |
|||
HIV Integrase Inhibitors | Integrase inhibitor Anti-HIV Agents |
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. | D27.505.519.389.375.400 D27.505.954.122.388.077.088.314 |
|||
HIV Protease Inhibitors | Protease inhibitor Anti-HIV Agents |
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. | D27.505.519.389.745.420 D27.505.954.122.388.077.088.420 |
|||
homonymous hemianopsia | hemianopia | C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
Homonymous hemianopsia | |||
hormone | signaling molecule Semiochemical chemical compound Hormones, Hormone Substitutes, and Hormone Antagonists drug |
chemical released by a cell or a gland in one part of the body that sends out messages that affect cells in other parts of the organism | D27.505.696.399.472 | Hormones | ||
Hormone Antagonists | Hormones, Hormone Substitutes, and Hormone Antagonists | Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites | D27.505.696.399.450 | |||
Hormones, Hormone Substitutes, and Hormone Antagonists | Physiological Effects of Drugs | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists | D27.505.696.399 | |||
hospital gown | clothing | short washable garment worn by patients in a hospital | E07.325.877 E07.858.594 |
Hospital gowns | ||
human body | body | entire structure of a human organism | I01.076.201.450.560 | Human body | ||
human leg | leg human anatomical structure |
lower extremity or limb of the human body (foot, lower leg, thigh and hip) | A01.378.610.500 | Human legs | ||
human lung | lung | primary organs of respiration in humans | A04.411 | Respiratory system | ||
human mouth | mouth | mouth of a human being; consists of the orbicularies oris muscles which also called kissing muscles | A01.456.505.631 | Human mouths | ||
human penis | penis | human male sexual organ | A05.360.444.492 | Human penis | ||
human skin | skin human body |
the outer covering of the human body | A17.815.180 | |||
human trafficking | crime trade |
trade of humans for the purpose of forced labor, sexual slavery, or commercial sexual exploitation for the trafficker or others | I01.198.240.748.470 I01.880.735.384.399 |
Human trafficking | ||
hydrops fetalis | fetal disease | Human disease | C13.703.277.060.480 C15.378.295.480 C15.378.420.826.100.350 C16.300.060.480 C16.320.365.826.100.350 C20.306.480 C23.888.277.395 |
|||
hydrothorax | pleural effusion | pleural effusion containing serous liquid | C08.528.476 | |||
Hygroscopic Agents | Specialty Uses of Chemicals | Materials that readily absorb moisture from their surroundings. | D27.720.375 | |||
hymen | segment of vagina | membrane that surrounds or partially covers the external vaginal opening | A05.360.319.779.479 | Hymen | ||
hyoid bone | bone | horseshoe-shaped bone situated in the anterior midline of the neck between the chin and the thyroid cartilage | A02.835.232.409 | Hyoid bones | ||
hyperacusis | hearing disorder | hearing disorder characterized by a sensitivity to sound | C09.218.458.505 C10.597.751.418.505 C23.888.592.763.393.505 |
|||
Hyperalgesia | somatosensory disorder Pain out of proportion |
C10.597.751.791.400 C23.888.592.763.770.400 |
||||
Hyperammonemia | amino acid metabolic disorder | C23.550.421 | ||||
hypercholesterolemia | hyperlipidemia | high levels of cholesterol in the blood | C18.452.584.500.500.396 | Hypercholesterolemia | ||
Hyperdontia | tooth disease genetic disease |
An extra tooth, erupted or unerupted, resembling or unlike the other teeth in the group to which it belongs. Its presence may cause malposition of adjacent teeth or prevent their eruption. | C07.650.800.850 C07.793.700.850 C16.131.850.800.850 |
Hyperdontia | ||
hyperemesis gravidarum | complication | Complications of pregnancy morning sickness |
human disorder of pregnancy | C13.703.407.500 C23.888.821.937.049.500 |
||
Hyperinsulinism | Phenotype | an above normal level of insulin in the blood | C18.452.394.968 | |||
hyperkalemia | mineral metabolism disease | elevated level of potassium (K+) in the blood serum. | C18.452.950.396 | Hyperkalemia | ||
Hyperkinesia | movement disorder | C10.597.350.350 C23.888.592.350.350 |
||||
Hyperosmolar hyperglycemic state | Diabetic coma Hyperosmolar syndrome |
Human disease | C19.246.099.750.490 | |||
hypersalivation | salivary gland disease | excessive production of saliva | C07.465.815.815 | |||
Hypertelorism | Craniofacial abnormality genetic disease |
condition in which there is an abnormally increased distance between two organs or bodily parts; most often, this term is referring to an increased distance between the orbits (orbital hypertelorism) | C05.116.099.370.231.480 C05.660.207.231.480 C16.131.621.207.231.480 |
Hypertelorism | ||
hyphema | intraocular hemorrhage iris disease |
Human disease | C11.290.484 C23.550.414.756.550 |
Hyphema | ||
Hypnotics and Sedatives | Central Nervous System Depressants | Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. | D27.505.696.277.350 D27.505.954.427.210.350 |
|||
hypoesthesia | somatosensory disorder | C10.597.751.791.500 C23.888.592.763.770.500 |
||||
Iliotibial band syndrome | occupational disease | C26.558.554.425 C26.844.150.425 |
Iliotibial band syndrome | |||
immune reconstitution inflammatory syndrome | immune system disease | C20.608 | ||||
Immunologic adjuvant | Immunologic Factors Adjuvant |
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are end | D27.505.696.477.067 | |||
Immunologic Factors | Physiological Effects of Drugs | Biologically active substances whose activities affect or play a role in the functioning of the immune system. | D27.505.696.477 | |||
Immunosorbents | surfactant | An insoluble support for an antigen or antibodies that is used in affinity chromatography to adsorb the homologous antibody or antigen from a mixture. Many different substances are used, among them sepharose; glutaraldehyde; copolymers of anhydrides | D27.720.877.501 | |||
immunosuppressive drug | Immunologic Factors | Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting dna synthesis. Others may act through activation of t-cells or by inhibiting the activation of helper cells. While | D27.505.696.477.656 | Immunosuppressants | ||
Immunotoxin | Noxae | Semisynthetic conjugates of various toxic molecules, including radioactive isotopes and bacterial or plant toxins, with specific immune substances such as immunoglobulins; monoclonal antibodies; and antigens. The antitumor or antiviral immune substa | D27.888.569.271 | Immunotoxins | ||
inbreeding | production of offspring from closely related organism | E05.820.150.520 G05.090.403 |
||||
incisor | tooth | A14.549.167.860.425 | Incisors | |||
Incretins | hormone | Peptides which stimulate insulin release from the pancreatic beta cells following oral nutrient ingestion, or postprandially | D27.505.696.399.472.580 | |||
Indicators and Reagents | Laboratory Chemicals | Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a | D27.720.470.410 | |||
inferior colliculus | Inferior colliculus | A08.186.211.132.659.237.364 | Inferior colliculus | |||
Inferior ganglion of vagus nerve | A08.340.390.550 | |||||
informatics | academic field | L01.313 | Computer science | |||
information science | science academic discipline |
field primarily concerned with the analysis, collection, classification, manipulation, storage, retrieval and dissemination of information | L L01 |
Information science | ||
ingrown nail | nail disease | C17.800.529.406 | Ingrown nail | |||
Inguinal canal | A01.047.412 | Inguinal canal | ||||
ink blot test | projective test | F04.711.647.622.341 | ||||
insect bite | Arthropod bites and stings diseases caused by insect |
wound caused by the bite of an insect | C25.723.127.071 C26.176.143 |
|||
insect repellent | pesticide Protective Agents Animal repellent |
substance which repels insects | D27.888.723.441 D27.505.696.706.434 D27.720.031.700.441 |
Insect repellents | ||
insecticide | phytopharmaceuticals zoocide pesticide |
pesticide used against insects | D27.888.723.491 D27.720.031.700.491 |
Insecticides | ||
Insulin Antagonists | Hormone Antagonists | Compounds which inhibit or antagonize the biosynthesis or action of insulin | D27.505.696.399.450.420 | |||
insulin resistance | diabetes mellitus drug resistance |
human disease | C18.452.394.968.500 | Insulin resistance | ||
Integrase inhibitor | enzyme inhibitor | Compounds which inhibit or antagonize biosynthesis or actions of integrase | D27.505.519.389.375 | Integrase inhibitors | ||
Intercalating Agents | Indicators and Reagents | Agents that are capable of inserting themselves between the successive bases in dna, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of dna | D27.720.470.410.360 | |||
Intercarpal articulations | A02.835.583.405.174 | |||||
Interferon Inducers | Immunologic Factors | Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. | D27.505.696.477.828 | |||
interneuron | cell type | neuron | A08.663.358 | |||
Intertarsal articulations | A02.835.583.378.831 | |||||
Interventricular foramina | A08.186.211.276 | Interventricular foramina | ||||
intervertebral disc | fastener | cartilage of spine | A02.165.308.410 | Intervertebral discs | ||
Intraductal carcinoma | breast carcinoma in situ | C04.557.470.200.025.275 C04.557.470.200.240.187.250 C04.557.470.615.275 |
||||
Intralipid | medical food Parenteral Nutrition Solutions |
pharmaceutical product | D27.505.954.578.733.500 D27.720.752.733.500 |
|||
Intrathecal | route of administration | route of administration | A08.186.566.166.686 | |||
involuntary commitment | hospitalization | legal process through which an individual who is deemed to have symptoms of severe mental disorder is court-ordered into treatment | F04.096.544.335.200 N03.706.535.351.200 |
|||
Ion Exchange Resins | Laboratory Chemicals | High molecular weight, insoluble polymers which contain functional groups that are capable of undergoing exchange reactions (ion exchange) with either cations or anions | D27.720.470.420 | |||
Ionic Liquids | solvent | Salts that melt below 100 c. Their low volatilization can be an advantage over volatile organic solvents | D27.720.844.500 | |||
Ionophore | Specialty Uses of Chemicals Membrane Transport Modulators |
Chemical agents that increase the permeability of biological or artificial lipid membranes to specific ions. Most ionophores are relatively small organic molecules that act as mobile carriers within membranes or coalesce to form ion permeable channe | D27.505.519.562.374 D27.720.395 |
Ionophores | ||
IQ test | psychological test | F04.711.141.493 | ||||
Iron Chelating Agents | Chelating Agents | Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in bi | D27.505.519.914.500.410 D27.720.832.500.410 |
|||
Irritants | Noxae Specialty Uses of Chemicals |
Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscess | D27.720.400 D27.888.569.300 |
|||
Islands of Calleja | A08.186.211.577.699.400 | |||||
itch | symptom somatosensory disorder |
disease | C17.800.685 C23.888.885.625 |
|||
Janus kinase inhibitor | Protein kinase inhibitor | Agents that inhibit janus kinases | D27.505.519.389.755.500 | |||
Jewish people | people ethnic group ethnoreligious group nation |
Semitic | ancient nation, race, and ethnoreligious group from the Levant | M01.686.754.600 | Jews | |
joint instability | hypermobility syndrome | D007593 | ||||
Kasabach–Merritt syndrome | hemangioma | A rare disease usually seen in infants | C04.557.645.375.617 C15.378.140.855.645 |
Kasabach–Merritt syndrome | ||
ketosis | disease of metabolism | C18.452.076.176.652 | ||||
knee | synovial joint | synovial joint joint |
joint between the thigh and lower leg | A01.378.610.450 | Knee | |
kombucha | tea fermented beverage |
D20.215.784.844.500 | Kombucha | |||
Kraurosis vulvae | vulvar disease Lichen sclerosus |
C13.351.500.944.815 | ||||
Laboratory Chemicals | Specialty Uses of Chemicals | Chemicals necessary to perform experimental and/or investigative procedures and for the preparation of drugs and other chemicals. | D27.720.470 | |||
lacrimal gland | exocrine gland | paired, almond-shaped exocrine gland, one for each eye, that secretes the aqueous layer of the tear film | A09.371.463 | |||
Lamellar corpuscle | Q1648747 | A08.675.650.915.750.700 | Lamellar corpuscle | |||
Laryngopharyngeal reflux | gastroesophageal reflux disease | retrograde flow of gastric contents to the upper aero-digestive tract, which causes a variety of symptoms, such as cough, hoarseness, and wheezing | C06.405.117.119.500.484.500 C08.360.577 |
|||
Latent autoimmune diabetes | type 1 diabetes mellitus | C18.452.394.750.714 C19.246.656 C20.111.576 |
||||
lathyrism | food poisoning | C25.723.756.558 | ||||
laxative | purgative Gastrointestinal Agents |
Agents that produce a soft formed stool, and relax and loosen the bowels, typically used over a protracted period, to relieve constipation | D27.505.954.483.620 | Laxatives | ||
lead poisoning | metal poisoning occupational disease chemical hazard rare intoxication |
C25.723.589 | Lead poisoning | |||
Leprostatic Agents | antibiotic | Substances that suppress mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions | D27.505.954.122.085.777 | |||
lesser omentum | A01.047.025.600.573 | |||||
leukocytosis | leukocyte disease | C15.378.553.475 C23.550.526 |
||||
Leukotriene Antagonists | Hormone Antagonists | A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level | D27.505.696.399.450.565 | |||
Lhermitte–Duclos disease | gangliocytoma | C04.445.435 C04.651.435 C04.700.435 C16.320.700.435 |
Lhermitte–Duclos disease | |||
life style | activity human behaviour |
typical way of life of an individual, group, or culture | F01.829.458 | |||
Ligamenta flava | A02.513.514.287 | |||||
ligand | Laboratory Chemicals | molecule or functional group that binds or can bind to the central atom in a coordination complex | D27.720.470.480 | Ligands | ||
lingual nerve | nerve | A08.800.800.120.760.500.450 | ||||
Lipid Regulating Agents | Therapeutic Uses | Substances that alter the metabolism of lipids | D27.505.954.557 | |||
lipoblastoma | lipoma connective tissue benign neoplasm |
C04.557.450.550.400.500 | ||||
Lipoprotein Lipase Activators | Lipotropic Agents Enzyme activator |
Compounds that increase the enzymatic activity of lipoprotein lipase. Lipoprotein lipase activators have a potential role in the treatment of obesity by increasing lipid metabolism. Note that substances that increase the synthesis of lipoprotein lip | D27.505.954.557.500.601.500 D27.505.519.374.600 |
|||
Lipotropic Agents | hypolipidemic Gastrointestinal Agents |
Endogenous factors or drugs that increase the transport and metabolism of lipids including the synthesis of lipoproteins by the liver and their uptake by extrahepatic tissues | D27.505.954.557.500.601 D27.505.519.186.071.601 D27.505.954.483.680 |
|||
Lipoxygenase inhibitor | enzyme inhibitor | Compounds that bind to and inhibit that enzymatic activity of lipoxygenases. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of leukotrienes | D27.505.519.389.480 | |||
List of thalamic nuclei | Wikimedia list article | Wikimedia list article | A08.186.211.730.385.826.701 | |||
liver | animal organ | vital organ in vertebrates and some other animals | A03.620 | Livers | ||
liver abscess | abdominal abscess liver disease |
C01.539.830.025.020.455 C06.552.597 |
Liver abscesses | |||
liver tumor | tumor liver disease |
C04.588.274.623 C06.301.623 C06.552.697 |
Ultrasound images of liver tumors | |||
long-term care insurance | health insurance | N03.219.521.576.343.508 | ||||
long-term effects of alcohol | Alcohol and health | health effects of drinking alcoholic beverages | C25.775.100 | |||
lower back pain | back pain low back disorder |
disorder involving muscles, nerves, bones of the back | C10.597.617.140.400 C23.888.592.612.107.400 |
Back pain | ||
lubricant | type of chemical components for an application | mixture Specialty Uses of Chemicals |
substance, usually organic, introduced to reduce friction between surfaces in mutual contact, which ultimately reduces the heat generated when the surfaces move | D27.720.556 | Lubricants | |
lumbar plexus | nerve plexus | A08.800.800.720.450 | Lumbar plexus | |||
Lumbosacral plexus | A08.800.800.720.450 | |||||
Luminescent Agents | Indicators and Reagents | Compound such as luminescent proteins that cause or emit light (physical luminescence) | D27.720.470.410.505 | |||
lunate bone | bone short bone carpal bone |
bone of the carpus | A02.835.232.087.144.663 | Lunate bone | ||
lung | animal organ | essential respiration organ in many air-breathing animals | A04.411 | Lungs | ||
Luteolytic Agents | Contraceptive Agents, Female Reproductive Control Agents |
Chemical compounds causing luteolysis or degeneration | D27.505.954.705.610 D27.505.954.705.360.276.450 D27.505.696.875.360.276.450 D27.505.696.875.610 |
|||
lymphadenopathy | immune system disease lymph node disease clinical sign |
disorder of lymph nodes | C15.604 C15.604.338 |
Lymphadenopathy | ||
Lymphocytosis | leukocytosis | C15.378.553.475.604 | ||||
machiavellianism | philosophy personality trait |
political philosophy sometimes measured as a personality trait | F01.752.650 | |||
macula of retina | A09.371.729.522 | Macula lutea | ||||
Major duodenal papilla | A03.159.183.079.300.950 | |||||
mammary gland | exocrine gland | exocrine gland in mammals that produces milk to feed young offspring | A01.236.249 | Mammary glands | ||
managed care | health insurance | a type of health insurance system | N03.219.521.576.343.800 N04.590.374.410 |
|||
mandibular fracture | bone fracture mandibular injury |
break through the mandibular bone | C10.900.300.284.500.400.255 C26.404.750.467.441 C26.915.300.425.500.400.255 C10.900.300.284.500.400 C26.404.750.467 C26.915.300.425.500.400 |
Fractures of the human mandible | ||
mandibular nerve | nerve | A08.800.800.120.760.500 | ||||
Marchiafava-Bignami disease | demyelinating disease | C10.228.140.163.510 C10.314.475 |
||||
Matrix metalloproteinase inhibitor | Protease inhibitor | Compounds that inhibit the enzyme activity or activation of matrix metalloproteinases | D27.505.519.389.745.610 | |||
maxilla | bone | upper jawbone formed from the fusion of two maxillary bones; includes the frontal portion of the palate of the mouth | A02.835.232.781.324.502.645 | Maxilla | ||
maxillary nerve | nerve | A08.800.800.120.760.550 | ||||
May–Thurner syndrome | vascular malformation | C14.240.850.906 C14.907.617.648 C16.131.240.850.890 |
||||
mechanism of action | means biochemistry Pharmacologic Actions |
biochemical interaction through which a drug produces its pharmacological effect | D27.505.519 | |||
Medial collateral ligament | A02.513.514.162.600 | |||||
Median eminence | A08.186.211.730.385.357.352.435.249 | |||||
Medicaid | publicly funded health care | United States social health care program for families and individuals with limited resources | N03.219.521.346.506.564.655 N03.706.615.693 |
|||
Medical savings account | health insurance | N03.219.151.170.650 N03.219.521.576.090.650 N03.219.521.576.343.830 N03.219.559.500 |
||||
Medigap | health insurance in the United States | supplemental health insurance that pays for costs not covered by Medicare or private health insurance | N03.219.521.576.343.539 | |||
Mediterranean diet | intangible cultural heritage | diet | intangible cultural heritage | E02.642.249.270 G07.203.650.240.270 |
Mediterranean diet | |
MEDLINE | bibliographic database medical database |
medical bibliographical database | L01.313.500.750.280.710.500 L01.313.500.750.280.750.500 L01.313.500.750.300.188.300.650.500 L01.313.500.750.300.710.500 L01.313.500.750.300.742.650.500 L01.470.750.500.650.500 |
|||
medulla oblongata | A08.186.211.132.810.406 | Medulla oblongata | ||||
Meibomian gland | A09.371.337.614 | |||||
Meigs syndrome | ovarian tumor neoplastic syndrome |
A rare syndrome affecting females. It is characterized by pleural effusion, ascites and non-malignant ovarian neoplasm. This syndrome usually follows a benign course. Prognosis is favorable following surgical resection of the ovarian mass. | C04.588.322.455.531 C13.351.500.056.630.705.531 C13.351.937.418.685.531 C19.344.410.531 C19.391.630.705.531 |
|||
Meissner's plexus | plexus | part of the enteric nervous system | A08.800.050.050.850 | |||
Melanocytic nevus | nevus | Human disease | C04.557.665.560.615 | Melanocytic nevus | ||
Membrane Transport Modulators | mechanism of action | Agents that affect ion pumps; ion channels; abc transporters; and other membrane transport proteins | D27.505.519.562 | |||
meninges | membranes that envelop the brain and spinal cord | A08.186.566 | Meninges | |||
menorrhagia | dysfunctional uterine bleeding | C13.351.500.852.691.449 C23.550.568.875 |
Menorrhagia | |||
Menstruation-Inducing Agents | Contraceptive Agents, Female Reproductive Control Agents |
Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (from dorland, 27th ed) | D27.505.696.875.650 D27.505.696.875.360.276.500 D27.505.954.705.650 D27.505.954.705.360.276.500 |
|||
mesenteric ischemia | infarction Bowel infarction |
C06.405.469.656 C06.844.460 C14.907.549 |
Mesenteric ischemia | |||
mesoderm | germ layer | A16.254.425.660 | Mesoderm | |||
mesonephros | A16.254.500 | |||||
messenger RNA | transcript | RNA | large family of RNA molecules that convey genetic information from DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression | D13.444.735.544 | MRNA | |
Metabolic Side Effects of Drugs and Substances | adverse drug reaction Pharmacologic Actions |
Specific effects of drugs and substances on metabolic pathways such as those occurring through the CYTOCHROME P-450 ENZYME SYSTEM. These include effects that often result in DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; and HERB-DRUG INTERACTI | D27.505.389 | |||
metatarsalgia | ankle or tarsus enthesopathy | C05.360.500 C05.550.610 C10.597.617.560 C23.888.592.612.540 |
||||
metathalamus | A08.186.211.730.385.826.701.444 | |||||
Metrorrhagia | dysfunctional uterine bleeding | C13.351.500.852.691.622 C23.550.414.993.700 |
||||
micrognathism | minor physical anomaly | C05.500.460.457 C05.660.207.540.460.457 C07.320.440.457 C07.650.500.460.457 C16.131.621.207.540.460.457 C16.131.850.500.460.457 |
Micrognathism | |||
Micronutrients | Growth Substances | Essential dietary elements or organic compounds that are required in only small quantities for normal physiologic processes to occur | D27.505.696.377.605 | |||
Midbrain tegmentum | A08.186.211.132.659.822 | |||||
mindfulness | technique | meditation | meditation practice | F02.463.551 F04.754.137.428.500 |
Mindfulness | |
mineralocorticoid | hormone | hormone | A group of corticosteroids primarily associated with water and electrolyte balance. This is accomplished through the effect on ion transport in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is its | D27.505.696.399.472.673 | Mineralocorticoids | |
Mineralocorticoid Receptor Antagonists | Hormone Antagonists Potassium-sparing diuretic |
Drugs that bind to and block the activation of mineralocorticoid receptors by mineralocorticoids such as aldosterone | D27.505.696.399.450.600 D27.505.696.560.500.726.249 |
|||
Minnesota Multiphasic Personality Inventory | personality test | personality test used in clinical psychology evaluations | F04.711.647.513.607 | |||
Miotics | Autonomic Agents | Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here | D27.505.696.663.050.495 | |||
Mirizzi's syndrome | cholestasis | C06.130.120.135.812 | Mirizzi's syndrome | |||
mitochondrial DNA | DNA | DNA located in organelles called mitochondria | D13.444.308.283.225 | Mitochondrial DNA | ||
Mitogens | Mitosis Modulators | Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with lectins, but also substances from streptococci (associated with streptolysin s) and from strains of alpha-toxin-producing staphylococci | D27.505.519.593.624 | |||
Mitosis Modulators | mechanism of action | Agents that affect mitosis of cells | D27.505.519.593 | |||
Mixed Müllerian tumor | Complex and mixed tumor | C04.557.435.540 | ||||
Modes of Toxic Action | chemical Actions and Uses | chemical actions with harmful or deadly effect on living organisms | D27.888 | |||
Molecular Probes | business | Laboratory Chemicals Diagnostic Uses of Chemicals |
A group of atoms or molecules attached to other molecules or cellular structures and used in studying the properties of these molecules and structures. Radioactive dna or rna sequences are used in molecular genetics to detect the presence of a compl | D27.720.470.530 D27.505.259.750 |
||
Molluscacides | pesticide | Agents destructive to snails and other mollusks | D27.888.723.596 D27.720.031.700.596 |
|||
Monoamine oxidase inhibitor | chemical substance enzyme inhibitor |
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (from gilman, et al., goodman and gilman's the pharmacological basis of therapeutics, 8th ed, p414) | D27.505.519.389.616 | Monoamine oxidase inhibitors | ||
Monteggia fracture | Ulna Fractures fracture dislocation |
C05.116.359.336.750 C26.289.336.750 C26.404.937.547 |
Monteggia fractures | |||
morning sickness | Symptoms and discomforts of pregnancy nausea |
C13.703.407 C23.888.821.937.049 |
||||
Morton's neuroma | foot disease | Pie isquierdo | C05.360.500.500 C05.550.610.500 C10.597.617.560.500 C10.597.617.682.275 C10.668.829.600.375 C23.888.592.612.540.500 C23.888.592.612.664.275 |
Morton's neuroma | ||
mouth | animal organ | first portion of the alimentary canal that receives food | A01.456.505.631 | Mouths | ||
mouthwash | product Biomedical and Dental Materials cosmetics |
rinse for oral hygiene or cosmetic purposes | D27.720.269.583 D27.720.102.583 |
Mouthwash | ||
moxibustion | Chinese medicine therapy | E02.190.044.588 | Moxibustion | |||
Münchausen syndrome | factitious disorder | Psychiatric Factitious Disorder | F03.875.375.600 | |||
muscarinic agonist | Cholinergic Agonists | activating agent of the muscarinic acetylcholine receptor | D27.505.696.577.120.140.500 D27.505.519.625.120.140.500 |
Muscarinic agonists | ||
Muscarinic antagonist | anticholinergic | A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists | D27.505.696.577.120.200.500 D27.505.519.625.120.200.500 |
Muscarinic antagonists | ||
Muscle Relaxants, Central | Central Nervous System Agents Neuromuscular Agents Physiological Effects of Drugs |
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, an | D27.505.954.427.525 D27.505.696.510 D27.505.696.663.700.600 |
|||
mushroom poisoning | poisoning food poisoning Mycotoxicosis |
harmful effects from ingestion of toxic substances present in a mushroom | C25.723.415.551 C25.723.680.551 |
Amanita | ||
Mutagen | Noxae | Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes | D27.888.569.468 | Mutagens | ||
Mydriatics | Autonomic Agents | Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics | D27.505.696.663.050.500 | |||
Myeloablative Agonists | antineoplastic immunosuppressive drug |
Agents that destroy bone marrow activity. They are used to prepare patients for bone marrow transplantation or stem cell transplantation | D27.505.696.477.656.750 D27.505.954.248.589 |
|||
Myelolipoma | adipose tissue neoplasm | C04.557.450.550.710 | Myelolipoma | |||
Myenteric plexus | plexus | part of the enteric nervous system | A08.800.050.050.500 | |||
myotonia | myotonic disease | C10.597.613.700 C23.888.592.608.700 |
||||
myxomatosis | rabbit disease | rabbit disease | C02.256.743.665 C22.627 |
Myxomatosis | ||
narcotic | psychoactive drug analgesic Central Nervous System Depressants |
chemical substance with psycho-active properties | D27.505.954.427.210.600 D27.505.696.277.600 D27.505.696.663.850.014.760 D27.505.954.427.040.550 |
Drugs | ||
Narcotic Antagonists | Central Nervous System Agents Sensory System Agents Physiological Effects of Drugs |
Agents inhibiting the effect of narcotics on the central nervous system | D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550 |
|||
nasal cavity | anatomical cavity | A04.531.449 | Nasal cavity | |||
Nasal Decongestants | Vasoconstrictor Agents Respiratory System Agents |
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that l | D27.505.954.411.793.610 D27.505.954.796.560 |
|||
nasolacrimal duct | duct | carries tears from the lacrimal sac of the eye into the nasal cavity. | A09.371.463.640 | |||
Natriuretic Agents | Cardiovascular Agents Physiological Effects of Drugs |
Endogenous or exogenous chemicals that regulate the water-electrolyte balance in the body. They consist of peptides and non-peptide compounds | D27.505.954.411.455 D27.505.696.560 |
|||
navicular bone | bone | bone of the ankle | A02.835.232.043.300.710 | Navicular bone | ||
neck of femur | zone of femur | A02.835.232.043.650.247.510 | ||||
neglected tropical disease | tropical disease diseases of poverty |
C23.550.291.890 | ||||
neonatal conjunctivitis | conjunctivitis | C01.252.354.225.625 C01.252.400.625.391.658 C01.539.375.354.220.625 C11.187.183.220.538 C11.294.354.220.625 C16.614.677 |
Neonatal conjunctivitis | |||
nephrogenic systemic fibrosis | fibrosis skin disease other acquired skin disease |
C17.800.553 C23.550.355.550 |
||||
nerve agent | chemical compound organophosphate chemical warfare agent Specialty Uses of Chemicals |
class of organophosphates; classified as weapons of mass destruction | D27.720.777.300.500 D27.720.599 |
Nerve agents | ||
Neuroborreliosis | Lyme disease | C01.252.200.450 C01.252.400.155.569.600 C01.252.400.825.480.700 C01.252.847.193.569.600 C10.228.228.180.437 |
||||
Neurolemma | A08.561.600 | |||||
Neuromuscular Agents | Peripheral Nervous System Agents | Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (neuromuscular blocking agents), and drugs that act centrally as skeletal muscle relaxants (muscle | D27.505.696.663.700 | |||
Neuromuscular Blocking Agents | Neuromuscular Agents | Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depo | D27.505.696.663.700.710 | |||
Neuromuscular Depolarizing Agents | Neuromuscular Blocking Agents | Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation | D27.505.696.663.700.710.550 | |||
Neuromuscular Nondepolarizing Agents | Neuromuscular Blocking Agents | Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatm | D27.505.696.663.700.710.575 | |||
neuromyotonia | Designated intractable/rare diseases | peripheral nerve hyperexcitability | C05.651.392 C10.668.829.425 |
|||
Neuronal Tract-Tracers | Indicators and Reagents Diagnostic Uses of Chemicals |
Substances used to identify the location and to characterize the types of neural pathways | D27.505.259.812 D27.720.470.410.577 |
|||
Neuroprotective Agents | Central Nervous System Agents Protective Agents |
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, bu | D27.505.696.706.548 D27.505.954.427.575 |
|||
neuropsychological test | psychological test | F04.711.513 | Neuropsychological tests | |||
neurotoxin | toxin Noxae |
substance poisonous or destructive to nerve tissue | D27.888.569.504 | Neurotoxins | ||
neurotransmitter | chemical compound mechanism of action Physiological Effects of Drugs |
endogenous chemicals that transmit signals across a synapse from one neuron to another | D27.505.519.625 D27.505.696.577 |
Neurotransmitters | ||
Neurotransmitter Uptake Inhibitors | neurotransmitter Membrane Transport Modulators |
Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the tra | D27.505.519.625.600 D27.505.696.577.600 D27.505.519.562.437 |
|||
nevus | skin benign neoplasm rare genetic developmental defect during embryogenesis rare skin tumor or hamartoma |
Human disease | C04.557.665.560 | Nevus | ||
Nicotinic agonist | Cholinergic Agonists | Drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the cent | D27.505.519.625.120.140.700 D27.505.696.577.120.140.700 |
Nicotinic agonists | ||
Nicotinic antagonist | anticholinergic | Drugs that bind to nicotinic cholinergic receptors (receptors, nicotinic) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, an | D27.505.696.577.120.200.700 D27.505.519.625.120.200.700 |
Nicotinic antagonists | ||
night horror | sleep disorder | C10.886.659.635.600 | ||||
Nitric Oxide Donors | Cardiovascular Agents mechanism of action |
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarcti | D27.505.954.411.590 D27.505.519.656 |
|||
nitrogen narcosis | effect hazard |
diving disorder | narcotic effect of high partial pressure respired nitrogen | C24.426 C25.723.455.571 |
||
NK1 receptor antagonist | neurotransmitter | Compounds that inhibit or block the activity of neurokinin-1 receptors | D27.505.519.625.487 D27.505.696.577.487 |
|||
noise-induced hearing loss | occupational disease sensorineural hearing loss Health effects from noise |
C09.218.458.341.887.460 C10.597.751.418.341.887.460 C23.888.592.763.393.341.887.460 |
||||
Non-24-hour sleep-wake disorder | obsolete chronobiology disease | C10.281 | ||||
non-opioid analgesic | analgesic | A subclass of analgesic agents that typically do not bind to opioid receptors and are not addictive. Many non-narcotic analgesics are offered as nonprescription drugs | D27.505.954.427.040.100 D27.505.696.663.850.014.040 |
|||
Nonsteroidal Anti-Androgens | Androgen Antagonists | Nonsteroidal agents which block the action or downregulate the synthesis of androgens | D27.505.696.399.450.065.500 | |||
nonverbal communication | communication | process of communication through sending and receiving wordless (mostly visual) cues between people | F01.145.209.530 L01.143.649 |
Non-verbal communication | ||
Norepinephrine reuptake inhibitor | antidepressant Neurotransmitter Uptake Inhibitors Adrenergic Agents |
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs | D27.505.696.577.600.050 D27.505.519.625.600.050 D27.505.519.562.437.050 D27.505.696.577.050.601 D27.505.519.625.050.601 |
Norepinephrine reuptake inhibitors | ||
notochord | flexible rod-shaped body found in embryos of all chordates | A16.254.610 | ||||
Noxae | Modes of Toxic Action | Agents capable of exerting a harmful effect on the body. | D27.888.569 | |||
nucleic acid inhibitor | enzyme inhibitor | Compounds that inhibit cell production of dna or rna | D27.505.519.389.675 | |||
Nucleic Acid Probes | Molecular Probes | Nucleic acid which complements a specific mrna or dna molecule, or fragment thereof; used for hybridization studies in order to identify microorganisms and for genetic studies | D27.505.259.750.600 D27.720.470.530.600 |
|||
nucleus accumbens | A08.186.211.730.885.105.683 | Nucleus accumbens | ||||
Nucleus raphe magnus | nucleus raphe magnus | A08.186.211.132.810.428.600.650.562.500 | ||||
Nutritive Sweeteners | sweetener | Any agent that adds not only sweet taste but some energy value to food. They include natural sugars such as sucrose; fructose; and galactose; and certain sugar alcohols | D27.720.372.300.353.609.750 | |||
nystagmus | eye and adnexa disease eye movement |
condition of involuntary eye movement | C10.292.562.675 C11.590.400 |
Nystagmus | ||
Obstetrical brachial plexus palsy | brachial plexus lesion obstetric paralysis |
neurological injury in newborns | C10.668.829.100 | |||
obstructed labor | obstetric labor complication | human disease | C13.703.420.288 | |||
occipital lobe | cerebral lobe | part of the brain | A08.186.211.730.885.213.571 | Occipital lobe | ||
Ointment Bases | Pharmaceutic Aids | Various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons; vehicles for medicinal substances intended for external application; there are four classes: hydrocarbon base, absorption base, water-removable base and water- | D27.720.744.523 | |||
olfactory bulb | organism substance anatomical structure |
help with smell | A08.186.211.577.699.573 | Olfactory bulb | ||
Olfactory epithelium | A04.531.520.573 | Olfactory epithelium | ||||
Oligodeoxyribonucleotides, Antisense | DNA, Antisense Antisense oligonucleotide |
Short fragments of dna that are used to alter the function of target rnas or dnas to which they hybridize | D27.720.470.530.600.150.640.640 D27.720.470.530.600.150.200.640 |
|||
Oligonucleotide Probes | Nucleic Acid Probes | Synthetic or natural oligonucleotides used in hybridization studies in order to identify and study specific nucleic acid fragments, e.g., dna segments near or within a specific gene locus or gene. The probe hybridizes with a specific mrna, if presen | D27.505.259.750.600.650 D27.720.470.530.600.650 |
|||
Oligoribonucleotides, Antisense | Antisense RNA Antisense oligonucleotide |
Short fragments of rna that are used to alter the function of target rnas or dnas to which they hybridize | D27.720.470.530.600.150.760.645 D27.720.470.530.600.150.640.645 |
|||
olivary body | A08.186.211.132.810.406.574 | |||||
omental bursa | A01.047.025.600.678 | |||||
onycholysis | nail disease | C17.800.529.478 | Onycholysis | |||
oocyte | germ cell | female gametocyte or germ cell involved in reproduction. In other words, it is an immature ovum, or egg cell. An oocyte is produced in the ovary during female gametogenesis | A05.360.490.690.680 | Oocytes | ||
Oogonium | A05.360.490.690.700 | |||||
ophthalmic nerve | sensory nerve | nerve | sensory nerve | A08.800.800.120.760.650 | ||
orbit | The cavity or socket of the skull in which the eye and its appendages are situated. | A02.835.232.781.324.690 | Orbit (anatomy) | |||
Orexin Receptor Antagonists | Sleep Aids, Pharmaceutical neurotransmitter |
Substances that bind to and inhibit the action of orexin receptors. Drugs in this class have been used as sleep aids | D27.505.696.577.663 D27.505.519.625.663 D27.505.954.842.500 |
|||
Ornithine Decarboxylase Inhibitors | enzyme inhibitor | Substances and drugs that inhibit or block the activity of ornithine decarboxylase | D27.505.519.389.705 | |||
Osseous spiral lamina | A09.246.631.246.930 | |||||
osteoma | benign neoplasm bone tumor |
C04.557.450.565.575.625 | Osteoma | |||
osteopenia | Demineralization bone disease |
C05.116.198.247 C18.452.104.247 |
Osteopenia | |||
otalgia | auditory system disease | pain in the ear | C09.218.350 C10.597.617.199 C23.888.592.612.302 |
|||
outlier | N03.219.521.710.305.200.080.550 | Outliers | ||||
oval window | A09.246.631.909.551 | |||||
overcrowding | determinants of health | condition where more people are located within a given space than is considered tolerable from a safety and health perspective which will depend on current environment and local cultural norms | F01.145.875.281 | |||
Oxidants, Photochemical | oxidizing agent | Compounds that accept electrons in an oxidation-reduction reaction. The reaction is induced by or accelerated by exposure to electromagnetic radiation in the spectrum of visible or ultraviolet light | D27.888.569.540.631 D27.720.642.631 |
|||
oxidizing agent | chemical substance | electron acceptor Noxae Specialty Uses of Chemicals |
chemical compound used to oxidize another substance in a chemical reaction | D27.720.642 D27.888.569.540 |
||
Oxytocics | Reproductive Control Agents | Drugs that stimulate contraction of the myometrium. They are used to induce labor, obstetric at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or wi | D27.505.696.875.737 D27.505.954.705.737 |
|||
ozone depletion | physical process hole |
stratospheric phenomena of Earth | G16.500.785 N06.230.300.100.700.500 |
Ozone layer | ||
ozone layer | layer | region of Earth's stratosphere that absorbs most of the Sun's UV radiation | D01.362.670.600.500 G16.500.275.063.700 N06.230.300.100.700 |
Ozone layer | ||
palatine bone | bone | facial bone | A02.835.232.781.324.502.660 | Palatine bones | ||
pancreas | gland organ |
glandular organ in the digestive system and endocrine system of vertebrates | A03.734 | Pancreas | ||
pancreatic duct | duct joining the pancreas to the common bile duct | A03.734.667 | Pancreatic duct | |||
paralysis | health problem | loss of muscle function for one or more muscles | C10.597.622 C23.888.592.636 |
Paralysis | ||
Paramesonephric duct | Primordium | A16.623 | Müllerian duct | |||
Paraproteinemia | Immunoproliferative disorder | Human disease | C15.378.147.780 C20.683.780 |
|||
parasitic worms | C03.335 | Helminths | ||||
parasomnia | sleep disorder | category of sleep disorders | C10.886.659 | |||
Parasympatholytic | Autonomic Agents | Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the muscarinic antagonists | D27.505.696.663.050.650 | |||
Parasympathomimetic drug | Autonomic Agents | Drugs which mimic the action of stimulation of cholinergic receptors. | D27.505.696.663.050.675 | Parasympathomimetics | ||
parathyroid | endocrine gland | endocrine gland | A06.407.560 | Parathyroid gland | ||
Paratuberculosishvjcb | mycobacterium infectious disease animal disease |
cattle disease | C01.252.410.040.552.588 C22.688 |
|||
Parenteral Nutrition Solutions | Pharmaceutical Solutions | Specialized solutions for parenteral nutrition. They may contain a variety of micronutrients; vitamins; amino acids; carbohydrates; lipids; and salts | D27.720.752.733 D27.505.954.578.733 |
|||
paresis | neurological disorder | condition typified by a weakness of voluntary movement | C10.597.636 C23.888.592.643 |
|||
paresthesia | somatosensory disorder | C10.597.751.791.875 C23.888.592.763.770.875 |
||||
Parotid duct | A03.556.500.760.640 | |||||
patella | bone | bone of the leg | A02.835.232.043.650.624 | Patella | ||
patellar ligament | A02.513.514.475 | |||||
patient advocacy | I01.880.604.631 N03.706.678 |
|||||
Patient portal | secure website used by patients to access their medical records or communicate with health care providers | E05.318.308.940.968.249.500.500 E05.318.308.940.968.249.750 |
||||
Patient Protection and Affordable Care Act | legislation Act of Congress |
United States federal statute | N03.219.521.576.343.918 N03.706.615.806 |
Patient Protection and Affordable Care Act | ||
Patient Self-Determination Act | N03.706.615.808 | |||||
patients' rights | human rights | I01.880.604.473.650 N03.706.437.650 |
||||
pay for performance | managed care | movement in health insurance | N03.219.521.710.305.380 | |||
PDE3 inhibitor | Phosphodiesterase inhibitor | Compounds that specifically inhibit phosphodiesterase 3 | D27.505.519.389.735.249 | |||
pectus carinatum | bone development disease deformity of chest and rib |
C05.116.099.739 C05.182.525 C05.660.745 C16.131.621.745 C17.300.182.525 |
Pectus carinatum | |||
pectus excavatum | bone development disease deformity of chest and rib genetic disease |
congenital deformity of the chest | C05.116.099.386 C05.660.386 C16.131.621.386 |
Pectus excavatum | ||
peer group | group of humans social group |
F01.829.316.483 | Peer group | |||
peer pressure | social influence | influence that a peer group, observers or individual exerts that encourages others to change their attitudes, values, or behaviors to conform the group norms. A group trying to convince a person to do something they don't wanna do. | F01.829.316.483.750 | |||
Peptidomimetics | mechanism of action | Compounds that are designed to mimic the 3d structure of a natural peptide or protein | D27.505.519.828 | |||
Performance-Enhancing Substances | Physiological Effects of Drugs | Agents that improve the ability to carry out activities such as athletics, mental endurance, work, and resistance to stress. The substances can include prescription drugs; dietary supplements; phytochemicals; and illicit drugs | D27.505.696.620 | |||
perfume | cosmetics aroma compound |
mixture used to produce a pleasant smell | D27.720.269.700 | Perfumes | ||
Peri-implantitis | periodontal disease | C07.465.714.282 | ||||
periaqueductal gray | A08.186.211.132.659.822.595 | |||||
pericardium | anatomical region | double-walled sac containing the heart and the roots of the great vessels | A07.541.795 | Hearts | ||
perineurium | A08.800.800 | |||||
Peripheral Nervous System Agents | Physiological Effects of Drugs | Drugs that act principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system. (from smith and reynard, textbook of pharmacology, 1991, p75) | D27.505.696.663 | |||
peripheral neuropathy | neurological disorder peripheral nervous system disease |
disease | C10.668.829 | |||
peritoneum | serous membrane mesothelium |
serous membrane that forms the lining of the abdominal cavity or the coelom—it covers most of the intra-abdominal (or coelomic) organs—in amniotes and some invertebrates | A01.047.025.600 | Peritoneum | ||
Peroxisome Proliferators | carcinogen | A class of nongenotoxic carcinogens that induce the production of hepatic peroxisomes and induce hepatic neoplasms after long-term administration | D27.888.569.100.675 | |||
persistent vegetative state | disorder of consciousness | disorder of consciousness caused by severe brain damage | C10.228.140.140.627 C10.597.606.358.800.400 C23.888.592.604.359.800.400 |
|||
person | descriptive item used as unit | subject individual agent item with given name property |
being that has certain capacities or attributes constituting personhood (avoid use with P31; use Q5 for humans) | M01 | Person | |
personality test | psychological test | psychological or character questionnaire | F04.711.647 | |||
pes cavus | foot deformity | C05.330.488.655.500 C05.330.495.681.500 C05.660.585.512.380.813.500 C16.131.621.585.512.500.681.500 |
||||
pesticide | biocide Modes of Toxic Action agrochemical |
substance used to destroy pests | D27.888.723 D27.720.031.700 |
Pesticides | ||
Pesticide Residues | pesticide | Pesticides or their breakdown products remaining in the environment following their normal use or accidental contamination | D27.888.723.697 D27.720.031.700.672 |
|||
Pesticide Synergists | pesticide | Chemicals that, while not possessing inherent pesticidal activity, nonetheless promote or enhance the effectiveness of other pesticides when combined | D27.720.031.700.748 D27.888.723.748 |
|||
Phantom limb | perceptual disorder | C10.597.606.762.700 C10.597.617.841.500 C23.550.767.700.500 C23.888.592.604.764.700 C23.888.592.612.832.500 |
Phantom limb | |||
Pharmaceutic Aids | Specialty Uses of Chemicals | Substances which are of little or no therapeutic value, but are necessary in the manufacture, compounding, storage, etc., of pharmaceutical preparations or drug dosage forms. They include solvents, diluting agents, and suspending agents, and emulsif | D27.720.744 | |||
Pharmaceutical Solutions | Specialty Uses of Chemicals Therapeutic Uses |
Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, the | D27.505.954.578 D27.720.752 |
|||
Pharmaceutical Vehicles | Pharmaceutic Aids | A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (dictionary of pharmacy, 1986) | D27.720.744.770 | |||
Pharmacologic Actions | chemical Actions and Uses | A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease | D27.505 | |||
Pharyngeal arch | A16.142 | |||||
phocomelia | dysmelia Ectromelia |
congenital disorder | C05.660.585.350 C16.131.621.585.350 |
Phocomelia | ||
Phosphodiesterase 4 Inhibitors | Phosphodiesterase inhibitor | Compounds that specifically inhibit phosphodiesterase 4 | D27.505.519.389.735.374 | |||
Phosphodiesterase 5 Inhibitors | Phosphodiesterase inhibitor | Compounds that specifically inhibit phosphodiesterase 5 | D27.505.519.389.735.500 | |||
Phosphodiesterase inhibitor | enzyme inhibitor | Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases | D27.505.519.389.735 | Phosphodiesterase inhibitors | ||
Phospholipase A2 Inhibitors | enzyme inhibitor | Compounds that inhibit or block the activity of a phospholipase a2 enzyme | D27.505.519.389.737 | |||
Photoaffinity labeling | Affinity Labels | Biologically active molecules which are covalently bound to the enzymes or binding proteins normally acting on them. Binding occurs due to activation of the label by ultraviolet light. These labels are used primarily to identify binding sites on pro | D27.720.470.410.080.600 | |||
Photoinitiators, Dental | Dental Materials | Chemical compound used to initiate polymerization of dental resins by the use of dental curing lights. It absorbs uv light and undergoes decomposition into free radicals that initiate polymerization process of the resins in the mix. Each photoinitia | D27.720.102.339.249 | |||
Photosensitizer | dermatologic drug Radiosensitizer |
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or | D27.505.954.600.710 D27.505.954.444.600 |
|||
physical science | natural science | the study of physics and chemistry in nature | H | Physical sciences | ||
Physiological Effects of Drugs | Pharmacologic Actions | Activities which affect organs and systemic functions without regard to a particular disease. | D27.505.696 | |||
Phytoestrogens | chemical substance Estrogens, Non-Steroidal |
Compounds derived from plants, primarily isoflavones that mimic or modulate endogenous estrogens, usually by binding to estrogen receptors | D27.505.696.399.472.277.540.500 | Phytoestrogens | ||
Pia mater | leptomeninx | delicate innermost layer of the meninges, the membranes surrounding the brain and spinal cord | A08.186.566.731 | Pia mater | ||
picibanil | D20.215.659 | |||||
pisiform bone | bone carpal bone |
bone of the wrist | A02.835.232.087.319.150.600 | Pisiform bone | ||
pituitary gland | endocrine gland | endocrine gland | A06.407.747 | Pituitary gland | ||
Pityriasis | papulosquamous disorder | disease | C17.800.859.600 | |||
Plant Growth Regulators | Growth Substances | Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins | D27.505.696.377.760 | |||
plasma cell dyscrasia | blood protein disease | C04.557.595 | ||||
Plasma Substitutes | blood substitute | Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used | D27.505.954.502.140.500 | |||
plasticizer | chemical substance film former emulsifier Specialty Uses of Chemicals |
additives that increase the plasticity or decrease the viscosity of a material | D27.720.760 | |||
platelet aggregation inhibitor | drug Hematologic Agents |
member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. | D27.505.954.502.780 | Antiplatelet drugs | ||
platelet-rich plasma | blood plasma | A12.207.152.693.600 A12.207.270.695.600 A15.145.693.600 |
||||
pleomorphic undifferentiated sarcoma | sarcoma | C04.557.450.565.590.425.360 C04.557.450.795.400 |
||||
pleural cavity | anatomical cavity | thin fluid-filled space between the two pulmonary pleurae (visceral and parietal) of each lung | A01.911.800.650 | |||
pleural effusion | pleural disease effusion |
accumulation of excess fluid in the pleural cavity | C08.528.652 | Pleural effusion | ||
poison | chemical substance Noxae Specialty Uses of Chemicals |
substance that causes disturbances to organisms | D27.720.777 D27.888.569.612 |
Poisons | ||
Poly(ADP-ribose) Polymerase Inhibitors | antineoplastic enzyme inhibitor |
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. | D27.505.519.389.739 D27.505.954.248.692 |
|||
polymerase chain reaction | chemical process | nucleic acid methods | E05.393.620.500 | Polymerase chain reaction | ||
polyneuritis | polyneuropathy | Human disease | C10.668.829.650 | |||
polyphagia | eating disorder | excessive hunger or increased appetite | C23.888.821.645 | |||
pons | brain region | part of the brainstem | A08.186.211.132.810.428.600 | Pons | ||
Positional plagiocephaly | Plagiocephaly | C05.660.207.707.624 C16.131.621.207.707.624 |
||||
posterior cruciate ligament | cruciate ligament | A02.513.514.600 | ||||
Posterior root of spinal nerve | nerve | one of two "roots" which emerge from the spinal cord | A08.800.800.720.725 | |||
Potassium channel blocker | Cardiovascular Agents Membrane Transport Modulators |
A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of action potentials. They are used as anti-arrhythmia agents and vasodilator agents | D27.505.519.562.500 D27.505.954.411.645 |
Potassium channel blockers | ||
Potassium Ionophores | Ionophore | Chemical agents that increase the permeability of cell membranes to potassium ions | D27.505.519.562.374.400 D27.720.395.400 |
|||
Potassium-sparing diuretic | diuretic | A subclass of diuretics that limits the secretion of potassium into the urine | D27.505.696.560.500.726 | Potassium-sparing diuretics | ||
preferred provider organization | organization managed care |
a type of health insurance plan where a group of health care providers agree to provide services for reduced fees | N03.219.521.576.343.800.750 N04.590.374.410.750 |
|||
premolar | molar | A14.549.167.860.150 | ||||
preoptic area | A08.186.211.730.385.357.342.450 | |||||
Preservatives, Pharmaceutical | Pharmaceutic Aids | Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include anti-bacterial agents and antioxidants | D27.720.744.771 | |||
Primitive streak | A16.254.412 | |||||
Principal sensory nucleus of trigeminal nerve | nerve | A08.186.211.132.810.428.600.650.718 | ||||
prisoner's dilemma | dilemma | canonical example of a game analyzed in game theory | E05.385.500 | Prisoner's dilemma | ||
Proctoscopy | E01.370.372.250.250.600 | Proctoscopy | ||||
Progestins | hormone | Compounds that interact with progesterone receptors in target tissues to bring about the effects similar to those of progesterone. Primary actions of progestins, including natural and synthetic steroids, are on the uterus and the mammary gland in pr | D27.505.696.399.472.858 | |||
projective test | psychological test | F04.711.647.622 | ||||
Prolyl-Hydroxylase Inhibitors | enzyme inhibitor | Compounds that inhibit the action of hydroxylases that act on proline to form hydroxyproline | D27.505.519.389.740 | |||
prostate | material anatomical entity anatomical structure |
gland of the male reproductive system in most mammals | A05.360.444.575 | Prostate | ||
Protease inhibitor | protein enzyme inhibitor |
molecule that prevents proteases from acting as such | D27.505.519.389.745 | Protease inhibitors | ||
Protective Agents | Specialty Uses of Chemicals Physiological Effects of Drugs |
Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. | D27.720.799 D27.505.696.706 |
|||
Protein kinase inhibitor | enzyme inhibitor | Agents that inhibit Protein kinases | D27.505.519.389.755 | Protein kinase inhibitors | ||
Protein synthesis inhibitor | reaction inhibitor enzyme inhibitor |
Compounds which inhibit the synthesis of proteins. They are usually anti-bacterial agents or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the a site of ribosomes, the misreading of | D27.505.519.389.760 | |||
Proton Ionophores | Ionophore Uncoupling Agents |
Chemical agents that increase the permeability of cell membranes to protons | D27.505.519.562.374.500 D27.720.395.500 D27.505.519.389.936.500 |
|||
Proton-pump inhibitor | drugs for acid-related disorders enzyme inhibitor |
group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production | D27.505.519.389.848 | Proton pump inhibitors | ||
Provitamin | vitamin | Precursor forms of vitamins | D27.505.696.377.605.600.354 | |||
pseudorabies | swine disease | Herpesviridae infectious disease | Human disease | C02.182.710 C02.256.466.793 C10.228.228.245.710 C22.742 |
Pseudorabies | |
psychological test | test | F04.711 | Psychological tests | |||
psychology | social science academic discipline |
social science | study of mental functions and behaviours | F04.096.628 | Psychology | |
Psychotropic Drugs | Central Nervous System Agents | A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents) | D27.505.954.427.700 | |||
pubic symphysis | symphysis | A02.835.583.656 | Pubic symphysis | |||
publication | creative work mass media distribution written work |
output of the act of publishing, and also refers to any printed copies | V | Publications | ||
Puerperal fever | puerperal disorder | Human disease | C01.539.674.715 C13.703.700.715 C13.703.844.757 |
|||
Pulmonary sequestration | respiratory system disease | congenital disorder of respiratory system | C08.695.214 C16.131.740.214 |
|||
Pulmonary Surfactants | Respiratory System Agents | Substances and drugs that lower the surface tension of the mucoid layer lining the pulmonary alveoli | D27.505.954.796.600 | |||
Pulp Capping and Pulpectomy Agents | Dental Materials | Materials used in dental pulp capping or pulpectomy | D27.720.102.339.500 | |||
Pure autonomic failure | orthostatic hypotension Dysautonomia |
C10.177.575.650 | ||||
Purinergic Agents | neurotransmitter | Compounds that act on purinergic receptors or influence the synthesis, storage, uptake, metabolism, or release of purinergic transmitters | D27.505.696.577.725 D27.505.519.625.725 |
|||
Purinergic Agonists | Purinergic Agents | Compounds that bind to and activate purinergic receptors | D27.505.696.577.725.200 D27.505.519.625.725.200 |
|||
Purinergic Antagonists | Purinergic Agents | Drugs that bind to and block the activation of purinergic receptors | D27.505.519.625.725.400 D27.505.696.577.725.400 |
|||
Purinergic P1 Receptor Agonists | Purinergic Agonists | Compounds that bind to and stimulate purinergic p1 receptors | D27.505.696.577.725.200.100 D27.505.519.625.725.200.100 |
|||
Purinergic P1 Receptor Antagonists | Purinergic Antagonists | Compounds that bind to and block the stimulation of purinergic p1 receptors | D27.505.696.577.725.400.100 D27.505.519.625.725.400.100 |
|||
Purinergic P2 Receptor Agonists | Purinergic Agonists | Compounds that bind to and stimulate purinergic p2 receptors | D27.505.519.625.725.200.200 D27.505.696.577.725.200.200 |
|||
Purinergic P2 Receptor Antagonists | Purinergic Antagonists | Compounds that bind to and block the stimulation of purinergic p2 receptors | D27.505.696.577.725.400.200 D27.505.519.625.725.400.200 |
|||
Purinergic P2X Receptor Agonists | Purinergic P2 Receptor Agonists | Compounds that bind to and stimulate purinergic p2x receptors. Included under this heading are agonists for specific p2x receptor subtypes | D27.505.696.577.725.200.200.100 D27.505.519.625.725.200.200.100 |
|||
Purinergic P2X Receptor Antagonists | Purinergic P2 Receptor Antagonists | Compounds that bind to and block the stimulation of purinergic p2x receptors. Included under this heading are antagonists for specific p2x receptor subtypes | D27.505.519.625.725.400.200.100 D27.505.696.577.725.400.200.100 |
|||
Purinergic P2Y Receptor Agonists | Purinergic P2 Receptor Agonists | Compounds that bind to and stimulate purinergic p2y receptors. Included under this heading are agonists for specific p2y receptor subtypes | D27.505.519.625.725.200.200.200 D27.505.696.577.725.200.200.200 |
|||
Purinergic P2Y Receptor Antagonists | Purinergic P2 Receptor Antagonists | Compounds that bind to and block the stimulation of purinergic p2y receptors. Included under this heading are antagonists for specific p2y receptor subtypes | D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200 |
|||
pyonephrosis | renal infectious disease | infection of the renal collecting system | C12.777.419.307.500 C13.351.968.419.307.500 |
|||
pyramidal tracts | nerve tract | A08.186.854.633 | ||||
Pyrogens | Noxae | Substances capable of increasing body temperature and cause fever and may be used for fever therapy. They may be of microbial origin, often polysaccharides, and may contaminate distilled water | D27.888.569.673 | |||
Quadrantanopia | Anopsia | C10.597.751.941.512 C11.966.075.500 C23.888.592.763.941.512 |
Quadrantanopia | |||
radial nerve | nerve | nerve in the human body that supplies the posterior portion of the upper limb | A08.800.800.720.050.700 | |||
Radiation-Protective Agents | Protective Agents | Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. Military, purposes | D27.720.799.763 D27.505.696.706.776 |
|||
radioactive waste | environmental issue | waste by-product Hazardous waste |
wastes that contain radioactive material | D27.888.426.500.638 | Nuclear waste | |
Radiopharmaceutical | Indicators and Reagents mechanism of action Diagnostic Uses of Chemicals |
Medicinal radiocompound | D27.720.470.410.650 D27.505.259.843 D27.505.519.871 |
Radiopharmaceuticals | ||
Radiosensitizer | Therapeutic Uses | Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells | D27.505.954.600 | |||
Raphe nuclei | A08.186.211.132.659.632 | |||||
rare disease | disease | disease that affects a small percentage of the population | C23.550.291.906 | Rare diseases | ||
Reagent Kits, Diagnostic | Indicators and Reagents Diagnostic Uses of Chemicals |
Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use | D27.505.259.875 D27.720.470.410.680 |
|||
Reagent Strips | Reagent Kits, Diagnostic | Narrow pieces of material impregnated or covered with a substance used to produce a chemical reaction. The strips are used in detecting, measuring, producing, etc., other substances. (from dorland, 28th ed) | D27.505.259.875.680 D27.720.470.410.680.680 |
|||
real-time polymerase chain reaction | polymerase chain reaction Quantitative polymerase chain reaction |
Method in molecular biology; laboratory technique of molecular biology based on the polymerase chain reaction (PCR) | E05.393.620.500.706 | Quantitative polymerase chain reaction | ||
recto-uterine pouch | A01.923.047.025.600.225 | |||||
red nucleus | A08.186.211.132.659.822.642 | Red nucleus | ||||
Reducing Agents | Indicators and Reagents | Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence. (from mcgraw-hill dictionary of scientific and technical terms, 5th ed) | D27.720.470.410.690 | |||
Refeeding syndrome | malnutrition | C18.654.521.687 | ||||
Renal Agents | Therapeutic Uses | Drugs used for their effects on the kidneys' regulation of body fluid composition and volume. The most commonly used are the diuretics. Also included are drugs used for their antidiuretic and uricosuric actions, for their effects on the kidneys' cle | D27.505.954.613 | |||
Renal stem cell | A05.810.453.736.560.610 | |||||
Reperfusion injury | vascular disease | the tissue damage caused when blood supply returns to the tissue after a period of ischemia or lack of oxygen (anoxia, hypoxia) | C14.907.725 C23.550.767.877 |
|||
repetitive strain injury | occupational disease musculoskeletal disorder |
injury to the musculoskeletal and nervous systems that may be caused by repetitive tasks, forceful exertions, vibrations, mechanical compression, or sustained or awkward positions | C26.844.150 | |||
Reproductive Control Agents | Physiological Effects of Drugs Therapeutic Uses |
Substances used either in the prevention or facilitation of pregnancy | D27.505.954.705 D27.505.696.875 |
|||
Respiratory System Agents | Therapeutic Uses | Drugs used for their effects on the respiratory system | D27.505.954.796 | |||
respiratory tract infection | infectious disease respiratory system disease |
any number of infectious diseases involving the respiratory tract | C01.539.739 C08.730 |
Respiratory infections | ||
rete testis | A05.360.444.849.600 | |||||
reticular formation | spinal trigeminal nucleus | A08.186.211.132.772 | Reticular formation | |||
Retroperitoneal fibrosis | IgG4-related disease immune system disease rare abdominal surgical disease |
Related to igG4-related disease | C23.550.355.700 | |||
retroperitoneal space | anatomical space in the abdominal cavity behind the peritoneum | A01.047.025.750 | Retroperitoneal space | |||
reverse transcription and polymerase chain reaction | polymerase chain reaction | method in molecular biology; variant of polymerase chain reaction (PCR), is a technique commonly used in molecular biology to detect RNA expression | E05.393.620.500.725 | |||
reverse-transcriptase inhibitor | nucleic acid inhibitor Anti-Retroviral Agents |
Inhibitors of reverse transcriptase (rna-directed dna polymerase), an enzyme that synthesizes dna on an rna template | D27.505.954.122.388.077.750 D27.505.519.389.675.850 |
Non-nucleoside reverse transcriptase inhibitors | ||
Rhabdomyoma | tumor | C04.557.450.590.540.700 | Rhabdomyoma | |||
Rhinencephalon | A08.186.211.577.699 | |||||
rhytidectomy | medical procedure | E02.218.765 | Rhytidectomy | |||
ribosomal RNA | non-coding RNA chemical compound |
RNA component of the ribosome, and is essential for protein synthesis in all living organisms | D13.444.735.686 | Ribosomal RNA | ||
Rigor mortis | decomposition | sign of death | C23.550.260.224.617.839 | Rigor mortis | ||
Riot Control Agents, Chemical | Noxae Specialty Uses of Chemicals |
Chemical substances which are employed during a riot in order to control or disperse the rioting parties | D27.888.569.734 D27.720.821 |
|||
RNA Probes | Nucleic Acid Probes | Rna, usually prepared by transcription from cloned dna, which complements a specific mrna or dna and is generally used for studies of virus genes, distribution of specific rna in tissues and cells, integration of viral dna into genomes, transcriptio | D27.720.470.530.600.825 D27.505.259.750.600.825 |
|||
RNA, Complementary | RNA Probes | Synthetic transcripts of a specific dna molecule or fragment, made by an in vitro transcription system. This crna can be labeled with radioactive uracil and then used as a probe. (king & stansfield, a dictionary of genetics, 4th ed) | D27.720.470.530.600.825.840 | |||
rodenticide | zoocide pesticide |
Substances used to destroy or inhibit the action of rats, mice, or other rodents | D27.888.723.853 D27.720.031.700.853 |
Rodenticides | ||
Root Canal Irrigants | Dental Disinfectants | Chemicals used mainly to disinfect root canals after pulpectomy and before obturation. The major ones are camphorated monochlorophenol, edta, formocresol, hydrogen peroxide, metacresylacetate, and sodium hypochlorite. Root canal irrigants include al | D27.505.954.122.425.300.500 D27.720.274.300.500 |
|||
Rosai–Dorfman disease | non-Langerhans-cell histiocytosis | C15.604.250.410.450 | Rosai–Dorfman disease | |||
round ligament of uterus | A05.360.319.114.803 | |||||
round window | A09.246.631.246.814 | |||||
Ruptured spleen | Blunt splenic trauma | C15.604.744.742 C26.017.680 C26.761.555 |
Splenic injury | |||
sarcopenia | muscle atrophy aging-associated diseases muscle weakness |
Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles | C10.597.613.612.500 C23.300.070.500.500 C23.888.592.608.612.500 |
Sarcopenia | ||
scaphoid bone | bone carpal bone |
bone of the carpus | A02.835.232.087.319.150.750 | Scaphoid bone | ||
Schistosomicides | Antiplatyhelmintic Agents | Agents that act systemically to kill adult schistosomes | D27.505.954.122.250.075.100.750 | |||
Sclerosing Solutions | Cardiovascular Agents Pharmaceutical Solutions |
Chemical agents injected into blood vessels and lymphatic sinuses to shrink or cause localized thrombosis; fibrosis, and obliteration of the vessels. This treatment is applied in a number of conditions such as varicose veins; hemorrhoids; gastric va | D27.505.954.578.822 D27.505.954.411.700 D27.720.752.822 |
|||
sebaceous gland | holocrine | microscopic exocrine glands in the skin that secrete an oily or waxy matter, called sebum, to lubricate and waterproof the skin and hair of mammals | A10.336.827 | Sebaceous gland | ||
Selective estrogen-receptor modulator | Estrogen Receptor Modulators | A structurally diverse group of compounds distinguished from estrogens by their ability to bind and activate estrogen receptors but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as eithe | D27.505.696.399.450.360.827 | Selective estrogen receptor modulators | ||
selective serotonin reuptake inhibitor | antidepressant Neurotransmitter Uptake Inhibitors Serotonin Agents |
a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder and anxiety disorders. | D27.505.519.625.850.900 D27.505.696.577.600.850 D27.505.519.625.600.850 D27.505.696.577.850.900 D27.505.519.562.437.850 |
Selective serotonin reuptake inhibitors | ||
semantic differential | rating scale personality test |
F02.694.663 F04.711.647.745 |
||||
seminal vesicle | pair of simple tubular glands posteroinferior to the urinary bladder of male mammals | A05.360.444.713 | ||||
seminiferous tubule | A05.360.444.849.700 | Seminiferous tubule | ||||
Sensory System Agents | Peripheral Nervous System Agents | Drugs that act on neuronal sensory receptors resulting in an increase, decrease, or modification of afferent nerve activity. (from smith and reynard, textbook of pharmacology, 1991, p367) | D27.505.696.663.850 | |||
sepsis | general infection | life-threatening organ dysfunction triggered by infection | C01.539.757 C23.550.470.790.500 |
Sepsis | ||
septum pellucidum | A08.186.211.276.814 | Septum pellucidum | ||||
Sequestering Agents | Specialty Uses of Chemicals mechanism of action |
Compounds that bind to and reduce the biological availability of a chemical or pharmaceutical agent. | D27.505.519.914 D27.720.832 |
|||
Serine Peptidase Inhibitors, Kazal Type | Serine Proteinase Inhibitors | A family of serine peptidase inhibitors that occur in animals, some single-cell eukaryotes, and higher plants. They contain variable numbers of kazal motifs and inhibit serine endopeptidases such as acrosin and trypsin | D27.505.519.389.745.800.562 | |||
Serine Proteinase Inhibitors | Protease inhibitor | Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. | D27.505.519.389.745.800 | |||
Serotonin 5-HT1 Receptor Agonists | serotonin receptor agonist | Endogenous compounds and drugs that specifically stimulate serotonin 5-ht1 receptors. Included under this heading are agonists for one or more of the specific 5-ht1 receptor subtypes | D27.505.696.577.850.800.100 D27.505.519.625.850.800.100 |
|||
Serotonin 5-HT1 Receptor Antagonists | serotonin antagonist | Drugs that bind to but do not activate serotonin 5-ht1 receptors, thereby blocking the actions of serotonin 5-ht1 receptor agonists. Included under this heading are antagonists for one or more of the specific 5-ht1 receptor subtypes | D27.505.519.625.850.850.100 D27.505.696.577.850.850.100 |
|||
Serotonin 5-HT2 Receptor Antagonists | serotonin antagonist | Drugs that bind to but do not activate serotonin 5-ht2 receptors, thereby blocking the actions of serotonin or serotonin 5-ht2 receptor agonists. Included under this heading are antagonists for one or more specific 5-ht2 receptor subtypes | D27.505.696.577.850.850.200 D27.505.519.625.850.850.200 |
|||
Serotonin 5-HT3 Receptor Agonists | serotonin receptor agonist | Endogenous compounds and drugs that specifically stimulate serotonin 5-ht3 receptors | D27.505.519.625.850.800.300 D27.505.696.577.850.800.300 |
|||
Serotonin 5-HT3 Receptor Antagonists | serotonin antagonist | Drugs that bind to but do not activate serotonin 5-ht3 receptors, thereby blocking the actions of serotonin or serotonin 5-ht3 receptor agonists | D27.505.519.625.850.850.300 D27.505.696.577.850.850.300 |
|||
Serotonin 5-HT4 Receptor Agonists | serotonin receptor agonist | Endogenous compounds and drugs that specifically stimulate serotonin 5-ht4 receptors | D27.505.696.577.850.800.400 D27.505.519.625.850.800.400 |
|||
Serotonin 5-HT4 Receptor Antagonists | serotonin antagonist | Drugs that bind to but do not activate serotonin 5-ht4 receptors, thereby blocking the actions of serotonin or serotonin receptor agonists | D27.505.696.577.850.850.400 D27.505.519.625.850.850.400 |
|||
Serotonin Agents | neurotransmitter | Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons | D27.505.519.625.850 D27.505.696.577.850 |
|||
Serotonin and Noradrenaline Reuptake Inhibitors | Neurotransmitter Uptake Inhibitors | Drugs that selectively block or suppress the plasma membrane transport of serotonin and noradrenaline into axon terminals and are used as antidepressive agents | D27.505.519.625.600.693 D27.505.696.577.600.693 D27.505.519.562.437.693 |
|||
serotonin antagonist | Serotonin Agents | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin receptor agonists | D27.505.696.577.850.850 D27.505.519.625.850.850 |
Serotonin receptor antagonists | ||
serotonin receptor agonist | Serotonin Agents | Endogenous compounds and drugs that bind to and activate serotonin receptors. Many serotonin receptor agonists are used as antidepressants; anxiolytics; and in the treatment of migraine disorders | D27.505.696.577.850.800 D27.505.519.625.850.800 |
Serotonin receptor agonists | ||
serotonin syndrome | adverse drug reaction rare disease with malignant hyperthermia |
Serotoninergic syndrome is characterised by an excess of serotonin in the central nervous system, associated with the use of various agents, including selective serotonin reuptake inhibitors (SSRIs) | C25.100.875 | |||
serous membrane | mesothelium | A10.615.789 | ||||
Serpins | Serine Proteinase Inhibitors | A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. Some members of the serpin family may be substrates rather than inhibitors of | D27.505.519.389.745.800.675 | |||
Sertoli cell | Sustentacular cell | A05.360.444.849.789 | ||||
set of intercostal nerves | set of ventral rami of spinal nerve | A08.800.800.720.800.350 | ||||
sexually transmitted infection | infectious disease | infection transmitted through human sexual behavior | C01.539.778 | Sexually transmitted diseases and disorders | ||
shamanism | alternative medical treatment | E02.190.488.830 E02.190.901.788 I01.076.201.450.654.830 |
Shamanism | |||
shellfish poisoning | poisoning food poisoning |
C25.723.415.792 | ||||
shin splints | occupational disease periostitis |
C05.651.426 C10.668.491.087 C26.558.705 |
Shin splints | |||
shoulder | anatomical region | part of the body | A01.378.800.750 | Shoulders | ||
Siderophore | Iron Chelating Agents | Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (the encyclopedia of molecular biology, 1994) | D27.720.832.500.410.750 D27.505.519.914.500.410.750 |
Siderophores | ||
single-payer health care | health insurance publicly funded health care |
N03.219.521.576.343.962 N03.219.521.855 N03.349.550.805 |
||||
Sinus tachycardia | tachycardia | heart rate greater than 100 beats/min (bpm) | C14.280.067.845.880.845 C23.550.073.845.880.845 |
Sinus tachycardia | ||
skin | animal organ material |
soft outer covering organ of vertebrates | A17.815.180 | Skin | ||
Skin Lightening Preparations | cosmetics | Substances used to obtain a lighter skin complexion or to treat hyperpigmentation disorders | D27.720.269.750 | |||
Sleep Aids, Pharmaceutical | Therapeutic Uses | Drugs used to induce sleep, prevent sleeplessness, or treat sleep initiation and maintenance disorders | D27.505.954.842 | |||
Small Molecule Libraries | Laboratory Chemicals | Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or ot | D27.720.470.765 | |||
smoke inhalation | Q3153683 Acute inhalation injury upper respiratory burn inhalation |
C26.200.322.800 | ||||
snack food | food | portion of food often smaller than a regular meal | G07.203.300.590.780 J02.500.590.780 |
Snack food | ||
soap | salt detergent |
sodium salt of fatty acids ( long chain carboxylic acids ), used for washing and cleaning | D27.720.877.265.861 | Soap | ||
Social mobility | I01.880.853.996.755.673 N01.824.782.673 |
Social mobility | ||||
Sodium Channel Agonists | Membrane Transport Modulators | A class of drugs that stimulate sodium influx through cell membrane channels | D27.505.519.562.625 | |||
Sodium channel blocker | Cardiovascular Agents Membrane Transport Modulators |
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity | D27.505.519.562.750 D27.505.954.411.720 |
Sodium channel blockers | ||
Sodium Chloride Symporter Inhibitors | diuretic Membrane Transport Modulators |
Agents that inhibit sodium chloride symporters. They act as diuretics. Excess use is associated with hypokalemia | D27.505.519.562.812 D27.505.696.560.500.863 |
|||
Sodium Ionophores | Ionophore | Chemical agents that increase the permeability of cell membranes to sodium ions | D27.505.519.562.374.750 D27.720.395.750 |
|||
Sodium Potassium Chloride Symporter Inhibitors | diuretic Membrane Transport Modulators |
Agents that inhibit sodium-potassium-chloride symporters which are concentrated in the thick ascending limb at the junction of the loop of henle and kidney tubules, distal. They act as diuretics. Excess use is associated with hypokalemia and hypergl | D27.505.696.560.500.931 D27.505.519.562.906 |
|||
Soil Pollutants | Environmental Pollutants | Substances which pollute the soil. Use for soil pollutants in general or for which there is no specific heading | D27.888.284.756 | |||
Soil Pollutants, Radioactive | Soil Pollutants | Pollutants, present in soil, which exhibit radioactivity | D27.888.284.756.674 | |||
Solitary nucleus | A08.186.211.132.810.406.750 | |||||
solvent | chemical substance Specialty Uses of Chemicals |
substance that dissolves a solute (a chemically different liquid, solid or gas), resulting in a solution | D27.720.844 | Solvents | ||
somatosensory disorder | sensation disorder | human disease | C10.597.751.791 C23.888.592.763.770 |
|||
somite | division of the body of an animal or embryo | A16.254.425.660.750 | Somites | |||
Specialty Uses of Chemicals | chemical Actions and Uses | Uses of chemicals in a research, industrial, or household setting. This does not include PHARMACOLOGIC ACTIONS | D27.720 | |||
Sperm Immobilizing Agents | Antispermatogenic Agents Contraceptive Agents, Female |
Chemical substances with sperm immobilizing activity used as topically administered vaginal contraceptives | D27.505.954.705.360.276.727 D27.888.569.071.379 D27.505.696.875.360.276.727 D27.505.696.138.379 |
|||
Spermatid | Gametid | A05.360.490.890.860 | ||||
Spermatogenesis-Blocking Agents | Antispermatogenic Agents | Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa | D27.888.569.071.760 D27.505.954.705.360.443.068.760 D27.505.696.138.760 D27.505.696.875.360.443.068.760 |
|||
Spermatogonium | A05.360.490.890.900 | |||||
spermatozoon | gamete | male reproductive cell | A05.360.490.890 | Spermatozoa | ||
Spermicide | birth control | Antispermatogenic Agents Contraceptive Agents, Female |
birth control | D27.888.569.071.569 D27.505.696.138.569 D27.505.696.875.360.276.827 D27.505.954.705.360.276.827 |
||
sphenoid bone | bone | unpaired bone situated at the front middle of the skull in front of the temporal bone and basilar part of the occipital bone | A02.835.232.781.802 | Sphenoid bones | ||
Sphincter of ampulla | A03.159.183.079.300.950.600 | |||||
spider bite | Arthropod bites and stings | bite caused by a spider | C25.723.127.723 C26.176.790 |
|||
spinal cord injury | spinal cord disease central nervous system trauma |
C10.228.854.770 C10.900.850 C26.819 C26.117.500 |
Spinal cord injuries | |||
spinal dysraphism | Congenital vertebral anomaly | D016135 | ||||
spinal nerve | peripheral nerve | nerve that carries signals between the spinal chord and the body | A08.800.800.720 | Spinal nerves | ||
Spinal trigeminal nucleus | A08.186.211.132.931.920 | |||||
Spiral ganglion | A08.340.390.800 | |||||
spirit possession | paranormal | belief that animas, demons, extraterrestrials, gods, or spirits can take control of a human body | K01.844.619.500 | |||
Stanford–Binet Intelligence Scales | IQ test | संतोष माली उज्जैन | F04.711.141.493.225 | |||
starvation | undernutrition | hunger | severe deficiency in caloric energy, nutrient, and vitamin intake | C18.654.521.750 | Starvation | |
statin | drug Anticholesteremic Agents enzyme inhibitor |
a class of drugs used to lower cholesterol levels | D27.505.519.389.370 D27.505.954.557.500.202.370 D27.505.519.186.071.202.370 |
Statins | ||
Stellate ganglion | A08.340.315.350.800 | |||||
Steroid Synthesis Inhibitors | enzyme inhibitor Hormone Antagonists |
Compounds that bind to and inhibit enzymes involved in the synthesis of steroids | D27.505.696.399.450.855 D27.505.519.389.870 |
|||
stimulant | psychoactive drug Central Nervous System Agents Physiological Effects of Drugs |
type of psychoactive drug | D27.505.954.427.220 D27.505.696.282 |
Stimulants | ||
Stimulants, Historical | Therapeutic Uses | Agents or remedies that historically have produced stimulation or excited functional activity | D27.505.954.888 | |||
Straight sinus | A07.231.908.224 | |||||
street child | child the poor |
homeless child living on the street | M01.325.400 | Street children | ||
subcutaneous tissue | connective tissue | lowermost layer of the integumentary system in vertebrates | A10.165.887 | |||
subfornical organ | A08.713.840 | |||||
submandibular duct | A03.556.500.760.640 | |||||
Substantia gelatinosa of Rolando | A08.186.854.697.500.500 | |||||
Substantia innominata | A08.186.211.577.820 | Substantia innominata | ||||
substantia nigra | A08.186.211.132.659.687 | Substantia nigra | ||||
Subtalar joint | Joints of foot | A02.835.583.378.831.780 | ||||
Sudden unexpected nocturnal death syndrome | sudden cardiac death | C14.280.067.322 | ||||
sugar substitute | food additive sweetener |
sweetener that contains significantly less food energy than sugar | D27.720.372.300.353.609.500 | Sweeteners | ||
suicide | killing | intentional act of causing one's own death | F01.145.126.980.875 | Suicide | ||
Sulfhydryl Reagents | Indicators and Reagents | Chemical agents that react with sh groups. This is a chemically diverse group that is used for a variety of purposes. Among these are enzyme inhibition, enzyme reactivation or protection, and labelling | D27.720.470.410.700 | |||
sunscreen | cosmetics dermatologic drug Radiation-Protective Agents |
topical skin product that helps protect against sunburn | D27.505.954.444.695 D27.720.799.763.764 D27.720.269.800 D27.505.696.706.776.800 |
Sunscreening agents | ||
Superior cervical ganglion | A08.340.315.350.850 | Superior cervical ganglion | ||||
superior colliculus | structure in the mammalian midbrain | A08.186.211.132.659.237.816 | Superior colliculus | |||
Superior hypogastric plexus | A08.800.050.050.400 | |||||
suprachiasmatic nucleus | A08.186.211.730.385.357.342.625 | Suprachiasmatic nucleus | ||||
Supraoptic nucleus | A08.186.211.730.385.357.342.650 | |||||
supraventricular tachycardia | tachycardia supraventricular arrhythmia paroxysmal tachycardia |
abnormally fast heart rhythm arising from improper electrical activity in the upper part of the heart | C14.280.067.845.880 C23.550.073.845.880 |
|||
Sural nerve | nerve | A08.800.800.720.450.760.820.820 | ||||
Surface plasmon resonance microscopy | E05.196.890 E05.601.043.700 |
|||||
surfactant | chemical substance emulsifier Specialty Uses of Chemicals |
group of chemical substances | D27.720.877 | Surfactants | ||
Susac's syndrome | microangiopathy immune system disease Autoimmune connective tissue disorder autoimmune disease of the nervous system rare central nervous system and retinal vascular disease |
C09.218.855 C10.228.140.300.787 C10.597.825 C11.768.400.500 C11.966.858 C14.907.137.780.500 C23.888.307.750 C23.888.592.848 |
Susac's syndrome | |||
sweat gland | exocrine gland | small tubular structures of the skin that produce sweat; a type of exocrine gland, which are glands that produce and secrete substances onto an epithelial surface by way of a duct | A10.336.899 | |||
sweetener | food additive flavoring agent |
substance added to food to give it the basic taste of sweetness | D27.720.372.300.353.609 | |||
Sydenham's chorea | choreatic disease postinfectious autoimmune disease with chorea |
Human disease | C10.228.662.262.249 C10.597.350.250 C23.888.592.350.250 |
|||
Sympatholytic | Autonomic Agents | medication that opposes the downstream effects of postganglionic nerve firing in effector organs innervated by the sympathetic nervous system | D27.505.696.663.050.850 | |||
Sympathomimetic drug | Autonomic Agents | stimulant compounds | D27.505.696.663.050.870 | Sympathomimetics | ||
Syncytiotrophoblast | A16.254.085.162 | |||||
systemic inflammatory response syndrome | inflammation | Human disease | C23.550.470.790 C23.550.835.900 |
|||
Tactile corpuscle | Q1648747 | A08.675.650.915.750 | Meissner's corpuscle | |||
Takotsubo cardiomyopathy | cardiomyopathy Ventricular Dysfunction, Left unclassified cardiomyopathy |
Sudden temporary weakening of the heart muscle | C14.280.945.900.500 | Takotsubo cardiomyopathy | ||
talus | bone | bone of the ankle | A02.835.232.043.300.710.780 | Talus | ||
tear gas | non-lethal weapon chemical weapon gas Riot Control Agents, Chemical |
non-lethal chemical weapon | D27.720.821.500 D27.888.569.734.500 |
Lachrymatory agents | ||
technology | applied science | making, modification, usage, and knowledge of tools, machines, techniques, crafts, systems, and methods of organization | J01.897 | Technology | ||
temporal bone | bone | bones situated at the sides and base of the skull, and lateral to the temporal lobes of the cerebrum | A02.835.232.781.885 | Temporal bone | ||
temporomandibular joint disorder | Internal Derangement Internal Displacement ankylosis |
joint dislocation Temporomandibular joint pathology |
Human disease | C05.500.607.221.897.897 C05.550.905.905 C05.651.243.897.897 C05.651.550.905 C07.320.610.291.897.897 C07.678.949 |
Temporomandibular joint dysfunction | |
tendinopathy | musculoskeletal disorder soft tissue disorder synovial, tendon or bursa disorder |
Bruised tendon | C05.651.869 C26.874.800 |
Tendinopathy | ||
Teratogen | Noxae | An agent that causes the production of physical defects in the developing embryo | D27.888.569.864 | Teratogens | ||
Teratospermia | male infertility | C12.294.365.700.877 | ||||
Thematic Apperception Test | projective test | projective psychological test | F04.711.647.622.851 | |||
Therapeutic Uses | Pharmacologic Actions | Uses of chemicals which affect the course of conditions, diseases, syndromes or pathology to benefit the health of an individual. | D27.505.954 | |||
Thiobarbituric Acid Reactive Substances | Indicators and Reagents | Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct | D27.720.470.410.750 | |||
Third metacarpal bone | metacarpal bone | A02.835.232.087.319.550 | Third metacarpal bone | |||
Thoracic duct | Lymph trunk | A15.382.520.301.750 | Thoracic duct | |||
Thoracic splanchnic nerves | A08.800.050.050.800 | |||||
thumb | finger | first digit of the hand | A01.378.800.667.430.705 | Thumbs | ||
thyroid cartilage | cartilage | A02.165.257.625.870 | Thyroid cartilage | |||
thyroid gloubu | endocrine gland lobular organ |
endocrine glandi | A06.407.900 | Thyroid | ||
tibia | bone | larger of the two bones of the leg below the knee for vertebrates | A02.835.232.043.650.883 | Tibia | ||
tibial nerve | nerve | A08.800.800.720.450.760.820 | ||||
tick-borne disease | zoonosis | disease caused by infectious agents transmitted by tick bites | C01.252.400.825 C02.081.885 C03.752.875 |
Tick-borne diseases | ||
Tietze syndrome | Tietze's syndrome | C05.182.790 C17.300.182.790 |
||||
tissue | multicellular structure biological component organism substance group of cells |
cellular organizational level intermediate between cells and a complete organism; cells that are grouped together with a common function | A10 | Biological tissue | ||
Tissue Adhesives | Biomedical and Dental Materials | Substances used to cause adherence of tissue to tissue or tissue to non-tissue surfaces, as for prostheses | D27.720.102.919 | |||
Tocolytic Agents | Reproductive Control Agents | Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (tocolysis). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adre | D27.505.954.705.825 D27.505.696.875.825 |
|||
tonsillectomy | lymphatic ectomy | surgical removal of the tonsils | E04.580.848 | Tonsillectomy | ||
Tooth Bleaching Agents | Bleaching Agents | Chemicals that are used to oxidize pigments in teeth and thus effect whitening | D27.720.642.315.500 | |||
tooth discoloration | change concept medical finding |
tooth disease | abnormal tooth color, hue or translucency | C07.793.735 | ||
Tooth impaction | failure of eruption of teeth | C07.793.846 | ||||
Topoisomerase I Inhibitors | Topoisomerase Inhibitor | Compounds that inhibit the activity of DNA TOPOISOMERASE I. | D27.505.954.248.794.500 D27.505.519.389.892.500 |
|||
Topoisomerase II Inhibitors | Topoisomerase Inhibitor | Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of | D27.505.954.248.794.750 D27.505.519.389.892.750 |
|||
Topoisomerase Inhibitor | antineoplastic enzyme inhibitor |
Topoisomerase inhibitors | D27.505.954.248.794 D27.505.519.389.892 |
Topoisomerase inhibitors | ||
Torsades de pointes | heart arrhythmia ventricular tachycardia |
specific type of abnormal heart rhythm that can lead to sudden cardiac death. It is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram | C14.280.067.845.940.700 C23.550.073.845.940.700 |
Torsades de pointes | ||
Torsion dystonia | generalized dystonia | C10.228.140.079.357 C10.228.662.300.200 C10.574.500.393 C16.320.400.330 |
||||
Total body irradiation | E02.815.814 | |||||
Trace Elements | Micronutrients | A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (from mcgraw-hill dictionary of scientific and technical terms, 4th ed) | D27.505.696.377.605.555 | |||
traditional medicine | alternative medicine | medicine based on traditional beliefs | E02.190.488 I01.076.201.450.654 |
Traditional medicine | ||
transfer RNA | non-coding RNA | D13.444.735.757 | TRNA | |||
transient tachypnea of the newborn | Respiratory Distress Syndrome, Newborn | Human disease | C08.381.842.737 C08.618.842.737 C08.618.961.500 C16.614.521.563.737 C23.888.852.944.500 |
|||
trapezium | bone | bone of the wrist | A02.835.232.087.319.150.800 | Trapezium (bone) | ||
trapezoid bone | bone | A02.835.232.087.319.150.805 | Trapezoid bone | |||
treponematosis | spirochetal diseases | Human disease | C01.252.400.840 C01.252.847.840 |
|||
Triangular fibrocartilage | A02.835.583.405.930.800 | |||||
Trichiasis | eyelid disease | C11.338.912 | Trichiasis | |||
tricyclic antidepressant | antidepressant | chemical compounds used primarily as antidepressants. | D27.505.954.427.700.122.055 | Tricyclic antidepressants | ||
Trigeminal ganglion | sensory ganglion of the trigeminal nerve | A08.340.390.850 | Trigeminal ganglion | |||
Trigeminal motor nucleus | A08.186.211.132.931 | |||||
Trigeminal nerve nuclei | nerve | A08.186.211.132.931 | ||||
triquetral bone | bone carpal bone |
bone in the wrist | A02.835.232.087.319.150.831 | Triquetral bone | ||
trophoblast | cells forming the outer layer of a blastocyst | A11.382.992 | ||||
truncus arteriosus | anatomical structure embryonic structure |
arterial trunk that is arising from fetal heart | A07.541.278.930 | |||
Trypanocidal Agents | antiprotozoal | Agents destructive to the protozoal organisms belonging to the suborder trypanosomatina | D27.505.954.122.250.100.875 | |||
Trypsin inhibitor | Serine Proteinase Inhibitors | Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds | D27.505.519.389.745.800.900 | |||
Tubulin Modulators | Antimitotic Agents | Agents that interact with tubulin to inhibit or promote polymerization of microtubules | D27.505.519.593.249.500 | |||
ulnar nerve | nerve | nerve which runs near the ulna bone | A08.800.800.720.050.850 | |||
Ulnar nerve entrapment | occupational disease ulnar nerve lesion nerve compression syndrome |
C10.668.829.500.850.600 C10.668.829.550.925 C26.844.150.957 |
||||
Ultimopharyngeal body | A13.939 | |||||
Uncoupling Agents | enzyme inhibitor | Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that atp synthesis does not occur. Included here are those ionophores that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial | D27.505.519.389.936 | |||
upper limb | anatomical structure | arm (hand + forearm + upper arm + shoulder) | A01.378.800 | Human upper extremities | ||
Urachus | A16.254.835 | Urachus | ||||
Uricosuric Agents | Gout Suppressants Renal Agents |
Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma | D27.505.954.613.860 D27.505.954.329.337.900 |
|||
Urological Agents | Therapeutic Uses | Drugs used in the treatment of urogenital conditions and diseases such as urinary incontinence; prostatic hyperplasia; and erectile dysfunction | D27.505.954.944 | |||
Uterine atony | abnormality of forces of labor | C13.703.420.288.728 | ||||
uterine prolapse | prolapse of female genital organ | C13.351.500.852.833 C23.300.842.624.750 |
Uterine prolapse | |||
uterus | sex organ | major female hormone-responsive reproductive sex organ of most mammals including humans | A05.360.319.679 | Uterus | ||
vaginismus | vaginal disease | C13.351.500.665.656 C13.351.500.894.870 |
||||
Value-Based Insurance Design | health insurance | N03.219.521.576.343.972 N04.761.744.750 |
||||
vas deferens | part of the male reproductive system of many vertebrates | A05.360.444.930 | Vas deferens | |||
Vasoconstrictor Agents | Cardiovascular Agents | Drugs used to cause constriction of the blood vessels | D27.505.954.411.793 | |||
Vasopeptidase Inhibitors | ACE inhibitor | A class of cardiovascular drugs indicated for hypertension and congestive heart failure that simultaneously inhibit both neutral endopeptidase and angiotensin converting enzyme. They increase the availability of natriuretic peptides and bradykinin a | D27.505.519.389.745.085.500 | |||
vein | blood vessel | blood vessels that carry blood towards the heart | A07.231.908 | Veins | ||
vertebra | bone | bone in the spinal column | A02.835.232.834 | Vertebrae | ||
vestibular nerve | nerve | A08.800.800.120.910.900 | ||||
Viral Fusion Protein Inhibitors | mechanism of action antiviral agent |
Drugs that are designed to block the action of viral fusion proteins and prevent viruses from entering the cell | D27.505.954.122.388.538 D27.505.519.957 |
|||
viral hemorrhagic fever | viral infectious disease | C02.782.417 | Viral hemorrhagic fevers | |||
Viremia | hematopoietic system diseases viral infectious disease |
C02.937 C23.550.470.790.500.900 |
||||
Viscoelastic Substances | Specialty Uses of Chemicals | Substances that display the physical properties of ELASTICITY and VISCOSITY. The dual-nature of these substances causes them to resist applied forces in a time-dependent manner. | D27.720.944 | |||
Viscosupplements | Protective Agents lubricant Viscoelastic Substances |
Viscoelastic solutions that are injected into joints in order to alleviate symptoms of joint-related disorders such as osteoarthritis | D27.720.944.500 D27.505.696.706.888 D27.720.556.500 |
|||
vision disorder | sensation disorder | human disease | C10.597.751.941 C11.966 C23.888.592.763.941 |
|||
visual impairment | eye disease vision disorder sensory loss |
decreased ability to see | C10.597.751.941.905 C11.966.905 C23.888.592.763.941.848 |
Visual impairment | ||
vitamin B | vitamin | vitamin | D27.505.696.377.605.600.708 | B vitamins | ||
vitamin E | vitamin group of chemical substances |
generic descriptor for all tocopherols and tocotrienols that exhibit alpha-tocopherol activity | D03.438.150.909 | Vitamin E | ||
Vitelline duct | A16.254.891 | |||||
vitelline membrane | structure directly adjacent to the outer surface of the plasma membrane of an ovum | A16.631.886 | ||||
vocal cord dysfunction | speech disorder upper respiratory tract disease |
C08.360.895 C08.618.980 C09.400.895 |
||||
vocal folds | anatomical structure | composed of twin infoldings of mucous membrane stretched horizontally, from back to front, across the larynx. They vibrate, modulating the flow of air being expelled from the lungs during phonation | A04.329.364.737 | Vocal folds | ||
Voltage-Gated Sodium Channel Agonists | Sodium Channel Agonists | Compounds that either stimulate the opening or prevent closure of voltage-gated sodium channels | D27.505.519.562.625.500 | |||
Voltage-Gated Sodium Channel Blockers | Sodium channel blocker | A class of drugs that inhibit the activation of voltage-gated sodium channels | D27.505.519.562.750.500 D27.505.954.411.720.500 |
|||
vulva | anatomical structure | external genital organs of the female mammal | A05.360.319.887 | Vulvas | ||
vulvodynia | vulvar disease dysesthesia |
C13.351.500.944.951 | Vulvodynia | |||
Wakefulness-Promoting Agents | stimulant | A specific category of drugs that prevent sleepiness by specifically targeting sleep-mechanisms in the brain. They are used to treat disorders of excessive somnolence such as narcolepsy. Note that this drug category does not include broadly-acting c | D27.505.954.427.220.612 | |||
Waldenström hyperglobulinemic purpura | hyperglobulinemic purpura | C14.907.454.550 C15.378.100.802.250 C15.378.463.515.550 C23.550.414.950.250 C23.888.885.687.250 |
||||
Wallerian degeneration | neurological disorder | C23.550.737.750 | ||||
Water Pollutants | Environmental Pollutants | Substances or organisms which pollute the water or bodies of water. Use for water pollutants in general or those for which there is no specific heading | D27.888.284.903 | |||
Water Pollutants, Chemical | Water Pollutants | Chemical compounds which pollute the water of rivers, streams, lakes, the sea, reservoirs, or other bodies of water | D27.888.284.903.655 | |||
Water Pollutants, Radioactive | Water Pollutants | Pollutants, present in water or bodies of water, which exhibit radioactivity | D27.888.284.903.821 | |||
waterborne disease | infectious disease | disease caused by pathogenic microorganisms that most commonly are transmitted in contaminated fresh water | C01.539.221.750 | |||
Wernicke encephalopathy | trifunctional transcriptional regulator/proline dehydrogenase/pyrroline-5-carboxylate dehydrogenase NRG857 04915 disease |
brain disease long-term effects of alcohol |
Human disease | C10.228.140.163.960 C18.452.132.960 C18.654.521.500.133.699.827.822 C25.775.100.625 |
||
Wetting Agents | surfactant | A surfactant that renders a surface wettable by water or enhances the spreading of water over the surface | D27.720.877.974 | |||
Whiplash | trauma Cervical fracture |
range of injuries to the neck related to a sudden distortion of the neck | C26.700.500 | Whiplash (medicine) | ||
Word association test | personality test | F04.711.647.905 | ||||
work accident | accident | occurrence during work that leads to physical or mental harm | N06.850.135.240 | Work accidents | ||
xiphoid process | small cartilaginous process (extension) of the lower part of the sternum which is usually ossified in the adult human | A02.835.232.904.766.825 | Xiphoid processes | |||
yolk sac | a membranous sac attached to an embryo, formed by cells of the hypoblast adjacent to the embryonic disk | A10.615.284.981 | ||||
Zona pellucida | A05.360.490.690.950 | Zona pellucida |
End of auto-generated list.